DDI-DrugBank.d610.s0|a|Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. 
DDI-DrugBank.d610.s0	30	37	abacavir	drug	DDI-DrugBank.d610.s0.e0
DDI-DrugBank.d610.s0	82	91	lamivudine	drug	DDI-DrugBank.d610.s0.e1
DDI-DrugBank.d610.s0	96	105	zidovudine	drug	DDI-DrugBank.d610.s0.e2
DDI-DrugBank.d610.s0	129	138	lamivudine	drug	DDI-DrugBank.d610.s0.e3
DDI-DrugBank.d610.s0	144	153	zidovudine	drug	DDI-DrugBank.d610.s0.e4
DDI-DrugBank.d610.s0	false	DDI-DrugBank.d610.s0.e0	DDI-DrugBank.d610.s0.e1
DDI-DrugBank.d610.s0	false	DDI-DrugBank.d610.s0.e0	DDI-DrugBank.d610.s0.e2
DDI-DrugBank.d610.s0	false	DDI-DrugBank.d610.s0.e0	DDI-DrugBank.d610.s0.e3
DDI-DrugBank.d610.s0	false	DDI-DrugBank.d610.s0.e0	DDI-DrugBank.d610.s0.e4
DDI-DrugBank.d610.s0	false	DDI-DrugBank.d610.s0.e1	DDI-DrugBank.d610.s0.e2
DDI-DrugBank.d610.s0	false	DDI-DrugBank.d610.s0.e1	DDI-DrugBank.d610.s0.e3
DDI-DrugBank.d610.s0	false	DDI-DrugBank.d610.s0.e1	DDI-DrugBank.d610.s0.e4
DDI-DrugBank.d610.s0	false	DDI-DrugBank.d610.s0.e2	DDI-DrugBank.d610.s0.e3
DDI-DrugBank.d610.s0	false	DDI-DrugBank.d610.s0.e2	DDI-DrugBank.d610.s0.e4
DDI-DrugBank.d610.s0	false	DDI-DrugBank.d610.s0.e3	DDI-DrugBank.d610.s0.e4
DDI-DrugBank.d610.s1|a|No clinically significant changes to lamivudine or zidovudine pharmacokinetics were observed following concomitant administration of abacavir. 
DDI-DrugBank.d610.s1	37	46	lamivudine	drug	DDI-DrugBank.d610.s1.e0
DDI-DrugBank.d610.s1	51	60	zidovudine	drug	DDI-DrugBank.d610.s1.e1
DDI-DrugBank.d610.s1	133	140	abacavir	drug	DDI-DrugBank.d610.s1.e2
DDI-DrugBank.d610.s1	false	DDI-DrugBank.d610.s1.e0	DDI-DrugBank.d610.s1.e1
DDI-DrugBank.d610.s1	false	DDI-DrugBank.d610.s1.e0	DDI-DrugBank.d610.s1.e2
DDI-DrugBank.d610.s1	false	DDI-DrugBank.d610.s1.e1	DDI-DrugBank.d610.s1.e2
DDI-DrugBank.d610.s2|a|Abacavir has no effect on the pharmacokinetic properties of ethanol. 
DDI-DrugBank.d610.s2	0	7	Abacavir	drug	DDI-DrugBank.d610.s2.e0
DDI-DrugBank.d610.s2	60	66	ethanol	drug	DDI-DrugBank.d610.s2.e1
DDI-DrugBank.d610.s2	false	DDI-DrugBank.d610.s2.e0	DDI-DrugBank.d610.s2.e1
DDI-DrugBank.d610.s3|a|Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. 
DDI-DrugBank.d610.s3	0	6	Ethanol	drug	DDI-DrugBank.d610.s3.e0
DDI-DrugBank.d610.s3	37	44	abacavir	drug	DDI-DrugBank.d610.s3.e1
DDI-DrugBank.d610.s3	104	112	methadone	drug	DDI-DrugBank.d610.s3.e2
DDI-DrugBank.d610.s3	188	195	abacavir	drug	DDI-DrugBank.d610.s3.e3
DDI-DrugBank.d610.s3	true	DDI-DrugBank.d610.s3.e0	DDI-DrugBank.d610.s3.e1
DDI-DrugBank.d610.s3	false	DDI-DrugBank.d610.s3.e0	DDI-DrugBank.d610.s3.e2
DDI-DrugBank.d610.s3	false	DDI-DrugBank.d610.s3.e0	DDI-DrugBank.d610.s3.e3
DDI-DrugBank.d610.s3	false	DDI-DrugBank.d610.s3.e1	DDI-DrugBank.d610.s3.e2
DDI-DrugBank.d610.s3	false	DDI-DrugBank.d610.s3.e1	DDI-DrugBank.d610.s3.e3
DDI-DrugBank.d610.s3	false	DDI-DrugBank.d610.s3.e2	DDI-DrugBank.d610.s3.e3
DDI-DrugBank.d610.s4|a|In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%). 
DDI-DrugBank.d610.s4	49	57	methadone	drug	DDI-DrugBank.d610.s4.e0
DDI-DrugBank.d610.s4	118	123	ZIAGEN	brand	DDI-DrugBank.d610.s4.e1
DDI-DrugBank.d610.s4	182	190	methadone	drug	DDI-DrugBank.d610.s4.e2
DDI-DrugBank.d610.s4	true	DDI-DrugBank.d610.s4.e0	DDI-DrugBank.d610.s4.e1
DDI-DrugBank.d610.s4	false	DDI-DrugBank.d610.s4.e0	DDI-DrugBank.d610.s4.e2
DDI-DrugBank.d610.s4	false	DDI-DrugBank.d610.s4.e1	DDI-DrugBank.d610.s4.e2
DDI-DrugBank.d610.s5|a|This alteration will not result in a methadone dose modification in the majority of patients; 
DDI-DrugBank.d610.s5	37	45	methadone	drug	DDI-DrugBank.d610.s5.e0
DDI-DrugBank.d610.s6|a|however, an increased methadone dose may be required in a small number of patients.
DDI-DrugBank.d610.s6	22	30	methadone	drug	DDI-DrugBank.d610.s6.e0
DDI-DrugBank.d572.s0|a|Cholestyramine: Concomitant cholestyramine administration decreased the mean AUC of total ezetimibe approximately 55%. 
DDI-DrugBank.d572.s0	0	13	Cholestyramine	drug	DDI-DrugBank.d572.s0.e0
DDI-DrugBank.d572.s0	28	41	cholestyramine	drug	DDI-DrugBank.d572.s0.e1
DDI-DrugBank.d572.s0	90	98	ezetimibe	drug	DDI-DrugBank.d572.s0.e2
DDI-DrugBank.d572.s0	false	DDI-DrugBank.d572.s0.e0	DDI-DrugBank.d572.s0.e1
DDI-DrugBank.d572.s0	false	DDI-DrugBank.d572.s0.e0	DDI-DrugBank.d572.s0.e2
DDI-DrugBank.d572.s0	true	DDI-DrugBank.d572.s0.e1	DDI-DrugBank.d572.s0.e2
DDI-DrugBank.d572.s1|a|The incremental LDL-C reduction due to adding ezetimibe to cholestyramine may be reduced by this interaction. 
DDI-DrugBank.d572.s1	46	54	ezetimibe	drug	DDI-DrugBank.d572.s1.e0
DDI-DrugBank.d572.s1	59	72	cholestyramine	drug	DDI-DrugBank.d572.s1.e1
DDI-DrugBank.d572.s1	true	DDI-DrugBank.d572.s1.e0	DDI-DrugBank.d572.s1.e1
DDI-DrugBank.d572.s2|a|Fibrates: The safety and effectiveness of ezetimibe administered with fibrates have not been established. 
DDI-DrugBank.d572.s2	0	7	Fibrates	group	DDI-DrugBank.d572.s2.e0
DDI-DrugBank.d572.s2	42	50	ezetimibe	drug	DDI-DrugBank.d572.s2.e1
DDI-DrugBank.d572.s2	70	77	fibrates	group	DDI-DrugBank.d572.s2.e2
DDI-DrugBank.d572.s2	false	DDI-DrugBank.d572.s2.e0	DDI-DrugBank.d572.s2.e1
DDI-DrugBank.d572.s2	false	DDI-DrugBank.d572.s2.e0	DDI-DrugBank.d572.s2.e2
DDI-DrugBank.d572.s2	false	DDI-DrugBank.d572.s2.e1	DDI-DrugBank.d572.s2.e2
DDI-DrugBank.d572.s3|a|Fibrates may increase cholesterol excretion into the bile, leading to cholelithiasis. 
DDI-DrugBank.d572.s3	0	7	Fibrates	group	DDI-DrugBank.d572.s3.e0
DDI-DrugBank.d572.s4|a|In a preclinical study in dogs, ezetimibe increased cholesterol in the gallbladder bile. 
DDI-DrugBank.d572.s4	32	40	ezetimibe	drug	DDI-DrugBank.d572.s4.e0
DDI-DrugBank.d572.s5|a|Co-administration of ZETIA with fibrates is not recommended until use in patients is studied. 
DDI-DrugBank.d572.s5	21	25	ZETIA	brand	DDI-DrugBank.d572.s5.e0
DDI-DrugBank.d572.s5	32	39	fibrates	group	DDI-DrugBank.d572.s5.e1
DDI-DrugBank.d572.s5	true	DDI-DrugBank.d572.s5.e0	DDI-DrugBank.d572.s5.e1
DDI-DrugBank.d572.s6|a|Fenofibrate: In a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold. 
DDI-DrugBank.d572.s6	0	10	Fenofibrate	drug	DDI-DrugBank.d572.s6.e0
DDI-DrugBank.d572.s6	53	63	fenofibrate	drug	DDI-DrugBank.d572.s6.e1
DDI-DrugBank.d572.s6	96	104	ezetimibe	drug	DDI-DrugBank.d572.s6.e2
DDI-DrugBank.d572.s6	false	DDI-DrugBank.d572.s6.e0	DDI-DrugBank.d572.s6.e1
DDI-DrugBank.d572.s6	false	DDI-DrugBank.d572.s6.e0	DDI-DrugBank.d572.s6.e2
DDI-DrugBank.d572.s6	true	DDI-DrugBank.d572.s6.e1	DDI-DrugBank.d572.s6.e2
DDI-DrugBank.d572.s7|a|Gemfibrozil: In a pharmacokinetic study, concomitant gemfibrozil administration increased total ezetimibe concentrations approximately 1.7-fold. 
DDI-DrugBank.d572.s7	0	10	Gemfibrozil	drug	DDI-DrugBank.d572.s7.e0
DDI-DrugBank.d572.s7	53	63	gemfibrozil	drug	DDI-DrugBank.d572.s7.e1
DDI-DrugBank.d572.s7	96	104	ezetimibe	drug	DDI-DrugBank.d572.s7.e2
DDI-DrugBank.d572.s7	false	DDI-DrugBank.d572.s7.e0	DDI-DrugBank.d572.s7.e1
DDI-DrugBank.d572.s7	false	DDI-DrugBank.d572.s7.e0	DDI-DrugBank.d572.s7.e2
DDI-DrugBank.d572.s7	false	DDI-DrugBank.d572.s7.e1	DDI-DrugBank.d572.s7.e2
DDI-DrugBank.d572.s8|a|HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. 
DDI-DrugBank.d572.s8	0	27	HMG-CoA reductase inhibitors	group	DDI-DrugBank.d572.s8.e0
DDI-DrugBank.d572.s8	100	108	ezetimibe	drug	DDI-DrugBank.d572.s8.e1
DDI-DrugBank.d572.s8	135	146	atorvastatin	drug	DDI-DrugBank.d572.s8.e2
DDI-DrugBank.d572.s8	149	159	simvastatin	drug	DDI-DrugBank.d572.s8.e3
DDI-DrugBank.d572.s8	162	172	pravastatin	drug	DDI-DrugBank.d572.s8.e4
DDI-DrugBank.d572.s8	175	184	lovastatin	drug	DDI-DrugBank.d572.s8.e5
DDI-DrugBank.d572.s8	190	200	fluvastatin	drug	DDI-DrugBank.d572.s8.e6
DDI-DrugBank.d572.s8	false	DDI-DrugBank.d572.s8.e0	DDI-DrugBank.d572.s8.e1
DDI-DrugBank.d572.s8	false	DDI-DrugBank.d572.s8.e0	DDI-DrugBank.d572.s8.e2
DDI-DrugBank.d572.s8	false	DDI-DrugBank.d572.s8.e0	DDI-DrugBank.d572.s8.e3
DDI-DrugBank.d572.s8	false	DDI-DrugBank.d572.s8.e0	DDI-DrugBank.d572.s8.e4
DDI-DrugBank.d572.s8	false	DDI-DrugBank.d572.s8.e0	DDI-DrugBank.d572.s8.e5
DDI-DrugBank.d572.s8	false	DDI-DrugBank.d572.s8.e0	DDI-DrugBank.d572.s8.e6
DDI-DrugBank.d572.s8	false	DDI-DrugBank.d572.s8.e1	DDI-DrugBank.d572.s8.e2
DDI-DrugBank.d572.s8	false	DDI-DrugBank.d572.s8.e1	DDI-DrugBank.d572.s8.e3
DDI-DrugBank.d572.s8	false	DDI-DrugBank.d572.s8.e1	DDI-DrugBank.d572.s8.e4
DDI-DrugBank.d572.s8	false	DDI-DrugBank.d572.s8.e1	DDI-DrugBank.d572.s8.e5
DDI-DrugBank.d572.s9|a|Cyclosporine: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine. 
DDI-DrugBank.d572.s9	0	11	Cyclosporine	drug	DDI-DrugBank.d572.s9.e0
DDI-DrugBank.d572.s9	24	32	ezetimibe	drug	DDI-DrugBank.d572.s9.e1
DDI-DrugBank.d572.s9	132	143	cyclosporine	drug	DDI-DrugBank.d572.s9.e2
DDI-DrugBank.d572.s9	false	DDI-DrugBank.d572.s9.e0	DDI-DrugBank.d572.s9.e1
DDI-DrugBank.d572.s9	false	DDI-DrugBank.d572.s9.e0	DDI-DrugBank.d572.s9.e2
DDI-DrugBank.d572.s9	true	DDI-DrugBank.d572.s9.e1	DDI-DrugBank.d572.s9.e2
DDI-DrugBank.d572.s10|a|Patients who take both ezetimibe and cyclosporine should be carefully monitored. 
DDI-DrugBank.d572.s10	23	31	ezetimibe	drug	DDI-DrugBank.d572.s10.e0
DDI-DrugBank.d572.s10	37	48	cyclosporine	drug	DDI-DrugBank.d572.s10.e1
DDI-DrugBank.d572.s10	true	DDI-DrugBank.d572.s10.e0	DDI-DrugBank.d572.s10.e1
DDI-DrugBank.d572.s11|a|Carcinogenesis, Mutagenesis, Impairment of Fertility A 104-week dietary carcinogenicity study with ezetimibe was conducted in rats at doses up to 1500 mg/kg/day (males) and 500 mg/kg/day (females) (~20 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe). 
DDI-DrugBank.d572.s11	99	107	ezetimibe	drug	DDI-DrugBank.d572.s11.e0
DDI-DrugBank.d572.s11	271	279	ezetimibe	drug	DDI-DrugBank.d572.s11.e1
DDI-DrugBank.d572.s11	false	DDI-DrugBank.d572.s11.e0	DDI-DrugBank.d572.s11.e1
DDI-DrugBank.d572.s12|a|A 104-week dietary carcinogenicity study with ezetimibe was also conducted in mice at doses up to 500 mg/kg/day (>150 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe). 
DDI-DrugBank.d572.s12	46	54	ezetimibe	drug	DDI-DrugBank.d572.s12.e0
DDI-DrugBank.d572.s12	187	195	ezetimibe	drug	DDI-DrugBank.d572.s12.e1
DDI-DrugBank.d572.s12	false	DDI-DrugBank.d572.s12.e0	DDI-DrugBank.d572.s12.e1
DDI-DrugBank.d572.s13|a|There were no statistically significant increases in tumor incidences in drug-treated rats or mice. 
DDI-DrugBank.d572.s14|a|No evidence of mutagenicity was observed in vitro in a microbial mutagenicity (Ames) test with Salmonella typhimurium and Escherichia coli with or without metabolic activation. 
DDI-DrugBank.d572.s15|a|No evidence of clastogenicity was observed in vitro in a chromosomal aberration assay in human peripheral blood lymphocytes with or without metabolic activation. 
DDI-DrugBank.d572.s16|a|In addition, there was no evidence of genotoxicity in the in vivo mouse micronucleus test. 
DDI-DrugBank.d572.s17|a|In oral (gavage) fertility studies of ezetimibe conducted in rats, there was no evidence of reproductive toxicity at doses up to 1000 mg/kg/day in male or female rats (~7 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe). 
DDI-DrugBank.d572.s17	38	46	ezetimibe	drug	DDI-DrugBank.d572.s17.e0
DDI-DrugBank.d572.s17	240	248	ezetimibe	drug	DDI-DrugBank.d572.s17.e1
DDI-DrugBank.d572.s17	false	DDI-DrugBank.d572.s17.e0	DDI-DrugBank.d572.s17.e1
DDI-DrugBank.d572.s18|a|Pregnancy Pregnancy Category: C There are no adequate and well-controlled studies of ezetimibe in pregnant women. 
DDI-DrugBank.d572.s18	85	93	ezetimibe	drug	DDI-DrugBank.d572.s18.e0
DDI-DrugBank.d572.s19|a|Ezetimibe should be used during pregnancy only if the potential benefit justifies the risk to the fetus. 
DDI-DrugBank.d572.s19	0	8	Ezetimibe	drug	DDI-DrugBank.d572.s19.e0
DDI-DrugBank.d572.s20|a|In oral (gavage) embryo-fetal development studies of ezetimibe conducted in rats and rabbits during organogenesis, there was no evidence of embryolethal effects at the doses tested (250, 500, 1000 mg/kg/day). 
DDI-DrugBank.d572.s20	53	61	ezetimibe	drug	DDI-DrugBank.d572.s20.e0
DDI-DrugBank.d572.s21|a|In rats, increased incidences of common fetal skeletal findings (extra pair of thoracic ribs, unossified cervical vertebral centra, shortened ribs) were observed at 1000 mg/kg/day (~10 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe). 
DDI-DrugBank.d572.s21	254	262	ezetimibe	drug	DDI-DrugBank.d572.s21.e0
DDI-DrugBank.d572.s22|a|In rabbits treated with ezetimibe, an increased incidence of extra thoracic ribs was observed at 1000 mg/kg/day (150 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe). 
DDI-DrugBank.d572.s22	24	32	ezetimibe	drug	DDI-DrugBank.d572.s22.e0
DDI-DrugBank.d572.s22	186	194	ezetimibe	drug	DDI-DrugBank.d572.s22.e1
DDI-DrugBank.d572.s22	false	DDI-DrugBank.d572.s22.e0	DDI-DrugBank.d572.s22.e1
DDI-DrugBank.d572.s23|a|Ezetimibe crossed the placenta when pregnant rats and rabbits were given multiple oral doses. 
DDI-DrugBank.d572.s23	0	8	Ezetimibe	drug	DDI-DrugBank.d572.s23.e0
DDI-DrugBank.d572.s24|a|Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. 
DDI-DrugBank.d572.s24	25	33	ezetimibe	drug	DDI-DrugBank.d572.s24.e0
DDI-DrugBank.d572.s24	61	88	HMG-CoA reductase inhibitors	group	DDI-DrugBank.d572.s24.e1
DDI-DrugBank.d572.s24	91	97	statins	group	DDI-DrugBank.d572.s24.e2
DDI-DrugBank.d572.s24	158	166	ezetimibe	drug	DDI-DrugBank.d572.s24.e3
DDI-DrugBank.d572.s24	false	DDI-DrugBank.d572.s24.e0	DDI-DrugBank.d572.s24.e1
DDI-DrugBank.d572.s24	false	DDI-DrugBank.d572.s24.e0	DDI-DrugBank.d572.s24.e2
DDI-DrugBank.d572.s24	false	DDI-DrugBank.d572.s24.e0	DDI-DrugBank.d572.s24.e3
DDI-DrugBank.d572.s24	false	DDI-DrugBank.d572.s24.e1	DDI-DrugBank.d572.s24.e2
DDI-DrugBank.d572.s24	false	DDI-DrugBank.d572.s24.e1	DDI-DrugBank.d572.s24.e3
DDI-DrugBank.d572.s24	false	DDI-DrugBank.d572.s24.e2	DDI-DrugBank.d572.s24.e3
DDI-DrugBank.d572.s25|a|Reproductive findings occur at lower doses in combination therapy compared to monotherapy. 
DDI-DrugBank.d572.s26|a|All HMG-CoA reductase inhibitors are contraindicated in pregnant and nursing women. 
DDI-DrugBank.d572.s26	4	31	HMG-CoA reductase inhibitors	group	DDI-DrugBank.d572.s26.e0
DDI-DrugBank.d572.s27|a|When ZETIA is administered with an HMG-CoA reductase inhibitor in a woman of childbearing potential, refer to the pregnancy category and package labeling for the HMG-CoA reductase inhibitor. 
DDI-DrugBank.d572.s27	5	9	ZETIA	brand	DDI-DrugBank.d572.s27.e0
DDI-DrugBank.d572.s27	35	61	HMG-CoA reductase inhibitor	group	DDI-DrugBank.d572.s27.e1
DDI-DrugBank.d572.s27	162	188	HMG-CoA reductase inhibitor	drug	DDI-DrugBank.d572.s27.e2
DDI-DrugBank.d572.s27	false	DDI-DrugBank.d572.s27.e0	DDI-DrugBank.d572.s27.e1
DDI-DrugBank.d572.s27	false	DDI-DrugBank.d572.s27.e0	DDI-DrugBank.d572.s27.e2
DDI-DrugBank.d572.s27	false	DDI-DrugBank.d572.s27.e1	DDI-DrugBank.d572.s27.e2
DDI-DrugBank.d572.s28|a|Labor and Delivery The effects of ZETIA on labor and delivery in pregnant women are unknown. 
DDI-DrugBank.d572.s28	34	38	ZETIA	brand	DDI-DrugBank.d572.s28.e0
DDI-DrugBank.d572.s29|a|Nursing Mothers In rat studies, exposure to total ezetimibe in nursing pups was up to half of that observed in maternal plasma. 
DDI-DrugBank.d572.s29	50	58	ezetimibe	drug	DDI-DrugBank.d572.s29.e0
DDI-DrugBank.d572.s30|a|It is not known whether ezetimibe is excreted into human breast milk; 
DDI-DrugBank.d572.s30	24	32	ezetimibe	drug	DDI-DrugBank.d572.s30.e0
DDI-DrugBank.d572.s31|a|therefore, ZETIA should not be used in nursing mothers unless the potential benefit justifies the potential risk to the infant. 
DDI-DrugBank.d572.s31	11	15	ZETIA	brand	DDI-DrugBank.d572.s31.e0
DDI-DrugBank.d572.s32|a|Pediatric Use The pharmacokinetics of ZETIA in adolescents (10 to 18 years) have been shown to be similar to that in adults. 
DDI-DrugBank.d572.s32	38	42	ZETIA	brand	DDI-DrugBank.d572.s32.e0
DDI-DrugBank.d572.s33|a|Treatment experience with ZETIA in the pediatric population is limited to 4 patients (9 to 17 years) in the sitosterolemia study and 5 patients (11 to 17 years) in the HoFH study. 
DDI-DrugBank.d572.s33	26	30	ZETIA	brand	DDI-DrugBank.d572.s33.e0
DDI-DrugBank.d572.s34|a|Treatment with ZETIA in children (<10 years) is not recommended. 
DDI-DrugBank.d572.s34	15	19	ZETIA	brand	DDI-DrugBank.d572.s34.e0
DDI-DrugBank.d572.s35|a|Geriatric Use Of the patients who received ZETIA in clinical studies, 948 were 65 and older (this included 206 who were 75 and older). 
DDI-DrugBank.d572.s35	43	47	ZETIA	brand	DDI-DrugBank.d572.s35.e0
DDI-DrugBank.d572.s36|a|The effectiveness and safety of ZETIA were similar between these patients and younger subjects. 
DDI-DrugBank.d572.s36	32	36	ZETIA	brand	DDI-DrugBank.d572.s36.e0
DDI-DrugBank.d572.s37|a|Greater sensitivity of some older individuals cannot be ruled out.
DDI-DrugBank.d776.s0|a|Clinically or potentially significant drug interactions between DIFLUCAN and the following agents/classes have been observed. 
DDI-DrugBank.d776.s0	64	71	DIFLUCAN	brand	DDI-DrugBank.d776.s0.e0
DDI-DrugBank.d776.s1|a|These are described in greater detail below: DIFLUCAN and the following agents/classes have been observed. 
DDI-DrugBank.d776.s1	45	52	DIFLUCAN	brand	DDI-DrugBank.d776.s1.e0
DDI-DrugBank.d776.s2|a|These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 
DDI-DrugBank.d776.s2	51	63	hypoglycemics	group	DDI-DrugBank.d776.s2.e0
DDI-DrugBank.d776.s2	66	93	Coumarin-type anticoagulants	group	DDI-DrugBank.d776.s2.e1
DDI-DrugBank.d776.s2	96	104	Phenytoin	drug	DDI-DrugBank.d776.s2.e2
DDI-DrugBank.d776.s2	107	118	Cyclosporine	drug	DDI-DrugBank.d776.s2.e3
DDI-DrugBank.d776.s2	121	128	Rifampin	drug	DDI-DrugBank.d776.s2.e4
DDI-DrugBank.d776.s2	131	142	Theophylline	drug	DDI-DrugBank.d776.s2.e5
DDI-DrugBank.d776.s2	145	155	Terfenadine	drug	DDI-DrugBank.d776.s2.e6
DDI-DrugBank.d776.s2	158	166	Cisapride	drug	DDI-DrugBank.d776.s2.e7
DDI-DrugBank.d776.s2	169	178	Astemizole	drug	DDI-DrugBank.d776.s2.e8
DDI-DrugBank.d776.s2	181	189	Rifabutin	drug	DDI-DrugBank.d776.s2.e9
DDI-DrugBank.d776.s2	false	DDI-DrugBank.d776.s2.e0	DDI-DrugBank.d776.s2.e1
DDI-DrugBank.d776.s2	false	DDI-DrugBank.d776.s2.e0	DDI-DrugBank.d776.s2.e2
DDI-DrugBank.d776.s2	false	DDI-DrugBank.d776.s2.e0	DDI-DrugBank.d776.s2.e3
DDI-DrugBank.d776.s2	false	DDI-DrugBank.d776.s2.e0	DDI-DrugBank.d776.s2.e4
DDI-DrugBank.d776.s2	false	DDI-DrugBank.d776.s2.e0	DDI-DrugBank.d776.s2.e5
DDI-DrugBank.d776.s2	false	DDI-DrugBank.d776.s2.e0	DDI-DrugBank.d776.s2.e6
DDI-DrugBank.d776.s2	false	DDI-DrugBank.d776.s2.e0	DDI-DrugBank.d776.s2.e7
DDI-DrugBank.d776.s2	false	DDI-DrugBank.d776.s2.e0	DDI-DrugBank.d776.s2.e8
DDI-DrugBank.d776.s2	false	DDI-DrugBank.d776.s2.e0	DDI-DrugBank.d776.s2.e9
DDI-DrugBank.d776.s2	false	DDI-DrugBank.d776.s2.e0	DDI-DrugBank.d776.s2.e10
DDI-DrugBank.d776.s3|a|one fatality has been reported from hypoglycemia in association with combined DIFLUCAN and glyburide use. 
DDI-DrugBank.d776.s3	78	85	DIFLUCAN	brand	DDI-DrugBank.d776.s3.e0
DDI-DrugBank.d776.s3	91	99	glyburide	drug	DDI-DrugBank.d776.s3.e1
DDI-DrugBank.d776.s3	true	DDI-DrugBank.d776.s3.e0	DDI-DrugBank.d776.s3.e1
DDI-DrugBank.d776.s4|a|DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. 
DDI-DrugBank.d776.s4	0	7	DIFLUCAN	brand	DDI-DrugBank.d776.s4.e0
DDI-DrugBank.d776.s4	35	45	tolbutamide	drug	DDI-DrugBank.d776.s4.e1
DDI-DrugBank.d776.s4	48	56	glyburide	drug	DDI-DrugBank.d776.s4.e2
DDI-DrugBank.d776.s4	63	71	glipizide	drug	DDI-DrugBank.d776.s4.e3
DDI-DrugBank.d776.s4	true	DDI-DrugBank.d776.s4.e0	DDI-DrugBank.d776.s4.e1
DDI-DrugBank.d776.s4	true	DDI-DrugBank.d776.s4.e0	DDI-DrugBank.d776.s4.e2
DDI-DrugBank.d776.s4	true	DDI-DrugBank.d776.s4.e0	DDI-DrugBank.d776.s4.e3
DDI-DrugBank.d776.s4	false	DDI-DrugBank.d776.s4.e1	DDI-DrugBank.d776.s4.e2
DDI-DrugBank.d776.s4	false	DDI-DrugBank.d776.s4.e1	DDI-DrugBank.d776.s4.e3
DDI-DrugBank.d776.s4	false	DDI-DrugBank.d776.s4.e2	DDI-DrugBank.d776.s4.e3
DDI-DrugBank.d776.s5|a|When DIFLUCAN is used concomitantly with these or other sulfonylurea oral hypoglycemic agents, blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary. 
DDI-DrugBank.d776.s5	5	12	DIFLUCAN	brand	DDI-DrugBank.d776.s5.e0
DDI-DrugBank.d776.s5	56	92	sulfonylurea oral hypoglycemic agents	group	DDI-DrugBank.d776.s5.e1
DDI-DrugBank.d776.s5	174	185	sulfonylurea	group	DDI-DrugBank.d776.s5.e2
DDI-DrugBank.d776.s5	true	DDI-DrugBank.d776.s5.e0	DDI-DrugBank.d776.s5.e1
DDI-DrugBank.d776.s5	false	DDI-DrugBank.d776.s5.e0	DDI-DrugBank.d776.s5.e2
DDI-DrugBank.d776.s5	false	DDI-DrugBank.d776.s5.e1	DDI-DrugBank.d776.s5.e2
DDI-DrugBank.d776.s6|a|Coumarin-type anticoagulants: Prothrombin time may be increased in patients receiving concomitant DIFLUCAN and coumarin-type anticoagulants. 
DDI-DrugBank.d776.s6	0	27	Coumarin-type anticoagulants	group	DDI-DrugBank.d776.s6.e0
DDI-DrugBank.d776.s6	98	105	DIFLUCAN	brand	DDI-DrugBank.d776.s6.e1
DDI-DrugBank.d776.s6	111	138	coumarin-type anticoagulants	group	DDI-DrugBank.d776.s6.e2
DDI-DrugBank.d776.s6	false	DDI-DrugBank.d776.s6.e0	DDI-DrugBank.d776.s6.e1
DDI-DrugBank.d776.s6	false	DDI-DrugBank.d776.s6.e0	DDI-DrugBank.d776.s6.e2
DDI-DrugBank.d776.s6	true	DDI-DrugBank.d776.s6.e1	DDI-DrugBank.d776.s6.e2
DDI-DrugBank.d776.s7|a|In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin. 
DDI-DrugBank.d776.s7	44	60	azole antifungals	group	DDI-DrugBank.d776.s7.e0
DDI-DrugBank.d776.s7	242	252	fluconazole	drug	DDI-DrugBank.d776.s7.e1
DDI-DrugBank.d776.s7	272	279	warfarin	drug	DDI-DrugBank.d776.s7.e2
DDI-DrugBank.d776.s7	false	DDI-DrugBank.d776.s7.e0	DDI-DrugBank.d776.s7.e1
DDI-DrugBank.d776.s7	false	DDI-DrugBank.d776.s7.e0	DDI-DrugBank.d776.s7.e2
DDI-DrugBank.d776.s7	true	DDI-DrugBank.d776.s7.e1	DDI-DrugBank.d776.s7.e2
DDI-DrugBank.d776.s8|a|Careful monitoring of prothrombin time in patients receiving DIFLUCAN and coumarin-type anticoagulants is recommended. 
DDI-DrugBank.d776.s8	61	68	DIFLUCAN	brand	DDI-DrugBank.d776.s8.e0
DDI-DrugBank.d776.s8	74	101	coumarin-type anticoagulants	group	DDI-DrugBank.d776.s8.e1
DDI-DrugBank.d776.s8	true	DDI-DrugBank.d776.s8.e0	DDI-DrugBank.d776.s8.e1
DDI-DrugBank.d776.s9|a|(See <a href= "flucon_cp.htm#CP">CLINICAL PHARMACOLOGY: Drug Interaction Studies.) 
DDI-DrugBank.d776.s10|a|Phenytoin: DIFLUCAN increases the plasma concentrations of phenytoin. 
DDI-DrugBank.d776.s10	0	8	Phenytoin	drug	DDI-DrugBank.d776.s10.e0
DDI-DrugBank.d776.s10	11	18	DIFLUCAN	brand	DDI-DrugBank.d776.s10.e1
DDI-DrugBank.d776.s10	59	67	phenytoin	drug	DDI-DrugBank.d776.s10.e2
DDI-DrugBank.d776.s10	false	DDI-DrugBank.d776.s10.e0	DDI-DrugBank.d776.s10.e1
DDI-DrugBank.d776.s10	false	DDI-DrugBank.d776.s10.e0	DDI-DrugBank.d776.s10.e2
DDI-DrugBank.d776.s10	true	DDI-DrugBank.d776.s10.e1	DDI-DrugBank.d776.s10.e2
DDI-DrugBank.d776.s11|a|Careful monitoring of phenytoin concentrations in patients receiving DIFLUCAN and phenytoin is recommended. 
DDI-DrugBank.d776.s11	22	30	phenytoin	drug	DDI-DrugBank.d776.s11.e0
DDI-DrugBank.d776.s11	69	76	DIFLUCAN	brand	DDI-DrugBank.d776.s11.e1
DDI-DrugBank.d776.s11	82	90	phenytoin	drug	DDI-DrugBank.d776.s11.e2
DDI-DrugBank.d776.s11	false	DDI-DrugBank.d776.s11.e0	DDI-DrugBank.d776.s11.e1
DDI-DrugBank.d776.s11	false	DDI-DrugBank.d776.s11.e0	DDI-DrugBank.d776.s11.e2
DDI-DrugBank.d776.s11	true	DDI-DrugBank.d776.s11.e1	DDI-DrugBank.d776.s11.e2
DDI-DrugBank.d776.s12|a|(See <a href= "flucon_cp.htm#CP">CLINICAL PHARMACOLOGY: Drug Interaction Studies.) 
DDI-DrugBank.d776.s13|a|Cyclosporine: DIFLUCAN may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment. 
DDI-DrugBank.d776.s13	0	11	Cyclosporine	drug	DDI-DrugBank.d776.s13.e0
DDI-DrugBank.d776.s13	14	21	DIFLUCAN	brand	DDI-DrugBank.d776.s13.e1
DDI-DrugBank.d776.s13	50	61	cyclosporine	drug	DDI-DrugBank.d776.s13.e2
DDI-DrugBank.d776.s13	false	DDI-DrugBank.d776.s13.e0	DDI-DrugBank.d776.s13.e1
DDI-DrugBank.d776.s13	false	DDI-DrugBank.d776.s13.e0	DDI-DrugBank.d776.s13.e2
DDI-DrugBank.d776.s13	true	DDI-DrugBank.d776.s13.e1	DDI-DrugBank.d776.s13.e2
DDI-DrugBank.d776.s14|a|Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and cyclosporine. 
DDI-DrugBank.d776.s14	22	33	cyclosporine	drug	DDI-DrugBank.d776.s14.e0
DDI-DrugBank.d776.s14	108	115	DIFLUCAN	brand	DDI-DrugBank.d776.s14.e1
DDI-DrugBank.d776.s14	121	132	cyclosporine	drug	DDI-DrugBank.d776.s14.e2
DDI-DrugBank.d776.s14	false	DDI-DrugBank.d776.s14.e0	DDI-DrugBank.d776.s14.e1
DDI-DrugBank.d776.s14	false	DDI-DrugBank.d776.s14.e0	DDI-DrugBank.d776.s14.e2
DDI-DrugBank.d776.s14	true	DDI-DrugBank.d776.s14.e1	DDI-DrugBank.d776.s14.e2
DDI-DrugBank.d776.s15|a|(See CLINICAL PHARMACOLOGY: Drug Interaction Studies.) 
DDI-DrugBank.d776.s16|a|Rifampin: Rifampin enhances the metabolism of concurrently administered DIFLUCAN. 
DDI-DrugBank.d776.s16	0	7	Rifampin	drug	DDI-DrugBank.d776.s16.e0
DDI-DrugBank.d776.s16	10	17	Rifampin	drug	DDI-DrugBank.d776.s16.e1
DDI-DrugBank.d776.s16	72	79	DIFLUCAN	brand	DDI-DrugBank.d776.s16.e2
DDI-DrugBank.d776.s16	false	DDI-DrugBank.d776.s16.e0	DDI-DrugBank.d776.s16.e1
DDI-DrugBank.d776.s16	false	DDI-DrugBank.d776.s16.e0	DDI-DrugBank.d776.s16.e2
DDI-DrugBank.d776.s16	true	DDI-DrugBank.d776.s16.e1	DDI-DrugBank.d776.s16.e2
DDI-DrugBank.d776.s17|a|Depending on clinical circumstances, consideration should be given to increasing the dose of DIFLUCAN when it is administered with rifampin. 
DDI-DrugBank.d776.s17	93	100	DIFLUCAN	brand	DDI-DrugBank.d776.s17.e0
DDI-DrugBank.d776.s17	131	138	rifampin	drug	DDI-DrugBank.d776.s17.e1
DDI-DrugBank.d776.s17	true	DDI-DrugBank.d776.s17.e0	DDI-DrugBank.d776.s17.e1
DDI-DrugBank.d776.s18|a|Theophylline: DIFLUCAN increases the serum concentrations of theophylline. 
DDI-DrugBank.d776.s18	0	11	Theophylline	drug	DDI-DrugBank.d776.s18.e0
DDI-DrugBank.d776.s18	14	21	DIFLUCAN	brand	DDI-DrugBank.d776.s18.e1
DDI-DrugBank.d776.s18	61	72	theophylline	drug	DDI-DrugBank.d776.s18.e2
DDI-DrugBank.d776.s18	false	DDI-DrugBank.d776.s18.e0	DDI-DrugBank.d776.s18.e1
DDI-DrugBank.d776.s18	false	DDI-DrugBank.d776.s18.e0	DDI-DrugBank.d776.s18.e2
DDI-DrugBank.d776.s18	true	DDI-DrugBank.d776.s18.e1	DDI-DrugBank.d776.s18.e2
DDI-DrugBank.d776.s19|a|Careful monitoring of serum theophylline concentrations in patients receiving DIFLUCAN and theophylline is recommended. 
DDI-DrugBank.d776.s19	28	39	theophylline	drug	DDI-DrugBank.d776.s19.e0
DDI-DrugBank.d776.s19	78	85	DIFLUCAN	brand	DDI-DrugBank.d776.s19.e1
DDI-DrugBank.d776.s19	91	102	theophylline	drug	DDI-DrugBank.d776.s19.e2
DDI-DrugBank.d776.s19	false	DDI-DrugBank.d776.s19.e0	DDI-DrugBank.d776.s19.e1
DDI-DrugBank.d776.s19	false	DDI-DrugBank.d776.s19.e0	DDI-DrugBank.d776.s19.e2
DDI-DrugBank.d776.s19	true	DDI-DrugBank.d776.s19.e1	DDI-DrugBank.d776.s19.e2
DDI-DrugBank.d776.s20|a|Terfenadine: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with terfenadine, interaction studies have been performed. 
DDI-DrugBank.d776.s20	0	10	Terfenadine	drug	DDI-DrugBank.d776.s20.e0
DDI-DrugBank.d776.s20	139	155	azole antifungals	group	DDI-DrugBank.d776.s20.e1
DDI-DrugBank.d776.s20	177	187	terfenadine	drug	DDI-DrugBank.d776.s20.e2
DDI-DrugBank.d776.s20	false	DDI-DrugBank.d776.s20.e0	DDI-DrugBank.d776.s20.e1
DDI-DrugBank.d776.s20	false	DDI-DrugBank.d776.s20.e0	DDI-DrugBank.d776.s20.e2
DDI-DrugBank.d776.s20	true	DDI-DrugBank.d776.s20.e1	DDI-DrugBank.d776.s20.e2
DDI-DrugBank.d776.s21|a|One study at a 200-mg daily dose of fluconazole failed to demonstrate a prolongation in QTc interval. 
DDI-DrugBank.d776.s21	36	46	fluconazole	drug	DDI-DrugBank.d776.s21.e0
DDI-DrugBank.d776.s22|a|Another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that DIFLUCAN taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly. 
DDI-DrugBank.d776.s22	51	61	fluconazole	drug	DDI-DrugBank.d776.s22.e0
DDI-DrugBank.d776.s22	81	88	DIFLUCAN	brand	DDI-DrugBank.d776.s22.e1
DDI-DrugBank.d776.s22	175	185	terfenadine	drug	DDI-DrugBank.d776.s22.e2
DDI-DrugBank.d776.s22	false	DDI-DrugBank.d776.s22.e0	DDI-DrugBank.d776.s22.e1
DDI-DrugBank.d776.s22	false	DDI-DrugBank.d776.s22.e0	DDI-DrugBank.d776.s22.e2
DDI-DrugBank.d776.s22	true	DDI-DrugBank.d776.s22.e1	DDI-DrugBank.d776.s22.e2
DDI-DrugBank.d776.s23|a|The combined use of fluconazole at doses of 400 mg or greater with terfenadine is contraindicated. 
DDI-DrugBank.d776.s23	20	30	fluconazole	drug	DDI-DrugBank.d776.s23.e0
DDI-DrugBank.d776.s23	67	77	terfenadine	drug	DDI-DrugBank.d776.s23.e1
DDI-DrugBank.d776.s23	true	DDI-DrugBank.d776.s23.e0	DDI-DrugBank.d776.s23.e1
DDI-DrugBank.d776.s24|a|The coadministration of fluconazole at doses lower than 400 mg/day with terfenadine should be carefully monitored. 
DDI-DrugBank.d776.s24	24	34	fluconazole	drug	DDI-DrugBank.d776.s24.e0
DDI-DrugBank.d776.s24	72	82	terfenadine	drug	DDI-DrugBank.d776.s24.e1
DDI-DrugBank.d776.s24	true	DDI-DrugBank.d776.s24.e0	DDI-DrugBank.d776.s24.e1
DDI-DrugBank.d776.s25|a|Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered. 
DDI-DrugBank.d776.s25	0	8	Cisapride	drug	DDI-DrugBank.d776.s25.e0
DDI-DrugBank.d776.s25	103	113	fluconazole	drug	DDI-DrugBank.d776.s25.e1
DDI-DrugBank.d776.s25	119	127	cisapride	drug	DDI-DrugBank.d776.s25.e2
DDI-DrugBank.d776.s25	false	DDI-DrugBank.d776.s25.e0	DDI-DrugBank.d776.s25.e1
DDI-DrugBank.d776.s25	false	DDI-DrugBank.d776.s25.e0	DDI-DrugBank.d776.s25.e2
DDI-DrugBank.d776.s25	true	DDI-DrugBank.d776.s25.e1	DDI-DrugBank.d776.s25.e2
DDI-DrugBank.d776.s26|a|A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.
DDI-DrugBank.d776.s26	42	52	fluconazole	drug	DDI-DrugBank.d776.s26.e0
DDI-DrugBank.d776.s26	76	84	cisapride	drug	DDI-DrugBank.d776.s26.e1
DDI-DrugBank.d776.s26	143	151	cisapride	drug	DDI-DrugBank.d776.s26.e2
DDI-DrugBank.d776.s26	true	DDI-DrugBank.d776.s26.e0	DDI-DrugBank.d776.s26.e1
DDI-DrugBank.d776.s26	false	DDI-DrugBank.d776.s26.e0	DDI-DrugBank.d776.s26.e2
DDI-DrugBank.d776.s26	false	DDI-DrugBank.d776.s26.e1	DDI-DrugBank.d776.s26.e2
DDI-DrugBank.d776.s27|a|The combined use of fluconazole with cisapride is contraindicated. 
DDI-DrugBank.d776.s27	20	30	fluconazole	drug	DDI-DrugBank.d776.s27.e0
DDI-DrugBank.d776.s27	37	45	cisapride	drug	DDI-DrugBank.d776.s27.e1
DDI-DrugBank.d776.s27	true	DDI-DrugBank.d776.s27.e0	DDI-DrugBank.d776.s27.e1
DDI-DrugBank.d776.s28|a|Astemizole: The use of fluconazole in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs. 
DDI-DrugBank.d776.s28	0	9	Astemizole	drug	DDI-DrugBank.d776.s28.e0
DDI-DrugBank.d776.s28	23	33	fluconazole	drug	DDI-DrugBank.d776.s28.e1
DDI-DrugBank.d776.s28	67	76	astemizole	drug	DDI-DrugBank.d776.s28.e2
DDI-DrugBank.d776.s28	false	DDI-DrugBank.d776.s28.e0	DDI-DrugBank.d776.s28.e1
DDI-DrugBank.d776.s28	false	DDI-DrugBank.d776.s28.e0	DDI-DrugBank.d776.s28.e2
DDI-DrugBank.d776.s28	true	DDI-DrugBank.d776.s28.e1	DDI-DrugBank.d776.s28.e2
DDI-DrugBank.d776.s29|a|In the absence of definitive information, caution should be used when coadministering fluconazole. 
DDI-DrugBank.d776.s29	86	96	fluconazole	drug	DDI-DrugBank.d776.s29.e0
DDI-DrugBank.d776.s30|a|Patients should be carefully monitored. 
DDI-DrugBank.d776.s31|a|Rifabutin: There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered. 
DDI-DrugBank.d776.s31	0	8	Rifabutin	drug	DDI-DrugBank.d776.s31.e0
DDI-DrugBank.d776.s31	66	76	fluconazole	drug	DDI-DrugBank.d776.s31.e1
DDI-DrugBank.d776.s31	82	90	rifabutin	drug	DDI-DrugBank.d776.s31.e2
DDI-DrugBank.d776.s31	false	DDI-DrugBank.d776.s31.e0	DDI-DrugBank.d776.s31.e1
DDI-DrugBank.d776.s31	false	DDI-DrugBank.d776.s31.e0	DDI-DrugBank.d776.s31.e2
DDI-DrugBank.d776.s31	true	DDI-DrugBank.d776.s31.e1	DDI-DrugBank.d776.s31.e2
DDI-DrugBank.d776.s32|a|Patients receiving rifabutin and fluconazole concomitantly should be carefully monitored. 
DDI-DrugBank.d776.s32	19	27	rifabutin	drug	DDI-DrugBank.d776.s32.e0
DDI-DrugBank.d776.s32	33	43	fluconazole	drug	DDI-DrugBank.d776.s32.e1
DDI-DrugBank.d776.s32	true	DDI-DrugBank.d776.s32.e0	DDI-DrugBank.d776.s32.e1
DDI-DrugBank.d776.s33|a|Tacrolimus: There have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were coadministered. 
DDI-DrugBank.d776.s33	0	9	Tacrolimus	drug	DDI-DrugBank.d776.s33.e0
DDI-DrugBank.d776.s33	74	84	fluconazole	drug	DDI-DrugBank.d776.s33.e1
DDI-DrugBank.d776.s33	90	99	tacrolimus	drug	DDI-DrugBank.d776.s33.e2
DDI-DrugBank.d776.s33	false	DDI-DrugBank.d776.s33.e0	DDI-DrugBank.d776.s33.e1
DDI-DrugBank.d776.s33	false	DDI-DrugBank.d776.s33.e0	DDI-DrugBank.d776.s33.e2
DDI-DrugBank.d776.s33	true	DDI-DrugBank.d776.s33.e1	DDI-DrugBank.d776.s33.e2
DDI-DrugBank.d776.s34|a|Patients receiving tacrolimus and fluconazole concomitantly should be carefully monitored. 
DDI-DrugBank.d776.s34	19	28	tacrolimus	drug	DDI-DrugBank.d776.s34.e0
DDI-DrugBank.d776.s34	34	44	fluconazole	drug	DDI-DrugBank.d776.s34.e1
DDI-DrugBank.d776.s34	true	DDI-DrugBank.d776.s34.e0	DDI-DrugBank.d776.s34.e1
DDI-DrugBank.d776.s35|a|Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. 
DDI-DrugBank.d776.s35	0	27	Short-acting Benzodiazepines	group	DDI-DrugBank.d776.s35.e0
DDI-DrugBank.d776.s35	63	71	midazolam	drug	DDI-DrugBank.d776.s35.e1
DDI-DrugBank.d776.s35	74	84	fluconazole	drug	DDI-DrugBank.d776.s35.e2
DDI-DrugBank.d776.s35	123	131	midazolam	drug	DDI-DrugBank.d776.s35.e3
DDI-DrugBank.d776.s35	false	DDI-DrugBank.d776.s35.e0	DDI-DrugBank.d776.s35.e1
DDI-DrugBank.d776.s35	false	DDI-DrugBank.d776.s35.e0	DDI-DrugBank.d776.s35.e2
DDI-DrugBank.d776.s35	false	DDI-DrugBank.d776.s35.e0	DDI-DrugBank.d776.s35.e3
DDI-DrugBank.d776.s35	true	DDI-DrugBank.d776.s35.e1	DDI-DrugBank.d776.s35.e2
DDI-DrugBank.d776.s35	false	DDI-DrugBank.d776.s35.e1	DDI-DrugBank.d776.s35.e3
DDI-DrugBank.d776.s35	false	DDI-DrugBank.d776.s35.e2	DDI-DrugBank.d776.s35.e3
DDI-DrugBank.d776.s36|a|This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously. 
DDI-DrugBank.d776.s36	15	23	midazolam	drug	DDI-DrugBank.d776.s36.e0
DDI-DrugBank.d776.s36	88	98	fluconazole	drug	DDI-DrugBank.d776.s36.e1
DDI-DrugBank.d776.s36	110	120	fluconazole	drug	DDI-DrugBank.d776.s36.e2
DDI-DrugBank.d776.s36	true	DDI-DrugBank.d776.s36.e0	DDI-DrugBank.d776.s36.e1
DDI-DrugBank.d776.s36	false	DDI-DrugBank.d776.s36.e0	DDI-DrugBank.d776.s36.e2
DDI-DrugBank.d776.s36	false	DDI-DrugBank.d776.s36.e1	DDI-DrugBank.d776.s36.e2
DDI-DrugBank.d776.s37|a|If short-acting benzodiazepines, which are metabolized by the cytochrome P450 system, are concomitantly administered with fluconazole, consideration should be given to decreasing the benzodiazepine dosage, and the patients should be appropriately monitored. 
DDI-DrugBank.d776.s37	3	30	short-acting benzodiazepines	group	DDI-DrugBank.d776.s37.e0
DDI-DrugBank.d776.s37	122	132	fluconazole	drug	DDI-DrugBank.d776.s37.e1
DDI-DrugBank.d776.s37	183	196	benzodiazepine	group	DDI-DrugBank.d776.s37.e2
DDI-DrugBank.d776.s37	true	DDI-DrugBank.d776.s37.e0	DDI-DrugBank.d776.s37.e1
DDI-DrugBank.d776.s37	false	DDI-DrugBank.d776.s37.e0	DDI-DrugBank.d776.s37.e2
DDI-DrugBank.d776.s37	false	DDI-DrugBank.d776.s37.e1	DDI-DrugBank.d776.s37.e2
DDI-DrugBank.d776.s38|a|Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; 
DDI-DrugBank.d776.s38	0	10	Fluconazole	drug	DDI-DrugBank.d776.s38.e0
DDI-DrugBank.d776.s38	40	56	ethinyl estradiol	drug	DDI-DrugBank.d776.s38.e1
DDI-DrugBank.d776.s38	63	76	levonorgestrel	drug	DDI-DrugBank.d776.s38.e2
DDI-DrugBank.d776.s38	94	107	contraceptives	group	DDI-DrugBank.d776.s38.e3
DDI-DrugBank.d776.s38	146	162	ethinyl estradiol	drug	DDI-DrugBank.d776.s38.e4
DDI-DrugBank.d776.s38	168	181	levonorgestrel	drug	DDI-DrugBank.d776.s38.e5
DDI-DrugBank.d776.s38	true	DDI-DrugBank.d776.s38.e0	DDI-DrugBank.d776.s38.e1
DDI-DrugBank.d776.s38	true	DDI-DrugBank.d776.s38.e0	DDI-DrugBank.d776.s38.e2
DDI-DrugBank.d776.s38	false	DDI-DrugBank.d776.s38.e0	DDI-DrugBank.d776.s38.e3
DDI-DrugBank.d776.s38	false	DDI-DrugBank.d776.s38.e0	DDI-DrugBank.d776.s38.e4
DDI-DrugBank.d776.s38	false	DDI-DrugBank.d776.s38.e0	DDI-DrugBank.d776.s38.e5
DDI-DrugBank.d776.s38	false	DDI-DrugBank.d776.s38.e1	DDI-DrugBank.d776.s38.e2
DDI-DrugBank.d776.s38	false	DDI-DrugBank.d776.s38.e1	DDI-DrugBank.d776.s38.e3
DDI-DrugBank.d776.s38	false	DDI-DrugBank.d776.s38.e1	DDI-DrugBank.d776.s38.e4
DDI-DrugBank.d776.s38	false	DDI-DrugBank.d776.s38.e1	DDI-DrugBank.d776.s38.e5
DDI-DrugBank.d776.s38	false	DDI-DrugBank.d776.s38.e2	DDI-DrugBank.d776.s38.e3
DDI-DrugBank.d776.s39|a|however, in some patients there were decreases up to 47% and 33% of ethinyl estradiol and levonorgestrel levels. 
DDI-DrugBank.d776.s39	68	84	ethinyl estradiol	drug	DDI-DrugBank.d776.s39.e0
DDI-DrugBank.d776.s39	90	103	levonorgestrel	drug	DDI-DrugBank.d776.s39.e1
DDI-DrugBank.d776.s39	false	DDI-DrugBank.d776.s39.e0	DDI-DrugBank.d776.s39.e1
DDI-DrugBank.d776.s40|a|The data presently available indicate that the decreases in some individual ethinyl estradiol and levonorgestrel AUC values with fluconazole treatment are likely the result of random variation. 
DDI-DrugBank.d776.s40	76	92	ethinyl estradiol	drug	DDI-DrugBank.d776.s40.e0
DDI-DrugBank.d776.s40	98	111	levonorgestrel	drug	DDI-DrugBank.d776.s40.e1
DDI-DrugBank.d776.s40	129	139	fluconazole	drug	DDI-DrugBank.d776.s40.e2
DDI-DrugBank.d776.s40	false	DDI-DrugBank.d776.s40.e0	DDI-DrugBank.d776.s40.e1
DDI-DrugBank.d776.s40	false	DDI-DrugBank.d776.s40.e0	DDI-DrugBank.d776.s40.e2
DDI-DrugBank.d776.s40	false	DDI-DrugBank.d776.s40.e1	DDI-DrugBank.d776.s40.e2
DDI-DrugBank.d776.s41|a|While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. 
DDI-DrugBank.d776.s41	29	39	fluconazole	drug	DDI-DrugBank.d776.s41.e0
DDI-DrugBank.d776.s41	71	87	ethinyl estradiol	drug	DDI-DrugBank.d776.s41.e1
DDI-DrugBank.d776.s41	93	106	levonorgestrel	drug	DDI-DrugBank.d776.s41.e2
DDI-DrugBank.d776.s41	135	145	fluconazole	drug	DDI-DrugBank.d776.s41.e3
DDI-DrugBank.d776.s41	167	183	ethinyl estradiol	drug	DDI-DrugBank.d776.s41.e4
DDI-DrugBank.d776.s41	188	201	levonorgestrel	drug	DDI-DrugBank.d776.s41.e5
DDI-DrugBank.d776.s41	true	DDI-DrugBank.d776.s41.e0	DDI-DrugBank.d776.s41.e1
DDI-DrugBank.d776.s41	true	DDI-DrugBank.d776.s41.e0	DDI-DrugBank.d776.s41.e2
DDI-DrugBank.d776.s41	false	DDI-DrugBank.d776.s41.e0	DDI-DrugBank.d776.s41.e3
DDI-DrugBank.d776.s41	false	DDI-DrugBank.d776.s41.e0	DDI-DrugBank.d776.s41.e4
DDI-DrugBank.d776.s41	false	DDI-DrugBank.d776.s41.e0	DDI-DrugBank.d776.s41.e5
DDI-DrugBank.d776.s41	false	DDI-DrugBank.d776.s41.e1	DDI-DrugBank.d776.s41.e2
DDI-DrugBank.d776.s41	false	DDI-DrugBank.d776.s41.e1	DDI-DrugBank.d776.s41.e3
DDI-DrugBank.d776.s41	false	DDI-DrugBank.d776.s41.e1	DDI-DrugBank.d776.s41.e4
DDI-DrugBank.d776.s41	false	DDI-DrugBank.d776.s41.e1	DDI-DrugBank.d776.s41.e5
DDI-DrugBank.d776.s41	false	DDI-DrugBank.d776.s41.e2	DDI-DrugBank.d776.s41.e3
DDI-DrugBank.d776.s42|a|The clinical significance of these effects is presently unknown. 
DDI-DrugBank.d776.s43|a|Physicians should be aware that interaction studies with medications other than those listed in the <a href= "flucon_cp.htm#CP">CLINICAL PHARMACOLOGY section have not been conducted, but such interactions may occur.
DDI-DrugBank.d716.s0|a|You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 
DDI-DrugBank.d716.s0	16	23	mazindol	drug	DDI-DrugBank.d716.s0.e0
DDI-DrugBank.d716.s0	45	71	monoamine oxidase inhibitor	group	DDI-DrugBank.d716.s0.e1
DDI-DrugBank.d716.s0	74	77	MAOI	group	DDI-DrugBank.d716.s0.e2
DDI-DrugBank.d716.s0	88	100	isocarboxazid	drug	DDI-DrugBank.d716.s0.e3
DDI-DrugBank.d716.s0	103	109	Marplan	brand	DDI-DrugBank.d716.s0.e4
DDI-DrugBank.d716.s0	113	127	tranylcypromine	drug	DDI-DrugBank.d716.s0.e5
DDI-DrugBank.d716.s0	130	136	Parnate	brand	DDI-DrugBank.d716.s0.e6
DDI-DrugBank.d716.s0	143	152	phenelzine	drug	DDI-DrugBank.d716.s0.e7
DDI-DrugBank.d716.s0	155	160	Nardil	brand	DDI-DrugBank.d716.s0.e8
DDI-DrugBank.d716.s0	true	DDI-DrugBank.d716.s0.e0	DDI-DrugBank.d716.s0.e1
DDI-DrugBank.d716.s0	true	DDI-DrugBank.d716.s0.e0	DDI-DrugBank.d716.s0.e2
DDI-DrugBank.d716.s0	true	DDI-DrugBank.d716.s0.e0	DDI-DrugBank.d716.s0.e3
DDI-DrugBank.d716.s0	true	DDI-DrugBank.d716.s0.e0	DDI-DrugBank.d716.s0.e4
DDI-DrugBank.d716.s0	true	DDI-DrugBank.d716.s0.e0	DDI-DrugBank.d716.s0.e5
DDI-DrugBank.d716.s0	true	DDI-DrugBank.d716.s0.e0	DDI-DrugBank.d716.s0.e6
DDI-DrugBank.d716.s0	true	DDI-DrugBank.d716.s0.e0	DDI-DrugBank.d716.s0.e7
DDI-DrugBank.d716.s0	true	DDI-DrugBank.d716.s0.e0	DDI-DrugBank.d716.s0.e8
DDI-DrugBank.d716.s0	false	DDI-DrugBank.d716.s0.e1	DDI-DrugBank.d716.s0.e2
DDI-DrugBank.d716.s0	false	DDI-DrugBank.d716.s0.e1	DDI-DrugBank.d716.s0.e3
DDI-DrugBank.d716.s1|a|Changes in insulin and other diabetes drug therapies may be necessary during treatment with mazindol.
DDI-DrugBank.d716.s1	11	17	insulin	drug	DDI-DrugBank.d716.s1.e0
DDI-DrugBank.d716.s1	92	99	mazindol	drug	DDI-DrugBank.d716.s1.e1
DDI-DrugBank.d716.s1	true	DDI-DrugBank.d716.s1.e0	DDI-DrugBank.d716.s1.e1
DDI-DrugBank.d716.s2|a|Mazindol may reduce the effects of guanethidine (Ismelin). 
DDI-DrugBank.d716.s2	0	7	Mazindol	drug	DDI-DrugBank.d716.s2.e0
DDI-DrugBank.d716.s2	35	46	guanethidine	drug	DDI-DrugBank.d716.s2.e1
DDI-DrugBank.d716.s2	49	55	Ismelin	brand	DDI-DrugBank.d716.s2.e2
DDI-DrugBank.d716.s2	true	DDI-DrugBank.d716.s2.e0	DDI-DrugBank.d716.s2.e1
DDI-DrugBank.d716.s2	true	DDI-DrugBank.d716.s2.e0	DDI-DrugBank.d716.s2.e2
DDI-DrugBank.d716.s2	false	DDI-DrugBank.d716.s2.e1	DDI-DrugBank.d716.s2.e2
DDI-DrugBank.d716.s3|a|This could lead to an increase in blood pressure. 
DDI-DrugBank.d716.s4|a|Tell your doctor if you are taking guanethidine. 
DDI-DrugBank.d716.s4	35	46	guanethidine	drug	DDI-DrugBank.d716.s4.e0
DDI-DrugBank.d716.s5|a|Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 
DDI-DrugBank.d716.s5	68	91	tricyclic antidepressant	group	DDI-DrugBank.d716.s5.e0
DDI-DrugBank.d716.s5	101	113	amitriptyline	drug	DDI-DrugBank.d716.s5.e1
DDI-DrugBank.d716.s5	116	121	Elavil	brand	DDI-DrugBank.d716.s5.e2
DDI-DrugBank.d716.s5	125	133	amoxapine	drug	DDI-DrugBank.d716.s5.e3
DDI-DrugBank.d716.s5	136	142	Asendin	brand	DDI-DrugBank.d716.s5.e4
DDI-DrugBank.d716.s5	146	152	doxepin	drug	DDI-DrugBank.d716.s5.e5
DDI-DrugBank.d716.s5	155	162	Sinequan	brand	DDI-DrugBank.d716.s5.e6
DDI-DrugBank.d716.s5	166	178	nortriptyline	drug	DDI-DrugBank.d716.s5.e7
DDI-DrugBank.d716.s5	181	187	Pamelor	brand	DDI-DrugBank.d716.s5.e8
DDI-DrugBank.d716.s5	191	200	imipramine	drug	DDI-DrugBank.d716.s5.e9
DDI-DrugBank.d716.s5	false	DDI-DrugBank.d716.s5.e0	DDI-DrugBank.d716.s5.e1
DDI-DrugBank.d716.s5	false	DDI-DrugBank.d716.s5.e0	DDI-DrugBank.d716.s5.e2
DDI-DrugBank.d716.s5	false	DDI-DrugBank.d716.s5.e0	DDI-DrugBank.d716.s5.e3
DDI-DrugBank.d716.s5	false	DDI-DrugBank.d716.s5.e0	DDI-DrugBank.d716.s5.e4
DDI-DrugBank.d716.s5	false	DDI-DrugBank.d716.s5.e0	DDI-DrugBank.d716.s5.e5
DDI-DrugBank.d716.s5	false	DDI-DrugBank.d716.s5.e0	DDI-DrugBank.d716.s5.e6
DDI-DrugBank.d716.s5	false	DDI-DrugBank.d716.s5.e0	DDI-DrugBank.d716.s5.e7
DDI-DrugBank.d716.s5	false	DDI-DrugBank.d716.s5.e0	DDI-DrugBank.d716.s5.e8
DDI-DrugBank.d716.s5	false	DDI-DrugBank.d716.s5.e0	DDI-DrugBank.d716.s5.e9
DDI-DrugBank.d716.s5	false	DDI-DrugBank.d716.s5.e0	DDI-DrugBank.d716.s5.e10
DDI-DrugBank.d716.s6|a|These drugs may decrease the effects of mazindol.
DDI-DrugBank.d716.s6	40	47	mazindol	drug	DDI-DrugBank.d716.s6.e0
DDI-DrugBank.d679.s0|a|Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.
DDI-DrugBank.d679.s0	35	44	cimetidine	drug	DDI-DrugBank.d679.s0.e0
DDI-DrugBank.d679.s0	55	65	mebendazole	drug	DDI-DrugBank.d679.s0.e1
DDI-DrugBank.d679.s0	136	146	mebendazole	drug	DDI-DrugBank.d679.s0.e2
DDI-DrugBank.d679.s0	true	DDI-DrugBank.d679.s0.e0	DDI-DrugBank.d679.s0.e1
DDI-DrugBank.d679.s0	false	DDI-DrugBank.d679.s0.e0	DDI-DrugBank.d679.s0.e2
DDI-DrugBank.d679.s0	false	DDI-DrugBank.d679.s0.e1	DDI-DrugBank.d679.s0.e2
DDI-DrugBank.d579.s0|a|Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers.  
DDI-DrugBank.d579.s0	19	29	antibiotics	group	DDI-DrugBank.d579.s0.e0
DDI-DrugBank.d579.s0	35	46	sulfonamides	group	DDI-DrugBank.d579.s0.e1
DDI-DrugBank.d579.s0	85	101	ganglion blockers	group	DDI-DrugBank.d579.s0.e2
DDI-DrugBank.d579.s0	false	DDI-DrugBank.d579.s0.e0	DDI-DrugBank.d579.s0.e1
DDI-DrugBank.d579.s0	true	DDI-DrugBank.d579.s0.e0	DDI-DrugBank.d579.s0.e2
DDI-DrugBank.d579.s0	true	DDI-DrugBank.d579.s0.e1	DDI-DrugBank.d579.s0.e2
DDI-DrugBank.d579.s1|a|The action of Mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol.
DDI-DrugBank.d579.s1	14	25	Mecamylamine	drug	DDI-DrugBank.d579.s1.e0
DDI-DrugBank.d579.s1	67	88	antihypertensive drugs	group	DDI-DrugBank.d579.s1.e1
DDI-DrugBank.d579.s1	94	100	alcohol	drug	DDI-DrugBank.d579.s1.e2
DDI-DrugBank.d579.s1	true	DDI-DrugBank.d579.s1.e0	DDI-DrugBank.d579.s1.e1
DDI-DrugBank.d579.s1	true	DDI-DrugBank.d579.s1.e0	DDI-DrugBank.d579.s1.e2
DDI-DrugBank.d579.s1	false	DDI-DrugBank.d579.s1.e1	DDI-DrugBank.d579.s1.e2
DDI-DrugBank.d623.s0|a|No drug-drug interaction studies have been conducted with depo-subQ provera 104. 
DDI-DrugBank.d623.s0	58	78	depo-subQ provera 104	brand	DDI-DrugBank.d623.s0.e0
DDI-DrugBank.d623.s1|a|Aminoglutethimide administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of MPA. 
DDI-DrugBank.d623.s1	0	16	Aminoglutethimide	drug	DDI-DrugBank.d623.s1.e0
DDI-DrugBank.d623.s1	50	70	depo-subQ provera 104	brand	DDI-DrugBank.d623.s1.e1
DDI-DrugBank.d623.s1	127	129	MPA	drug	DDI-DrugBank.d623.s1.e2
DDI-DrugBank.d623.s1	true	DDI-DrugBank.d623.s1.e0	DDI-DrugBank.d623.s1.e1
DDI-DrugBank.d623.s1	false	DDI-DrugBank.d623.s1.e0	DDI-DrugBank.d623.s1.e2
DDI-DrugBank.d623.s1	false	DDI-DrugBank.d623.s1.e1	DDI-DrugBank.d623.s1.e2
DDI-DrugBank.d623.s2|a|Laboratory Tests The pathologist should be advised of progestin therapy when relevant specimens are submitted. 
DDI-DrugBank.d623.s3|a|The physician should be informed that certain endocrine and liver function tests, and blood components may be affected by progestin therapy: (a) Plasma and urinary steroid levels are decreased (e.g., progesterone, estradiol, pregnanediol, testosterone, cortisol). 
DDI-DrugBank.d623.s4|a|(b) Plasma and urinary gonadotropin levels are decreased (e.g., LH, FSH). 
DDI-DrugBank.d623.s5|a|(c) SHBG concentrations are decreased. 
DDI-DrugBank.d623.s6|a|(d) T3-uptake values may decrease. 
DDI-DrugBank.d623.s7|a|(e) There may be small changes in coagulation factors. 
DDI-DrugBank.d623.s8|a|(f) Sulfobromophthalein and other liver function test values may be increased slightly. 
DDI-DrugBank.d623.s9|a|(g) There may be small changes in lipid profiles.
DDI-DrugBank.d688.s0|a|Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or rifabutin to warrant dosage adjustment when megestrol acetate is administered with these drugs. 
DDI-DrugBank.d688.s0	104	113	zidovudine	drug	DDI-DrugBank.d688.s0.e0
DDI-DrugBank.d688.s0	118	126	rifabutin	drug	DDI-DrugBank.d688.s0.e1
DDI-DrugBank.d688.s0	162	178	megestrol acetate	drug	DDI-DrugBank.d688.s0.e2
DDI-DrugBank.d688.s0	false	DDI-DrugBank.d688.s0.e0	DDI-DrugBank.d688.s0.e1
DDI-DrugBank.d688.s0	false	DDI-DrugBank.d688.s0.e0	DDI-DrugBank.d688.s0.e2
DDI-DrugBank.d688.s0	false	DDI-DrugBank.d688.s0.e1	DDI-DrugBank.d688.s0.e2
DDI-DrugBank.d688.s1|a|A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir. 
DDI-DrugBank.d688.s1	62	78	megestrol acetate	drug	DDI-DrugBank.d688.s1.e0
DDI-DrugBank.d688.s1	84	92	indinavir	drug	DDI-DrugBank.d688.s1.e1
DDI-DrugBank.d688.s1	198	206	indinavir	drug	DDI-DrugBank.d688.s1.e2
DDI-DrugBank.d688.s1	true	DDI-DrugBank.d688.s1.e0	DDI-DrugBank.d688.s1.e1
DDI-DrugBank.d688.s1	false	DDI-DrugBank.d688.s1.e0	DDI-DrugBank.d688.s1.e2
DDI-DrugBank.d688.s1	false	DDI-DrugBank.d688.s1.e1	DDI-DrugBank.d688.s1.e2
DDI-DrugBank.d688.s2|a|Administration of a higher dose of indinavir should be considered when coadministering with megestrol acetate. 
DDI-DrugBank.d688.s2	35	43	indinavir	drug	DDI-DrugBank.d688.s2.e0
DDI-DrugBank.d688.s2	92	108	megestrol acetate	drug	DDI-DrugBank.d688.s2.e1
DDI-DrugBank.d688.s2	true	DDI-DrugBank.d688.s2.e0	DDI-DrugBank.d688.s2.e1
DDI-DrugBank.d688.s3|a|The effects of indinavir, zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.
DDI-DrugBank.d688.s3	15	23	indinavir	drug	DDI-DrugBank.d688.s3.e0
DDI-DrugBank.d688.s3	26	35	zidovudine	drug	DDI-DrugBank.d688.s3.e1
DDI-DrugBank.d688.s3	40	48	rifabutin	drug	DDI-DrugBank.d688.s3.e2
DDI-DrugBank.d688.s3	77	93	megestrol acetate	drug	DDI-DrugBank.d688.s3.e3
DDI-DrugBank.d688.s3	false	DDI-DrugBank.d688.s3.e0	DDI-DrugBank.d688.s3.e1
DDI-DrugBank.d688.s3	false	DDI-DrugBank.d688.s3.e0	DDI-DrugBank.d688.s3.e2
DDI-DrugBank.d688.s3	false	DDI-DrugBank.d688.s3.e0	DDI-DrugBank.d688.s3.e3
DDI-DrugBank.d688.s3	false	DDI-DrugBank.d688.s3.e1	DDI-DrugBank.d688.s3.e2
DDI-DrugBank.d688.s3	false	DDI-DrugBank.d688.s3.e1	DDI-DrugBank.d688.s3.e3
DDI-DrugBank.d688.s3	false	DDI-DrugBank.d688.s3.e2	DDI-DrugBank.d688.s3.e3
DDI-DrugBank.d643.s0|a|Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
DDI-DrugBank.d643.s0	0	8	Melatonin	drug	DDI-DrugBank.d643.s0.e0
DDI-DrugBank.d643.s0	49	55	aspirin	brand	DDI-DrugBank.d643.s0.e1
DDI-DrugBank.d643.s0	67	72	NSAIDs	group	DDI-DrugBank.d643.s0.e2
DDI-DrugBank.d643.s0	85	93	melatonin	drug	DDI-DrugBank.d643.s0.e3
DDI-DrugBank.d643.s0	104	114	fluvoxamine	drug	DDI-DrugBank.d643.s0.e4
DDI-DrugBank.d643.s0	141	149	melatonin	drug	DDI-DrugBank.d643.s0.e5
DDI-DrugBank.d643.s0	188	200	beta blockers	group	DDI-DrugBank.d643.s0.e6
DDI-DrugBank.d643.s0	216	224	melatonin	drug	DDI-DrugBank.d643.s0.e7
DDI-DrugBank.d643.s0	235	244	fluoxetine	drug	DDI-DrugBank.d643.s0.e8
DDI-DrugBank.d643.s0	299	307	progestin	group	DDI-DrugBank.d643.s0.e9
DDI-DrugBank.d643.s0	true	DDI-DrugBank.d643.s0.e0	DDI-DrugBank.d643.s0.e1
DDI-DrugBank.d643.s0	true	DDI-DrugBank.d643.s0.e0	DDI-DrugBank.d643.s0.e2
DDI-DrugBank.d643.s0	false	DDI-DrugBank.d643.s0.e0	DDI-DrugBank.d643.s0.e3
DDI-DrugBank.d643.s0	true	DDI-DrugBank.d643.s0.e0	DDI-DrugBank.d643.s0.e4
DDI-DrugBank.d643.s0	false	DDI-DrugBank.d643.s0.e0	DDI-DrugBank.d643.s0.e5
DDI-DrugBank.d643.s0	true	DDI-DrugBank.d643.s0.e0	DDI-DrugBank.d643.s0.e6
DDI-DrugBank.d643.s0	false	DDI-DrugBank.d643.s0.e0	DDI-DrugBank.d643.s0.e7
DDI-DrugBank.d643.s0	true	DDI-DrugBank.d643.s0.e0	DDI-DrugBank.d643.s0.e8
DDI-DrugBank.d643.s0	true	DDI-DrugBank.d643.s0.e0	DDI-DrugBank.d643.s0.e9
DDI-DrugBank.d643.s0	false	DDI-DrugBank.d643.s0.e0	DDI-DrugBank.d643.s0.e10
DDI-DrugBank.d597.s0|a|ACE inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibitors. 
DDI-DrugBank.d597.s0	0	13	ACE inhibitors	group	DDI-DrugBank.d597.s0.e0
DDI-DrugBank.d597.s0	36	41	NSAIDs	group	DDI-DrugBank.d597.s0.e1
DDI-DrugBank.d597.s0	87	132	angiotensin-converting enzyme (ACE) inhibitors	group	DDI-DrugBank.d597.s0.e2
DDI-DrugBank.d597.s0	false	DDI-DrugBank.d597.s0.e0	DDI-DrugBank.d597.s0.e1
DDI-DrugBank.d597.s0	false	DDI-DrugBank.d597.s0.e0	DDI-DrugBank.d597.s0.e2
DDI-DrugBank.d597.s0	true	DDI-DrugBank.d597.s0.e1	DDI-DrugBank.d597.s0.e2
DDI-DrugBank.d597.s1|a|This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. 
DDI-DrugBank.d597.s1	66	71	NSAIDs	group	DDI-DrugBank.d597.s1.e0
DDI-DrugBank.d597.s1	92	105	ACE inhibitors	group	DDI-DrugBank.d597.s1.e1
DDI-DrugBank.d597.s1	true	DDI-DrugBank.d597.s1.e0	DDI-DrugBank.d597.s1.e1
DDI-DrugBank.d597.s2|a|Aspirin: Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of meloxicam. 
DDI-DrugBank.d597.s2	0	6	Aspirin	brand	DDI-DrugBank.d597.s2.e0
DDI-DrugBank.d597.s2	39	45	aspirin	brand	DDI-DrugBank.d597.s2.e1
DDI-DrugBank.d597.s2	134	142	meloxicam	drug	DDI-DrugBank.d597.s2.e2
DDI-DrugBank.d597.s2	false	DDI-DrugBank.d597.s2.e0	DDI-DrugBank.d597.s2.e1
DDI-DrugBank.d597.s2	false	DDI-DrugBank.d597.s2.e0	DDI-DrugBank.d597.s2.e2
DDI-DrugBank.d597.s2	true	DDI-DrugBank.d597.s2.e1	DDI-DrugBank.d597.s2.e2
DDI-DrugBank.d597.s3|a|The clinical significance of this interaction is not known; 
DDI-DrugBank.d597.s4|a|however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects. 
DDI-DrugBank.d597.s4	23	28	NSAIDs	group	DDI-DrugBank.d597.s4.e0
DDI-DrugBank.d597.s4	61	69	meloxicam	drug	DDI-DrugBank.d597.s4.e1
DDI-DrugBank.d597.s4	75	81	aspirin	brand	DDI-DrugBank.d597.s4.e2
DDI-DrugBank.d597.s4	false	DDI-DrugBank.d597.s4.e0	DDI-DrugBank.d597.s4.e1
DDI-DrugBank.d597.s4	true	DDI-DrugBank.d597.s4.e0	DDI-DrugBank.d597.s4.e2
DDI-DrugBank.d597.s4	true	DDI-DrugBank.d597.s4.e1	DDI-DrugBank.d597.s4.e2
DDI-DrugBank.d597.s5|a|Concomitant administration of low-dose aspirin with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone. 
DDI-DrugBank.d597.s5	39	45	aspirin	brand	DDI-DrugBank.d597.s5.e0
DDI-DrugBank.d597.s5	52	56	MOBIC	brand	DDI-DrugBank.d597.s5.e1
DDI-DrugBank.d597.s5	150	154	MOBIC	brand	DDI-DrugBank.d597.s5.e2
DDI-DrugBank.d597.s5	true	DDI-DrugBank.d597.s5.e0	DDI-DrugBank.d597.s5.e1
DDI-DrugBank.d597.s5	false	DDI-DrugBank.d597.s5.e0	DDI-DrugBank.d597.s5.e2
DDI-DrugBank.d597.s5	false	DDI-DrugBank.d597.s5.e1	DDI-DrugBank.d597.s5.e2
DDI-DrugBank.d597.s6|a|MOBIC is not a substitute for aspirin for cardiovascular prophylaxis. 
DDI-DrugBank.d597.s6	0	4	MOBIC	brand	DDI-DrugBank.d597.s6.e0
DDI-DrugBank.d597.s6	30	36	aspirin	brand	DDI-DrugBank.d597.s6.e1
DDI-DrugBank.d597.s6	false	DDI-DrugBank.d597.s6.e0	DDI-DrugBank.d597.s6.e1
DDI-DrugBank.d597.s7|a|Cholestyramine: Pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50%. 
DDI-DrugBank.d597.s7	0	13	Cholestyramine	drug	DDI-DrugBank.d597.s7.e0
DDI-DrugBank.d597.s7	48	61	cholestyramine	drug	DDI-DrugBank.d597.s7.e1
DDI-DrugBank.d597.s7	104	112	meloxicam	drug	DDI-DrugBank.d597.s7.e2
DDI-DrugBank.d597.s7	false	DDI-DrugBank.d597.s7.e0	DDI-DrugBank.d597.s7.e1
DDI-DrugBank.d597.s7	false	DDI-DrugBank.d597.s7.e0	DDI-DrugBank.d597.s7.e2
DDI-DrugBank.d597.s7	true	DDI-DrugBank.d597.s7.e1	DDI-DrugBank.d597.s7.e2
DDI-DrugBank.d597.s8|a|This resulted in a decrease in t1/2, from 19.2 hours to 12.5 hours, and a 35% reduction in AUC. 
DDI-DrugBank.d597.s9|a|This suggests the existence of a recirculation pathway for meloxicam in the gastrointestinal tract. 
DDI-DrugBank.d597.s9	59	67	meloxicam	drug	DDI-DrugBank.d597.s9.e0
DDI-DrugBank.d597.s10|a|The clinical relevance of this interaction has not been established. 
DDI-DrugBank.d597.s11|a|Cimetidine: Concomitant administration of 200 mg cimetidine QID did not alter the single-dose pharmacokinetics of 30 mg meloxicam. 
DDI-DrugBank.d597.s11	0	9	Cimetidine	drug	DDI-DrugBank.d597.s11.e0
DDI-DrugBank.d597.s11	49	58	cimetidine	drug	DDI-DrugBank.d597.s11.e1
DDI-DrugBank.d597.s11	120	128	meloxicam	drug	DDI-DrugBank.d597.s11.e2
DDI-DrugBank.d597.s11	false	DDI-DrugBank.d597.s11.e0	DDI-DrugBank.d597.s11.e1
DDI-DrugBank.d597.s11	false	DDI-DrugBank.d597.s11.e0	DDI-DrugBank.d597.s11.e2
DDI-DrugBank.d597.s11	false	DDI-DrugBank.d597.s11.e1	DDI-DrugBank.d597.s11.e2
DDI-DrugBank.d597.s12|a|Digoxin: Meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after b-acetyldigoxin administration for 7 days at clinical doses. 
DDI-DrugBank.d597.s12	0	6	Digoxin	drug	DDI-DrugBank.d597.s12.e0
DDI-DrugBank.d597.s12	9	17	Meloxicam	drug	DDI-DrugBank.d597.s12.e1
DDI-DrugBank.d597.s12	97	103	digoxin	drug	DDI-DrugBank.d597.s12.e2
DDI-DrugBank.d597.s12	false	DDI-DrugBank.d597.s12.e0	DDI-DrugBank.d597.s12.e1
DDI-DrugBank.d597.s12	false	DDI-DrugBank.d597.s12.e0	DDI-DrugBank.d597.s12.e2
DDI-DrugBank.d597.s12	false	DDI-DrugBank.d597.s12.e1	DDI-DrugBank.d597.s12.e2
DDI-DrugBank.d597.s13|a|In vitro testing found no protein binding drug interaction between digoxin and meloxicam. 
DDI-DrugBank.d597.s13	67	73	digoxin	drug	DDI-DrugBank.d597.s13.e0
DDI-DrugBank.d597.s13	79	87	meloxicam	drug	DDI-DrugBank.d597.s13.e1
DDI-DrugBank.d597.s13	false	DDI-DrugBank.d597.s13.e0	DDI-DrugBank.d597.s13.e1
DDI-DrugBank.d597.s14|a|Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. 
DDI-DrugBank.d597.s14	0	9	Furosemide	drug	DDI-DrugBank.d597.s14.e0
DDI-DrugBank.d597.s14	86	91	NSAIDs	group	DDI-DrugBank.d597.s14.e1
DDI-DrugBank.d597.s14	130	139	furosemide	drug	DDI-DrugBank.d597.s14.e2
DDI-DrugBank.d597.s14	145	162	thiazide diuretics	group	DDI-DrugBank.d597.s14.e3
DDI-DrugBank.d597.s14	false	DDI-DrugBank.d597.s14.e0	DDI-DrugBank.d597.s14.e1
DDI-DrugBank.d597.s14	false	DDI-DrugBank.d597.s14.e0	DDI-DrugBank.d597.s14.e2
DDI-DrugBank.d597.s14	false	DDI-DrugBank.d597.s14.e0	DDI-DrugBank.d597.s14.e3
DDI-DrugBank.d597.s14	true	DDI-DrugBank.d597.s14.e1	DDI-DrugBank.d597.s14.e2
DDI-DrugBank.d597.s14	true	DDI-DrugBank.d597.s14.e1	DDI-DrugBank.d597.s14.e3
DDI-DrugBank.d597.s14	false	DDI-DrugBank.d597.s14.e2	DDI-DrugBank.d597.s14.e3
DDI-DrugBank.d597.s15|a|This effect has been attributed to inhibition of renal prostaglandin synthesis. 
DDI-DrugBank.d597.s16|a|Studies with furosemide agents and meloxicam have not demonstrated a reduction in natriuretic effect. 
DDI-DrugBank.d597.s16	13	22	furosemide	drug	DDI-DrugBank.d597.s16.e0
DDI-DrugBank.d597.s16	35	43	meloxicam	drug	DDI-DrugBank.d597.s16.e1
DDI-DrugBank.d597.s16	false	DDI-DrugBank.d597.s16.e0	DDI-DrugBank.d597.s16.e1
DDI-DrugBank.d597.s17|a|Furosemide: single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of meloxicam. 
DDI-DrugBank.d597.s17	0	9	Furosemide	drug	DDI-DrugBank.d597.s17.e0
DDI-DrugBank.d597.s17	113	121	meloxicam	drug	DDI-DrugBank.d597.s17.e1
DDI-DrugBank.d597.s17	false	DDI-DrugBank.d597.s17.e0	DDI-DrugBank.d597.s17.e1
DDI-DrugBank.d597.s18|a|Nevertheless, during concomitant therapy with furosemide and MOBIC, patients should be observed closely for signs of declining renal function, as well as to assure diuretic efficacy. 
DDI-DrugBank.d597.s18	46	55	furosemide	drug	DDI-DrugBank.d597.s18.e0
DDI-DrugBank.d597.s18	61	65	MOBIC	brand	DDI-DrugBank.d597.s18.e1
DDI-DrugBank.d597.s18	true	DDI-DrugBank.d597.s18.e0	DDI-DrugBank.d597.s18.e1
DDI-DrugBank.d597.s19|a|Lithium: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. 
DDI-DrugBank.d597.s19	0	6	Lithium	drug	DDI-DrugBank.d597.s19.e0
DDI-DrugBank.d597.s19	29	34	NSAIDs	group	DDI-DrugBank.d597.s19.e1
DDI-DrugBank.d597.s19	73	79	lithium	drug	DDI-DrugBank.d597.s19.e2
DDI-DrugBank.d597.s19	113	119	lithium	drug	DDI-DrugBank.d597.s19.e3
DDI-DrugBank.d597.s19	false	DDI-DrugBank.d597.s19.e0	DDI-DrugBank.d597.s19.e1
DDI-DrugBank.d597.s19	false	DDI-DrugBank.d597.s19.e0	DDI-DrugBank.d597.s19.e2
DDI-DrugBank.d597.s19	false	DDI-DrugBank.d597.s19.e0	DDI-DrugBank.d597.s19.e3
DDI-DrugBank.d597.s19	true	DDI-DrugBank.d597.s19.e1	DDI-DrugBank.d597.s19.e2
DDI-DrugBank.d597.s19	false	DDI-DrugBank.d597.s19.e1	DDI-DrugBank.d597.s19.e3
DDI-DrugBank.d597.s19	false	DDI-DrugBank.d597.s19.e2	DDI-DrugBank.d597.s19.e3
DDI-DrugBank.d597.s20|a|In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. 
DDI-DrugBank.d597.s20	56	62	lithium	drug	DDI-DrugBank.d597.s20.e0
DDI-DrugBank.d597.s20	130	136	lithium	drug	DDI-DrugBank.d597.s20.e1
DDI-DrugBank.d597.s20	181	189	meloxicam	drug	DDI-DrugBank.d597.s20.e2
DDI-DrugBank.d597.s20	234	240	lithium	drug	DDI-DrugBank.d597.s20.e3
DDI-DrugBank.d597.s20	false	DDI-DrugBank.d597.s20.e0	DDI-DrugBank.d597.s20.e1
DDI-DrugBank.d597.s20	false	DDI-DrugBank.d597.s20.e0	DDI-DrugBank.d597.s20.e2
DDI-DrugBank.d597.s20	false	DDI-DrugBank.d597.s20.e0	DDI-DrugBank.d597.s20.e3
DDI-DrugBank.d597.s20	true	DDI-DrugBank.d597.s20.e1	DDI-DrugBank.d597.s20.e2
DDI-DrugBank.d597.s20	false	DDI-DrugBank.d597.s20.e1	DDI-DrugBank.d597.s20.e3
DDI-DrugBank.d597.s20	false	DDI-DrugBank.d597.s20.e2	DDI-DrugBank.d597.s20.e3
DDI-DrugBank.d597.s21|a|These effects have been attributed to inhibition of renal prostaglandin synthesis by MOBIC. 
DDI-DrugBank.d597.s21	85	89	MOBIC	brand	DDI-DrugBank.d597.s21.e0
DDI-DrugBank.d597.s22|a|Patients on lithium treatment should be closely monitored when MOBIC is introduced or withdrawn. 
DDI-DrugBank.d597.s22	12	18	lithium	drug	DDI-DrugBank.d597.s22.e0
DDI-DrugBank.d597.s22	63	67	MOBIC	brand	DDI-DrugBank.d597.s22.e1
DDI-DrugBank.d597.s22	true	DDI-DrugBank.d597.s22.e0	DDI-DrugBank.d597.s22.e1
DDI-DrugBank.d597.s23|a|Methotrexate: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of methotrexate taken once weekly. 
DDI-DrugBank.d597.s23	0	11	Methotrexate	drug	DDI-DrugBank.d597.s23.e0
DDI-DrugBank.d597.s23	106	114	meloxicam	drug	DDI-DrugBank.d597.s23.e1
DDI-DrugBank.d597.s23	143	154	methotrexate	drug	DDI-DrugBank.d597.s23.e2
DDI-DrugBank.d597.s23	false	DDI-DrugBank.d597.s23.e0	DDI-DrugBank.d597.s23.e1
DDI-DrugBank.d597.s23	false	DDI-DrugBank.d597.s23.e0	DDI-DrugBank.d597.s23.e2
DDI-DrugBank.d597.s23	false	DDI-DrugBank.d597.s23.e1	DDI-DrugBank.d597.s23.e2
DDI-DrugBank.d597.s24|a|Meloxicam did not have a significant effect on the pharmacokinetics of single doses of methotrexate. 
DDI-DrugBank.d597.s24	0	8	Meloxicam	drug	DDI-DrugBank.d597.s24.e0
DDI-DrugBank.d597.s24	87	98	methotrexate	drug	DDI-DrugBank.d597.s24.e1
DDI-DrugBank.d597.s24	false	DDI-DrugBank.d597.s24.e0	DDI-DrugBank.d597.s24.e1
DDI-DrugBank.d597.s25|a|In vitro, methotrexate did not displace meloxicam from its human serum binding sites. 
DDI-DrugBank.d597.s25	10	21	methotrexate	drug	DDI-DrugBank.d597.s25.e0
DDI-DrugBank.d597.s25	40	48	meloxicam	drug	DDI-DrugBank.d597.s25.e1
DDI-DrugBank.d597.s25	false	DDI-DrugBank.d597.s25.e0	DDI-DrugBank.d597.s25.e1
DDI-DrugBank.d597.s26|a|Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing MOBIC therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding. 
DDI-DrugBank.d597.s26	0	7	Warfarin	drug	DDI-DrugBank.d597.s26.e0
DDI-DrugBank.d597.s26	118	122	MOBIC	brand	DDI-DrugBank.d597.s26.e1
DDI-DrugBank.d597.s26	154	161	warfarin	drug	DDI-DrugBank.d597.s26.e2
DDI-DrugBank.d597.s26	false	DDI-DrugBank.d597.s26.e0	DDI-DrugBank.d597.s26.e1
DDI-DrugBank.d597.s26	false	DDI-DrugBank.d597.s26.e0	DDI-DrugBank.d597.s26.e2
DDI-DrugBank.d597.s26	true	DDI-DrugBank.d597.s26.e1	DDI-DrugBank.d597.s26.e2
DDI-DrugBank.d597.s27|a|The effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR (International Normalized Ratio) between 1.2 and 1.8. 
DDI-DrugBank.d597.s27	14	22	meloxicam	drug	DDI-DrugBank.d597.s27.e0
DDI-DrugBank.d597.s27	55	62	warfarin	drug	DDI-DrugBank.d597.s27.e1
DDI-DrugBank.d597.s27	132	139	warfarin	drug	DDI-DrugBank.d597.s27.e2
DDI-DrugBank.d597.s27	false	DDI-DrugBank.d597.s27.e0	DDI-DrugBank.d597.s27.e1
DDI-DrugBank.d597.s27	false	DDI-DrugBank.d597.s27.e0	DDI-DrugBank.d597.s27.e2
DDI-DrugBank.d597.s27	false	DDI-DrugBank.d597.s27.e1	DDI-DrugBank.d597.s27.e2
DDI-DrugBank.d597.s28|a|In these subjects, meloxicam did not alter warfarin pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time. 
DDI-DrugBank.d597.s28	19	27	meloxicam	drug	DDI-DrugBank.d597.s28.e0
DDI-DrugBank.d597.s28	43	50	warfarin	drug	DDI-DrugBank.d597.s28.e1
DDI-DrugBank.d597.s28	109	116	warfarin	drug	DDI-DrugBank.d597.s28.e2
DDI-DrugBank.d597.s28	false	DDI-DrugBank.d597.s28.e0	DDI-DrugBank.d597.s28.e1
DDI-DrugBank.d597.s28	false	DDI-DrugBank.d597.s28.e0	DDI-DrugBank.d597.s28.e2
DDI-DrugBank.d597.s28	false	DDI-DrugBank.d597.s28.e1	DDI-DrugBank.d597.s28.e2
DDI-DrugBank.d597.s29|a|However, one subject showed an increase in INR from 1.5 to 2.1. 
DDI-DrugBank.d597.s30|a|Caution should be used when administering MOBIC with warfarin since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.
DDI-DrugBank.d597.s30	42	46	MOBIC	brand	DDI-DrugBank.d597.s30.e0
DDI-DrugBank.d597.s30	53	60	warfarin	drug	DDI-DrugBank.d597.s30.e1
DDI-DrugBank.d597.s30	80	87	warfarin	drug	DDI-DrugBank.d597.s30.e2
DDI-DrugBank.d597.s30	true	DDI-DrugBank.d597.s30.e0	DDI-DrugBank.d597.s30.e1
DDI-DrugBank.d597.s30	false	DDI-DrugBank.d597.s30.e0	DDI-DrugBank.d597.s30.e2
DDI-DrugBank.d597.s30	false	DDI-DrugBank.d597.s30.e1	DDI-DrugBank.d597.s30.e2
DDI-DrugBank.d625.s0|a|DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  
DDI-DrugBank.d625.s0	71	77	ALKERAN	brand	DDI-DrugBank.d625.s0.e0
DDI-DrugBank.d625.s0	98	119	live organism vaccines	group	DDI-DrugBank.d625.s0.e1
DDI-DrugBank.d625.s0	175	188	Nalidixic acid	drug	DDI-DrugBank.d625.s0.e2
DDI-DrugBank.d625.s0	226	234	melphalan	drug	DDI-DrugBank.d625.s0.e3
DDI-DrugBank.d625.s0	false	DDI-DrugBank.d625.s0.e0	DDI-DrugBank.d625.s0.e1
DDI-DrugBank.d625.s0	false	DDI-DrugBank.d625.s0.e0	DDI-DrugBank.d625.s0.e2
DDI-DrugBank.d625.s0	false	DDI-DrugBank.d625.s0.e0	DDI-DrugBank.d625.s0.e3
DDI-DrugBank.d625.s0	false	DDI-DrugBank.d625.s0.e1	DDI-DrugBank.d625.s0.e2
DDI-DrugBank.d625.s0	false	DDI-DrugBank.d625.s0.e1	DDI-DrugBank.d625.s0.e3
DDI-DrugBank.d625.s0	true	DDI-DrugBank.d625.s0.e2	DDI-DrugBank.d625.s0.e3
DDI-DrugBank.d625.s1|a|Impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous melphalan and who subsequently received cyclosporin to prevent graft-versus-host disease
DDI-DrugBank.d625.s1	126	134	melphalan	drug	DDI-DrugBank.d625.s1.e0
DDI-DrugBank.d625.s1	166	176	cyclosporin	drug	DDI-DrugBank.d625.s1.e1
DDI-DrugBank.d625.s1	true	DDI-DrugBank.d625.s1.e0	DDI-DrugBank.d625.s1.e1
DDI-DrugBank.d585.s0|a|The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
DDI-DrugBank.d585.s0	69	89	anticholinergic drugs	group	DDI-DrugBank.d585.s0.e0
DDI-DrugBank.d585.s0	92	101	amantadine	drug	DDI-DrugBank.d585.s0.e1
DDI-DrugBank.d585.s0	104	135	antiarrhythmic agents of class I	group	DDI-DrugBank.d585.s0.e2
DDI-DrugBank.d585.s0	144	152	quinidine	drug	DDI-DrugBank.d585.s0.e3
DDI-DrugBank.d585.s0	156	169	antihistamines	group	DDI-DrugBank.d585.s0.e4
DDI-DrugBank.d585.s0	172	191	antipsychotic agents	group	DDI-DrugBank.d585.s0.e5
DDI-DrugBank.d585.s0	200	213	phenothiazines	group	DDI-DrugBank.d585.s0.e6
DDI-DrugBank.d585.s0	217	231	benzodiazepines	group	DDI-DrugBank.d585.s0.e7
DDI-DrugBank.d585.s0	234	247	MAO inhibitors	group	DDI-DrugBank.d585.s0.e8
DDI-DrugBank.d585.s0	250	268	narcotic analgesics	group	DDI-DrugBank.d585.s0.e9
DDI-DrugBank.d585.s0	true	DDI-DrugBank.d585.s0.e0	DDI-DrugBank.d585.s0.e1
DDI-DrugBank.d585.s0	true	DDI-DrugBank.d585.s0.e0	DDI-DrugBank.d585.s0.e2
DDI-DrugBank.d585.s0	true	DDI-DrugBank.d585.s0.e0	DDI-DrugBank.d585.s0.e3
DDI-DrugBank.d585.s0	true	DDI-DrugBank.d585.s0.e0	DDI-DrugBank.d585.s0.e4
DDI-DrugBank.d585.s0	true	DDI-DrugBank.d585.s0.e0	DDI-DrugBank.d585.s0.e5
DDI-DrugBank.d585.s0	true	DDI-DrugBank.d585.s0.e0	DDI-DrugBank.d585.s0.e6
DDI-DrugBank.d585.s0	true	DDI-DrugBank.d585.s0.e0	DDI-DrugBank.d585.s0.e7
DDI-DrugBank.d585.s0	true	DDI-DrugBank.d585.s0.e0	DDI-DrugBank.d585.s0.e8
DDI-DrugBank.d585.s0	true	DDI-DrugBank.d585.s0.e0	DDI-DrugBank.d585.s0.e9
DDI-DrugBank.d585.s0	true	DDI-DrugBank.d585.s0.e0	DDI-DrugBank.d585.s0.e10
DDI-DrugBank.d585.s1|a|Anticholinergics antagonize the effects of antiglaucoma agents. 
DDI-DrugBank.d585.s1	0	15	Anticholinergics	group	DDI-DrugBank.d585.s1.e0
DDI-DrugBank.d585.s1	43	61	antiglaucoma agents	group	DDI-DrugBank.d585.s1.e1
DDI-DrugBank.d585.s1	true	DDI-DrugBank.d585.s1.e0	DDI-DrugBank.d585.s1.e1
DDI-DrugBank.d585.s2|a|Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids. 
DDI-DrugBank.d585.s2	0	20	Anticholinergic drugs	group	DDI-DrugBank.d585.s2.e0
DDI-DrugBank.d585.s2	133	147	corticosteroids	group	DDI-DrugBank.d585.s2.e1
DDI-DrugBank.d585.s2	true	DDI-DrugBank.d585.s2.e0	DDI-DrugBank.d585.s2.e1
DDI-DrugBank.d585.s3|a|Anticholinergic agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin; 
DDI-DrugBank.d585.s3	0	21	Anticholinergic agents	group	DDI-DrugBank.d585.s3.e0
DDI-DrugBank.d585.s3	122	128	digoxin	drug	DDI-DrugBank.d585.s3.e1
DDI-DrugBank.d585.s3	true	DDI-DrugBank.d585.s3.e0	DDI-DrugBank.d585.s3.e1
DDI-DrugBank.d585.s4|a|increased serum digoxin concentrations may result. 
DDI-DrugBank.d585.s4	16	22	digoxin	drug	DDI-DrugBank.d585.s4.e0
DDI-DrugBank.d585.s5|a|Anticholinergic drugs may antagonize the effects of drugs that alter gastrointestinal motility, such as metoclopramide. 
DDI-DrugBank.d585.s5	0	20	Anticholinergic drugs	group	DDI-DrugBank.d585.s5.e0
DDI-DrugBank.d585.s5	104	117	metoclopramide	drug	DDI-DrugBank.d585.s5.e1
DDI-DrugBank.d585.s5	true	DDI-DrugBank.d585.s5.e0	DDI-DrugBank.d585.s5.e1
DDI-DrugBank.d585.s6|a|Because antacids may interfere with the absorption of anticholinergic agents, simultaneous use of these drugs should be avoided. 
DDI-DrugBank.d585.s6	8	15	antacids	group	DDI-DrugBank.d585.s6.e0
DDI-DrugBank.d585.s6	54	75	anticholinergic agents	group	DDI-DrugBank.d585.s6.e1
DDI-DrugBank.d585.s6	true	DDI-DrugBank.d585.s6.e0	DDI-DrugBank.d585.s6.e1
DDI-DrugBank.d585.s7|a|The inhibiting effects of anticholinergic drugs on gastric hydrochloric acid secretion are antagonized by agents used to treat achlorhydria and those used to test gastric secretion.
DDI-DrugBank.d585.s7	26	46	anticholinergic drugs	group	DDI-DrugBank.d585.s7.e0
DDI-DrugBank.d703.s0|a|Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 
DDI-DrugBank.d703.s0	23	56	Central Nervous System Depressants	group	DDI-DrugBank.d703.s0.e0
DDI-DrugBank.d703.s0	59	68	MEPERIDINE	drug	DDI-DrugBank.d703.s0.e1
DDI-DrugBank.d703.s0	175	193	NARCOTIC ANALGESICS	group	DDI-DrugBank.d703.s0.e2
DDI-DrugBank.d703.s0	204	214	ANESTHETICS	group	DDI-DrugBank.d703.s0.e3
DDI-DrugBank.d703.s0	217	230	PHENOTHIAZINES	group	DDI-DrugBank.d703.s0.e4
DDI-DrugBank.d703.s0	239	251	TRANQUILIZERS	group	DDI-DrugBank.d703.s0.e5
DDI-DrugBank.d703.s0	254	271	SEDATIVE-HYPNOTICS	group	DDI-DrugBank.d703.s0.e6
DDI-DrugBank.d703.s0	284	295	BARBITURATES	group	DDI-DrugBank.d703.s0.e7
DDI-DrugBank.d703.s0	299	323	TRICYCLIC ANTIDEPRESSANTS	group	DDI-DrugBank.d703.s0.e8
DDI-DrugBank.d703.s0	335	349	CNS DEPRESSANTS	group	DDI-DrugBank.d703.s0.e9
DDI-DrugBank.d703.s0	false	DDI-DrugBank.d703.s0.e0	DDI-DrugBank.d703.s0.e1
DDI-DrugBank.d703.s0	false	DDI-DrugBank.d703.s0.e0	DDI-DrugBank.d703.s0.e2
DDI-DrugBank.d703.s0	false	DDI-DrugBank.d703.s0.e0	DDI-DrugBank.d703.s0.e3
DDI-DrugBank.d703.s0	false	DDI-DrugBank.d703.s0.e0	DDI-DrugBank.d703.s0.e4
DDI-DrugBank.d703.s0	false	DDI-DrugBank.d703.s0.e0	DDI-DrugBank.d703.s0.e5
DDI-DrugBank.d703.s0	false	DDI-DrugBank.d703.s0.e0	DDI-DrugBank.d703.s0.e6
DDI-DrugBank.d703.s0	false	DDI-DrugBank.d703.s0.e0	DDI-DrugBank.d703.s0.e7
DDI-DrugBank.d703.s0	false	DDI-DrugBank.d703.s0.e0	DDI-DrugBank.d703.s0.e8
DDI-DrugBank.d703.s0	false	DDI-DrugBank.d703.s0.e0	DDI-DrugBank.d703.s0.e9
DDI-DrugBank.d703.s0	false	DDI-DrugBank.d703.s0.e0	DDI-DrugBank.d703.s0.e10
DDI-DrugBank.d703.s1|a|RESPIRATORY DEPRESSION, HYPOTENSION, AND PROFOUND SEDATION OR COMA MAY RESULT.
DDI-DrugBank.d636.s0|a|Some anticonvulsants may interact with Mephenytoin. 
DDI-DrugBank.d636.s0	5	19	anticonvulsants	group	DDI-DrugBank.d636.s0.e0
DDI-DrugBank.d636.s0	39	49	Mephenytoin	drug	DDI-DrugBank.d636.s0.e1
DDI-DrugBank.d636.s0	true	DDI-DrugBank.d636.s0.e0	DDI-DrugBank.d636.s0.e1
DDI-DrugBank.d636.s1|a|They can either increase or decrease the effect of Mephenytoin. 
DDI-DrugBank.d636.s1	51	61	Mephenytoin	drug	DDI-DrugBank.d636.s1.e0
DDI-DrugBank.d636.s2|a|Those anticonvulsants include divalproex sodium, valproic acid, and phenobarbital. 
DDI-DrugBank.d636.s2	6	20	anticonvulsants	group	DDI-DrugBank.d636.s2.e0
DDI-DrugBank.d636.s2	30	46	divalproex sodium	drug	DDI-DrugBank.d636.s2.e1
DDI-DrugBank.d636.s2	49	61	valproic acid	drug	DDI-DrugBank.d636.s2.e2
DDI-DrugBank.d636.s2	68	80	phenobarbital	drug	DDI-DrugBank.d636.s2.e3
DDI-DrugBank.d636.s2	false	DDI-DrugBank.d636.s2.e0	DDI-DrugBank.d636.s2.e1
DDI-DrugBank.d636.s2	false	DDI-DrugBank.d636.s2.e0	DDI-DrugBank.d636.s2.e2
DDI-DrugBank.d636.s2	false	DDI-DrugBank.d636.s2.e0	DDI-DrugBank.d636.s2.e3
DDI-DrugBank.d636.s2	false	DDI-DrugBank.d636.s2.e1	DDI-DrugBank.d636.s2.e2
DDI-DrugBank.d636.s2	false	DDI-DrugBank.d636.s2.e1	DDI-DrugBank.d636.s2.e3
DDI-DrugBank.d636.s2	false	DDI-DrugBank.d636.s2.e2	DDI-DrugBank.d636.s2.e3
DDI-DrugBank.d636.s3|a|Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
DDI-DrugBank.d636.s3	0	10	Mephenytoin	drug	DDI-DrugBank.d636.s3.e0
DDI-DrugBank.d636.s3	75	93	steroid medications	group	DDI-DrugBank.d636.s3.e1
DDI-DrugBank.d636.s3	96	103	warfarin	drug	DDI-DrugBank.d636.s3.e2
DDI-DrugBank.d636.s3	152	175	anti-infective medicines	group	DDI-DrugBank.d636.s3.e3
DDI-DrugBank.d636.s3	178	187	furosemide	drug	DDI-DrugBank.d636.s3.e4
DDI-DrugBank.d636.s3	193	204	theophylline	drug	DDI-DrugBank.d636.s3.e5
DDI-DrugBank.d636.s3	223	233	Mephenytoin	drug	DDI-DrugBank.d636.s3.e6
DDI-DrugBank.d636.s3	true	DDI-DrugBank.d636.s3.e0	DDI-DrugBank.d636.s3.e1
DDI-DrugBank.d636.s3	true	DDI-DrugBank.d636.s3.e0	DDI-DrugBank.d636.s3.e2
DDI-DrugBank.d636.s3	true	DDI-DrugBank.d636.s3.e0	DDI-DrugBank.d636.s3.e3
DDI-DrugBank.d636.s3	true	DDI-DrugBank.d636.s3.e0	DDI-DrugBank.d636.s3.e4
DDI-DrugBank.d636.s3	true	DDI-DrugBank.d636.s3.e0	DDI-DrugBank.d636.s3.e5
DDI-DrugBank.d636.s3	false	DDI-DrugBank.d636.s3.e0	DDI-DrugBank.d636.s3.e6
DDI-DrugBank.d636.s3	false	DDI-DrugBank.d636.s3.e1	DDI-DrugBank.d636.s3.e2
DDI-DrugBank.d636.s3	false	DDI-DrugBank.d636.s3.e1	DDI-DrugBank.d636.s3.e3
DDI-DrugBank.d636.s3	false	DDI-DrugBank.d636.s3.e1	DDI-DrugBank.d636.s3.e4
DDI-DrugBank.d636.s3	false	DDI-DrugBank.d636.s3.e1	DDI-DrugBank.d636.s3.e5
DDI-DrugBank.d699.s0|a|Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.
DDI-DrugBank.d699.s0	0	10	Mequitazine	drug	DDI-DrugBank.d699.s0.e0
DDI-DrugBank.d699.s0	30	43	CNS depressant	group	DDI-DrugBank.d699.s0.e1
DDI-DrugBank.d699.s0	46	61	antichlolinergic	group	DDI-DrugBank.d699.s0.e2
DDI-DrugBank.d699.s0	64	66	TCA	group	DDI-DrugBank.d699.s0.e3
DDI-DrugBank.d699.s0	69	73	MAOIs	group	DDI-DrugBank.d699.s0.e4
DDI-DrugBank.d699.s0	80	86	alcohol	drug	DDI-DrugBank.d699.s0.e5
DDI-DrugBank.d699.s0	true	DDI-DrugBank.d699.s0.e0	DDI-DrugBank.d699.s0.e1
DDI-DrugBank.d699.s0	true	DDI-DrugBank.d699.s0.e0	DDI-DrugBank.d699.s0.e2
DDI-DrugBank.d699.s0	true	DDI-DrugBank.d699.s0.e0	DDI-DrugBank.d699.s0.e3
DDI-DrugBank.d699.s0	true	DDI-DrugBank.d699.s0.e0	DDI-DrugBank.d699.s0.e4
DDI-DrugBank.d699.s0	true	DDI-DrugBank.d699.s0.e0	DDI-DrugBank.d699.s0.e5
DDI-DrugBank.d699.s0	false	DDI-DrugBank.d699.s0.e1	DDI-DrugBank.d699.s0.e2
DDI-DrugBank.d699.s0	false	DDI-DrugBank.d699.s0.e1	DDI-DrugBank.d699.s0.e3
DDI-DrugBank.d699.s0	false	DDI-DrugBank.d699.s0.e1	DDI-DrugBank.d699.s0.e4
DDI-DrugBank.d699.s0	false	DDI-DrugBank.d699.s0.e1	DDI-DrugBank.d699.s0.e5
DDI-DrugBank.d699.s0	false	DDI-DrugBank.d699.s0.e2	DDI-DrugBank.d699.s0.e3
DDI-DrugBank.d762.s0|a|Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem. 
DDI-DrugBank.d762.s0	0	9	Probenecid	drug	DDI-DrugBank.d762.s0.e0
DDI-DrugBank.d762.s0	25	33	meropenem	drug	DDI-DrugBank.d762.s0.e1
DDI-DrugBank.d762.s0	105	113	meropenem	drug	DDI-DrugBank.d762.s0.e2
DDI-DrugBank.d762.s0	true	DDI-DrugBank.d762.s0.e0	DDI-DrugBank.d762.s0.e1
DDI-DrugBank.d762.s0	false	DDI-DrugBank.d762.s0.e0	DDI-DrugBank.d762.s0.e2
DDI-DrugBank.d762.s0	false	DDI-DrugBank.d762.s0.e1	DDI-DrugBank.d762.s0.e2
DDI-DrugBank.d762.s1|a|This led to statistically significant increases in the elimination half-life (38%) and in the extent of systemic exposure (56%). 
DDI-DrugBank.d762.s2|a|Therefore, the coadministration of probenecid with meropenem is not recommended. 
DDI-DrugBank.d762.s2	35	44	probenecid	drug	DDI-DrugBank.d762.s2.e0
DDI-DrugBank.d762.s2	51	59	meropenem	drug	DDI-DrugBank.d762.s2.e1
DDI-DrugBank.d762.s2	true	DDI-DrugBank.d762.s2.e0	DDI-DrugBank.d762.s2.e1
DDI-DrugBank.d762.s3|a|There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).
DDI-DrugBank.d762.s3	23	31	meropenem	drug	DDI-DrugBank.d762.s3.e0
DDI-DrugBank.d762.s3	60	72	valproic acid	drug	DDI-DrugBank.d762.s3.e1
DDI-DrugBank.d762.s3	159	167	valproate	drug	DDI-DrugBank.d762.s3.e2
DDI-DrugBank.d762.s3	true	DDI-DrugBank.d762.s3.e0	DDI-DrugBank.d762.s3.e1
DDI-DrugBank.d762.s3	false	DDI-DrugBank.d762.s3.e0	DDI-DrugBank.d762.s3.e2
DDI-DrugBank.d762.s3	false	DDI-DrugBank.d762.s3.e1	DDI-DrugBank.d762.s3.e2
DDI-DrugBank.d746.s0|a|ARAMINE should be used with caution in digitalized patients, since the combination of digitalis and sympathomimetic amines may cause ectopic arrhythmias. 
DDI-DrugBank.d746.s0	0	6	ARAMINE	brand	DDI-DrugBank.d746.s0.e0
DDI-DrugBank.d746.s0	86	94	digitalis	group	DDI-DrugBank.d746.s0.e1
DDI-DrugBank.d746.s0	100	121	sympathomimetic amines	group	DDI-DrugBank.d746.s0.e2
DDI-DrugBank.d746.s0	false	DDI-DrugBank.d746.s0.e0	DDI-DrugBank.d746.s0.e1
DDI-DrugBank.d746.s0	false	DDI-DrugBank.d746.s0.e0	DDI-DrugBank.d746.s0.e2
DDI-DrugBank.d746.s0	true	DDI-DrugBank.d746.s0.e1	DDI-DrugBank.d746.s0.e2
DDI-DrugBank.d746.s1|a|Monoamine oxidase inhibitors or tricyclic antidepressants may potentiate the action of sympathomimetic amines. 
DDI-DrugBank.d746.s1	0	27	Monoamine oxidase inhibitors	group	DDI-DrugBank.d746.s1.e0
DDI-DrugBank.d746.s1	32	56	tricyclic antidepressants	group	DDI-DrugBank.d746.s1.e1
DDI-DrugBank.d746.s1	87	108	sympathomimetic amines	group	DDI-DrugBank.d746.s1.e2
DDI-DrugBank.d746.s1	false	DDI-DrugBank.d746.s1.e0	DDI-DrugBank.d746.s1.e1
DDI-DrugBank.d746.s1	true	DDI-DrugBank.d746.s1.e0	DDI-DrugBank.d746.s1.e2
DDI-DrugBank.d746.s1	true	DDI-DrugBank.d746.s1.e1	DDI-DrugBank.d746.s1.e2
DDI-DrugBank.d746.s2|a|Therefore, when initiating pressor therapy in patients receiving these drugs, the initial dose should be small and given with caution.
DDI-DrugBank.d605.s0|a|SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.
DDI-DrugBank.d605.s0	0	7	SKELAXIN	brand	DDI-DrugBank.d605.s0.e0
DDI-DrugBank.d605.s0	36	42	alcohol	drug	DDI-DrugBank.d605.s0.e1
DDI-DrugBank.d605.s0	45	56	barbiturates	group	DDI-DrugBank.d605.s0.e2
DDI-DrugBank.d605.s0	68	82	CNS depressants	group	DDI-DrugBank.d605.s0.e3
DDI-DrugBank.d605.s0	true	DDI-DrugBank.d605.s0.e0	DDI-DrugBank.d605.s0.e1
DDI-DrugBank.d605.s0	true	DDI-DrugBank.d605.s0.e0	DDI-DrugBank.d605.s0.e2
DDI-DrugBank.d605.s0	true	DDI-DrugBank.d605.s0.e0	DDI-DrugBank.d605.s0.e3
DDI-DrugBank.d605.s0	false	DDI-DrugBank.d605.s0.e1	DDI-DrugBank.d605.s0.e2
DDI-DrugBank.d605.s0	false	DDI-DrugBank.d605.s0.e1	DDI-DrugBank.d605.s0.e3
DDI-DrugBank.d605.s0	false	DDI-DrugBank.d605.s0.e2	DDI-DrugBank.d605.s0.e3
DDI-DrugBank.d630.s0|a|Methazolamide should be used with caution in patients on steroid therapy because of the potential for developing hypokalemia. 
DDI-DrugBank.d630.s0	0	12	Methazolamide	drug	DDI-DrugBank.d630.s0.e0
DDI-DrugBank.d630.s1|a|Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.
DDI-DrugBank.d630.s1	52	58	aspirin	brand	DDI-DrugBank.d630.s1.e0
DDI-DrugBank.d630.s1	64	76	methazolamide	drug	DDI-DrugBank.d630.s1.e1
DDI-DrugBank.d630.s1	195	201	aspirin	brand	DDI-DrugBank.d630.s1.e2
DDI-DrugBank.d630.s1	207	235	carbonic anhydrase inhibitors	group	DDI-DrugBank.d630.s1.e3
DDI-DrugBank.d630.s1	true	DDI-DrugBank.d630.s1.e0	DDI-DrugBank.d630.s1.e1
DDI-DrugBank.d630.s1	false	DDI-DrugBank.d630.s1.e0	DDI-DrugBank.d630.s1.e2
DDI-DrugBank.d630.s1	false	DDI-DrugBank.d630.s1.e0	DDI-DrugBank.d630.s1.e3
DDI-DrugBank.d630.s1	false	DDI-DrugBank.d630.s1.e1	DDI-DrugBank.d630.s1.e2
DDI-DrugBank.d630.s1	false	DDI-DrugBank.d630.s1.e1	DDI-DrugBank.d630.s1.e3
DDI-DrugBank.d630.s1	true	DDI-DrugBank.d630.s1.e2	DDI-DrugBank.d630.s1.e3
DDI-DrugBank.d634.s0|a|Anticoagulants (oral): The activity of oral anticoagulants may be potentiated by anti-vitamin-K activity attributed to methimazole.    
DDI-DrugBank.d634.s0	0	13	Anticoagulants	group	DDI-DrugBank.d634.s0.e0
DDI-DrugBank.d634.s0	44	57	anticoagulants	group	DDI-DrugBank.d634.s0.e1
DDI-DrugBank.d634.s0	119	129	methimazole	drug	DDI-DrugBank.d634.s0.e2
DDI-DrugBank.d634.s0	false	DDI-DrugBank.d634.s0.e0	DDI-DrugBank.d634.s0.e1
DDI-DrugBank.d634.s0	false	DDI-DrugBank.d634.s0.e0	DDI-DrugBank.d634.s0.e2
DDI-DrugBank.d634.s0	true	DDI-DrugBank.d634.s0.e1	DDI-DrugBank.d634.s0.e2
DDI-DrugBank.d634.s1|a|-adrenergic blocking agents: Hyperthyroidism may cause an increased clearance of beta ratio. 
DDI-DrugBank.d634.s1	1	26	adrenergic blocking agents	group	DDI-DrugBank.d634.s1.e0
DDI-DrugBank.d634.s2|a|A dose reduction of beta-adrenergic blockers may be needed when a hyperthyroid patient becomes euthyroid. 
DDI-DrugBank.d634.s2	20	43	beta-adrenergic blockers	group	DDI-DrugBank.d634.s2.e0
DDI-DrugBank.d634.s3|a|Digitalis glycosides: Serum digitalis levels may be increased when hyperthyroid patients on a stable digitalis glycoside regimen become euthyroid; 
DDI-DrugBank.d634.s3	0	19	Digitalis glycosides	group	DDI-DrugBank.d634.s3.e0
DDI-DrugBank.d634.s3	101	119	digitalis glycoside	group	DDI-DrugBank.d634.s3.e1
DDI-DrugBank.d634.s3	false	DDI-DrugBank.d634.s3.e0	DDI-DrugBank.d634.s3.e1
DDI-DrugBank.d634.s4|a|reduced dosage of digitalis glycosides may be required. 
DDI-DrugBank.d634.s4	18	37	digitalis glycosides	group	DDI-DrugBank.d634.s4.e0
DDI-DrugBank.d634.s5|a|Theophylline: Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; 
DDI-DrugBank.d634.s5	0	11	Theophylline	drug	DDI-DrugBank.d634.s5.e0
DDI-DrugBank.d634.s5	14	25	Theophylline	drug	DDI-DrugBank.d634.s5.e1
DDI-DrugBank.d634.s5	89	100	theophylline	drug	DDI-DrugBank.d634.s5.e2
DDI-DrugBank.d634.s5	false	DDI-DrugBank.d634.s5.e0	DDI-DrugBank.d634.s5.e1
DDI-DrugBank.d634.s5	false	DDI-DrugBank.d634.s5.e0	DDI-DrugBank.d634.s5.e2
DDI-DrugBank.d634.s5	false	DDI-DrugBank.d634.s5.e1	DDI-DrugBank.d634.s5.e2
DDI-DrugBank.d634.s6|a|a reduced dose of theophylline may be needed.    
DDI-DrugBank.d634.s6	18	29	theophylline	drug	DDI-DrugBank.d634.s6.e0
DDI-DrugBank.d756.s0|a|Dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids. 
DDI-DrugBank.d756.s0	38	44	opioids	group	DDI-DrugBank.d756.s0.e0
DDI-DrugBank.d756.s0	95	109	levomepromazine	drug	DDI-DrugBank.d756.s0.e1
DDI-DrugBank.d756.s0	165	171	opioids	group	DDI-DrugBank.d756.s0.e2
DDI-DrugBank.d756.s0	true	DDI-DrugBank.d756.s0.e0	DDI-DrugBank.d756.s0.e1
DDI-DrugBank.d756.s0	false	DDI-DrugBank.d756.s0.e0	DDI-DrugBank.d756.s0.e2
DDI-DrugBank.d756.s0	true	DDI-DrugBank.d756.s0.e1	DDI-DrugBank.d756.s0.e2
DDI-DrugBank.d756.s1|a|Combination with tramadol (Ultram) is associated with increased risk of seizures. 
DDI-DrugBank.d756.s1	17	24	tramadol	drug	DDI-DrugBank.d756.s1.e0
DDI-DrugBank.d756.s1	27	32	Ultram	brand	DDI-DrugBank.d756.s1.e1
DDI-DrugBank.d756.s1	false	DDI-DrugBank.d756.s1.e0	DDI-DrugBank.d756.s1.e1
DDI-DrugBank.d756.s2|a|Additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates. 
DDI-DrugBank.d756.s2	63	77	levomepromazine	drug	DDI-DrugBank.d756.s2.e0
DDI-DrugBank.d756.s2	93	107	benzodiazepines	group	DDI-DrugBank.d756.s2.e1
DDI-DrugBank.d756.s2	112	123	barbiturates	group	DDI-DrugBank.d756.s2.e2
DDI-DrugBank.d756.s2	true	DDI-DrugBank.d756.s2.e0	DDI-DrugBank.d756.s2.e1
DDI-DrugBank.d756.s2	true	DDI-DrugBank.d756.s2.e0	DDI-DrugBank.d756.s2.e2
DDI-DrugBank.d756.s2	false	DDI-DrugBank.d756.s2.e1	DDI-DrugBank.d756.s2.e2
DDI-DrugBank.d756.s3|a|This may be avoided by using the lowest dose possible with the substances in question. 
DDI-DrugBank.d756.s4|a|Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. 
DDI-DrugBank.d756.s4	38	52	levomepromazine	drug	DDI-DrugBank.d756.s4.e0
DDI-DrugBank.d756.s4	65	85	anticholinergic drugs	group	DDI-DrugBank.d756.s4.e1
DDI-DrugBank.d756.s4	88	112	tricyclic antidepressants	group	DDI-DrugBank.d756.s4.e2
DDI-DrugBank.d756.s4	118	140	antiparkinsonian-agents	group	DDI-DrugBank.d756.s4.e3
DDI-DrugBank.d756.s4	true	DDI-DrugBank.d756.s4.e0	DDI-DrugBank.d756.s4.e1
DDI-DrugBank.d756.s4	true	DDI-DrugBank.d756.s4.e0	DDI-DrugBank.d756.s4.e2
DDI-DrugBank.d756.s4	true	DDI-DrugBank.d756.s4.e0	DDI-DrugBank.d756.s4.e3
DDI-DrugBank.d756.s4	false	DDI-DrugBank.d756.s4.e1	DDI-DrugBank.d756.s4.e2
DDI-DrugBank.d756.s4	false	DDI-DrugBank.d756.s4.e1	DDI-DrugBank.d756.s4.e3
DDI-DrugBank.d756.s4	false	DDI-DrugBank.d756.s4.e2	DDI-DrugBank.d756.s4.e3
DDI-DrugBank.d756.s5|a|Reduce both the dose of levomepromazine and the dose of the other drug. 
DDI-DrugBank.d756.s5	24	38	levomepromazine	drug	DDI-DrugBank.d756.s5.e0
DDI-DrugBank.d756.s6|a|If possible, avoid such combinations. 
DDI-DrugBank.d756.s7|a|Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. 
DDI-DrugBank.d756.s7	0	7	Caffeine	drug	DDI-DrugBank.d756.s7.e0
DDI-DrugBank.d756.s7	35	43	ephedrine	drug	DDI-DrugBank.d756.s7.e1
DDI-DrugBank.d756.s7	45	55	amphetamine	drug	DDI-DrugBank.d756.s7.e2
DDI-DrugBank.d756.s7	101	115	levomepromazine	drug	DDI-DrugBank.d756.s7.e3
DDI-DrugBank.d756.s7	false	DDI-DrugBank.d756.s7.e0	DDI-DrugBank.d756.s7.e1
DDI-DrugBank.d756.s7	false	DDI-DrugBank.d756.s7.e0	DDI-DrugBank.d756.s7.e2
DDI-DrugBank.d756.s7	true	DDI-DrugBank.d756.s7.e0	DDI-DrugBank.d756.s7.e3
DDI-DrugBank.d756.s7	false	DDI-DrugBank.d756.s7.e1	DDI-DrugBank.d756.s7.e2
DDI-DrugBank.d756.s7	true	DDI-DrugBank.d756.s7.e1	DDI-DrugBank.d756.s7.e3
DDI-DrugBank.d756.s7	true	DDI-DrugBank.d756.s7.e2	DDI-DrugBank.d756.s7.e3
DDI-DrugBank.d756.s8|a|Concomitant use of these substances should be avoided. 
DDI-DrugBank.d756.s9|a|Coffee and black tea should be avoided because they decrease the absorption of levomepromazine considerably. 
DDI-DrugBank.d756.s9	79	93	levomepromazine	drug	DDI-DrugBank.d756.s9.e0
DDI-DrugBank.d756.s10|a|The same is true for antacids; 
DDI-DrugBank.d756.s10	21	28	antacids	group	DDI-DrugBank.d756.s10.e0
DDI-DrugBank.d756.s11|a|these should be given 1 to 2 hours before or after oral administration of leveomepromazine.
DDI-DrugBank.d756.s11	74	89	leveomepromazine	drug	DDI-DrugBank.d756.s11.e0
DDI-DrugBank.d587.s0|a|Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).
DDI-DrugBank.d587.s0	6	13	Celontin	brand	DDI-DrugBank.d587.s0.e0
DDI-DrugBank.d587.s0	16	27	methsuximide	drug	DDI-DrugBank.d587.s0.e1
DDI-DrugBank.d587.s0	74	92	antiepileptic drugs	group	DDI-DrugBank.d587.s0.e2
DDI-DrugBank.d587.s0	167	178	methsuximide	drug	DDI-DrugBank.d587.s0.e3
DDI-DrugBank.d587.s0	222	230	phenytoin	drug	DDI-DrugBank.d587.s0.e4
DDI-DrugBank.d587.s0	236	248	phenobarbital	drug	DDI-DrugBank.d587.s0.e5
DDI-DrugBank.d587.s0	false	DDI-DrugBank.d587.s0.e0	DDI-DrugBank.d587.s0.e1
DDI-DrugBank.d587.s0	true	DDI-DrugBank.d587.s0.e0	DDI-DrugBank.d587.s0.e2
DDI-DrugBank.d587.s0	false	DDI-DrugBank.d587.s0.e0	DDI-DrugBank.d587.s0.e3
DDI-DrugBank.d587.s0	false	DDI-DrugBank.d587.s0.e0	DDI-DrugBank.d587.s0.e4
DDI-DrugBank.d587.s0	false	DDI-DrugBank.d587.s0.e0	DDI-DrugBank.d587.s0.e5
DDI-DrugBank.d587.s0	true	DDI-DrugBank.d587.s0.e1	DDI-DrugBank.d587.s0.e2
DDI-DrugBank.d587.s0	false	DDI-DrugBank.d587.s0.e1	DDI-DrugBank.d587.s0.e3
DDI-DrugBank.d587.s0	false	DDI-DrugBank.d587.s0.e1	DDI-DrugBank.d587.s0.e4
DDI-DrugBank.d587.s0	false	DDI-DrugBank.d587.s0.e1	DDI-DrugBank.d587.s0.e5
DDI-DrugBank.d587.s0	false	DDI-DrugBank.d587.s0.e2	DDI-DrugBank.d587.s0.e3
DDI-DrugBank.d736.s0|a|Hypokalemia can sensitize or exaggerate the response of the heart to the toxic effects of digitalis (e.g., increased ventricular irritability). 
DDI-DrugBank.d736.s0	90	98	digitalis	group	DDI-DrugBank.d736.s0.e0
DDI-DrugBank.d736.s1|a|Hypokalemia may develop during concomitant use of steroids or ACTH. 
DDI-DrugBank.d736.s1	50	57	steroids	group	DDI-DrugBank.d736.s1.e0
DDI-DrugBank.d736.s1	62	65	ACTH	drug	DDI-DrugBank.d736.s1.e1
DDI-DrugBank.d736.s1	false	DDI-DrugBank.d736.s1.e0	DDI-DrugBank.d736.s1.e1
DDI-DrugBank.d736.s2|a|Insulin requirements in diabetic patients may be increased, decreased, or unchanged. 
DDI-DrugBank.d736.s2	0	6	Insulin	drug	DDI-DrugBank.d736.s2.e0
DDI-DrugBank.d736.s3|a|Thiazides may decrease arterial responsiveness to norepinephrine. 
DDI-DrugBank.d736.s3	0	8	Thiazides	group	DDI-DrugBank.d736.s3.e0
DDI-DrugBank.d736.s3	50	63	norepinephrine	drug	DDI-DrugBank.d736.s3.e1
DDI-DrugBank.d736.s3	true	DDI-DrugBank.d736.s3.e0	DDI-DrugBank.d736.s3.e1
DDI-DrugBank.d736.s4|a|This diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. 
DDI-DrugBank.d736.s5|a|Thiazide drugs may increase the responsiveness of tubocurarine. 
DDI-DrugBank.d736.s5	0	13	Thiazide drugs	group	DDI-DrugBank.d736.s5.e0
DDI-DrugBank.d736.s5	50	61	tubocurarine	drug	DDI-DrugBank.d736.s5.e1
DDI-DrugBank.d736.s5	true	DDI-DrugBank.d736.s5.e0	DDI-DrugBank.d736.s5.e1
DDI-DrugBank.d736.s6|a|Lithium renal clearance is reduced by thiazides, increasing the risk of lithium toxicity. 
DDI-DrugBank.d736.s6	0	6	Lithium	drug	DDI-DrugBank.d736.s6.e0
DDI-DrugBank.d736.s6	38	46	thiazides	group	DDI-DrugBank.d736.s6.e1
DDI-DrugBank.d736.s6	72	78	lithium	drug	DDI-DrugBank.d736.s6.e2
DDI-DrugBank.d736.s6	true	DDI-DrugBank.d736.s6.e0	DDI-DrugBank.d736.s6.e1
DDI-DrugBank.d736.s6	false	DDI-DrugBank.d736.s6.e0	DDI-DrugBank.d736.s6.e2
DDI-DrugBank.d736.s6	false	DDI-DrugBank.d736.s6.e1	DDI-DrugBank.d736.s6.e2
DDI-DrugBank.d736.s7|a|Thiazides may add to or potentiate the action of other antihypertensive drugs. 
DDI-DrugBank.d736.s7	0	8	Thiazides	group	DDI-DrugBank.d736.s7.e0
DDI-DrugBank.d736.s7	55	76	antihypertensive drugs	group	DDI-DrugBank.d736.s7.e1
DDI-DrugBank.d736.s7	true	DDI-DrugBank.d736.s7.e0	DDI-DrugBank.d736.s7.e1
DDI-DrugBank.d736.s8|a|Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs.
DDI-DrugBank.d736.s8	25	34	ganglionic adrenergic blocking drugs	group	DDI-DrugBank.d736.s8.e0
DDI-DrugBank.d736.s8	50	74	ganglionic adrenergic blocking drugs	group	DDI-DrugBank.d736.s8.e0
DDI-DrugBank.d736.s8	39	74	peripheral adrenergic blocking drugs	group	DDI-DrugBank.d736.s8.e1
DDI-DrugBank.d736.s8	false	DDI-DrugBank.d736.s8.e0	DDI-DrugBank.d736.s8.e1
DDI-DrugBank.d779.s0|a|When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. 
DDI-DrugBank.d779.s0	5	14	methyldopa	drug	DDI-DrugBank.d779.s0.e0
DDI-DrugBank.d779.s0	35	56	antihypertensive drugs	group	DDI-DrugBank.d779.s0.e1
DDI-DrugBank.d779.s0	true	DDI-DrugBank.d779.s0.e0	DDI-DrugBank.d779.s0.e1
DDI-DrugBank.d779.s1|a|Patients should be followed carefully to detect side reactions or unusual manifestations of drug idiosyncrasy. 
DDI-DrugBank.d779.s2|a|Patients may require reduced doses of anesthetics when on methyldopa. 
DDI-DrugBank.d779.s2	38	48	anesthetics	group	DDI-DrugBank.d779.s2.e0
DDI-DrugBank.d779.s2	58	67	methyldopa	drug	DDI-DrugBank.d779.s2.e1
DDI-DrugBank.d779.s2	true	DDI-DrugBank.d779.s2.e0	DDI-DrugBank.d779.s2.e1
DDI-DrugBank.d779.s3|a|If hypotension does occur during anesthesia, it usually can be controlled by vasopressors. 
DDI-DrugBank.d779.s3	77	88	vasopressors	group	DDI-DrugBank.d779.s3.e0
DDI-DrugBank.d779.s4|a|The adrenergic receptors remain sensitive during treatment with methyldopa. 
DDI-DrugBank.d779.s4	64	73	methyldopa	drug	DDI-DrugBank.d779.s4.e0
DDI-DrugBank.d779.s5|a|When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity. 
DDI-DrugBank.d779.s5	5	14	methyldopa	drug	DDI-DrugBank.d779.s5.e0
DDI-DrugBank.d779.s5	20	26	lithium	drug	DDI-DrugBank.d779.s5.e1
DDI-DrugBank.d779.s5	110	116	lithium	drug	DDI-DrugBank.d779.s5.e2
DDI-DrugBank.d779.s5	true	DDI-DrugBank.d779.s5.e0	DDI-DrugBank.d779.s5.e1
DDI-DrugBank.d779.s5	false	DDI-DrugBank.d779.s5.e0	DDI-DrugBank.d779.s5.e2
DDI-DrugBank.d779.s5	false	DDI-DrugBank.d779.s5.e1	DDI-DrugBank.d779.s5.e2
DDI-DrugBank.d779.s6|a|Read the circular for lithium preparations. 
DDI-DrugBank.d779.s6	22	28	lithium	drug	DDI-DrugBank.d779.s6.e0
DDI-DrugBank.d779.s7|a|Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate. 
DDI-DrugBank.d779.s7	65	74	methyldopa	drug	DDI-DrugBank.d779.s7.e0
DDI-DrugBank.d779.s7	101	115	ferrous sulfate	drug	DDI-DrugBank.d779.s7.e1
DDI-DrugBank.d779.s7	120	136	ferrous gluconate	drug	DDI-DrugBank.d779.s7.e2
DDI-DrugBank.d779.s7	true	DDI-DrugBank.d779.s7.e0	DDI-DrugBank.d779.s7.e1
DDI-DrugBank.d779.s7	true	DDI-DrugBank.d779.s7.e0	DDI-DrugBank.d779.s7.e2
DDI-DrugBank.d779.s7	false	DDI-DrugBank.d779.s7.e1	DDI-DrugBank.d779.s7.e2
DDI-DrugBank.d779.s8|a|This may adversely affect blood pressure control in patients treated with methyldopa. 
DDI-DrugBank.d779.s8	74	83	methyldopa	drug	DDI-DrugBank.d779.s8.e0
DDI-DrugBank.d779.s9|a|Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended. 
DDI-DrugBank.d779.s9	20	29	methyldopa	drug	DDI-DrugBank.d779.s9.e0
DDI-DrugBank.d779.s9	36	50	ferrous sulfate	drug	DDI-DrugBank.d779.s9.e1
DDI-DrugBank.d779.s9	55	71	ferrous gluconate	drug	DDI-DrugBank.d779.s9.e2
DDI-DrugBank.d779.s9	true	DDI-DrugBank.d779.s9.e0	DDI-DrugBank.d779.s9.e1
DDI-DrugBank.d779.s9	true	DDI-DrugBank.d779.s9.e0	DDI-DrugBank.d779.s9.e2
DDI-DrugBank.d779.s9	false	DDI-DrugBank.d779.s9.e1	DDI-DrugBank.d779.s9.e2
DDI-DrugBank.d779.s10|a|Monoamine oxidase (MAO) inhibitors: See CONTRAINDICATIONS. 
DDI-DrugBank.d779.s10	0	33	Monoamine oxidase (MAO) inhibitors	group	DDI-DrugBank.d779.s10.e0
DDI-DrugBank.d779.s11|a|Drug/Laboratory Test Interactions Methyldopa may interfere with measurement of: urinary uric acid by the phosphotungstate method, serum creatinine by the alkaline picrate method, and SGOT by colorimetric methods. 
DDI-DrugBank.d779.s11	34	43	Methyldopa	drug	DDI-DrugBank.d779.s11.e0
DDI-DrugBank.d779.s12|a|Interference with spectrophotometric methods for SGOT analysis has not been reported. 
DDI-DrugBank.d779.s13|a|Since methyldopa causes fluorescence in urine samples at the same wave lengths as catecholamines, falsely high levels of urinary catecholamines may be reported. 
DDI-DrugBank.d779.s13	6	15	methyldopa	drug	DDI-DrugBank.d779.s13.e0
DDI-DrugBank.d779.s14|a|This will interfere with the diagnosis of pheochromocytoma. 
DDI-DrugBank.d779.s15|a|It is important to recognize this phenomenon before a patient with a possible pheochromocytoma is subjected to surgery. 
DDI-DrugBank.d779.s16|a|Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. 
DDI-DrugBank.d779.s16	0	9	Methyldopa	drug	DDI-DrugBank.d779.s16.e0
DDI-DrugBank.d779.s16	50	52	VMA	drug_n	DDI-DrugBank.d779.s16.e1
DDI-DrugBank.d779.s16	55	75	vanillylmandelic acid	drug_n	DDI-DrugBank.d779.s16.e2
DDI-DrugBank.d779.s16	139	141	VMA	drug_n	DDI-DrugBank.d779.s16.e3
DDI-DrugBank.d779.s16	146	153	vanillin	drug_n	DDI-DrugBank.d779.s16.e4
DDI-DrugBank.d779.s16	false	DDI-DrugBank.d779.s16.e0	DDI-DrugBank.d779.s16.e1
DDI-DrugBank.d779.s16	false	DDI-DrugBank.d779.s16.e0	DDI-DrugBank.d779.s16.e2
DDI-DrugBank.d779.s16	false	DDI-DrugBank.d779.s16.e0	DDI-DrugBank.d779.s16.e3
DDI-DrugBank.d779.s16	false	DDI-DrugBank.d779.s16.e0	DDI-DrugBank.d779.s16.e4
DDI-DrugBank.d779.s16	false	DDI-DrugBank.d779.s16.e1	DDI-DrugBank.d779.s16.e2
DDI-DrugBank.d779.s16	false	DDI-DrugBank.d779.s16.e1	DDI-DrugBank.d779.s16.e3
DDI-DrugBank.d779.s16	false	DDI-DrugBank.d779.s16.e1	DDI-DrugBank.d779.s16.e4
DDI-DrugBank.d779.s16	false	DDI-DrugBank.d779.s16.e2	DDI-DrugBank.d779.s16.e3
DDI-DrugBank.d779.s16	false	DDI-DrugBank.d779.s16.e2	DDI-DrugBank.d779.s16.e4
DDI-DrugBank.d779.s16	false	DDI-DrugBank.d779.s16.e3	DDI-DrugBank.d779.s16.e4
DDI-DrugBank.d779.s17|a|Methyldopa is not recommended for the treatment of patients with pheochromocytoma. 
DDI-DrugBank.d779.s17	0	9	Methyldopa	drug	DDI-DrugBank.d779.s17.e0
DDI-DrugBank.d779.s18|a|Rarely, when urine is exposed to air after voiding, it may darken because of breakdown of methyldopa or its metabolites.    
DDI-DrugBank.d779.s18	90	99	methyldopa	drug	DDI-DrugBank.d779.s18.e0
DDI-DrugBank.d675.s0|a|CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. 
DDI-DrugBank.d675.s0	25	45	Macrolide Antibiotics	group	DDI-DrugBank.d675.s0.e0
DDI-DrugBank.d675.s0	51	69	Protease Inhibitors	group	DDI-DrugBank.d675.s0.e1
DDI-DrugBank.d675.s0	178	197	ergot alkaloid drugs	group	DDI-DrugBank.d675.s0.e2
DDI-DrugBank.d675.s0	205	221	dihydroergotamine	drug	DDI-DrugBank.d675.s0.e3
DDI-DrugBank.d675.s0	227	236	ergotamine	drug	DDI-DrugBank.d675.s0.e4
DDI-DrugBank.d675.s0	false	DDI-DrugBank.d675.s0.e0	DDI-DrugBank.d675.s0.e1
DDI-DrugBank.d675.s0	false	DDI-DrugBank.d675.s0.e0	DDI-DrugBank.d675.s0.e2
DDI-DrugBank.d675.s0	false	DDI-DrugBank.d675.s0.e0	DDI-DrugBank.d675.s0.e3
DDI-DrugBank.d675.s0	false	DDI-DrugBank.d675.s0.e0	DDI-DrugBank.d675.s0.e4
DDI-DrugBank.d675.s0	false	DDI-DrugBank.d675.s0.e1	DDI-DrugBank.d675.s0.e2
DDI-DrugBank.d675.s0	false	DDI-DrugBank.d675.s0.e1	DDI-DrugBank.d675.s0.e3
DDI-DrugBank.d675.s0	false	DDI-DrugBank.d675.s0.e1	DDI-DrugBank.d675.s0.e4
DDI-DrugBank.d675.s0	false	DDI-DrugBank.d675.s0.e2	DDI-DrugBank.d675.s0.e3
DDI-DrugBank.d675.s0	false	DDI-DrugBank.d675.s0.e2	DDI-DrugBank.d675.s0.e4
DDI-DrugBank.d675.s0	false	DDI-DrugBank.d675.s0.e3	DDI-DrugBank.d675.s0.e4
DDI-DrugBank.d675.s1|a|Although there have been no reports of such interactions with methylergonovine alone, potent CYP 3A4 inhibitors should not be coadministered with methylergonovine. 
DDI-DrugBank.d675.s1	62	77	methylergonovine	drug	DDI-DrugBank.d675.s1.e0
DDI-DrugBank.d675.s2|a|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 
DDI-DrugBank.d675.s2	63	83	macrolide antibiotics	group	DDI-DrugBank.d675.s2.e0
DDI-DrugBank.d675.s2	92	103	erythromycin	drug	DDI-DrugBank.d675.s2.e1
DDI-DrugBank.d675.s2	106	119	troleandomycin	drug	DDI-DrugBank.d675.s2.e2
DDI-DrugBank.d675.s2	122	135	clarithromycin	drug	DDI-DrugBank.d675.s2.e3
DDI-DrugBank.d675.s2	139	150	HIV protease inhibitors	group	DDI-DrugBank.d675.s2.e4
DDI-DrugBank.d675.s2	177	186	HIV protease inhibitors	group	DDI-DrugBank.d675.s2.e4
DDI-DrugBank.d675.s2	155	186	reverse transcriptase inhibitors	group	DDI-DrugBank.d675.s2.e5
DDI-DrugBank.d675.s2	195	203	ritonavir	drug	DDI-DrugBank.d675.s2.e6
DDI-DrugBank.d675.s2	206	214	indinavir	drug	DDI-DrugBank.d675.s2.e7
DDI-DrugBank.d675.s2	217	226	nelfinavir	drug	DDI-DrugBank.d675.s2.e8
DDI-DrugBank.d675.s2	229	239	delavirdine	drug	DDI-DrugBank.d675.s2.e9
DDI-DrugBank.d675.s2	false	DDI-DrugBank.d675.s2.e0	DDI-DrugBank.d675.s2.e1
DDI-DrugBank.d675.s2	false	DDI-DrugBank.d675.s2.e0	DDI-DrugBank.d675.s2.e2
DDI-DrugBank.d675.s2	false	DDI-DrugBank.d675.s2.e0	DDI-DrugBank.d675.s2.e3
DDI-DrugBank.d675.s2	false	DDI-DrugBank.d675.s2.e0	DDI-DrugBank.d675.s2.e4
DDI-DrugBank.d675.s2	false	DDI-DrugBank.d675.s2.e0	DDI-DrugBank.d675.s2.e5
DDI-DrugBank.d675.s2	false	DDI-DrugBank.d675.s2.e0	DDI-DrugBank.d675.s2.e6
DDI-DrugBank.d675.s2	false	DDI-DrugBank.d675.s2.e0	DDI-DrugBank.d675.s2.e7
DDI-DrugBank.d675.s2	false	DDI-DrugBank.d675.s2.e0	DDI-DrugBank.d675.s2.e8
DDI-DrugBank.d675.s2	false	DDI-DrugBank.d675.s2.e0	DDI-DrugBank.d675.s2.e9
DDI-DrugBank.d675.s2	false	DDI-DrugBank.d675.s2.e0	DDI-DrugBank.d675.s2.e10
DDI-DrugBank.d675.s3|a|Less potent CYP 3A4 inhibitors should be administered with caution. 
DDI-DrugBank.d675.s4|a|Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. 
DDI-DrugBank.d675.s4	31	40	saquinavir	drug	DDI-DrugBank.d675.s4.e0
DDI-DrugBank.d675.s4	43	52	nefazodone	drug	DDI-DrugBank.d675.s4.e1
DDI-DrugBank.d675.s4	55	65	fluconazole	drug	DDI-DrugBank.d675.s4.e2
DDI-DrugBank.d675.s4	86	95	fluoxetine	drug	DDI-DrugBank.d675.s4.e3
DDI-DrugBank.d675.s4	98	108	fluvoxamine	drug	DDI-DrugBank.d675.s4.e4
DDI-DrugBank.d675.s4	111	118	zileuton	drug	DDI-DrugBank.d675.s4.e5
DDI-DrugBank.d675.s4	125	136	clotrimazole	drug	DDI-DrugBank.d675.s4.e6
DDI-DrugBank.d675.s4	false	DDI-DrugBank.d675.s4.e0	DDI-DrugBank.d675.s4.e1
DDI-DrugBank.d675.s4	false	DDI-DrugBank.d675.s4.e0	DDI-DrugBank.d675.s4.e2
DDI-DrugBank.d675.s4	false	DDI-DrugBank.d675.s4.e0	DDI-DrugBank.d675.s4.e3
DDI-DrugBank.d675.s4	false	DDI-DrugBank.d675.s4.e0	DDI-DrugBank.d675.s4.e4
DDI-DrugBank.d675.s4	false	DDI-DrugBank.d675.s4.e0	DDI-DrugBank.d675.s4.e5
DDI-DrugBank.d675.s4	false	DDI-DrugBank.d675.s4.e0	DDI-DrugBank.d675.s4.e6
DDI-DrugBank.d675.s4	false	DDI-DrugBank.d675.s4.e1	DDI-DrugBank.d675.s4.e2
DDI-DrugBank.d675.s4	false	DDI-DrugBank.d675.s4.e1	DDI-DrugBank.d675.s4.e3
DDI-DrugBank.d675.s4	false	DDI-DrugBank.d675.s4.e1	DDI-DrugBank.d675.s4.e4
DDI-DrugBank.d675.s4	false	DDI-DrugBank.d675.s4.e1	DDI-DrugBank.d675.s4.e5
DDI-DrugBank.d675.s5|a|These lists are not exhaustive, and the prescriber should consider the effects on CYP 3A4 of other agents being considered for concomitant use with methylergonovine. 
DDI-DrugBank.d675.s5	148	163	methylergonovine	drug	DDI-DrugBank.d675.s5.e0
DDI-DrugBank.d675.s6|a|No pharmacokinetic interactions involving other cytochrome P450 isoenzymes are known. 
DDI-DrugBank.d675.s7|a|Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.
DDI-DrugBank.d675.s7	33	42	Methergine	brand	DDI-DrugBank.d675.s7.e0
DDI-DrugBank.d675.s7	48	71	methylergonovine maleate	drug	DDI-DrugBank.d675.s7.e1
DDI-DrugBank.d675.s7	106	121	vasoconstrictors	group	DDI-DrugBank.d675.s7.e2
DDI-DrugBank.d675.s7	126	140	ergot alkaloids	group	DDI-DrugBank.d675.s7.e3
DDI-DrugBank.d675.s7	false	DDI-DrugBank.d675.s7.e0	DDI-DrugBank.d675.s7.e1
DDI-DrugBank.d675.s7	true	DDI-DrugBank.d675.s7.e0	DDI-DrugBank.d675.s7.e2
DDI-DrugBank.d675.s7	true	DDI-DrugBank.d675.s7.e0	DDI-DrugBank.d675.s7.e3
DDI-DrugBank.d675.s7	true	DDI-DrugBank.d675.s7.e1	DDI-DrugBank.d675.s7.e2
DDI-DrugBank.d675.s7	false	DDI-DrugBank.d675.s7.e1	DDI-DrugBank.d675.s7.e3
DDI-DrugBank.d675.s7	false	DDI-DrugBank.d675.s7.e2	DDI-DrugBank.d675.s7.e3
DDI-DrugBank.d638.s0|a|Ritalin may decrease the hypotensive effect of guanethidine. 
DDI-DrugBank.d638.s0	0	6	Ritalin	brand	DDI-DrugBank.d638.s0.e0
DDI-DrugBank.d638.s0	47	58	guanethidine	drug	DDI-DrugBank.d638.s0.e1
DDI-DrugBank.d638.s0	true	DDI-DrugBank.d638.s0.e0	DDI-DrugBank.d638.s0.e1
DDI-DrugBank.d638.s1|a|Use cautiously with pressor agents. 
DDI-DrugBank.d638.s2|a|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 
DDI-DrugBank.d638.s2	44	50	Ritalin	brand	DDI-DrugBank.d638.s2.e0
DDI-DrugBank.d638.s2	82	104	coumarin anticoagulants	group	DDI-DrugBank.d638.s2.e1
DDI-DrugBank.d638.s2	107	121	anticonvulsants	group	DDI-DrugBank.d638.s2.e2
DDI-DrugBank.d638.s2	124	136	phenobarbital	drug	DDI-DrugBank.d638.s2.e3
DDI-DrugBank.d638.s2	139	155	diphenylhydantoin	drug	DDI-DrugBank.d638.s2.e4
DDI-DrugBank.d638.s2	158	166	primidone	drug	DDI-DrugBank.d638.s2.e5
DDI-DrugBank.d638.s2	170	183	phenylbutazone	drug	DDI-DrugBank.d638.s2.e6
DDI-DrugBank.d638.s2	190	204	tricyclic drugs	group	DDI-DrugBank.d638.s2.e7
DDI-DrugBank.d638.s2	207	216	imipramine	drug	DDI-DrugBank.d638.s2.e8
DDI-DrugBank.d638.s2	219	230	clomipramine	drug	DDI-DrugBank.d638.s2.e9
DDI-DrugBank.d638.s2	true	DDI-DrugBank.d638.s2.e0	DDI-DrugBank.d638.s2.e1
DDI-DrugBank.d638.s2	true	DDI-DrugBank.d638.s2.e0	DDI-DrugBank.d638.s2.e2
DDI-DrugBank.d638.s2	true	DDI-DrugBank.d638.s2.e0	DDI-DrugBank.d638.s2.e3
DDI-DrugBank.d638.s2	true	DDI-DrugBank.d638.s2.e0	DDI-DrugBank.d638.s2.e4
DDI-DrugBank.d638.s2	true	DDI-DrugBank.d638.s2.e0	DDI-DrugBank.d638.s2.e5
DDI-DrugBank.d638.s2	true	DDI-DrugBank.d638.s2.e0	DDI-DrugBank.d638.s2.e6
DDI-DrugBank.d638.s2	true	DDI-DrugBank.d638.s2.e0	DDI-DrugBank.d638.s2.e7
DDI-DrugBank.d638.s2	true	DDI-DrugBank.d638.s2.e0	DDI-DrugBank.d638.s2.e8
DDI-DrugBank.d638.s2	true	DDI-DrugBank.d638.s2.e0	DDI-DrugBank.d638.s2.e9
DDI-DrugBank.d638.s2	true	DDI-DrugBank.d638.s2.e0	DDI-DrugBank.d638.s2.e10
DDI-DrugBank.d638.s3|a|Downward dosage adjustments of these drugs may be required when given concomitantly with Ritalin. 
DDI-DrugBank.d638.s3	89	95	Ritalin	brand	DDI-DrugBank.d638.s3.e0
DDI-DrugBank.d638.s4|a|Serious adverse events have been reported in concomitant use with clonidine, although no causality for the combination has been established. 
DDI-DrugBank.d638.s4	66	74	clonidine	drug	DDI-DrugBank.d638.s4.e0
DDI-DrugBank.d638.s5|a|The safety of using methylphenidate in combination with clonidine or other centrally acting alpha-2 agonists has not been systemically evaluated.    
DDI-DrugBank.d638.s5	20	34	methylphenidate	drug	DDI-DrugBank.d638.s5.e0
DDI-DrugBank.d638.s5	56	64	clonidine	drug	DDI-DrugBank.d638.s5.e1
DDI-DrugBank.d638.s5	92	107	alpha-2 agonists	group	DDI-DrugBank.d638.s5.e2
DDI-DrugBank.d638.s5	false	DDI-DrugBank.d638.s5.e0	DDI-DrugBank.d638.s5.e1
DDI-DrugBank.d638.s5	false	DDI-DrugBank.d638.s5.e0	DDI-DrugBank.d638.s5.e2
DDI-DrugBank.d638.s5	false	DDI-DrugBank.d638.s5.e1	DDI-DrugBank.d638.s5.e2
DDI-DrugBank.d578.s0|a|The pharmacokinetic interactions listed below are potentially clinically important. 
DDI-DrugBank.d578.s1|a|Mutual inhibition of metabolism occurs with concurrent use of cyclosporin and methylprednisolone; 
DDI-DrugBank.d578.s1	62	72	cyclosporin	drug	DDI-DrugBank.d578.s1.e0
DDI-DrugBank.d578.s1	78	95	methylprednisolone	drug	DDI-DrugBank.d578.s1.e1
DDI-DrugBank.d578.s1	true	DDI-DrugBank.d578.s1.e0	DDI-DrugBank.d578.s1.e1
DDI-DrugBank.d578.s2|a|therefore, it is possible that adverse events associated with the individual use of either drug may be more apt to occur. 
DDI-DrugBank.d578.s3|a|convulsions have been reported with concurrent use of methylprednisolone and cyclosporin. 
DDI-DrugBank.d578.s3	54	71	methylprednisolone	drug	DDI-DrugBank.d578.s3.e0
DDI-DrugBank.d578.s3	77	87	cyclosporin	drug	DDI-DrugBank.d578.s3.e1
DDI-DrugBank.d578.s3	true	DDI-DrugBank.d578.s3.e0	DDI-DrugBank.d578.s3.e1
DDI-DrugBank.d578.s4|a|Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. 
DDI-DrugBank.d578.s4	42	54	phenobarbital	drug	DDI-DrugBank.d578.s4.e0
DDI-DrugBank.d578.s4	57	65	phenytoin	drug	DDI-DrugBank.d578.s4.e1
DDI-DrugBank.d578.s4	72	79	rifampin	drug	DDI-DrugBank.d578.s4.e2
DDI-DrugBank.d578.s4	111	128	methylprednisolone	drug	DDI-DrugBank.d578.s4.e3
DDI-DrugBank.d578.s4	159	176	methylprednisolone	drug	DDI-DrugBank.d578.s4.e4
DDI-DrugBank.d578.s4	false	DDI-DrugBank.d578.s4.e0	DDI-DrugBank.d578.s4.e1
DDI-DrugBank.d578.s4	false	DDI-DrugBank.d578.s4.e0	DDI-DrugBank.d578.s4.e2
DDI-DrugBank.d578.s4	true	DDI-DrugBank.d578.s4.e0	DDI-DrugBank.d578.s4.e3
DDI-DrugBank.d578.s4	true	DDI-DrugBank.d578.s4.e0	DDI-DrugBank.d578.s4.e4
DDI-DrugBank.d578.s4	false	DDI-DrugBank.d578.s4.e1	DDI-DrugBank.d578.s4.e2
DDI-DrugBank.d578.s4	true	DDI-DrugBank.d578.s4.e1	DDI-DrugBank.d578.s4.e3
DDI-DrugBank.d578.s4	true	DDI-DrugBank.d578.s4.e1	DDI-DrugBank.d578.s4.e4
DDI-DrugBank.d578.s4	true	DDI-DrugBank.d578.s4.e2	DDI-DrugBank.d578.s4.e3
DDI-DrugBank.d578.s4	true	DDI-DrugBank.d578.s4.e2	DDI-DrugBank.d578.s4.e4
DDI-DrugBank.d578.s4	false	DDI-DrugBank.d578.s4.e3	DDI-DrugBank.d578.s4.e4
DDI-DrugBank.d578.s5|a|Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. 
DDI-DrugBank.d578.s5	14	27	troleandomycin	drug	DDI-DrugBank.d578.s5.e0
DDI-DrugBank.d578.s5	33	44	ketoconazole	drug	DDI-DrugBank.d578.s5.e1
DDI-DrugBank.d578.s5	76	93	methylprednisolone	drug	DDI-DrugBank.d578.s5.e2
DDI-DrugBank.d578.s5	false	DDI-DrugBank.d578.s5.e0	DDI-DrugBank.d578.s5.e1
DDI-DrugBank.d578.s5	true	DDI-DrugBank.d578.s5.e0	DDI-DrugBank.d578.s5.e2
DDI-DrugBank.d578.s5	true	DDI-DrugBank.d578.s5.e1	DDI-DrugBank.d578.s5.e2
DDI-DrugBank.d578.s6|a|Therefore, the dose of methylprednisolone should be titrated to avoid steroid toxicity. 
DDI-DrugBank.d578.s6	23	40	methylprednisolone	drug	DDI-DrugBank.d578.s6.e0
DDI-DrugBank.d578.s7|a|Methylprednisolone may increase the clearance of chronic high dose aspirin. 
DDI-DrugBank.d578.s7	0	17	Methylprednisolone	drug	DDI-DrugBank.d578.s7.e0
DDI-DrugBank.d578.s7	67	73	aspirin	brand	DDI-DrugBank.d578.s7.e1
DDI-DrugBank.d578.s7	true	DDI-DrugBank.d578.s7.e0	DDI-DrugBank.d578.s7.e1
DDI-DrugBank.d578.s8|a|This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn. 
DDI-DrugBank.d578.s8	29	38	salicylate	group	DDI-DrugBank.d578.s8.e0
DDI-DrugBank.d578.s8	77	86	salicylate	group	DDI-DrugBank.d578.s8.e1
DDI-DrugBank.d578.s8	102	119	methylprednisolone	drug	DDI-DrugBank.d578.s8.e2
DDI-DrugBank.d578.s8	false	DDI-DrugBank.d578.s8.e0	DDI-DrugBank.d578.s8.e1
DDI-DrugBank.d578.s8	false	DDI-DrugBank.d578.s8.e0	DDI-DrugBank.d578.s8.e2
DDI-DrugBank.d578.s8	true	DDI-DrugBank.d578.s8.e1	DDI-DrugBank.d578.s8.e2
DDI-DrugBank.d578.s9|a|Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia. 
DDI-DrugBank.d578.s9	0	6	Aspirin	brand	DDI-DrugBank.d578.s9.e0
DDI-DrugBank.d578.s9	54	68	corticosteroids	group	DDI-DrugBank.d578.s9.e1
DDI-DrugBank.d578.s9	true	DDI-DrugBank.d578.s9.e0	DDI-DrugBank.d578.s9.e1
DDI-DrugBank.d578.s10|a|The effect of methylprednisolone on oral anticoagulants is variable. 
DDI-DrugBank.d578.s10	14	31	methylprednisolone	drug	DDI-DrugBank.d578.s10.e0
DDI-DrugBank.d578.s10	41	54	anticoagulants	group	DDI-DrugBank.d578.s10.e1
DDI-DrugBank.d578.s10	false	DDI-DrugBank.d578.s10.e0	DDI-DrugBank.d578.s10.e1
DDI-DrugBank.d578.s11|a|There are reports of enhanced as well as diminished effects of anticoagulant when given concurrently with corticosteroids. 
DDI-DrugBank.d578.s11	63	75	anticoagulant	group	DDI-DrugBank.d578.s11.e0
DDI-DrugBank.d578.s11	106	120	corticosteroids	group	DDI-DrugBank.d578.s11.e1
DDI-DrugBank.d578.s11	true	DDI-DrugBank.d578.s11.e0	DDI-DrugBank.d578.s11.e1
DDI-DrugBank.d578.s12|a|Therefore, coagulation indices should be monitored to maintain the desired anticoagulant effect.
DDI-DrugBank.d655.s0|a|Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
DDI-DrugBank.d655.s0	0	14	Methscopolamine	drug	DDI-DrugBank.d655.s0.e0
DDI-DrugBank.d655.s0	34	48	antidepressants	group	DDI-DrugBank.d655.s0.e1
DDI-DrugBank.d655.s0	51	59	tricyclic	group	DDI-DrugBank.d655.s0.e2
DDI-DrugBank.d655.s0	68	81	MAO inhibitors	group	DDI-DrugBank.d655.s0.e3
DDI-DrugBank.d655.s0	90	99	phenelzine	drug	DDI-DrugBank.d655.s0.e4
DDI-DrugBank.d655.s0	102	110	linezolid	drug	DDI-DrugBank.d655.s0.e5
DDI-DrugBank.d655.s0	113	127	tranylcypromine	drug	DDI-DrugBank.d655.s0.e6
DDI-DrugBank.d655.s0	130	142	isocarboxazid	drug	DDI-DrugBank.d655.s0.e7
DDI-DrugBank.d655.s0	145	154	selegiline	drug	DDI-DrugBank.d655.s0.e8
DDI-DrugBank.d655.s0	157	168	furazolidone	drug	DDI-DrugBank.d655.s0.e9
DDI-DrugBank.d655.s0	false	DDI-DrugBank.d655.s0.e0	DDI-DrugBank.d655.s0.e1
DDI-DrugBank.d655.s0	true	DDI-DrugBank.d655.s0.e0	DDI-DrugBank.d655.s0.e2
DDI-DrugBank.d655.s0	true	DDI-DrugBank.d655.s0.e0	DDI-DrugBank.d655.s0.e3
DDI-DrugBank.d655.s0	true	DDI-DrugBank.d655.s0.e0	DDI-DrugBank.d655.s0.e4
DDI-DrugBank.d655.s0	true	DDI-DrugBank.d655.s0.e0	DDI-DrugBank.d655.s0.e5
DDI-DrugBank.d655.s0	true	DDI-DrugBank.d655.s0.e0	DDI-DrugBank.d655.s0.e6
DDI-DrugBank.d655.s0	true	DDI-DrugBank.d655.s0.e0	DDI-DrugBank.d655.s0.e7
DDI-DrugBank.d655.s0	true	DDI-DrugBank.d655.s0.e0	DDI-DrugBank.d655.s0.e8
DDI-DrugBank.d655.s0	true	DDI-DrugBank.d655.s0.e0	DDI-DrugBank.d655.s0.e9
DDI-DrugBank.d655.s0	true	DDI-DrugBank.d655.s0.e0	DDI-DrugBank.d655.s0.e10
DDI-DrugBank.d600.s0|a|Methyprylon may interact with other addictive medications, in that it may increase the likelyhood of addiction and abuse. 
DDI-DrugBank.d600.s0	0	10	Methyprylon	drug	DDI-DrugBank.d600.s0.e0
DDI-DrugBank.d600.s1|a|Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.
DDI-DrugBank.d600.s1	18	24	alcohol	drug	DDI-DrugBank.d600.s1.e0
DDI-DrugBank.d600.s1	36	65	CNS depression-producing drugs	group	DDI-DrugBank.d600.s1.e1
DDI-DrugBank.d600.s1	110	120	methyprylon	drug	DDI-DrugBank.d600.s1.e2
DDI-DrugBank.d600.s1	false	DDI-DrugBank.d600.s1.e0	DDI-DrugBank.d600.s1.e1
DDI-DrugBank.d600.s1	true	DDI-DrugBank.d600.s1.e0	DDI-DrugBank.d600.s1.e2
DDI-DrugBank.d600.s1	true	DDI-DrugBank.d600.s1.e1	DDI-DrugBank.d600.s1.e2
DDI-DrugBank.d696.s0|a|Methysergide may reverse the analgesic activity of narcotic analgesics. 
DDI-DrugBank.d696.s0	0	11	Methysergide	drug	DDI-DrugBank.d696.s0.e0
DDI-DrugBank.d696.s0	51	69	narcotic analgesics	group	DDI-DrugBank.d696.s0.e1
DDI-DrugBank.d696.s0	true	DDI-DrugBank.d696.s0.e0	DDI-DrugBank.d696.s0.e1
DDI-DrugBank.d696.s1|a|Concurrent use with vasoconstrictor agents including ergot alkaloids, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.
DDI-DrugBank.d696.s1	20	41	vasoconstrictor agents	group	DDI-DrugBank.d696.s1.e0
DDI-DrugBank.d696.s1	53	67	ergot alkaloids	group	DDI-DrugBank.d696.s1.e1
DDI-DrugBank.d696.s1	70	80	sumatriptan	drug	DDI-DrugBank.d696.s1.e2
DDI-DrugBank.d696.s1	87	94	nicotine	drug	DDI-DrugBank.d696.s1.e3
DDI-DrugBank.d696.s1	false	DDI-DrugBank.d696.s1.e0	DDI-DrugBank.d696.s1.e1
DDI-DrugBank.d696.s1	false	DDI-DrugBank.d696.s1.e0	DDI-DrugBank.d696.s1.e2
DDI-DrugBank.d696.s1	false	DDI-DrugBank.d696.s1.e0	DDI-DrugBank.d696.s1.e3
DDI-DrugBank.d696.s1	false	DDI-DrugBank.d696.s1.e1	DDI-DrugBank.d696.s1.e2
DDI-DrugBank.d696.s1	false	DDI-DrugBank.d696.s1.e1	DDI-DrugBank.d696.s1.e3
DDI-DrugBank.d696.s1	false	DDI-DrugBank.d696.s1.e2	DDI-DrugBank.d696.s1.e3
DDI-DrugBank.d652.s0|a|The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics. 
DDI-DrugBank.d652.s0	15	28	metoclopramide	drug	DDI-DrugBank.d652.s0.e0
DDI-DrugBank.d652.s0	78	98	anticholinergic drugs	group	DDI-DrugBank.d652.s0.e1
DDI-DrugBank.d652.s0	104	122	narcotic analgesics	group	DDI-DrugBank.d652.s0.e2
DDI-DrugBank.d652.s0	true	DDI-DrugBank.d652.s0.e0	DDI-DrugBank.d652.s0.e1
DDI-DrugBank.d652.s0	true	DDI-DrugBank.d652.s0.e0	DDI-DrugBank.d652.s0.e2
DDI-DrugBank.d652.s0	false	DDI-DrugBank.d652.s0.e1	DDI-DrugBank.d652.s0.e2
DDI-DrugBank.d652.s1|a|Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. 
DDI-DrugBank.d652.s1	41	54	metoclopramide	drug	DDI-DrugBank.d652.s1.e0
DDI-DrugBank.d652.s1	70	76	alcohol	drug	DDI-DrugBank.d652.s1.e1
DDI-DrugBank.d652.s1	79	87	sedatives	group	DDI-DrugBank.d652.s1.e2
DDI-DrugBank.d652.s1	90	98	hypnotics	group	DDI-DrugBank.d652.s1.e3
DDI-DrugBank.d652.s1	101	109	narcotics	group	DDI-DrugBank.d652.s1.e4
DDI-DrugBank.d652.s1	115	127	tranquilizers	group	DDI-DrugBank.d652.s1.e5
DDI-DrugBank.d652.s1	true	DDI-DrugBank.d652.s1.e0	DDI-DrugBank.d652.s1.e1
DDI-DrugBank.d652.s1	true	DDI-DrugBank.d652.s1.e0	DDI-DrugBank.d652.s1.e2
DDI-DrugBank.d652.s1	true	DDI-DrugBank.d652.s1.e0	DDI-DrugBank.d652.s1.e3
DDI-DrugBank.d652.s1	true	DDI-DrugBank.d652.s1.e0	DDI-DrugBank.d652.s1.e4
DDI-DrugBank.d652.s1	true	DDI-DrugBank.d652.s1.e0	DDI-DrugBank.d652.s1.e5
DDI-DrugBank.d652.s1	false	DDI-DrugBank.d652.s1.e1	DDI-DrugBank.d652.s1.e2
DDI-DrugBank.d652.s1	false	DDI-DrugBank.d652.s1.e1	DDI-DrugBank.d652.s1.e3
DDI-DrugBank.d652.s1	false	DDI-DrugBank.d652.s1.e1	DDI-DrugBank.d652.s1.e4
DDI-DrugBank.d652.s1	false	DDI-DrugBank.d652.s1.e1	DDI-DrugBank.d652.s1.e5
DDI-DrugBank.d652.s1	false	DDI-DrugBank.d652.s1.e2	DDI-DrugBank.d652.s1.e3
DDI-DrugBank.d652.s2|a|The finding that metoclopramide releases catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving monoamine oxi-dase inhibitors. 
DDI-DrugBank.d652.s2	17	30	metoclopramide	drug	DDI-DrugBank.d652.s2.e0
DDI-DrugBank.d652.s2	173	201	monoamine oxi-dase inhibitors	group	DDI-DrugBank.d652.s2.e1
DDI-DrugBank.d652.s2	true	DDI-DrugBank.d652.s2.e0	DDI-DrugBank.d652.s2.e1
DDI-DrugBank.d652.s3|a|Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). 
DDI-DrugBank.d652.s3	62	68	digoxin	drug	DDI-DrugBank.d652.s3.e0
DDI-DrugBank.d652.s3	74	87	metoclopramide	drug	DDI-DrugBank.d652.s3.e1
DDI-DrugBank.d652.s3	189	201	acetaminophen	drug	DDI-DrugBank.d652.s3.e2
DDI-DrugBank.d652.s3	204	215	tetracycline	drug	DDI-DrugBank.d652.s3.e3
DDI-DrugBank.d652.s3	218	225	levodopa	drug	DDI-DrugBank.d652.s3.e4
DDI-DrugBank.d652.s3	228	234	ethanol	drug	DDI-DrugBank.d652.s3.e5
DDI-DrugBank.d652.s3	237	248	cyclosporine	drug	DDI-DrugBank.d652.s3.e6
DDI-DrugBank.d652.s3	true	DDI-DrugBank.d652.s3.e0	DDI-DrugBank.d652.s3.e1
DDI-DrugBank.d652.s3	false	DDI-DrugBank.d652.s3.e0	DDI-DrugBank.d652.s3.e2
DDI-DrugBank.d652.s3	false	DDI-DrugBank.d652.s3.e0	DDI-DrugBank.d652.s3.e3
DDI-DrugBank.d652.s3	false	DDI-DrugBank.d652.s3.e0	DDI-DrugBank.d652.s3.e4
DDI-DrugBank.d652.s3	false	DDI-DrugBank.d652.s3.e0	DDI-DrugBank.d652.s3.e5
DDI-DrugBank.d652.s3	false	DDI-DrugBank.d652.s3.e0	DDI-DrugBank.d652.s3.e6
DDI-DrugBank.d652.s3	true	DDI-DrugBank.d652.s3.e1	DDI-DrugBank.d652.s3.e2
DDI-DrugBank.d652.s3	false	DDI-DrugBank.d652.s3.e1	DDI-DrugBank.d652.s3.e3
DDI-DrugBank.d652.s3	false	DDI-DrugBank.d652.s3.e1	DDI-DrugBank.d652.s3.e4
DDI-DrugBank.d652.s3	false	DDI-DrugBank.d652.s3.e1	DDI-DrugBank.d652.s3.e5
DDI-DrugBank.d652.s4|a|Gastroparesis (gastric stasis) may be responsible for poor diabetic control in some patients. 
DDI-DrugBank.d652.s5|a|Exogenously administered insulin may begin to act before food has left the stomach and lead to hypoglycemia. 
DDI-DrugBank.d652.s5	25	31	insulin	drug	DDI-DrugBank.d652.s5.e0
DDI-DrugBank.d652.s6|a|Because the action of metoclopramide will influence the delivery of food to the intestines and thus the rate of absorption, insulin dosage or timing of dosage may require adjustment.
DDI-DrugBank.d652.s6	22	35	metoclopramide	drug	DDI-DrugBank.d652.s6.e0
DDI-DrugBank.d652.s6	124	130	insulin	drug	DDI-DrugBank.d652.s6.e1
DDI-DrugBank.d652.s6	true	DDI-DrugBank.d652.s6.e0	DDI-DrugBank.d652.s6.e1
DDI-DrugBank.d588.s0|a|Diuretics: Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes. 
DDI-DrugBank.d588.s0	0	8	Diuretics	group	DDI-DrugBank.d588.s0.e0
DDI-DrugBank.d588.s0	11	20	Furosemide	drug	DDI-DrugBank.d588.s0.e1
DDI-DrugBank.d588.s0	41	54	loop diuretics	group	DDI-DrugBank.d588.s0.e2
DDI-DrugBank.d588.s0	81	90	metolazone	drug	DDI-DrugBank.d588.s0.e3
DDI-DrugBank.d588.s0	false	DDI-DrugBank.d588.s0.e0	DDI-DrugBank.d588.s0.e1
DDI-DrugBank.d588.s0	false	DDI-DrugBank.d588.s0.e0	DDI-DrugBank.d588.s0.e2
DDI-DrugBank.d588.s0	false	DDI-DrugBank.d588.s0.e0	DDI-DrugBank.d588.s0.e3
DDI-DrugBank.d588.s0	false	DDI-DrugBank.d588.s0.e1	DDI-DrugBank.d588.s0.e2
DDI-DrugBank.d588.s0	true	DDI-DrugBank.d588.s0.e1	DDI-DrugBank.d588.s0.e3
DDI-DrugBank.d588.s0	true	DDI-DrugBank.d588.s0.e2	DDI-DrugBank.d588.s0.e3
DDI-DrugBank.d588.s1|a|Other Antihypertensives: When MYKROX Tablets are used with other antihypertensive drugs, care must be taken, especially during initial therapy. 
DDI-DrugBank.d588.s1	6	22	Antihypertensives	group	DDI-DrugBank.d588.s1.e0
DDI-DrugBank.d588.s1	30	35	MYKROX	brand	DDI-DrugBank.d588.s1.e1
DDI-DrugBank.d588.s1	65	86	antihypertensive drugs	group	DDI-DrugBank.d588.s1.e2
DDI-DrugBank.d588.s1	false	DDI-DrugBank.d588.s1.e0	DDI-DrugBank.d588.s1.e1
DDI-DrugBank.d588.s1	false	DDI-DrugBank.d588.s1.e0	DDI-DrugBank.d588.s1.e2
DDI-DrugBank.d588.s1	true	DDI-DrugBank.d588.s1.e1	DDI-DrugBank.d588.s1.e2
DDI-DrugBank.d588.s2|a|Dosage adjustments of other antihypertensives may be necessary. 
DDI-DrugBank.d588.s2	28	44	antihypertensives	group	DDI-DrugBank.d588.s2.e0
DDI-DrugBank.d588.s3|a|Alcohol, Barbiturates, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy. 
DDI-DrugBank.d588.s3	0	6	Alcohol	drug	DDI-DrugBank.d588.s3.e0
DDI-DrugBank.d588.s3	9	20	Barbiturates	group	DDI-DrugBank.d588.s3.e1
DDI-DrugBank.d588.s3	27	35	Narcotics	group	DDI-DrugBank.d588.s3.e2
DDI-DrugBank.d588.s3	150	159	metolazone	drug	DDI-DrugBank.d588.s3.e3
DDI-DrugBank.d588.s3	false	DDI-DrugBank.d588.s3.e0	DDI-DrugBank.d588.s3.e1
DDI-DrugBank.d588.s3	false	DDI-DrugBank.d588.s3.e0	DDI-DrugBank.d588.s3.e2
DDI-DrugBank.d588.s3	false	DDI-DrugBank.d588.s3.e0	DDI-DrugBank.d588.s3.e3
DDI-DrugBank.d588.s3	false	DDI-DrugBank.d588.s3.e1	DDI-DrugBank.d588.s3.e2
DDI-DrugBank.d588.s3	false	DDI-DrugBank.d588.s3.e1	DDI-DrugBank.d588.s3.e3
DDI-DrugBank.d588.s3	false	DDI-DrugBank.d588.s3.e2	DDI-DrugBank.d588.s3.e3
DDI-DrugBank.d588.s4|a|Digitalis Glycosides: Diuretic-induced hypokalemia can increase the sensitivity of the myocardium to digitalis. 
DDI-DrugBank.d588.s4	0	19	Digitalis Glycosides	group	DDI-DrugBank.d588.s4.e0
DDI-DrugBank.d588.s4	22	29	Diuretic	group	DDI-DrugBank.d588.s4.e1
DDI-DrugBank.d588.s4	101	109	digitalis	group	DDI-DrugBank.d588.s4.e2
DDI-DrugBank.d588.s4	false	DDI-DrugBank.d588.s4.e0	DDI-DrugBank.d588.s4.e1
DDI-DrugBank.d588.s4	false	DDI-DrugBank.d588.s4.e0	DDI-DrugBank.d588.s4.e2
DDI-DrugBank.d588.s4	true	DDI-DrugBank.d588.s4.e1	DDI-DrugBank.d588.s4.e2
DDI-DrugBank.d588.s5|a|Serious arrhythmias can result. 
DDI-DrugBank.d588.s6|a|Corticosteroids or ACTH: May increase the risk of hypokalemia and increase salt and water retention. 
DDI-DrugBank.d588.s6	0	14	Corticosteroids	group	DDI-DrugBank.d588.s6.e0
DDI-DrugBank.d588.s6	19	22	ACTH	drug	DDI-DrugBank.d588.s6.e1
DDI-DrugBank.d588.s6	false	DDI-DrugBank.d588.s6.e0	DDI-DrugBank.d588.s6.e1
DDI-DrugBank.d588.s7|a|Lithium: Serum lithium levels may increase. 
DDI-DrugBank.d588.s7	0	6	Lithium	drug	DDI-DrugBank.d588.s7.e0
DDI-DrugBank.d588.s7	15	21	lithium	drug	DDI-DrugBank.d588.s7.e1
DDI-DrugBank.d588.s7	false	DDI-DrugBank.d588.s7.e0	DDI-DrugBank.d588.s7.e1
DDI-DrugBank.d588.s8|a|Curariform Drugs: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea. 
DDI-DrugBank.d588.s8	0	15	Curariform Drugs	group	DDI-DrugBank.d588.s8.e0
DDI-DrugBank.d588.s8	18	25	Diuretic	group	DDI-DrugBank.d588.s8.e1
DDI-DrugBank.d588.s8	93	108	curariform drugs	group	DDI-DrugBank.d588.s8.e2
DDI-DrugBank.d588.s8	119	130	tubocurarine	drug	DDI-DrugBank.d588.s8.e3
DDI-DrugBank.d588.s8	false	DDI-DrugBank.d588.s8.e0	DDI-DrugBank.d588.s8.e1
DDI-DrugBank.d588.s8	false	DDI-DrugBank.d588.s8.e0	DDI-DrugBank.d588.s8.e2
DDI-DrugBank.d588.s8	false	DDI-DrugBank.d588.s8.e0	DDI-DrugBank.d588.s8.e3
DDI-DrugBank.d588.s8	true	DDI-DrugBank.d588.s8.e1	DDI-DrugBank.d588.s8.e2
DDI-DrugBank.d588.s8	true	DDI-DrugBank.d588.s8.e1	DDI-DrugBank.d588.s8.e3
DDI-DrugBank.d588.s8	false	DDI-DrugBank.d588.s8.e2	DDI-DrugBank.d588.s8.e3
DDI-DrugBank.d588.s9|a|Accordingly, it may be advisable to discontinue MYKROX Tablets three days before elective surgery. 
DDI-DrugBank.d588.s9	48	53	MYKROX	brand	DDI-DrugBank.d588.s9.e0
DDI-DrugBank.d588.s10|a|Salicylates and Other Non-Steroidal Anti-Inflammatory Drugs: May decrease the antihypertensive effects of MYKROX Tablets. 
DDI-DrugBank.d588.s10	0	10	Salicylates	group	DDI-DrugBank.d588.s10.e0
DDI-DrugBank.d588.s10	22	58	Non-Steroidal Anti-Inflammatory Drugs	group	DDI-DrugBank.d588.s10.e1
DDI-DrugBank.d588.s10	106	111	MYKROX	brand	DDI-DrugBank.d588.s10.e2
DDI-DrugBank.d588.s10	false	DDI-DrugBank.d588.s10.e0	DDI-DrugBank.d588.s10.e1
DDI-DrugBank.d588.s10	true	DDI-DrugBank.d588.s10.e0	DDI-DrugBank.d588.s10.e2
DDI-DrugBank.d588.s10	true	DDI-DrugBank.d588.s10.e1	DDI-DrugBank.d588.s10.e2
DDI-DrugBank.d588.s11|a|Sympathomimetics: Metolazone may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. 
DDI-DrugBank.d588.s11	0	15	Sympathomimetics	group	DDI-DrugBank.d588.s11.e0
DDI-DrugBank.d588.s11	18	27	Metolazone	drug	DDI-DrugBank.d588.s11.e1
DDI-DrugBank.d588.s11	69	82	norepinephrine	drug	DDI-DrugBank.d588.s11.e2
DDI-DrugBank.d588.s11	false	DDI-DrugBank.d588.s11.e0	DDI-DrugBank.d588.s11.e1
DDI-DrugBank.d588.s11	false	DDI-DrugBank.d588.s11.e0	DDI-DrugBank.d588.s11.e2
DDI-DrugBank.d588.s11	true	DDI-DrugBank.d588.s11.e1	DDI-DrugBank.d588.s11.e2
DDI-DrugBank.d588.s12|a|Methenamine: Efficacy may be decreased due to urinary alkalizing effect of metolazone. 
DDI-DrugBank.d588.s12	0	10	Methenamine	drug	DDI-DrugBank.d588.s12.e0
DDI-DrugBank.d588.s12	75	84	metolazone	drug	DDI-DrugBank.d588.s12.e1
DDI-DrugBank.d588.s12	true	DDI-DrugBank.d588.s12.e0	DDI-DrugBank.d588.s12.e1
DDI-DrugBank.d588.s13|a|Anticoagulants: Metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants; 
DDI-DrugBank.d588.s13	0	13	Anticoagulants	group	DDI-DrugBank.d588.s13.e0
DDI-DrugBank.d588.s13	16	25	Metolazone	drug	DDI-DrugBank.d588.s13.e1
DDI-DrugBank.d588.s13	45	67	thiazide-like diuretics	group	DDI-DrugBank.d588.s13.e2
DDI-DrugBank.d588.s13	117	130	anticoagulants	group	DDI-DrugBank.d588.s13.e3
DDI-DrugBank.d588.s13	false	DDI-DrugBank.d588.s13.e0	DDI-DrugBank.d588.s13.e1
DDI-DrugBank.d588.s13	false	DDI-DrugBank.d588.s13.e0	DDI-DrugBank.d588.s13.e2
DDI-DrugBank.d588.s13	false	DDI-DrugBank.d588.s13.e0	DDI-DrugBank.d588.s13.e3
DDI-DrugBank.d588.s13	false	DDI-DrugBank.d588.s13.e1	DDI-DrugBank.d588.s13.e2
DDI-DrugBank.d588.s13	true	DDI-DrugBank.d588.s13.e1	DDI-DrugBank.d588.s13.e3
DDI-DrugBank.d588.s13	false	DDI-DrugBank.d588.s13.e2	DDI-DrugBank.d588.s13.e3
DDI-DrugBank.d588.s14|a|dosage adjustments may be necessary.
DDI-DrugBank.d706.s0|a|Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. 
DDI-DrugBank.d706.s0	37	45	reserpine	drug	DDI-DrugBank.d706.s0.e0
DDI-DrugBank.d706.s0	92	111	beta-blocking agents	group	DDI-DrugBank.d706.s0.e1
DDI-DrugBank.d706.s0	true	DDI-DrugBank.d706.s0.e0	DDI-DrugBank.d706.s0.e1
DDI-DrugBank.d706.s1|a|Patients treated with extended release metoprolol succinate plus a catecholamine depletor should therefore be closely observed for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.
DDI-DrugBank.d706.s1	39	58	metoprolol succinate	drug	DDI-DrugBank.d706.s1.e0
DDI-DrugBank.d629.s0|a|Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. 
DDI-DrugBank.d629.s0	5	17	metronidazole	drug	DDI-DrugBank.d629.s0.e0
DDI-DrugBank.d629.s0	79	86	coumarin	group	DDI-DrugBank.d629.s0.e1
DDI-DrugBank.d629.s0	92	99	warfarin	drug	DDI-DrugBank.d629.s0.e2
DDI-DrugBank.d629.s0	true	DDI-DrugBank.d629.s0.e0	DDI-DrugBank.d629.s0.e1
DDI-DrugBank.d629.s0	true	DDI-DrugBank.d629.s0.e0	DDI-DrugBank.d629.s0.e2
DDI-DrugBank.d629.s0	false	DDI-DrugBank.d629.s0.e1	DDI-DrugBank.d629.s0.e2
DDI-DrugBank.d629.s1|a|Drug interactions should be kept in mind when METROGEL (metronidazole gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical metronidazole administration because of low absorption.    
DDI-DrugBank.d629.s1	46	53	METROGEL	brand	DDI-DrugBank.d629.s1.e0
DDI-DrugBank.d629.s1	56	68	metronidazole	drug	DDI-DrugBank.d629.s1.e1
DDI-DrugBank.d629.s1	201	213	metronidazole	drug	DDI-DrugBank.d629.s1.e2
DDI-DrugBank.d629.s1	false	DDI-DrugBank.d629.s1.e0	DDI-DrugBank.d629.s1.e1
DDI-DrugBank.d629.s1	false	DDI-DrugBank.d629.s1.e0	DDI-DrugBank.d629.s1.e2
DDI-DrugBank.d629.s1	false	DDI-DrugBank.d629.s1.e1	DDI-DrugBank.d629.s1.e2
DDI-DrugBank.d678.s0|a|Drugs affecting pituitary or adrenocortical function, including all corticosteroid therapy, must be discontinued prior to and during testing with Metopirone. 
DDI-DrugBank.d678.s0	146	155	Metopirone	brand	DDI-DrugBank.d678.s0.e0
DDI-DrugBank.d678.s1|a|The metabolism of Metopirone is accelerated by phenytoin; 
DDI-DrugBank.d678.s1	18	27	Metopirone	brand	DDI-DrugBank.d678.s1.e0
DDI-DrugBank.d678.s1	47	55	phenytoin	drug	DDI-DrugBank.d678.s1.e1
DDI-DrugBank.d678.s1	true	DDI-DrugBank.d678.s1.e0	DDI-DrugBank.d678.s1.e1
DDI-DrugBank.d678.s2|a|therefore, results of the test may be inaccurate in patients taking phenytoin within two weeks before. 
DDI-DrugBank.d678.s2	68	76	phenytoin	drug	DDI-DrugBank.d678.s2.e0
DDI-DrugBank.d678.s3|a|Asubnormal response may occur in patients on estrogen therapy. 
DDI-DrugBank.d678.s4|a|Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.
DDI-DrugBank.d678.s4	0	9	Metopirone	brand	DDI-DrugBank.d678.s4.e0
DDI-DrugBank.d678.s4	43	55	acetaminophen	drug	DDI-DrugBank.d678.s4.e1
DDI-DrugBank.d678.s4	87	99	acetaminophen	drug	DDI-DrugBank.d678.s4.e2
DDI-DrugBank.d678.s4	true	DDI-DrugBank.d678.s4.e0	DDI-DrugBank.d678.s4.e1
DDI-DrugBank.d678.s4	true	DDI-DrugBank.d678.s4.e0	DDI-DrugBank.d678.s4.e2
DDI-DrugBank.d678.s4	false	DDI-DrugBank.d678.s4.e1	DDI-DrugBank.d678.s4.e2
DDI-DrugBank.d715.s0|a|Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. 
DDI-DrugBank.d715.s0	44	49	DEMSER	brand	DDI-DrugBank.d715.s0.e0
DDI-DrugBank.d715.s0	73	86	phenothiazines	group	DDI-DrugBank.d715.s0.e1
DDI-DrugBank.d715.s0	91	101	haloperidol	drug	DDI-DrugBank.d715.s0.e2
DDI-DrugBank.d715.s0	true	DDI-DrugBank.d715.s0.e0	DDI-DrugBank.d715.s0.e1
DDI-DrugBank.d715.s0	true	DDI-DrugBank.d715.s0.e0	DDI-DrugBank.d715.s0.e2
DDI-DrugBank.d715.s0	false	DDI-DrugBank.d715.s0.e1	DDI-DrugBank.d715.s0.e2
DDI-DrugBank.d715.s1|a|Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.
DDI-DrugBank.d715.s1	18	23	DEMSER	brand	DDI-DrugBank.d715.s1.e0
DDI-DrugBank.d715.s1	30	36	alcohol	drug	DDI-DrugBank.d715.s1.e1
DDI-DrugBank.d715.s1	47	61	CNS depressants	drug	DDI-DrugBank.d715.s1.e2
DDI-DrugBank.d715.s1	true	DDI-DrugBank.d715.s1.e0	DDI-DrugBank.d715.s1.e1
DDI-DrugBank.d715.s1	true	DDI-DrugBank.d715.s1.e0	DDI-DrugBank.d715.s1.e2
DDI-DrugBank.d715.s1	false	DDI-DrugBank.d715.s1.e1	DDI-DrugBank.d715.s1.e2
DDI-DrugBank.d633.s0|a|Since MEXITIL is a substrate for the metabolic pathways involving CYP2D6 and CYP1A2 enzymes, inhibition or induction of either of these enzymes would be expected to alter mexiletine plasma concentrations. 
DDI-DrugBank.d633.s0	6	12	MEXITIL	brand	DDI-DrugBank.d633.s0.e0
DDI-DrugBank.d633.s0	171	180	mexiletine	drug	DDI-DrugBank.d633.s0.e1
DDI-DrugBank.d633.s0	false	DDI-DrugBank.d633.s0.e0	DDI-DrugBank.d633.s0.e1
DDI-DrugBank.d633.s1|a|In a formal, single-dose interaction study (n = 6 males) the clearance of mexiletine was decreased by 38% following the coadministration of fluvoxamine, an inhibitor of CYP1A2. 
DDI-DrugBank.d633.s1	74	83	mexiletine	drug	DDI-DrugBank.d633.s1.e0
DDI-DrugBank.d633.s1	140	150	fluvoxamine	drug	DDI-DrugBank.d633.s1.e1
DDI-DrugBank.d633.s1	true	DDI-DrugBank.d633.s1.e0	DDI-DrugBank.d633.s1.e1
DDI-DrugBank.d633.s2|a|In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6), coadministration of propafenone did not alter the kinetics of mexiletine in the poor CYP2D6 metabolizer group. 
DDI-DrugBank.d633.s2	101	111	propafenone	drug	DDI-DrugBank.d633.s2.e0
DDI-DrugBank.d633.s2	143	152	mexiletine	drug	DDI-DrugBank.d633.s2.e1
DDI-DrugBank.d633.s2	false	DDI-DrugBank.d633.s2.e0	DDI-DrugBank.d633.s2.e1
DDI-DrugBank.d633.s3|a|However, the metabolic clearance of mexiletine in the extensive metabolizer phenotype decreased by about 70% making the poor and extensive metabolizer groups indistinguishable. 
DDI-DrugBank.d633.s3	36	45	mexiletine	drug	DDI-DrugBank.d633.s3.e0
DDI-DrugBank.d633.s4|a|In this crossover steady state study, the pharmacokinetics of propafenone were unaffected in either phenotype by the coadministration of mexiletine. 
DDI-DrugBank.d633.s4	62	72	propafenone	drug	DDI-DrugBank.d633.s4.e0
DDI-DrugBank.d633.s4	137	146	mexiletine	drug	DDI-DrugBank.d633.s4.e1
DDI-DrugBank.d633.s4	false	DDI-DrugBank.d633.s4.e0	DDI-DrugBank.d633.s4.e1
DDI-DrugBank.d633.s5|a|Addition of mexiletine to propafenone did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than propafenone alone. 
DDI-DrugBank.d633.s5	12	21	mexiletine	drug	DDI-DrugBank.d633.s5.e0
DDI-DrugBank.d633.s5	26	36	propafenone	drug	DDI-DrugBank.d633.s5.e1
DDI-DrugBank.d633.s5	141	151	propafenone	drug	DDI-DrugBank.d633.s5.e2
DDI-DrugBank.d633.s5	false	DDI-DrugBank.d633.s5.e0	DDI-DrugBank.d633.s5.e1
DDI-DrugBank.d633.s5	false	DDI-DrugBank.d633.s5.e0	DDI-DrugBank.d633.s5.e2
DDI-DrugBank.d633.s5	false	DDI-DrugBank.d633.s5.e1	DDI-DrugBank.d633.s5.e2
DDI-DrugBank.d633.s6|a|When concomitant administration of either of these two drugs with mexiletine is initiated, the dose of mexiletine should be slowly titrated to desired effect. 
DDI-DrugBank.d633.s6	66	75	mexiletine	drug	DDI-DrugBank.d633.s6.e0
DDI-DrugBank.d633.s6	103	112	mexiletine	drug	DDI-DrugBank.d633.s6.e1
DDI-DrugBank.d633.s6	false	DDI-DrugBank.d633.s6.e0	DDI-DrugBank.d633.s6.e1
DDI-DrugBank.d633.s7|a|In a large compassionate use program Mexitil    has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. 
DDI-DrugBank.d633.s7	37	43	Mexitil	brand	DDI-DrugBank.d633.s7.e0
DDI-DrugBank.d633.s7	111	126	antihypertensive	group	DDI-DrugBank.d633.s7.e1
DDI-DrugBank.d633.s7	133	151	anticoagulant drugs	group	DDI-DrugBank.d633.s7.e2
DDI-DrugBank.d633.s7	false	DDI-DrugBank.d633.s7.e0	DDI-DrugBank.d633.s7.e1
DDI-DrugBank.d633.s7	false	DDI-DrugBank.d633.s7.e0	DDI-DrugBank.d633.s7.e2
DDI-DrugBank.d633.s7	false	DDI-DrugBank.d633.s7.e1	DDI-DrugBank.d633.s7.e2
DDI-DrugBank.d633.s8|a|A variety of antiarrhythmics such as quinidine or propranolol were also added, sometimes with improved control of ventricular ectopy. 
DDI-DrugBank.d633.s8	13	27	antiarrhythmics	group	DDI-DrugBank.d633.s8.e0
DDI-DrugBank.d633.s8	37	45	quinidine	drug	DDI-DrugBank.d633.s8.e1
DDI-DrugBank.d633.s8	50	60	propranolol	drug	DDI-DrugBank.d633.s8.e2
DDI-DrugBank.d633.s8	false	DDI-DrugBank.d633.s8.e0	DDI-DrugBank.d633.s8.e1
DDI-DrugBank.d633.s8	false	DDI-DrugBank.d633.s8.e0	DDI-DrugBank.d633.s8.e2
DDI-DrugBank.d633.s8	false	DDI-DrugBank.d633.s8.e1	DDI-DrugBank.d633.s8.e2
DDI-DrugBank.d633.s9|a|When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. 
DDI-DrugBank.d633.s9	5	13	phenytoin	drug	DDI-DrugBank.d633.s9.e0
DDI-DrugBank.d633.s9	56	63	rifampin	drug	DDI-DrugBank.d633.s9.e1
DDI-DrugBank.d633.s9	69	81	phenobarbital	drug	DDI-DrugBank.d633.s9.e2
DDI-DrugBank.d633.s9	117	123	Mexitil	brand	DDI-DrugBank.d633.s9.e3
DDI-DrugBank.d633.s9	137	143	Mexitil	brand	DDI-DrugBank.d633.s9.e4
DDI-DrugBank.d633.s9	false	DDI-DrugBank.d633.s9.e0	DDI-DrugBank.d633.s9.e1
DDI-DrugBank.d633.s9	false	DDI-DrugBank.d633.s9.e0	DDI-DrugBank.d633.s9.e2
DDI-DrugBank.d633.s9	true	DDI-DrugBank.d633.s9.e0	DDI-DrugBank.d633.s9.e3
DDI-DrugBank.d633.s9	false	DDI-DrugBank.d633.s9.e0	DDI-DrugBank.d633.s9.e4
DDI-DrugBank.d633.s9	false	DDI-DrugBank.d633.s9.e1	DDI-DrugBank.d633.s9.e2
DDI-DrugBank.d633.s9	true	DDI-DrugBank.d633.s9.e1	DDI-DrugBank.d633.s9.e3
DDI-DrugBank.d633.s9	false	DDI-DrugBank.d633.s9.e1	DDI-DrugBank.d633.s9.e4
DDI-DrugBank.d633.s9	true	DDI-DrugBank.d633.s9.e2	DDI-DrugBank.d633.s9.e3
DDI-DrugBank.d633.s9	false	DDI-DrugBank.d633.s9.e2	DDI-DrugBank.d633.s9.e4
DDI-DrugBank.d633.s9	false	DDI-DrugBank.d633.s9.e3	DDI-DrugBank.d633.s9.e4
DDI-DrugBank.d633.s10|a|Monitoring of Mexitil    plasma levels is recommended during such concurrent use to avoid ineffective therapy. 
DDI-DrugBank.d633.s10	14	20	Mexitil	brand	DDI-DrugBank.d633.s10.e0
DDI-DrugBank.d633.s11|a|In a formal study, benzodiazepines were shown not to affect Mexitil    plasma concentrations. 
DDI-DrugBank.d633.s11	19	33	benzodiazepines	group	DDI-DrugBank.d633.s11.e0
DDI-DrugBank.d633.s11	60	66	Mexitil	brand	DDI-DrugBank.d633.s11.e1
DDI-DrugBank.d633.s11	false	DDI-DrugBank.d633.s11.e0	DDI-DrugBank.d633.s11.e1
DDI-DrugBank.d633.s12|a|ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and digoxin, diuretics, or propranolol. 
DDI-DrugBank.d633.s12	64	70	Mexitil	brand	DDI-DrugBank.d633.s12.e0
DDI-DrugBank.d633.s12	79	85	digoxin	drug	DDI-DrugBank.d633.s12.e1
DDI-DrugBank.d633.s12	88	96	diuretics	group	DDI-DrugBank.d633.s12.e2
DDI-DrugBank.d633.s12	102	112	propranolol	drug	DDI-DrugBank.d633.s12.e3
DDI-DrugBank.d633.s12	false	DDI-DrugBank.d633.s12.e0	DDI-DrugBank.d633.s12.e1
DDI-DrugBank.d633.s12	false	DDI-DrugBank.d633.s12.e0	DDI-DrugBank.d633.s12.e2
DDI-DrugBank.d633.s12	false	DDI-DrugBank.d633.s12.e0	DDI-DrugBank.d633.s12.e3
DDI-DrugBank.d633.s12	false	DDI-DrugBank.d633.s12.e1	DDI-DrugBank.d633.s12.e2
DDI-DrugBank.d633.s12	false	DDI-DrugBank.d633.s12.e1	DDI-DrugBank.d633.s12.e3
DDI-DrugBank.d633.s12	false	DDI-DrugBank.d633.s12.e2	DDI-DrugBank.d633.s12.e3
DDI-DrugBank.d633.s13|a|Concurrent administration of cimetidine and Mexitil    has been reported to increase, decrease, or leave unchanged Mexitil    plasma levels; 
DDI-DrugBank.d633.s13	29	38	cimetidine	drug	DDI-DrugBank.d633.s13.e0
DDI-DrugBank.d633.s13	44	50	Mexitil	brand	DDI-DrugBank.d633.s13.e1
DDI-DrugBank.d633.s13	115	121	Mexitil	brand	DDI-DrugBank.d633.s13.e2
DDI-DrugBank.d633.s13	true	DDI-DrugBank.d633.s13.e0	DDI-DrugBank.d633.s13.e1
DDI-DrugBank.d633.s13	false	DDI-DrugBank.d633.s13.e0	DDI-DrugBank.d633.s13.e2
DDI-DrugBank.d633.s13	false	DDI-DrugBank.d633.s13.e1	DDI-DrugBank.d633.s13.e2
DDI-DrugBank.d633.s14|a|therefore patients should be followed carefully during concurrent therapy. 
DDI-DrugBank.d633.s15|a|Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. 
DDI-DrugBank.d633.s15	0	6	Mexitil	brand	DDI-DrugBank.d633.s15.e0
DDI-DrugBank.d633.s15	32	38	digoxin	drug	DDI-DrugBank.d633.s15.e1
DDI-DrugBank.d633.s15	51	78	magnesium-aluminum hydroxide	drug	DDI-DrugBank.d633.s15.e2
DDI-DrugBank.d633.s15	133	139	Mexitil	brand	DDI-DrugBank.d633.s15.e3
DDI-DrugBank.d633.s15	178	184	digoxin	drug	DDI-DrugBank.d633.s15.e4
DDI-DrugBank.d633.s15	false	DDI-DrugBank.d633.s15.e0	DDI-DrugBank.d633.s15.e1
DDI-DrugBank.d633.s15	false	DDI-DrugBank.d633.s15.e0	DDI-DrugBank.d633.s15.e2
DDI-DrugBank.d633.s15	false	DDI-DrugBank.d633.s15.e0	DDI-DrugBank.d633.s15.e3
DDI-DrugBank.d633.s15	false	DDI-DrugBank.d633.s15.e0	DDI-DrugBank.d633.s15.e4
DDI-DrugBank.d633.s15	false	DDI-DrugBank.d633.s15.e1	DDI-DrugBank.d633.s15.e2
DDI-DrugBank.d633.s15	false	DDI-DrugBank.d633.s15.e1	DDI-DrugBank.d633.s15.e3
DDI-DrugBank.d633.s15	false	DDI-DrugBank.d633.s15.e1	DDI-DrugBank.d633.s15.e4
DDI-DrugBank.d633.s15	false	DDI-DrugBank.d633.s15.e2	DDI-DrugBank.d633.s15.e3
DDI-DrugBank.d633.s15	true	DDI-DrugBank.d633.s15.e2	DDI-DrugBank.d633.s15.e4
DDI-DrugBank.d633.s15	false	DDI-DrugBank.d633.s15.e3	DDI-DrugBank.d633.s15.e4
DDI-DrugBank.d633.s16|a|Concurrent use of Mexitil    and theophylline may lead to increased plasma theophylline levels. 
DDI-DrugBank.d633.s16	18	24	Mexitil	brand	DDI-DrugBank.d633.s16.e0
DDI-DrugBank.d633.s16	33	44	theophylline	drug	DDI-DrugBank.d633.s16.e1
DDI-DrugBank.d633.s16	75	86	theophylline	drug	DDI-DrugBank.d633.s16.e2
DDI-DrugBank.d633.s16	true	DDI-DrugBank.d633.s16.e0	DDI-DrugBank.d633.s16.e1
DDI-DrugBank.d633.s16	false	DDI-DrugBank.d633.s16.e0	DDI-DrugBank.d633.s16.e2
DDI-DrugBank.d633.s16	false	DDI-DrugBank.d633.s16.e1	DDI-DrugBank.d633.s16.e2
DDI-DrugBank.d633.s17|a|One controlled study in eight normal subjects showed a 72% mean increase (range 35-136%) in plasma theophylline levels. 
DDI-DrugBank.d633.s17	99	110	theophylline	drug	DDI-DrugBank.d633.s17.e0
DDI-DrugBank.d633.s18|a|This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 
DDI-DrugBank.d633.s18	91	97	Mexitil	brand	DDI-DrugBank.d633.s18.e0
DDI-DrugBank.d633.s18	103	114	Theophylline	drug	DDI-DrugBank.d633.s18.e1
DDI-DrugBank.d633.s18	146	152	Mexitil	brand	DDI-DrugBank.d633.s18.e2
DDI-DrugBank.d633.s18	200	206	Mexitil	brand	DDI-DrugBank.d633.s18.e3
DDI-DrugBank.d633.s18	215	221	Mexitil	brand	DDI-DrugBank.d633.s18.e4
DDI-DrugBank.d633.s18	227	238	theophylline	drug	DDI-DrugBank.d633.s18.e5
DDI-DrugBank.d633.s18	269	280	theophylline	drug	DDI-DrugBank.d633.s18.e6
DDI-DrugBank.d633.s18	338	344	Mexitil	brand	DDI-DrugBank.d633.s18.e7
DDI-DrugBank.d633.s18	false	DDI-DrugBank.d633.s18.e0	DDI-DrugBank.d633.s18.e1
DDI-DrugBank.d633.s18	false	DDI-DrugBank.d633.s18.e0	DDI-DrugBank.d633.s18.e2
DDI-DrugBank.d633.s18	false	DDI-DrugBank.d633.s18.e0	DDI-DrugBank.d633.s18.e3
DDI-DrugBank.d633.s18	false	DDI-DrugBank.d633.s18.e0	DDI-DrugBank.d633.s18.e4
DDI-DrugBank.d633.s18	false	DDI-DrugBank.d633.s18.e0	DDI-DrugBank.d633.s18.e5
DDI-DrugBank.d633.s18	false	DDI-DrugBank.d633.s18.e0	DDI-DrugBank.d633.s18.e6
DDI-DrugBank.d633.s18	false	DDI-DrugBank.d633.s18.e0	DDI-DrugBank.d633.s18.e7
DDI-DrugBank.d633.s18	false	DDI-DrugBank.d633.s18.e1	DDI-DrugBank.d633.s18.e2
DDI-DrugBank.d633.s18	true	DDI-DrugBank.d633.s18.e1	DDI-DrugBank.d633.s18.e3
DDI-DrugBank.d633.s18	false	DDI-DrugBank.d633.s18.e1	DDI-DrugBank.d633.s18.e4
DDI-DrugBank.d633.s19|a|An appropriate adjustment in theophylline dose should be considered. 
DDI-DrugBank.d633.s19	29	40	theophylline	drug	DDI-DrugBank.d633.s19.e0
DDI-DrugBank.d633.s20|a|Additionally, in one controlled study in five normal subjects and seven patients, the clearance of caffeine was decreased 50% following the administration of Mexitil   .
DDI-DrugBank.d633.s20	99	106	caffeine	drug	DDI-DrugBank.d633.s20.e0
DDI-DrugBank.d633.s20	158	164	Mexitil	brand	DDI-DrugBank.d633.s20.e1
DDI-DrugBank.d633.s20	true	DDI-DrugBank.d633.s20.e0	DDI-DrugBank.d633.s20.e1
DDI-DrugBank.d783.s0|a|Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. 
DDI-DrugBank.d783.s0	0	6	Posicor	brand	DDI-DrugBank.d783.s0.e0
DDI-DrugBank.d783.s0	78	88	terfenadine	drug	DDI-DrugBank.d783.s0.e1
DDI-DrugBank.d783.s0	91	100	astemizole	drug	DDI-DrugBank.d783.s0.e2
DDI-DrugBank.d783.s0	103	111	cisapride	drug	DDI-DrugBank.d783.s0.e3
DDI-DrugBank.d783.s0	114	125	cyclosporine	drug	DDI-DrugBank.d783.s0.e4
DDI-DrugBank.d783.s0	132	156	tricyclic antidepressants	group	DDI-DrugBank.d783.s0.e5
DDI-DrugBank.d783.s0	true	DDI-DrugBank.d783.s0.e0	DDI-DrugBank.d783.s0.e1
DDI-DrugBank.d783.s0	true	DDI-DrugBank.d783.s0.e0	DDI-DrugBank.d783.s0.e2
DDI-DrugBank.d783.s0	true	DDI-DrugBank.d783.s0.e0	DDI-DrugBank.d783.s0.e3
DDI-DrugBank.d783.s0	true	DDI-DrugBank.d783.s0.e0	DDI-DrugBank.d783.s0.e4
DDI-DrugBank.d783.s0	true	DDI-DrugBank.d783.s0.e0	DDI-DrugBank.d783.s0.e5
DDI-DrugBank.d783.s0	false	DDI-DrugBank.d783.s0.e1	DDI-DrugBank.d783.s0.e2
DDI-DrugBank.d783.s0	false	DDI-DrugBank.d783.s0.e1	DDI-DrugBank.d783.s0.e3
DDI-DrugBank.d783.s0	false	DDI-DrugBank.d783.s0.e1	DDI-DrugBank.d783.s0.e4
DDI-DrugBank.d783.s0	false	DDI-DrugBank.d783.s0.e1	DDI-DrugBank.d783.s0.e5
DDI-DrugBank.d783.s0	false	DDI-DrugBank.d783.s0.e2	DDI-DrugBank.d783.s0.e3
DDI-DrugBank.d783.s1|a|Thus the concentrations of these drugs would increase meaning side effects may be seen. 
DDI-DrugBank.d783.s2|a|A dose adjustment may be required.
DDI-DrugBank.d735.s0|a|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 
DDI-DrugBank.d735.s0	140	147	MYCAMINE	brand	DDI-DrugBank.d735.s0.e0
DDI-DrugBank.d735.s0	153	173	mycophenolate mofetil	drug	DDI-DrugBank.d735.s0.e1
DDI-DrugBank.d735.s0	176	187	cyclosporine	drug	DDI-DrugBank.d735.s0.e2
DDI-DrugBank.d735.s0	190	199	tacrolimus	drug	DDI-DrugBank.d735.s0.e3
DDI-DrugBank.d735.s0	202	213	prednisolone	drug	DDI-DrugBank.d735.s0.e4
DDI-DrugBank.d735.s0	216	224	sirolimus	drug	DDI-DrugBank.d735.s0.e5
DDI-DrugBank.d735.s0	227	236	nifedipine	drug	DDI-DrugBank.d735.s0.e6
DDI-DrugBank.d735.s0	239	249	fluconazole	drug	DDI-DrugBank.d735.s0.e7
DDI-DrugBank.d735.s0	252	260	ritonavir	drug	DDI-DrugBank.d735.s0.e8
DDI-DrugBank.d735.s0	267	274	rifampin	drug	DDI-DrugBank.d735.s0.e9
DDI-DrugBank.d735.s0	false	DDI-DrugBank.d735.s0.e0	DDI-DrugBank.d735.s0.e1
DDI-DrugBank.d735.s0	false	DDI-DrugBank.d735.s0.e0	DDI-DrugBank.d735.s0.e2
DDI-DrugBank.d735.s0	false	DDI-DrugBank.d735.s0.e0	DDI-DrugBank.d735.s0.e3
DDI-DrugBank.d735.s0	false	DDI-DrugBank.d735.s0.e0	DDI-DrugBank.d735.s0.e4
DDI-DrugBank.d735.s0	false	DDI-DrugBank.d735.s0.e0	DDI-DrugBank.d735.s0.e5
DDI-DrugBank.d735.s0	false	DDI-DrugBank.d735.s0.e0	DDI-DrugBank.d735.s0.e6
DDI-DrugBank.d735.s0	false	DDI-DrugBank.d735.s0.e0	DDI-DrugBank.d735.s0.e7
DDI-DrugBank.d735.s0	false	DDI-DrugBank.d735.s0.e0	DDI-DrugBank.d735.s0.e8
DDI-DrugBank.d735.s0	false	DDI-DrugBank.d735.s0.e0	DDI-DrugBank.d735.s0.e9
DDI-DrugBank.d735.s0	false	DDI-DrugBank.d735.s0.e1	DDI-DrugBank.d735.s0.e2
DDI-DrugBank.d735.s1|a|In these studies, no interaction that altered the pharmacokinetics of micafungin was observed. 
DDI-DrugBank.d735.s1	70	79	micafungin	drug	DDI-DrugBank.d735.s1.e0
DDI-DrugBank.d735.s2|a|There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. 
DDI-DrugBank.d735.s2	58	65	MYCAMINE	brand	DDI-DrugBank.d735.s2.e0
DDI-DrugBank.d735.s2	70	90	mycophenolate mofetil	drug	DDI-DrugBank.d735.s2.e1
DDI-DrugBank.d735.s2	93	104	cyclosporine	drug	DDI-DrugBank.d735.s2.e2
DDI-DrugBank.d735.s2	107	116	tacrolimus	drug	DDI-DrugBank.d735.s2.e3
DDI-DrugBank.d735.s2	119	130	prednisolone	drug	DDI-DrugBank.d735.s2.e4
DDI-DrugBank.d735.s2	137	147	fluconazole	drug	DDI-DrugBank.d735.s2.e5
DDI-DrugBank.d735.s2	false	DDI-DrugBank.d735.s2.e0	DDI-DrugBank.d735.s2.e1
DDI-DrugBank.d735.s2	false	DDI-DrugBank.d735.s2.e0	DDI-DrugBank.d735.s2.e2
DDI-DrugBank.d735.s2	false	DDI-DrugBank.d735.s2.e0	DDI-DrugBank.d735.s2.e3
DDI-DrugBank.d735.s2	false	DDI-DrugBank.d735.s2.e0	DDI-DrugBank.d735.s2.e4
DDI-DrugBank.d735.s2	false	DDI-DrugBank.d735.s2.e0	DDI-DrugBank.d735.s2.e5
DDI-DrugBank.d735.s2	false	DDI-DrugBank.d735.s2.e1	DDI-DrugBank.d735.s2.e2
DDI-DrugBank.d735.s2	false	DDI-DrugBank.d735.s2.e1	DDI-DrugBank.d735.s2.e3
DDI-DrugBank.d735.s2	false	DDI-DrugBank.d735.s2.e1	DDI-DrugBank.d735.s2.e4
DDI-DrugBank.d735.s2	false	DDI-DrugBank.d735.s2.e1	DDI-DrugBank.d735.s2.e5
DDI-DrugBank.d735.s2	false	DDI-DrugBank.d735.s2.e2	DDI-DrugBank.d735.s2.e3
DDI-DrugBank.d735.s3|a|Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state MYCAMINE compared with sirolimus alone. 
DDI-DrugBank.d735.s3	0	8	Sirolimus	drug	DDI-DrugBank.d735.s3.e0
DDI-DrugBank.d735.s3	90	97	MYCAMINE	brand	DDI-DrugBank.d735.s3.e1
DDI-DrugBank.d735.s3	113	121	sirolimus	drug	DDI-DrugBank.d735.s3.e2
DDI-DrugBank.d735.s3	true	DDI-DrugBank.d735.s3.e0	DDI-DrugBank.d735.s3.e1
DDI-DrugBank.d735.s3	false	DDI-DrugBank.d735.s3.e0	DDI-DrugBank.d735.s3.e2
DDI-DrugBank.d735.s3	false	DDI-DrugBank.d735.s3.e1	DDI-DrugBank.d735.s3.e2
DDI-DrugBank.d735.s4|a|Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with nifedipine alone. 
DDI-DrugBank.d735.s4	0	9	Nifedipine	drug	DDI-DrugBank.d735.s4.e0
DDI-DrugBank.d735.s4	101	108	MYCAMINE	brand	DDI-DrugBank.d735.s4.e1
DDI-DrugBank.d735.s4	124	133	nifedipine	drug	DDI-DrugBank.d735.s4.e2
DDI-DrugBank.d735.s4	true	DDI-DrugBank.d735.s4.e0	DDI-DrugBank.d735.s4.e1
DDI-DrugBank.d735.s4	false	DDI-DrugBank.d735.s4.e0	DDI-DrugBank.d735.s4.e2
DDI-DrugBank.d735.s4	false	DDI-DrugBank.d735.s4.e1	DDI-DrugBank.d735.s4.e2
DDI-DrugBank.d735.s5|a|Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. 
DDI-DrugBank.d735.s5	19	27	sirolimus	drug	DDI-DrugBank.d735.s5.e0
DDI-DrugBank.d735.s5	32	41	nifedipine	drug	DDI-DrugBank.d735.s5.e1
DDI-DrugBank.d735.s5	63	70	MYCAMINE	brand	DDI-DrugBank.d735.s5.e2
DDI-DrugBank.d735.s5	96	104	sirolimus	drug	DDI-DrugBank.d735.s5.e3
DDI-DrugBank.d735.s5	109	118	nifedipine	drug	DDI-DrugBank.d735.s5.e4
DDI-DrugBank.d735.s5	133	141	sirolimus	drug	DDI-DrugBank.d735.s5.e5
DDI-DrugBank.d735.s5	146	155	nifedipine	drug	DDI-DrugBank.d735.s5.e6
DDI-DrugBank.d735.s5	false	DDI-DrugBank.d735.s5.e0	DDI-DrugBank.d735.s5.e1
DDI-DrugBank.d735.s5	true	DDI-DrugBank.d735.s5.e0	DDI-DrugBank.d735.s5.e2
DDI-DrugBank.d735.s5	false	DDI-DrugBank.d735.s5.e0	DDI-DrugBank.d735.s5.e3
DDI-DrugBank.d735.s5	false	DDI-DrugBank.d735.s5.e0	DDI-DrugBank.d735.s5.e4
DDI-DrugBank.d735.s5	false	DDI-DrugBank.d735.s5.e0	DDI-DrugBank.d735.s5.e5
DDI-DrugBank.d735.s5	false	DDI-DrugBank.d735.s5.e0	DDI-DrugBank.d735.s5.e6
DDI-DrugBank.d735.s5	true	DDI-DrugBank.d735.s5.e1	DDI-DrugBank.d735.s5.e2
DDI-DrugBank.d735.s5	false	DDI-DrugBank.d735.s5.e1	DDI-DrugBank.d735.s5.e3
DDI-DrugBank.d735.s5	false	DDI-DrugBank.d735.s5.e1	DDI-DrugBank.d735.s5.e4
DDI-DrugBank.d735.s5	false	DDI-DrugBank.d735.s5.e1	DDI-DrugBank.d735.s5.e5
DDI-DrugBank.d735.s6|a|Micafungin is not an inhibitor of P-glycoprotein and, therefore, would not be expected to alter P-glycoprotein-mediated drug transport activity.    
DDI-DrugBank.d735.s6	0	9	Micafungin	drug	DDI-DrugBank.d735.s6.e0
DDI-DrugBank.d752.s0|a|Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). 
DDI-DrugBank.d752.s0	74	82	midazolam	drug	DDI-DrugBank.d752.s0.e0
DDI-DrugBank.d752.s0	228	245	azole antimycotics	group	DDI-DrugBank.d752.s0.e1
DDI-DrugBank.d752.s0	248	266	protease inhibitors	group	DDI-DrugBank.d752.s0.e2
DDI-DrugBank.d752.s0	269	295	calcium channel antagonists	group	DDI-DrugBank.d752.s0.e3
DDI-DrugBank.d752.s0	302	322	macrolide antibiotics	group	DDI-DrugBank.d752.s0.e4
DDI-DrugBank.d752.s0	true	DDI-DrugBank.d752.s0.e0	DDI-DrugBank.d752.s0.e1
DDI-DrugBank.d752.s0	true	DDI-DrugBank.d752.s0.e0	DDI-DrugBank.d752.s0.e2
DDI-DrugBank.d752.s0	true	DDI-DrugBank.d752.s0.e0	DDI-DrugBank.d752.s0.e3
DDI-DrugBank.d752.s0	true	DDI-DrugBank.d752.s0.e0	DDI-DrugBank.d752.s0.e4
DDI-DrugBank.d752.s0	false	DDI-DrugBank.d752.s0.e1	DDI-DrugBank.d752.s0.e2
DDI-DrugBank.d752.s0	false	DDI-DrugBank.d752.s0.e1	DDI-DrugBank.d752.s0.e3
DDI-DrugBank.d752.s0	false	DDI-DrugBank.d752.s0.e1	DDI-DrugBank.d752.s0.e4
DDI-DrugBank.d752.s0	false	DDI-DrugBank.d752.s0.e2	DDI-DrugBank.d752.s0.e3
DDI-DrugBank.d752.s0	false	DDI-DrugBank.d752.s0.e2	DDI-DrugBank.d752.s0.e4
DDI-DrugBank.d752.s0	false	DDI-DrugBank.d752.s0.e3	DDI-DrugBank.d752.s0.e4
DDI-DrugBank.d752.s1|a|Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. 
DDI-DrugBank.d752.s1	14	25	erythromycin	drug	DDI-DrugBank.d752.s1.e0
DDI-DrugBank.d752.s1	28	36	diltiazem	drug	DDI-DrugBank.d752.s1.e1
DDI-DrugBank.d752.s1	39	47	verapamil	drug	DDI-DrugBank.d752.s1.e2
DDI-DrugBank.d752.s1	50	61	ketoconazole	drug	DDI-DrugBank.d752.s1.e3
DDI-DrugBank.d752.s1	64	74	fluconazole	drug	DDI-DrugBank.d752.s1.e4
DDI-DrugBank.d752.s1	80	91	itraconazole	drug	DDI-DrugBank.d752.s1.e5
DDI-DrugBank.d752.s1	171	179	midazolam	drug	DDI-DrugBank.d752.s1.e6
DDI-DrugBank.d752.s1	false	DDI-DrugBank.d752.s1.e0	DDI-DrugBank.d752.s1.e1
DDI-DrugBank.d752.s1	false	DDI-DrugBank.d752.s1.e0	DDI-DrugBank.d752.s1.e2
DDI-DrugBank.d752.s1	false	DDI-DrugBank.d752.s1.e0	DDI-DrugBank.d752.s1.e3
DDI-DrugBank.d752.s1	false	DDI-DrugBank.d752.s1.e0	DDI-DrugBank.d752.s1.e4
DDI-DrugBank.d752.s1	false	DDI-DrugBank.d752.s1.e0	DDI-DrugBank.d752.s1.e5
DDI-DrugBank.d752.s1	true	DDI-DrugBank.d752.s1.e0	DDI-DrugBank.d752.s1.e6
DDI-DrugBank.d752.s1	false	DDI-DrugBank.d752.s1.e1	DDI-DrugBank.d752.s1.e2
DDI-DrugBank.d752.s1	false	DDI-DrugBank.d752.s1.e1	DDI-DrugBank.d752.s1.e3
DDI-DrugBank.d752.s1	false	DDI-DrugBank.d752.s1.e1	DDI-DrugBank.d752.s1.e4
DDI-DrugBank.d752.s1	false	DDI-DrugBank.d752.s1.e1	DDI-DrugBank.d752.s1.e5
DDI-DrugBank.d752.s2|a|These drug interactions may result in increased and prolonged sedation due to a decrease in plasma clearance of midazolam. 
DDI-DrugBank.d752.s2	112	120	midazolam	drug	DDI-DrugBank.d752.s2.e0
DDI-DrugBank.d752.s3|a|Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. 
DDI-DrugBank.d752.s3	64	72	ritonavir	drug	DDI-DrugBank.d752.s3.e0
DDI-DrugBank.d752.s3	78	87	nelfinavir	drug	DDI-DrugBank.d752.s3.e1
DDI-DrugBank.d752.s3	198	206	midazolam	drug	DDI-DrugBank.d752.s3.e2
DDI-DrugBank.d752.s3	false	DDI-DrugBank.d752.s3.e0	DDI-DrugBank.d752.s3.e1
DDI-DrugBank.d752.s3	true	DDI-DrugBank.d752.s3.e0	DDI-DrugBank.d752.s3.e2
DDI-DrugBank.d752.s3	true	DDI-DrugBank.d752.s3.e1	DDI-DrugBank.d752.s3.e2
DDI-DrugBank.d752.s4|a|Caution is advised when VERSED Syrup is used concomitantly with these drugs. 
DDI-DrugBank.d752.s4	24	35	VERSED Syrup	brand	DDI-DrugBank.d752.s4.e0
DDI-DrugBank.d752.s5|a|Dose adjustments should be considered and possible prolongation and intensity of effect should be anticipated. 
DDI-DrugBank.d752.s6|a|Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. 
DDI-DrugBank.d752.s6	63	70	rifampin	drug	DDI-DrugBank.d752.s6.e0
DDI-DrugBank.d752.s6	73	85	carbamazepine	drug	DDI-DrugBank.d752.s6.e1
DDI-DrugBank.d752.s6	92	100	phenytoin	drug	DDI-DrugBank.d752.s6.e2
DDI-DrugBank.d752.s6	175	183	midazolam	drug	DDI-DrugBank.d752.s6.e3
DDI-DrugBank.d752.s6	false	DDI-DrugBank.d752.s6.e0	DDI-DrugBank.d752.s6.e1
DDI-DrugBank.d752.s6	false	DDI-DrugBank.d752.s6.e0	DDI-DrugBank.d752.s6.e2
DDI-DrugBank.d752.s6	true	DDI-DrugBank.d752.s6.e0	DDI-DrugBank.d752.s6.e3
DDI-DrugBank.d752.s6	false	DDI-DrugBank.d752.s6.e1	DDI-DrugBank.d752.s6.e2
DDI-DrugBank.d752.s6	true	DDI-DrugBank.d752.s6.e1	DDI-DrugBank.d752.s6.e3
DDI-DrugBank.d752.s6	true	DDI-DrugBank.d752.s6.e2	DDI-DrugBank.d752.s6.e3
DDI-DrugBank.d752.s7|a|Although clinical studies have not been performed, phenobarbital is expected to have the same effect. 
DDI-DrugBank.d752.s7	51	63	phenobarbital	drug	DDI-DrugBank.d752.s7.e0
DDI-DrugBank.d752.s8|a|Caution is advised when administering VERSED Syrup to patients receiving these medications and if necessary dose adjustments should be considered. 
DDI-DrugBank.d752.s8	38	49	VERSED Syrup	brand	DDI-DrugBank.d752.s8.e0
DDI-DrugBank.d752.s9|a|The difficulty in achieving adequate sedation may have been the result of decreased absorption of the sedatives due to both the gastrointestinal effects and stimulant effects of methylphenidate. 
DDI-DrugBank.d752.s9	102	110	sedatives	group	DDI-DrugBank.d752.s9.e0
DDI-DrugBank.d752.s9	178	192	methylphenidate	drug	DDI-DrugBank.d752.s9.e1
DDI-DrugBank.d752.s9	false	DDI-DrugBank.d752.s9.e0	DDI-DrugBank.d752.s9.e1
DDI-DrugBank.d752.s10|a|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 
DDI-DrugBank.d752.s10	23	34	VERSED Syrup	brand	DDI-DrugBank.d752.s10.e0
DDI-DrugBank.d752.s10	153	161	narcotics	group	DDI-DrugBank.d752.s10.e1
DDI-DrugBank.d752.s10	168	175	morphine	drug	DDI-DrugBank.d752.s10.e2
DDI-DrugBank.d752.s10	178	187	meperidine	drug	DDI-DrugBank.d752.s10.e3
DDI-DrugBank.d752.s10	193	200	fentanyl	drug	DDI-DrugBank.d752.s10.e4
DDI-DrugBank.d752.s10	204	211	propofol	drug	DDI-DrugBank.d752.s10.e5
DDI-DrugBank.d752.s10	214	221	ketamine	drug	DDI-DrugBank.d752.s10.e6
DDI-DrugBank.d752.s10	224	236	nitrous oxide	drug	DDI-DrugBank.d752.s10.e7
DDI-DrugBank.d752.s10	239	250	secobarbital	drug	DDI-DrugBank.d752.s10.e8
DDI-DrugBank.d752.s10	256	265	droperidol	drug	DDI-DrugBank.d752.s10.e9
DDI-DrugBank.d752.s10	true	DDI-DrugBank.d752.s10.e0	DDI-DrugBank.d752.s10.e1
DDI-DrugBank.d752.s10	true	DDI-DrugBank.d752.s10.e0	DDI-DrugBank.d752.s10.e2
DDI-DrugBank.d752.s10	true	DDI-DrugBank.d752.s10.e0	DDI-DrugBank.d752.s10.e3
DDI-DrugBank.d752.s10	true	DDI-DrugBank.d752.s10.e0	DDI-DrugBank.d752.s10.e4
DDI-DrugBank.d752.s10	true	DDI-DrugBank.d752.s10.e0	DDI-DrugBank.d752.s10.e5
DDI-DrugBank.d752.s10	true	DDI-DrugBank.d752.s10.e0	DDI-DrugBank.d752.s10.e6
DDI-DrugBank.d752.s10	true	DDI-DrugBank.d752.s10.e0	DDI-DrugBank.d752.s10.e7
DDI-DrugBank.d752.s10	true	DDI-DrugBank.d752.s10.e0	DDI-DrugBank.d752.s10.e8
DDI-DrugBank.d752.s10	true	DDI-DrugBank.d752.s10.e0	DDI-DrugBank.d752.s10.e9
DDI-DrugBank.d752.s10	false	DDI-DrugBank.d752.s10.e1	DDI-DrugBank.d752.s10.e2
DDI-DrugBank.d752.s11|a|Consequently, the dose of VERSED Syrup should be adjusted according to the type and amount of concomitant medications administered and the desired clinical response. 
DDI-DrugBank.d752.s11	26	37	VERSED Syrup	brand	DDI-DrugBank.d752.s11.e0
DDI-DrugBank.d752.s12|a|No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.
DDI-DrugBank.d752.s12	72	79	atropine	drug	DDI-DrugBank.d752.s12.e0
DDI-DrugBank.d752.s12	82	92	scopolamine	drug	DDI-DrugBank.d752.s12.e1
DDI-DrugBank.d752.s12	95	108	glycopyrrolate	drug	DDI-DrugBank.d752.s12.e2
DDI-DrugBank.d752.s12	111	118	diazepam	drug	DDI-DrugBank.d752.s12.e3
DDI-DrugBank.d752.s12	121	131	hydroxyzine	drug	DDI-DrugBank.d752.s12.e4
DDI-DrugBank.d752.s12	144	159	muscle relaxants	group	DDI-DrugBank.d752.s12.e5
DDI-DrugBank.d752.s12	171	181	anesthetics	group	DDI-DrugBank.d752.s12.e6
DDI-DrugBank.d752.s12	false	DDI-DrugBank.d752.s12.e0	DDI-DrugBank.d752.s12.e1
DDI-DrugBank.d752.s12	false	DDI-DrugBank.d752.s12.e0	DDI-DrugBank.d752.s12.e2
DDI-DrugBank.d752.s12	false	DDI-DrugBank.d752.s12.e0	DDI-DrugBank.d752.s12.e3
DDI-DrugBank.d752.s12	false	DDI-DrugBank.d752.s12.e0	DDI-DrugBank.d752.s12.e4
DDI-DrugBank.d752.s12	false	DDI-DrugBank.d752.s12.e0	DDI-DrugBank.d752.s12.e5
DDI-DrugBank.d752.s12	false	DDI-DrugBank.d752.s12.e0	DDI-DrugBank.d752.s12.e6
DDI-DrugBank.d752.s12	false	DDI-DrugBank.d752.s12.e1	DDI-DrugBank.d752.s12.e2
DDI-DrugBank.d752.s12	false	DDI-DrugBank.d752.s12.e1	DDI-DrugBank.d752.s12.e3
DDI-DrugBank.d752.s12	false	DDI-DrugBank.d752.s12.e1	DDI-DrugBank.d752.s12.e4
DDI-DrugBank.d752.s12	false	DDI-DrugBank.d752.s12.e1	DDI-DrugBank.d752.s12.e5
DDI-DrugBank.d603.s0|a|When administered concomitantly with ProAmatine   , cardiac glycosides may enhance or precipitate bradycardia, A.V. 
DDI-DrugBank.d603.s0	37	46	ProAmatine	brand	DDI-DrugBank.d603.s0.e0
DDI-DrugBank.d603.s0	52	69	cardiac glycosides	group	DDI-DrugBank.d603.s0.e1
DDI-DrugBank.d603.s0	true	DDI-DrugBank.d603.s0.e0	DDI-DrugBank.d603.s0.e1
DDI-DrugBank.d603.s1|a|block or arrhythmia. 
DDI-DrugBank.d603.s2|a|The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. 
DDI-DrugBank.d603.s2	66	78	phenylephrine	drug	DDI-DrugBank.d603.s2.e0
DDI-DrugBank.d603.s2	81	95	pseudoephedrine	drug	DDI-DrugBank.d603.s2.e1
DDI-DrugBank.d603.s2	98	106	ephedrine	drug	DDI-DrugBank.d603.s2.e2
DDI-DrugBank.d603.s2	109	127	phenylpropanolamine	drug	DDI-DrugBank.d603.s2.e3
DDI-DrugBank.d603.s2	132	148	dihydroergotamine	drug	DDI-DrugBank.d603.s2.e4
DDI-DrugBank.d603.s2	200	209	ProAmatine	brand	DDI-DrugBank.d603.s2.e5
DDI-DrugBank.d603.s2	254	263	ProAmatine	brand	DDI-DrugBank.d603.s2.e6
DDI-DrugBank.d603.s2	false	DDI-DrugBank.d603.s2.e0	DDI-DrugBank.d603.s2.e1
DDI-DrugBank.d603.s2	false	DDI-DrugBank.d603.s2.e0	DDI-DrugBank.d603.s2.e2
DDI-DrugBank.d603.s2	false	DDI-DrugBank.d603.s2.e0	DDI-DrugBank.d603.s2.e3
DDI-DrugBank.d603.s2	false	DDI-DrugBank.d603.s2.e0	DDI-DrugBank.d603.s2.e4
DDI-DrugBank.d603.s2	true	DDI-DrugBank.d603.s2.e0	DDI-DrugBank.d603.s2.e5
DDI-DrugBank.d603.s2	false	DDI-DrugBank.d603.s2.e0	DDI-DrugBank.d603.s2.e6
DDI-DrugBank.d603.s2	false	DDI-DrugBank.d603.s2.e1	DDI-DrugBank.d603.s2.e2
DDI-DrugBank.d603.s2	false	DDI-DrugBank.d603.s2.e1	DDI-DrugBank.d603.s2.e3
DDI-DrugBank.d603.s2	false	DDI-DrugBank.d603.s2.e1	DDI-DrugBank.d603.s2.e4
DDI-DrugBank.d603.s2	true	DDI-DrugBank.d603.s2.e1	DDI-DrugBank.d603.s2.e5
DDI-DrugBank.d603.s3|a|ProAmatine    has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e., fludrocortisone acetate), with or without salt supplementation. 
DDI-DrugBank.d603.s3	0	9	ProAmatine	brand	DDI-DrugBank.d603.s3.e0
DDI-DrugBank.d603.s3	105	127	fludrocortisone acetate	drug	DDI-DrugBank.d603.s3.e1
DDI-DrugBank.d603.s3	false	DDI-DrugBank.d603.s3.e0	DDI-DrugBank.d603.s3.e1
DDI-DrugBank.d603.s4|a|The potential for supine hypertension should be carefully monitored in these patients and may be minimized by either reducing the dose of fludrocortisone acetate or decreasing the salt intake prior to initiation of treatment with. 
DDI-DrugBank.d603.s4	138	160	fludrocortisone acetate	drug	DDI-DrugBank.d603.s4.e0
DDI-DrugBank.d603.s5|a|ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 
DDI-DrugBank.d603.s5	0	9	ProAmatine	brand	DDI-DrugBank.d603.s5.e0
DDI-DrugBank.d603.s5	12	43	Alpha-adrenergic blocking agents	group	DDI-DrugBank.d603.s5.e1
DDI-DrugBank.d603.s5	54	61	prazosin	drug	DDI-DrugBank.d603.s5.e2
DDI-DrugBank.d603.s5	64	72	terazosin	drug	DDI-DrugBank.d603.s5.e3
DDI-DrugBank.d603.s5	79	87	doxazosin	drug	DDI-DrugBank.d603.s5.e4
DDI-DrugBank.d603.s5	120	129	ProAmatine	brand	DDI-DrugBank.d603.s5.e5
DDI-DrugBank.d603.s5	274	288	desglymidodrine	drug_n	DDI-DrugBank.d603.s5.e6
DDI-DrugBank.d603.s5	415	423	metformin	drug	DDI-DrugBank.d603.s5.e7
DDI-DrugBank.d603.s5	426	435	cimetidine	drug	DDI-DrugBank.d603.s5.e8
DDI-DrugBank.d603.s5	438	447	ranitidine	drug	DDI-DrugBank.d603.s5.e9
DDI-DrugBank.d603.s5	false	DDI-DrugBank.d603.s5.e0	DDI-DrugBank.d603.s5.e1
DDI-DrugBank.d603.s5	false	DDI-DrugBank.d603.s5.e0	DDI-DrugBank.d603.s5.e2
DDI-DrugBank.d603.s5	false	DDI-DrugBank.d603.s5.e0	DDI-DrugBank.d603.s5.e3
DDI-DrugBank.d603.s5	false	DDI-DrugBank.d603.s5.e0	DDI-DrugBank.d603.s5.e4
DDI-DrugBank.d603.s5	false	DDI-DrugBank.d603.s5.e0	DDI-DrugBank.d603.s5.e5
DDI-DrugBank.d603.s5	false	DDI-DrugBank.d603.s5.e0	DDI-DrugBank.d603.s5.e6
DDI-DrugBank.d603.s5	false	DDI-DrugBank.d603.s5.e0	DDI-DrugBank.d603.s5.e7
DDI-DrugBank.d603.s5	false	DDI-DrugBank.d603.s5.e0	DDI-DrugBank.d603.s5.e8
DDI-DrugBank.d603.s5	false	DDI-DrugBank.d603.s5.e0	DDI-DrugBank.d603.s5.e9
DDI-DrugBank.d603.s5	false	DDI-DrugBank.d603.s5.e0	DDI-DrugBank.d603.s5.e10
DDI-DrugBank.d603.s6|a|Thus there may be a potential for drug-drug interactions with these drugs.
DDI-DrugBank.d668.s0|a|Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). 
DDI-DrugBank.d668.s0	49	60	mifepristone	drug	DDI-DrugBank.d668.s0.e0
DDI-DrugBank.d668.s0	158	169	ketoconazole	drug	DDI-DrugBank.d668.s0.e1
DDI-DrugBank.d668.s0	172	183	itraconazole	drug	DDI-DrugBank.d668.s0.e2
DDI-DrugBank.d668.s0	186	197	erythromycin	drug	DDI-DrugBank.d668.s0.e3
DDI-DrugBank.d668.s0	276	287	mifepristone	drug	DDI-DrugBank.d668.s0.e4
DDI-DrugBank.d668.s0	false	DDI-DrugBank.d668.s0.e0	DDI-DrugBank.d668.s0.e1
DDI-DrugBank.d668.s0	false	DDI-DrugBank.d668.s0.e0	DDI-DrugBank.d668.s0.e2
DDI-DrugBank.d668.s0	false	DDI-DrugBank.d668.s0.e0	DDI-DrugBank.d668.s0.e3
DDI-DrugBank.d668.s0	false	DDI-DrugBank.d668.s0.e0	DDI-DrugBank.d668.s0.e4
DDI-DrugBank.d668.s0	false	DDI-DrugBank.d668.s0.e1	DDI-DrugBank.d668.s0.e2
DDI-DrugBank.d668.s0	false	DDI-DrugBank.d668.s0.e1	DDI-DrugBank.d668.s0.e3
DDI-DrugBank.d668.s0	true	DDI-DrugBank.d668.s0.e1	DDI-DrugBank.d668.s0.e4
DDI-DrugBank.d668.s0	false	DDI-DrugBank.d668.s0.e2	DDI-DrugBank.d668.s0.e3
DDI-DrugBank.d668.s0	true	DDI-DrugBank.d668.s0.e2	DDI-DrugBank.d668.s0.e4
DDI-DrugBank.d668.s0	true	DDI-DrugBank.d668.s0.e3	DDI-DrugBank.d668.s0.e4
DDI-DrugBank.d668.s1|a|Furthermore, rifampin, dexamethasone, St. 
DDI-DrugBank.d668.s1	13	20	rifampin	drug	DDI-DrugBank.d668.s1.e0
DDI-DrugBank.d668.s1	23	35	dexamethasone	drug	DDI-DrugBank.d668.s1.e1
DDI-DrugBank.d668.s1	false	DDI-DrugBank.d668.s1.e0	DDI-DrugBank.d668.s1.e1
DDI-DrugBank.d668.s2|a|John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). 
DDI-DrugBank.d668.s2	27	41	anticonvulsants	group	DDI-DrugBank.d668.s2.e0
DDI-DrugBank.d668.s2	44	52	phenytoin	drug	DDI-DrugBank.d668.s2.e1
DDI-DrugBank.d668.s2	55	67	phenobarbital	drug	DDI-DrugBank.d668.s2.e2
DDI-DrugBank.d668.s2	70	82	carbamazepine	drug	DDI-DrugBank.d668.s2.e3
DDI-DrugBank.d668.s2	96	107	mifepristone	drug	DDI-DrugBank.d668.s2.e4
DDI-DrugBank.d668.s2	146	157	mifepristone	drug	DDI-DrugBank.d668.s2.e5
DDI-DrugBank.d668.s2	false	DDI-DrugBank.d668.s2.e0	DDI-DrugBank.d668.s2.e1
DDI-DrugBank.d668.s2	false	DDI-DrugBank.d668.s2.e0	DDI-DrugBank.d668.s2.e2
DDI-DrugBank.d668.s2	false	DDI-DrugBank.d668.s2.e0	DDI-DrugBank.d668.s2.e3
DDI-DrugBank.d668.s2	true	DDI-DrugBank.d668.s2.e0	DDI-DrugBank.d668.s2.e4
DDI-DrugBank.d668.s2	false	DDI-DrugBank.d668.s2.e0	DDI-DrugBank.d668.s2.e5
DDI-DrugBank.d668.s2	false	DDI-DrugBank.d668.s2.e1	DDI-DrugBank.d668.s2.e2
DDI-DrugBank.d668.s2	false	DDI-DrugBank.d668.s2.e1	DDI-DrugBank.d668.s2.e3
DDI-DrugBank.d668.s2	true	DDI-DrugBank.d668.s2.e1	DDI-DrugBank.d668.s2.e4
DDI-DrugBank.d668.s2	false	DDI-DrugBank.d668.s2.e1	DDI-DrugBank.d668.s2.e5
DDI-DrugBank.d668.s2	false	DDI-DrugBank.d668.s2.e2	DDI-DrugBank.d668.s2.e3
DDI-DrugBank.d668.s3|a|Based on in vitro inhibition information, coadministration of mifepristone may lead to an increase in serum levels of drugs that are CYP 3A4 substrates. 
DDI-DrugBank.d668.s3	62	73	mifepristone	drug	DDI-DrugBank.d668.s3.e0
DDI-DrugBank.d668.s4|a|Due to the slow elimination of mifepristone from the body, such interaction may be observed for a prolonged period after its administration. 
DDI-DrugBank.d668.s4	31	42	mifepristone	drug	DDI-DrugBank.d668.s4.e0
DDI-DrugBank.d668.s5|a|Therefore, caution should be exercised when mifepristone is administered with drugs that are CYP 3A4 substrates and have narrow therapeutic range, including some agents used during general anesthesia.
DDI-DrugBank.d668.s5	44	55	mifepristone	drug	DDI-DrugBank.d668.s5.e0
DDI-DrugBank.d695.s0|a|While co-administration of ZAVESCA    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme. 
DDI-DrugBank.d695.s0	27	33	ZAVESCA	brand	DDI-DrugBank.d695.s0.e0
DDI-DrugBank.d695.s0	76	83	Cerezyme	brand	DDI-DrugBank.d695.s0.e1
DDI-DrugBank.d695.s0	218	225	Cerezyme	brand	DDI-DrugBank.d695.s0.e2
DDI-DrugBank.d695.s0	true	DDI-DrugBank.d695.s0.e0	DDI-DrugBank.d695.s0.e1
DDI-DrugBank.d695.s0	false	DDI-DrugBank.d695.s0.e0	DDI-DrugBank.d695.s0.e2
DDI-DrugBank.d695.s0	false	DDI-DrugBank.d695.s0.e1	DDI-DrugBank.d695.s0.e2
DDI-DrugBank.d695.s1|a|Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.
DDI-DrugBank.d695.s1	25	32	Cerezyme	brand	DDI-DrugBank.d695.s1.e0
DDI-DrugBank.d695.s1	38	49	imiglucerase	drug	DDI-DrugBank.d695.s1.e1
DDI-DrugBank.d695.s1	56	62	ZAVESCA	brand	DDI-DrugBank.d695.s1.e2
DDI-DrugBank.d695.s1	false	DDI-DrugBank.d695.s1.e0	DDI-DrugBank.d695.s1.e1
DDI-DrugBank.d695.s1	true	DDI-DrugBank.d695.s1.e0	DDI-DrugBank.d695.s1.e2
DDI-DrugBank.d695.s1	true	DDI-DrugBank.d695.s1.e1	DDI-DrugBank.d695.s1.e2
DDI-DrugBank.d711.s0|a|Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. 
DDI-DrugBank.d711.s0	8	20	tetracyclines	group	DDI-DrugBank.d711.s0.e0
DDI-DrugBank.d711.s0	98	110	anticoagulant	group	DDI-DrugBank.d711.s0.e1
DDI-DrugBank.d711.s0	161	173	anticoagulant	group	DDI-DrugBank.d711.s0.e2
DDI-DrugBank.d711.s0	true	DDI-DrugBank.d711.s0.e0	DDI-DrugBank.d711.s0.e1
DDI-DrugBank.d711.s0	false	DDI-DrugBank.d711.s0.e0	DDI-DrugBank.d711.s0.e2
DDI-DrugBank.d711.s0	false	DDI-DrugBank.d711.s0.e1	DDI-DrugBank.d711.s0.e2
DDI-DrugBank.d711.s1|a|Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline class drugs in conjunction with penicillin. 
DDI-DrugBank.d711.s1	73	82	penicillin	drug	DDI-DrugBank.d711.s1.e0
DDI-DrugBank.d711.s1	117	140	tetracycline class drugs	group	DDI-DrugBank.d711.s1.e1
DDI-DrugBank.d711.s1	162	171	penicillin	drug	DDI-DrugBank.d711.s1.e2
DDI-DrugBank.d711.s1	false	DDI-DrugBank.d711.s1.e0	DDI-DrugBank.d711.s1.e1
DDI-DrugBank.d711.s1	false	DDI-DrugBank.d711.s1.e0	DDI-DrugBank.d711.s1.e2
DDI-DrugBank.d711.s1	true	DDI-DrugBank.d711.s1.e1	DDI-DrugBank.d711.s1.e2
DDI-DrugBank.d711.s2|a|Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. 
DDI-DrugBank.d711.s2	14	26	tetracyclines	group	DDI-DrugBank.d711.s2.e0
DDI-DrugBank.d711.s2	43	50	antacids	group	DDI-DrugBank.d711.s2.e1
DDI-DrugBank.d711.s2	63	70	aluminum	drug	DDI-DrugBank.d711.s2.e2
DDI-DrugBank.d711.s2	73	79	calcium	drug	DDI-DrugBank.d711.s2.e3
DDI-DrugBank.d711.s2	84	92	magnesium	drug	DDI-DrugBank.d711.s2.e4
DDI-DrugBank.d711.s2	99	102	iron	drug	DDI-DrugBank.d711.s2.e5
DDI-DrugBank.d711.s2	false	DDI-DrugBank.d711.s2.e0	DDI-DrugBank.d711.s2.e1
DDI-DrugBank.d711.s2	true	DDI-DrugBank.d711.s2.e0	DDI-DrugBank.d711.s2.e2
DDI-DrugBank.d711.s2	true	DDI-DrugBank.d711.s2.e0	DDI-DrugBank.d711.s2.e3
DDI-DrugBank.d711.s2	true	DDI-DrugBank.d711.s2.e0	DDI-DrugBank.d711.s2.e4
DDI-DrugBank.d711.s2	true	DDI-DrugBank.d711.s2.e0	DDI-DrugBank.d711.s2.e5
DDI-DrugBank.d711.s2	false	DDI-DrugBank.d711.s2.e1	DDI-DrugBank.d711.s2.e2
DDI-DrugBank.d711.s2	false	DDI-DrugBank.d711.s2.e1	DDI-DrugBank.d711.s2.e3
DDI-DrugBank.d711.s2	false	DDI-DrugBank.d711.s2.e1	DDI-DrugBank.d711.s2.e4
DDI-DrugBank.d711.s2	false	DDI-DrugBank.d711.s2.e1	DDI-DrugBank.d711.s2.e5
DDI-DrugBank.d711.s2	false	DDI-DrugBank.d711.s2.e2	DDI-DrugBank.d711.s2.e3
DDI-DrugBank.d711.s3|a|The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. 
DDI-DrugBank.d711.s3	22	33	tetracycline	group	DDI-DrugBank.d711.s3.e0
DDI-DrugBank.d711.s3	39	52	methoxyflurane	drug	DDI-DrugBank.d711.s3.e1
DDI-DrugBank.d711.s3	true	DDI-DrugBank.d711.s3.e0	DDI-DrugBank.d711.s3.e1
DDI-DrugBank.d711.s4|a|Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.
DDI-DrugBank.d711.s4	18	30	tetracyclines	group	DDI-DrugBank.d711.s4.e0
DDI-DrugBank.d711.s4	42	55	contraceptives	group	DDI-DrugBank.d711.s4.e1
DDI-DrugBank.d711.s4	73	86	contraceptives	group	DDI-DrugBank.d711.s4.e2
DDI-DrugBank.d711.s4	true	DDI-DrugBank.d711.s4.e0	DDI-DrugBank.d711.s4.e1
DDI-DrugBank.d711.s4	false	DDI-DrugBank.d711.s4.e0	DDI-DrugBank.d711.s4.e2
DDI-DrugBank.d711.s4	false	DDI-DrugBank.d711.s4.e1	DDI-DrugBank.d711.s4.e2
DDI-DrugBank.d573.s0|a|Interaction with Guanethidine: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects. 
DDI-DrugBank.d573.s0	17	28	Guanethidine	drug	DDI-DrugBank.d573.s0.e0
DDI-DrugBank.d573.s0	40	48	minoxidil	drug	DDI-DrugBank.d573.s0.e1
DDI-DrugBank.d573.s0	146	157	guanethidine	drug	DDI-DrugBank.d573.s0.e2
DDI-DrugBank.d573.s0	false	DDI-DrugBank.d573.s0.e0	DDI-DrugBank.d573.s0.e1
DDI-DrugBank.d573.s0	false	DDI-DrugBank.d573.s0.e0	DDI-DrugBank.d573.s0.e2
DDI-DrugBank.d573.s0	true	DDI-DrugBank.d573.s0.e1	DDI-DrugBank.d573.s0.e2
DDI-DrugBank.d573.s1|a|If at all possible guanethidine should be discontinued well before minoxidil is begun. 
DDI-DrugBank.d573.s1	19	30	guanethidine	drug	DDI-DrugBank.d573.s1.e0
DDI-DrugBank.d573.s1	67	75	minoxidil	drug	DDI-DrugBank.d573.s1.e1
DDI-DrugBank.d573.s1	true	DDI-DrugBank.d573.s1.e0	DDI-DrugBank.d573.s1.e1
DDI-DrugBank.d573.s2|a|Where this is not possible, minoxidil therapy should be started in the hospital and the patient should remain institutionalized until severe orthostatic effects are no longer present or the patient has learned to avoid activities that provoke them.
DDI-DrugBank.d573.s2	28	36	minoxidil	drug	DDI-DrugBank.d573.s2.e0
DDI-DrugBank.d742.s0|a|As with other drugs, the potential for interaction by a variety of mechanisms (e.g., pharmacodynamic, pharmacokinetic inhibition or enhancement, etc.) 
DDI-DrugBank.d742.s1|a|is a possibility. 
DDI-DrugBank.d742.s2|a|Drugs Affecting Hepatic Metabolism The metabolism and pharmacokinetics of REMERON SolTab    (mirtazapine) Orally Disintegrating Tablets may be affected by the induction or inhibition of drug-metab-olizing enzymes. 
DDI-DrugBank.d742.s2	74	87	REMERON SolTab	brand	DDI-DrugBank.d742.s2.e0
DDI-DrugBank.d742.s2	93	103	mirtazapine	drug	DDI-DrugBank.d742.s2.e1
DDI-DrugBank.d742.s2	false	DDI-DrugBank.d742.s2.e0	DDI-DrugBank.d742.s2.e1
DDI-DrugBank.d742.s3|a|Drugs that are Metabolized by and/or Inhibit Cytochrome P450 Enzymes Many drugs are metabolized by and/or inhibit various cytochrome P450 enzymes, e.g., 2D6, 1A2, 3A4, etc. 
DDI-DrugBank.d742.s4|a|In vitro studies have shown that mirtazapine is a substrate for several of these enzymes, including 2D6, 1A2, and 3A4. 
DDI-DrugBank.d742.s4	33	43	mirtazapine	drug	DDI-DrugBank.d742.s4.e0
DDI-DrugBank.d742.s5|a|While in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes, an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of REMERON SolTab with most other drugs metabolized by these enzymes has not been formally studied. 
DDI-DrugBank.d742.s5	39	49	mirtazapine	drug	DDI-DrugBank.d742.s5.e0
DDI-DrugBank.d742.s5	121	131	mirtazapine	drug	DDI-DrugBank.d742.s5.e1
DDI-DrugBank.d742.s5	309	322	REMERON SolTab	brand	DDI-DrugBank.d742.s5.e2
DDI-DrugBank.d742.s5	false	DDI-DrugBank.d742.s5.e0	DDI-DrugBank.d742.s5.e1
DDI-DrugBank.d742.s5	false	DDI-DrugBank.d742.s5.e0	DDI-DrugBank.d742.s5.e2
DDI-DrugBank.d742.s5	false	DDI-DrugBank.d742.s5.e1	DDI-DrugBank.d742.s5.e2
DDI-DrugBank.d742.s6|a|Consequently, it is not possible to make any definitive statements about the risks of coadministration of REMERON SolTab    with such drugs. 
DDI-DrugBank.d742.s6	106	119	REMERON SolTab	brand	DDI-DrugBank.d742.s6.e0
DDI-DrugBank.d742.s7|a|Alcohol: Concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of mirtazapine (15 mg) in 6 healthy male subjects. 
DDI-DrugBank.d742.s7	0	6	Alcohol	drug	DDI-DrugBank.d742.s7.e0
DDI-DrugBank.d742.s7	39	45	alcohol	drug	DDI-DrugBank.d742.s7.e1
DDI-DrugBank.d742.s7	109	119	mirtazapine	drug	DDI-DrugBank.d742.s7.e2
DDI-DrugBank.d742.s7	false	DDI-DrugBank.d742.s7.e0	DDI-DrugBank.d742.s7.e1
DDI-DrugBank.d742.s7	false	DDI-DrugBank.d742.s7.e0	DDI-DrugBank.d742.s7.e2
DDI-DrugBank.d742.s7	true	DDI-DrugBank.d742.s7.e1	DDI-DrugBank.d742.s7.e2
DDI-DrugBank.d742.s8|a|However, the impairment of cognitive and motor skills produced by REMERON    were shown to be additive with those produced by alcohol. 
DDI-DrugBank.d742.s8	66	72	REMERON	brand	DDI-DrugBank.d742.s8.e0
DDI-DrugBank.d742.s8	126	132	alcohol	drug	DDI-DrugBank.d742.s8.e1
DDI-DrugBank.d742.s8	true	DDI-DrugBank.d742.s8.e0	DDI-DrugBank.d742.s8.e1
DDI-DrugBank.d742.s9|a|Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. 
DDI-DrugBank.d742.s9	49	55	alcohol	drug	DDI-DrugBank.d742.s9.e0
DDI-DrugBank.d742.s9	70	83	REMERON SolTab	brand	DDI-DrugBank.d742.s9.e1
DDI-DrugBank.d742.s9	86	93	Diazepam	drug	DDI-DrugBank.d742.s9.e2
DDI-DrugBank.d742.s9	126	133	diazepam	drug	DDI-DrugBank.d742.s9.e3
DDI-DrugBank.d742.s9	184	194	mirtazapine	drug	DDI-DrugBank.d742.s9.e4
DDI-DrugBank.d742.s9	true	DDI-DrugBank.d742.s9.e0	DDI-DrugBank.d742.s9.e1
DDI-DrugBank.d742.s9	false	DDI-DrugBank.d742.s9.e0	DDI-DrugBank.d742.s9.e2
DDI-DrugBank.d742.s9	false	DDI-DrugBank.d742.s9.e0	DDI-DrugBank.d742.s9.e3
DDI-DrugBank.d742.s9	false	DDI-DrugBank.d742.s9.e0	DDI-DrugBank.d742.s9.e4
DDI-DrugBank.d742.s9	false	DDI-DrugBank.d742.s9.e1	DDI-DrugBank.d742.s9.e2
DDI-DrugBank.d742.s9	false	DDI-DrugBank.d742.s9.e1	DDI-DrugBank.d742.s9.e3
DDI-DrugBank.d742.s9	false	DDI-DrugBank.d742.s9.e1	DDI-DrugBank.d742.s9.e4
DDI-DrugBank.d742.s9	false	DDI-DrugBank.d742.s9.e2	DDI-DrugBank.d742.s9.e3
DDI-DrugBank.d742.s9	false	DDI-DrugBank.d742.s9.e2	DDI-DrugBank.d742.s9.e4
DDI-DrugBank.d742.s9	true	DDI-DrugBank.d742.s9.e3	DDI-DrugBank.d742.s9.e4
DDI-DrugBank.d742.s10|a|However, the impairment of motor skills produced by REMERON has been shown to be additive with those caused by diazepam. 
DDI-DrugBank.d742.s10	52	58	REMERON	brand	DDI-DrugBank.d742.s10.e0
DDI-DrugBank.d742.s10	111	118	diazepam	drug	DDI-DrugBank.d742.s10.e1
DDI-DrugBank.d742.s10	true	DDI-DrugBank.d742.s10.e0	DDI-DrugBank.d742.s10.e1
DDI-DrugBank.d742.s11|a|Accordingly, patients should be advised to avoid diazepam and other similar drugs while taking REMERON SolTab.
DDI-DrugBank.d742.s11	49	56	diazepam	drug	DDI-DrugBank.d742.s11.e0
DDI-DrugBank.d742.s11	95	108	REMERON SolTab	brand	DDI-DrugBank.d742.s11.e1
DDI-DrugBank.d742.s11	true	DDI-DrugBank.d742.s11.e0	DDI-DrugBank.d742.s11.e1
DDI-DrugBank.d717.s0|a|Mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin. 
DDI-DrugBank.d717.s0	0	7	Mitotane	drug	DDI-DrugBank.d717.s0.e0
DDI-DrugBank.d717.s0	59	66	warfarin	drug	DDI-DrugBank.d717.s0.e1
DDI-DrugBank.d717.s0	175	182	warfarin	drug	DDI-DrugBank.d717.s0.e2
DDI-DrugBank.d717.s0	true	DDI-DrugBank.d717.s0.e0	DDI-DrugBank.d717.s0.e1
DDI-DrugBank.d717.s0	false	DDI-DrugBank.d717.s0.e0	DDI-DrugBank.d717.s0.e2
DDI-DrugBank.d717.s0	false	DDI-DrugBank.d717.s0.e1	DDI-DrugBank.d717.s0.e2
DDI-DrugBank.d717.s1|a|Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering Mitotane to patients on coumarin-type anticoagulants. 
DDI-DrugBank.d717.s1	70	82	anticoagulant	group	DDI-DrugBank.d717.s1.e0
DDI-DrugBank.d717.s1	123	130	Mitotane	drug	DDI-DrugBank.d717.s1.e1
DDI-DrugBank.d717.s1	147	174	coumarin-type anticoagulants	group	DDI-DrugBank.d717.s1.e2
DDI-DrugBank.d717.s1	false	DDI-DrugBank.d717.s1.e0	DDI-DrugBank.d717.s1.e1
DDI-DrugBank.d717.s1	false	DDI-DrugBank.d717.s1.e0	DDI-DrugBank.d717.s1.e2
DDI-DrugBank.d717.s1	true	DDI-DrugBank.d717.s1.e1	DDI-DrugBank.d717.s1.e2
DDI-DrugBank.d717.s2|a|In addition, Mitotane should be given with caution to patients receiving other drugs susceptible to the influence of hepatic enzyme induction.
DDI-DrugBank.d717.s2	13	20	Mitotane	drug	DDI-DrugBank.d717.s2.e0
DDI-DrugBank.d775.s0|a|Although MIVACRON (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between MIVACRON and succinylcholine has not been systematically studied. 
DDI-DrugBank.d775.s0	9	16	MIVACRON	brand	DDI-DrugBank.d775.s0.e0
DDI-DrugBank.d775.s0	165	172	MIVACRON	brand	DDI-DrugBank.d775.s0.e1
DDI-DrugBank.d775.s0	178	192	succinylcholine	drug	DDI-DrugBank.d775.s0.e2
DDI-DrugBank.d775.s0	false	DDI-DrugBank.d775.s0.e0	DDI-DrugBank.d775.s0.e1
DDI-DrugBank.d775.s0	false	DDI-DrugBank.d775.s0.e0	DDI-DrugBank.d775.s0.e2
DDI-DrugBank.d775.s0	false	DDI-DrugBank.d775.s0.e1	DDI-DrugBank.d775.s0.e2
DDI-DrugBank.d775.s1|a|Prior administration of succinylcholine can potentiate the neuromuscular blocking effects of nondepolarizing agents. 
DDI-DrugBank.d775.s1	24	38	succinylcholine	drug	DDI-DrugBank.d775.s1.e0
DDI-DrugBank.d775.s1	93	114	nondepolarizing agents	group	DDI-DrugBank.d775.s1.e1
DDI-DrugBank.d775.s1	true	DDI-DrugBank.d775.s1.e0	DDI-DrugBank.d775.s1.e1
DDI-DrugBank.d775.s2|a|Evidence of spontaneous recovery from succinylcholine should be observed before the administration of MIVACRON. 
DDI-DrugBank.d775.s2	38	52	succinylcholine	drug	DDI-DrugBank.d775.s2.e0
DDI-DrugBank.d775.s2	102	109	MIVACRON	brand	DDI-DrugBank.d775.s2.e1
DDI-DrugBank.d775.s2	true	DDI-DrugBank.d775.s2.e0	DDI-DrugBank.d775.s2.e1
DDI-DrugBank.d775.s3|a|The use of MIVACRON before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied. 
DDI-DrugBank.d775.s3	11	18	MIVACRON	brand	DDI-DrugBank.d775.s3.e0
DDI-DrugBank.d775.s3	27	41	succinylcholine	drug	DDI-DrugBank.d775.s3.e1
DDI-DrugBank.d775.s3	84	98	succinylcholine	drug	DDI-DrugBank.d775.s3.e2
DDI-DrugBank.d775.s3	false	DDI-DrugBank.d775.s3.e0	DDI-DrugBank.d775.s3.e1
DDI-DrugBank.d775.s3	false	DDI-DrugBank.d775.s3.e0	DDI-DrugBank.d775.s3.e2
DDI-DrugBank.d775.s3	false	DDI-DrugBank.d775.s3.e1	DDI-DrugBank.d775.s3.e2
DDI-DrugBank.d775.s4|a|There are no clinical data on the use of MIVACRON with other nondepolarizing neuromuscular blocking agents. 
DDI-DrugBank.d775.s4	41	48	MIVACRON	brand	DDI-DrugBank.d775.s4.e0
DDI-DrugBank.d775.s4	61	105	nondepolarizing neuromuscular blocking agents	group	DDI-DrugBank.d775.s4.e1
DDI-DrugBank.d775.s4	false	DDI-DrugBank.d775.s4.e0	DDI-DrugBank.d775.s4.e1
DDI-DrugBank.d775.s5|a|Isoflurane and enflurane (administered with nitrous oxide/oxygen to achieve 1.25 M.C. 
DDI-DrugBank.d775.s5	0	9	Isoflurane	drug	DDI-DrugBank.d775.s5.e0
DDI-DrugBank.d775.s5	15	23	enflurane	drug	DDI-DrugBank.d775.s5.e1
DDI-DrugBank.d775.s5	44	56	nitrous oxide	drug	DDI-DrugBank.d775.s5.e2
DDI-DrugBank.d775.s5	58	63	oxygen	drug	DDI-DrugBank.d775.s5.e3
DDI-DrugBank.d775.s5	false	DDI-DrugBank.d775.s5.e0	DDI-DrugBank.d775.s5.e1
DDI-DrugBank.d775.s5	false	DDI-DrugBank.d775.s5.e0	DDI-DrugBank.d775.s5.e2
DDI-DrugBank.d775.s5	false	DDI-DrugBank.d775.s5.e0	DDI-DrugBank.d775.s5.e3
DDI-DrugBank.d775.s5	false	DDI-DrugBank.d775.s5.e1	DDI-DrugBank.d775.s5.e2
DDI-DrugBank.d775.s5	false	DDI-DrugBank.d775.s5.e1	DDI-DrugBank.d775.s5.e3
DDI-DrugBank.d775.s5	false	DDI-DrugBank.d775.s5.e2	DDI-DrugBank.d775.s5.e3
DDI-DrugBank.d775.s6|a|decrease the ED50 of MIVACRON by as much as 25% (see CLINICAL PHARMACOLOGY: Pharmacodynamics and Individualization of Dosages). 
DDI-DrugBank.d775.s6	21	28	MIVACRON	brand	DDI-DrugBank.d775.s6.e0
DDI-DrugBank.d775.s7|a|These agents may also prolong the clinically effective duration of action and decrease the average infusion requirement of MIVACRON by as much as 35% to 40%. 
DDI-DrugBank.d775.s7	123	130	MIVACRON	brand	DDI-DrugBank.d775.s7.e0
DDI-DrugBank.d775.s8|a|A greater potentiation of the neuromuscular blocking effects of MIVACRON may be expected with higher concentrations of enflurane or isoflurane. 
DDI-DrugBank.d775.s8	64	71	MIVACRON	brand	DDI-DrugBank.d775.s8.e0
DDI-DrugBank.d775.s8	119	127	enflurane	drug	DDI-DrugBank.d775.s8.e1
DDI-DrugBank.d775.s8	132	141	isoflurane	drug	DDI-DrugBank.d775.s8.e2
DDI-DrugBank.d775.s8	false	DDI-DrugBank.d775.s8.e0	DDI-DrugBank.d775.s8.e1
DDI-DrugBank.d775.s8	false	DDI-DrugBank.d775.s8.e0	DDI-DrugBank.d775.s8.e2
DDI-DrugBank.d775.s8	false	DDI-DrugBank.d775.s8.e1	DDI-DrugBank.d775.s8.e2
DDI-DrugBank.d775.s9|a|Halothane has little or no effect on the ED50 , but may prolong the duration of action and decrease the average infusion requirement by as much as 20%. 
DDI-DrugBank.d775.s9	0	8	Halothane	drug	DDI-DrugBank.d775.s9.e0
DDI-DrugBank.d775.s10|a|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 
DDI-DrugBank.d775.s10	67	88	nondepolarizing agents	drug	DDI-DrugBank.d775.s10.e0
DDI-DrugBank.d775.s10	98	105	MIVACRON	brand	DDI-DrugBank.d775.s10.e1
DDI-DrugBank.d775.s10	123	133	antibiotics	group	DDI-DrugBank.d775.s10.e2
DDI-DrugBank.d775.s10	142	156	aminoglycosides	group	DDI-DrugBank.d775.s10.e3
DDI-DrugBank.d775.s10	159	171	tetracyclines	group	DDI-DrugBank.d775.s10.e4
DDI-DrugBank.d775.s10	174	183	bacitracin	drug	DDI-DrugBank.d775.s10.e5
DDI-DrugBank.d775.s10	186	195	polymyxins	group	DDI-DrugBank.d775.s10.e6
DDI-DrugBank.d775.s10	198	207	lincomycin	drug	DDI-DrugBank.d775.s10.e7
DDI-DrugBank.d775.s10	210	220	clindamycin	drug	DDI-DrugBank.d775.s10.e8
DDI-DrugBank.d775.s10	223	230	colistin	drug	DDI-DrugBank.d775.s10.e9
DDI-DrugBank.d775.s10	false	DDI-DrugBank.d775.s10.e0	DDI-DrugBank.d775.s10.e1
DDI-DrugBank.d775.s10	true	DDI-DrugBank.d775.s10.e0	DDI-DrugBank.d775.s10.e2
DDI-DrugBank.d775.s10	true	DDI-DrugBank.d775.s10.e0	DDI-DrugBank.d775.s10.e3
DDI-DrugBank.d775.s10	true	DDI-DrugBank.d775.s10.e0	DDI-DrugBank.d775.s10.e4
DDI-DrugBank.d775.s10	true	DDI-DrugBank.d775.s10.e0	DDI-DrugBank.d775.s10.e5
DDI-DrugBank.d775.s10	true	DDI-DrugBank.d775.s10.e0	DDI-DrugBank.d775.s10.e6
DDI-DrugBank.d775.s10	true	DDI-DrugBank.d775.s10.e0	DDI-DrugBank.d775.s10.e7
DDI-DrugBank.d775.s10	true	DDI-DrugBank.d775.s10.e0	DDI-DrugBank.d775.s10.e8
DDI-DrugBank.d775.s10	true	DDI-DrugBank.d775.s10.e0	DDI-DrugBank.d775.s10.e9
DDI-DrugBank.d775.s10	true	DDI-DrugBank.d775.s10.e0	DDI-DrugBank.d775.s10.e10
DDI-DrugBank.d775.s11|a|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. 
DDI-DrugBank.d775.s11	37	44	MIVACRON	brand	DDI-DrugBank.d775.s11.e0
DDI-DrugBank.d775.s11	151	164	contraceptives	group	DDI-DrugBank.d775.s11.e1
DDI-DrugBank.d775.s11	167	181	glucocorticoids	group	DDI-DrugBank.d775.s11.e2
DDI-DrugBank.d775.s11	195	222	monoamine oxidase inhibitors	group	DDI-DrugBank.d775.s11.e3
DDI-DrugBank.d775.s11	354	382	neuromuscular blocking agents	group	DDI-DrugBank.d775.s11.e4
DDI-DrugBank.d775.s11	443	451	phenytoin	drug	DDI-DrugBank.d775.s11.e5
DDI-DrugBank.d775.s11	456	468	carbamazepine	drug	DDI-DrugBank.d775.s11.e6
DDI-DrugBank.d775.s11	true	DDI-DrugBank.d775.s11.e0	DDI-DrugBank.d775.s11.e1
DDI-DrugBank.d775.s11	true	DDI-DrugBank.d775.s11.e0	DDI-DrugBank.d775.s11.e2
DDI-DrugBank.d775.s11	true	DDI-DrugBank.d775.s11.e0	DDI-DrugBank.d775.s11.e3
DDI-DrugBank.d775.s11	false	DDI-DrugBank.d775.s11.e0	DDI-DrugBank.d775.s11.e4
DDI-DrugBank.d775.s11	false	DDI-DrugBank.d775.s11.e0	DDI-DrugBank.d775.s11.e5
DDI-DrugBank.d775.s11	false	DDI-DrugBank.d775.s11.e0	DDI-DrugBank.d775.s11.e6
DDI-DrugBank.d775.s11	false	DDI-DrugBank.d775.s11.e1	DDI-DrugBank.d775.s11.e2
DDI-DrugBank.d775.s11	false	DDI-DrugBank.d775.s11.e1	DDI-DrugBank.d775.s11.e3
DDI-DrugBank.d775.s11	false	DDI-DrugBank.d775.s11.e1	DDI-DrugBank.d775.s11.e4
DDI-DrugBank.d775.s11	false	DDI-DrugBank.d775.s11.e1	DDI-DrugBank.d775.s11.e5
DDI-DrugBank.d775.s12|a|While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. 
DDI-DrugBank.d775.s12	29	37	phenytoin	drug	DDI-DrugBank.d775.s12.e0
DDI-DrugBank.d775.s12	42	54	carbamazepine	drug	DDI-DrugBank.d775.s12.e1
DDI-DrugBank.d775.s12	81	88	MIVACRON	brand	DDI-DrugBank.d775.s12.e2
DDI-DrugBank.d775.s12	false	DDI-DrugBank.d775.s12.e0	DDI-DrugBank.d775.s12.e1
DDI-DrugBank.d775.s12	true	DDI-DrugBank.d775.s12.e0	DDI-DrugBank.d775.s12.e2
DDI-DrugBank.d775.s12	true	DDI-DrugBank.d775.s12.e1	DDI-DrugBank.d775.s12.e2
DDI-DrugBank.d775.s13|a|Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13	53	67	corticosteroids	group	DDI-DrugBank.d775.s13.e0
DDI-DrugBank.d775.s13	176	184	phenytoin	drug	DDI-DrugBank.d775.s13.e1
DDI-DrugBank.d775.s13	189	201	carbamazepine	drug	DDI-DrugBank.d775.s13.e2
DDI-DrugBank.d775.s13	213	223	antibiotics	group	DDI-DrugBank.d775.s13.e3
DDI-DrugBank.d775.s13	246	254	cisplatin	drug	DDI-DrugBank.d775.s13.e4
DDI-DrugBank.d775.s13	258	268	edrophonium	drug	DDI-DrugBank.d775.s13.e5
DDI-DrugBank.d775.s13	272	282	neostigmine	drug	DDI-DrugBank.d775.s13.e6
DDI-DrugBank.d775.s13	286	296	polymyxin B	drug	DDI-DrugBank.d775.s13.e7
DDI-DrugBank.d775.s13	301	310	bacitracin	drug	DDI-DrugBank.d775.s13.e8
DDI-DrugBank.d775.s13	320	330	anesthetics	group	DDI-DrugBank.d775.s13.e9
DDI-DrugBank.d775.s13	false	DDI-DrugBank.d775.s13.e0	DDI-DrugBank.d775.s13.e1
DDI-DrugBank.d775.s13	false	DDI-DrugBank.d775.s13.e0	DDI-DrugBank.d775.s13.e2
DDI-DrugBank.d775.s13	false	DDI-DrugBank.d775.s13.e0	DDI-DrugBank.d775.s13.e3
DDI-DrugBank.d775.s13	false	DDI-DrugBank.d775.s13.e0	DDI-DrugBank.d775.s13.e4
DDI-DrugBank.d775.s13	false	DDI-DrugBank.d775.s13.e0	DDI-DrugBank.d775.s13.e5
DDI-DrugBank.d775.s13	false	DDI-DrugBank.d775.s13.e0	DDI-DrugBank.d775.s13.e6
DDI-DrugBank.d775.s13	false	DDI-DrugBank.d775.s13.e0	DDI-DrugBank.d775.s13.e7
DDI-DrugBank.d775.s13	false	DDI-DrugBank.d775.s13.e0	DDI-DrugBank.d775.s13.e8
DDI-DrugBank.d775.s13	false	DDI-DrugBank.d775.s13.e0	DDI-DrugBank.d775.s13.e9
DDI-DrugBank.d775.s13	false	DDI-DrugBank.d775.s13.e0	DDI-DrugBank.d775.s13.e10
DDI-DrugBank.d640.s0|a|Diuretics: Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. 
DDI-DrugBank.d640.s0	0	8	Diuretics	group	DDI-DrugBank.d640.s0.e0
DDI-DrugBank.d640.s0	97	110	ACE inhibitors	group	DDI-DrugBank.d640.s0.e1
DDI-DrugBank.d640.s0	false	DDI-DrugBank.d640.s0.e0	DDI-DrugBank.d640.s0.e1
DDI-DrugBank.d640.s1|a|The possibility of hypotensive effects with UNIVASC    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with UNIVASC   . If this is not possible, the starting dose of moexpril should be reduced.. 
DDI-DrugBank.d640.s1	44	50	UNIVASC	brand	DDI-DrugBank.d640.s1.e0
DDI-DrugBank.d640.s1	196	202	UNIVASC	brand	DDI-DrugBank.d640.s1.e1
DDI-DrugBank.d640.s1	254	261	moexpril	drug	DDI-DrugBank.d640.s1.e2
DDI-DrugBank.d640.s1	false	DDI-DrugBank.d640.s1.e0	DDI-DrugBank.d640.s1.e1
DDI-DrugBank.d640.s1	false	DDI-DrugBank.d640.s1.e0	DDI-DrugBank.d640.s1.e2
DDI-DrugBank.d640.s1	false	DDI-DrugBank.d640.s1.e1	DDI-DrugBank.d640.s1.e2
DDI-DrugBank.d640.s2|a|Potassium Supplements and Potassium-Sparing Diuretics: UNIVASC    can increase serum potassium because it decreases aldosterone secretion. 
DDI-DrugBank.d640.s2	0	8	Potassium	drug	DDI-DrugBank.d640.s2.e0
DDI-DrugBank.d640.s2	26	52	Potassium-Sparing Diuretics	group	DDI-DrugBank.d640.s2.e1
DDI-DrugBank.d640.s2	55	61	UNIVASC	brand	DDI-DrugBank.d640.s2.e2
DDI-DrugBank.d640.s2	false	DDI-DrugBank.d640.s2.e0	DDI-DrugBank.d640.s2.e1
DDI-DrugBank.d640.s2	false	DDI-DrugBank.d640.s2.e0	DDI-DrugBank.d640.s2.e2
DDI-DrugBank.d640.s2	false	DDI-DrugBank.d640.s2.e1	DDI-DrugBank.d640.s2.e2
DDI-DrugBank.d640.s3|a|Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. 
DDI-DrugBank.d640.s3	7	33	potassium-sparing diuretics	group	DDI-DrugBank.d640.s3.e0
DDI-DrugBank.d640.s3	36	49	spironolactone	drug	DDI-DrugBank.d640.s3.e1
DDI-DrugBank.d640.s3	52	62	triamterene	drug	DDI-DrugBank.d640.s3.e2
DDI-DrugBank.d640.s3	65	73	amiloride	drug	DDI-DrugBank.d640.s3.e3
DDI-DrugBank.d640.s3	79	87	potassium	drug	DDI-DrugBank.d640.s3.e4
DDI-DrugBank.d640.s3	120	133	ACE inhibitors	group	DDI-DrugBank.d640.s3.e5
DDI-DrugBank.d640.s3	false	DDI-DrugBank.d640.s3.e0	DDI-DrugBank.d640.s3.e1
DDI-DrugBank.d640.s3	false	DDI-DrugBank.d640.s3.e0	DDI-DrugBank.d640.s3.e2
DDI-DrugBank.d640.s3	false	DDI-DrugBank.d640.s3.e0	DDI-DrugBank.d640.s3.e3
DDI-DrugBank.d640.s3	false	DDI-DrugBank.d640.s3.e0	DDI-DrugBank.d640.s3.e4
DDI-DrugBank.d640.s3	true	DDI-DrugBank.d640.s3.e0	DDI-DrugBank.d640.s3.e5
DDI-DrugBank.d640.s3	false	DDI-DrugBank.d640.s3.e1	DDI-DrugBank.d640.s3.e2
DDI-DrugBank.d640.s3	false	DDI-DrugBank.d640.s3.e1	DDI-DrugBank.d640.s3.e3
DDI-DrugBank.d640.s3	false	DDI-DrugBank.d640.s3.e1	DDI-DrugBank.d640.s3.e4
DDI-DrugBank.d640.s3	true	DDI-DrugBank.d640.s3.e1	DDI-DrugBank.d640.s3.e5
DDI-DrugBank.d640.s3	false	DDI-DrugBank.d640.s3.e2	DDI-DrugBank.d640.s3.e3
DDI-DrugBank.d640.s4|a|Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patient's serum potassium should be monitored. 
DDI-DrugBank.d640.s5|a|Oral Anticoagulants: Interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect. 
DDI-DrugBank.d640.s5	5	18	Anticoagulants	group	DDI-DrugBank.d640.s5.e0
DDI-DrugBank.d640.s5	46	53	warfarin	drug	DDI-DrugBank.d640.s5.e1
DDI-DrugBank.d640.s5	141	153	anticoagulant	group	DDI-DrugBank.d640.s5.e2
DDI-DrugBank.d640.s5	false	DDI-DrugBank.d640.s5.e0	DDI-DrugBank.d640.s5.e1
DDI-DrugBank.d640.s5	false	DDI-DrugBank.d640.s5.e0	DDI-DrugBank.d640.s5.e2
DDI-DrugBank.d640.s5	false	DDI-DrugBank.d640.s5.e1	DDI-DrugBank.d640.s5.e2
DDI-DrugBank.d640.s6|a|Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. 
DDI-DrugBank.d640.s6	0	6	Lithium	drug	DDI-DrugBank.d640.s6.e0
DDI-DrugBank.d640.s6	25	31	lithium	drug	DDI-DrugBank.d640.s6.e1
DDI-DrugBank.d640.s6	56	62	lithium	drug	DDI-DrugBank.d640.s6.e2
DDI-DrugBank.d640.s6	114	127	ACE inhibitors	group	DDI-DrugBank.d640.s6.e3
DDI-DrugBank.d640.s6	149	155	lithium	drug	DDI-DrugBank.d640.s6.e4
DDI-DrugBank.d640.s6	false	DDI-DrugBank.d640.s6.e0	DDI-DrugBank.d640.s6.e1
DDI-DrugBank.d640.s6	false	DDI-DrugBank.d640.s6.e0	DDI-DrugBank.d640.s6.e2
DDI-DrugBank.d640.s6	false	DDI-DrugBank.d640.s6.e0	DDI-DrugBank.d640.s6.e3
DDI-DrugBank.d640.s6	false	DDI-DrugBank.d640.s6.e0	DDI-DrugBank.d640.s6.e4
DDI-DrugBank.d640.s6	false	DDI-DrugBank.d640.s6.e1	DDI-DrugBank.d640.s6.e2
DDI-DrugBank.d640.s6	false	DDI-DrugBank.d640.s6.e1	DDI-DrugBank.d640.s6.e3
DDI-DrugBank.d640.s6	false	DDI-DrugBank.d640.s6.e1	DDI-DrugBank.d640.s6.e4
DDI-DrugBank.d640.s6	false	DDI-DrugBank.d640.s6.e2	DDI-DrugBank.d640.s6.e3
DDI-DrugBank.d640.s6	false	DDI-DrugBank.d640.s6.e2	DDI-DrugBank.d640.s6.e4
DDI-DrugBank.d640.s6	true	DDI-DrugBank.d640.s6.e3	DDI-DrugBank.d640.s6.e4
DDI-DrugBank.d640.s7|a|These drugs should be coadministered with caution, and frequent monitoring of serum lithium levels is recommended. 
DDI-DrugBank.d640.s7	84	90	lithium	drug	DDI-DrugBank.d640.s7.e0
DDI-DrugBank.d640.s8|a|If a diuretic is also used, the risk of lithium toxicity may be increased. 
DDI-DrugBank.d640.s8	5	12	diuretic	group	DDI-DrugBank.d640.s8.e0
DDI-DrugBank.d640.s8	40	46	lithium	drug	DDI-DrugBank.d640.s8.e1
DDI-DrugBank.d640.s8	true	DDI-DrugBank.d640.s8.e0	DDI-DrugBank.d640.s8.e1
DDI-DrugBank.d640.s9|a|Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine. 
DDI-DrugBank.d640.s9	81	87	UNIVASC	brand	DDI-DrugBank.d640.s9.e0
DDI-DrugBank.d640.s9	128	146	hydrochlorothiazide	drug	DDI-DrugBank.d640.s9.e1
DDI-DrugBank.d640.s9	149	155	digoxin	drug	DDI-DrugBank.d640.s9.e2
DDI-DrugBank.d640.s9	161	170	cimetidine	drug	DDI-DrugBank.d640.s9.e3
DDI-DrugBank.d640.s9	false	DDI-DrugBank.d640.s9.e0	DDI-DrugBank.d640.s9.e1
DDI-DrugBank.d640.s9	false	DDI-DrugBank.d640.s9.e0	DDI-DrugBank.d640.s9.e2
DDI-DrugBank.d640.s9	false	DDI-DrugBank.d640.s9.e0	DDI-DrugBank.d640.s9.e3
DDI-DrugBank.d640.s9	false	DDI-DrugBank.d640.s9.e1	DDI-DrugBank.d640.s9.e2
DDI-DrugBank.d640.s9	false	DDI-DrugBank.d640.s9.e1	DDI-DrugBank.d640.s9.e3
DDI-DrugBank.d640.s9	false	DDI-DrugBank.d640.s9.e2	DDI-DrugBank.d640.s9.e3
DDI-DrugBank.d640.s10|a|UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. 
DDI-DrugBank.d640.s10	0	6	UNIVASC	brand	DDI-DrugBank.d640.s10.e0
DDI-DrugBank.d640.s10	63	93	calcium-channel-blocking agents	group	DDI-DrugBank.d640.s10.e1
DDI-DrugBank.d640.s10	96	104	diuretics	group	DDI-DrugBank.d640.s10.e2
DDI-DrugBank.d640.s10	107	117	H2 blockers	group	DDI-DrugBank.d640.s10.e3
DDI-DrugBank.d640.s10	120	126	digoxin	drug	DDI-DrugBank.d640.s10.e4
DDI-DrugBank.d640.s10	134	152	hypoglycemic agents	group	DDI-DrugBank.d640.s10.e5
DDI-DrugBank.d640.s10	false	DDI-DrugBank.d640.s10.e0	DDI-DrugBank.d640.s10.e1
DDI-DrugBank.d640.s10	false	DDI-DrugBank.d640.s10.e0	DDI-DrugBank.d640.s10.e2
DDI-DrugBank.d640.s10	false	DDI-DrugBank.d640.s10.e0	DDI-DrugBank.d640.s10.e3
DDI-DrugBank.d640.s10	false	DDI-DrugBank.d640.s10.e0	DDI-DrugBank.d640.s10.e4
DDI-DrugBank.d640.s10	false	DDI-DrugBank.d640.s10.e0	DDI-DrugBank.d640.s10.e5
DDI-DrugBank.d640.s10	false	DDI-DrugBank.d640.s10.e1	DDI-DrugBank.d640.s10.e2
DDI-DrugBank.d640.s10	false	DDI-DrugBank.d640.s10.e1	DDI-DrugBank.d640.s10.e3
DDI-DrugBank.d640.s10	false	DDI-DrugBank.d640.s10.e1	DDI-DrugBank.d640.s10.e4
DDI-DrugBank.d640.s10	false	DDI-DrugBank.d640.s10.e1	DDI-DrugBank.d640.s10.e5
DDI-DrugBank.d640.s10	false	DDI-DrugBank.d640.s10.e2	DDI-DrugBank.d640.s10.e3
DDI-DrugBank.d640.s11|a|There was no evidence of clinically important adverse interactions.
DDI-DrugBank.d580.s0|a|In clinical studies, the concurrent administration of the ASMANEX TWISTHALER    inhaler and other drugs commonly used in the treatment of asthma was not associated with any unusual adverse events. 
DDI-DrugBank.d580.s0	58	75	ASMANEX TWISTHALER	brand	DDI-DrugBank.d580.s0.e0
DDI-DrugBank.d580.s1|a|However, ketoconazole, a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing.
DDI-DrugBank.d580.s1	9	20	ketoconazole	drug	DDI-DrugBank.d580.s1.e0
DDI-DrugBank.d580.s1	96	113	mometasone furoate	drug	DDI-DrugBank.d580.s1.e1
DDI-DrugBank.d580.s1	true	DDI-DrugBank.d580.s1.e0	DDI-DrugBank.d580.s1.e1
DDI-DrugBank.d739.s0|a|Montelukast at a Dose of 10 mg Once Daily Dosed to Pharmacokinetic Steady State  - did not cause clinically significant changes in the kinetics of a single intravenous dose of theophylline (predominantly a cytochrome P450 1A2 substrate). 
DDI-DrugBank.d739.s0	0	10	Montelukast	drug	DDI-DrugBank.d739.s0.e0
DDI-DrugBank.d739.s0	176	187	theophylline	drug	DDI-DrugBank.d739.s0.e1
DDI-DrugBank.d739.s0	false	DDI-DrugBank.d739.s0.e0	DDI-DrugBank.d739.s0.e1
DDI-DrugBank.d739.s1|a|- did not change the pharmacokinetic profile of warfarin (a substrate of cytochromes P450 2A6 and 2C9) or influence the effect of a single 30-mg oral dose of warfarin on prothrombin time or the INR (International Normalized Ratio). 
DDI-DrugBank.d739.s1	48	55	warfarin	drug	DDI-DrugBank.d739.s1.e0
DDI-DrugBank.d739.s1	158	165	warfarin	drug	DDI-DrugBank.d739.s1.e1
DDI-DrugBank.d739.s1	false	DDI-DrugBank.d739.s1.e0	DDI-DrugBank.d739.s1.e1
DDI-DrugBank.d739.s2|a|- did not change the pharmacokinetic profile or urinary excretion of immunoreactive digoxin. 
DDI-DrugBank.d739.s2	84	90	digoxin	drug	DDI-DrugBank.d739.s2.e0
DDI-DrugBank.d739.s3|a|- did not change the plasma concentration profile of terfenadine (a substrate of cytochrome P450 3A4) or fexofenadine, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with terfenadine 60 mg twice daily. 
DDI-DrugBank.d739.s3	53	63	terfenadine	drug	DDI-DrugBank.d739.s3.e0
DDI-DrugBank.d739.s3	105	116	fexofenadine	drug	DDI-DrugBank.d739.s3.e1
DDI-DrugBank.d739.s3	218	228	terfenadine	drug	DDI-DrugBank.d739.s3.e2
DDI-DrugBank.d739.s3	false	DDI-DrugBank.d739.s3.e0	DDI-DrugBank.d739.s3.e1
DDI-DrugBank.d739.s3	false	DDI-DrugBank.d739.s3.e0	DDI-DrugBank.d739.s3.e2
DDI-DrugBank.d739.s3	false	DDI-DrugBank.d739.s3.e1	DDI-DrugBank.d739.s3.e2
DDI-DrugBank.d739.s4|a|Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg. 
DDI-DrugBank.d739.s4	0	10	Montelukast	drug	DDI-DrugBank.d739.s4.e0
DDI-DrugBank.d739.s4	167	179	contraceptive	group	DDI-DrugBank.d739.s4.e1
DDI-DrugBank.d739.s4	192	204	norethindrone	drug	DDI-DrugBank.d739.s4.e2
DDI-DrugBank.d739.s4	219	227	estradiol	drug	DDI-DrugBank.d739.s4.e3
DDI-DrugBank.d739.s4	false	DDI-DrugBank.d739.s4.e0	DDI-DrugBank.d739.s4.e1
DDI-DrugBank.d739.s4	false	DDI-DrugBank.d739.s4.e0	DDI-DrugBank.d739.s4.e2
DDI-DrugBank.d739.s4	false	DDI-DrugBank.d739.s4.e0	DDI-DrugBank.d739.s4.e3
DDI-DrugBank.d739.s4	false	DDI-DrugBank.d739.s4.e1	DDI-DrugBank.d739.s4.e2
DDI-DrugBank.d739.s4	false	DDI-DrugBank.d739.s4.e1	DDI-DrugBank.d739.s4.e3
DDI-DrugBank.d739.s4	false	DDI-DrugBank.d739.s4.e2	DDI-DrugBank.d739.s4.e3
DDI-DrugBank.d739.s5|a|- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.  
DDI-DrugBank.d739.s5	72	81	prednisone	drug	DDI-DrugBank.d739.s5.e0
DDI-DrugBank.d739.s5	86	97	prednisolone	drug	DDI-DrugBank.d739.s5.e1
DDI-DrugBank.d739.s5	139	148	prednisone	drug	DDI-DrugBank.d739.s5.e2
DDI-DrugBank.d739.s5	165	176	prednisolone	drug	DDI-DrugBank.d739.s5.e3
DDI-DrugBank.d739.s5	false	DDI-DrugBank.d739.s5.e0	DDI-DrugBank.d739.s5.e1
DDI-DrugBank.d739.s5	false	DDI-DrugBank.d739.s5.e0	DDI-DrugBank.d739.s5.e2
DDI-DrugBank.d739.s5	false	DDI-DrugBank.d739.s5.e0	DDI-DrugBank.d739.s5.e3
DDI-DrugBank.d739.s5	false	DDI-DrugBank.d739.s5.e1	DDI-DrugBank.d739.s5.e2
DDI-DrugBank.d739.s5	false	DDI-DrugBank.d739.s5.e1	DDI-DrugBank.d739.s5.e3
DDI-DrugBank.d739.s5	false	DDI-DrugBank.d739.s5.e2	DDI-DrugBank.d739.s5.e3
DDI-DrugBank.d739.s6|a|Phenobarbital, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of montelukast. 
DDI-DrugBank.d739.s6	0	12	Phenobarbital	drug	DDI-DrugBank.d739.s6.e0
DDI-DrugBank.d739.s6	70	80	montelukast	drug	DDI-DrugBank.d739.s6.e1
DDI-DrugBank.d739.s6	133	143	montelukast	drug	DDI-DrugBank.d739.s6.e2
DDI-DrugBank.d739.s6	false	DDI-DrugBank.d739.s6.e0	DDI-DrugBank.d739.s6.e1
DDI-DrugBank.d739.s6	false	DDI-DrugBank.d739.s6.e0	DDI-DrugBank.d739.s6.e2
DDI-DrugBank.d739.s6	false	DDI-DrugBank.d739.s6.e1	DDI-DrugBank.d739.s6.e2
DDI-DrugBank.d739.s7|a|No dosage adjustment for montelukast is recommended. 
DDI-DrugBank.d739.s7	25	35	montelukast	drug	DDI-DrugBank.d739.s7.e0
DDI-DrugBank.d739.s8|a|It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast. 
DDI-DrugBank.d739.s8	112	124	phenobarbital	drug	DDI-DrugBank.d739.s8.e0
DDI-DrugBank.d739.s8	129	136	rifampin	drug	DDI-DrugBank.d739.s8.e1
DDI-DrugBank.d739.s8	164	174	montelukast	drug	DDI-DrugBank.d739.s8.e2
DDI-DrugBank.d739.s8	false	DDI-DrugBank.d739.s8.e0	DDI-DrugBank.d739.s8.e1
DDI-DrugBank.d739.s8	true	DDI-DrugBank.d739.s8.e0	DDI-DrugBank.d739.s8.e2
DDI-DrugBank.d739.s8	true	DDI-DrugBank.d739.s8.e1	DDI-DrugBank.d739.s8.e2
DDI-DrugBank.d739.s9|a|Montelukast has been administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma with no apparent increase in adverse reactions. 
DDI-DrugBank.d739.s9	0	10	Montelukast	drug	DDI-DrugBank.d739.s9.e0
DDI-DrugBank.d739.s10|a|In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 
DDI-DrugBank.d739.s10	62	72	montelukast	drug	DDI-DrugBank.d739.s10.e0
DDI-DrugBank.d739.s10	164	175	theophylline	drug	DDI-DrugBank.d739.s10.e1
DDI-DrugBank.d739.s10	178	187	prednisone	drug	DDI-DrugBank.d739.s10.e2
DDI-DrugBank.d739.s10	190	201	prednisolone	drug	DDI-DrugBank.d739.s10.e3
DDI-DrugBank.d739.s10	209	222	contraceptives	group	DDI-DrugBank.d739.s10.e4
DDI-DrugBank.d739.s10	225	237	norethindrone	drug	DDI-DrugBank.d739.s10.e5
DDI-DrugBank.d739.s10	244	260	ethinyl estradiol	drug	DDI-DrugBank.d739.s10.e6
DDI-DrugBank.d739.s10	271	281	terfenadine	drug	DDI-DrugBank.d739.s10.e7
DDI-DrugBank.d739.s10	284	290	digoxin	drug	DDI-DrugBank.d739.s10.e8
DDI-DrugBank.d739.s10	297	304	warfarin	drug	DDI-DrugBank.d739.s10.e9
DDI-DrugBank.d739.s10	false	DDI-DrugBank.d739.s10.e0	DDI-DrugBank.d739.s10.e1
DDI-DrugBank.d739.s10	false	DDI-DrugBank.d739.s10.e0	DDI-DrugBank.d739.s10.e2
DDI-DrugBank.d739.s10	false	DDI-DrugBank.d739.s10.e0	DDI-DrugBank.d739.s10.e3
DDI-DrugBank.d739.s10	false	DDI-DrugBank.d739.s10.e0	DDI-DrugBank.d739.s10.e4
DDI-DrugBank.d739.s10	false	DDI-DrugBank.d739.s10.e0	DDI-DrugBank.d739.s10.e5
DDI-DrugBank.d739.s10	false	DDI-DrugBank.d739.s10.e0	DDI-DrugBank.d739.s10.e6
DDI-DrugBank.d739.s10	false	DDI-DrugBank.d739.s10.e0	DDI-DrugBank.d739.s10.e7
DDI-DrugBank.d739.s10	false	DDI-DrugBank.d739.s10.e0	DDI-DrugBank.d739.s10.e8
DDI-DrugBank.d739.s10	false	DDI-DrugBank.d739.s10.e0	DDI-DrugBank.d739.s10.e9
DDI-DrugBank.d739.s10	false	DDI-DrugBank.d739.s10.e1	DDI-DrugBank.d739.s10.e2
DDI-DrugBank.d739.s11|a|Although additional specific interaction studies were not performed, montelukast was used concomitantly with a wide range of commonly prescribed drugs in clinical studies without evidence of clinical adverse interactions. 
DDI-DrugBank.d739.s11	69	79	montelukast	drug	DDI-DrugBank.d739.s11.e0
DDI-DrugBank.d739.s12|a|These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. 
DDI-DrugBank.d739.s12	27	42	thyroid hormones	group	DDI-DrugBank.d739.s12.e0
DDI-DrugBank.d739.s12	45	62	sedative hypnotics	group	DDI-DrugBank.d739.s12.e1
DDI-DrugBank.d739.s12	65	102	non-steroidal anti-inflammatory agents	group	DDI-DrugBank.d739.s12.e2
DDI-DrugBank.d739.s12	105	119	benzodiazepines	group	DDI-DrugBank.d739.s12.e3
DDI-DrugBank.d739.s12	126	138	decongestants	group	DDI-DrugBank.d739.s12.e4
DDI-DrugBank.d739.s12	false	DDI-DrugBank.d739.s12.e0	DDI-DrugBank.d739.s12.e1
DDI-DrugBank.d739.s12	false	DDI-DrugBank.d739.s12.e0	DDI-DrugBank.d739.s12.e2
DDI-DrugBank.d739.s12	false	DDI-DrugBank.d739.s12.e0	DDI-DrugBank.d739.s12.e3
DDI-DrugBank.d739.s12	false	DDI-DrugBank.d739.s12.e0	DDI-DrugBank.d739.s12.e4
DDI-DrugBank.d739.s12	false	DDI-DrugBank.d739.s12.e1	DDI-DrugBank.d739.s12.e2
DDI-DrugBank.d739.s12	false	DDI-DrugBank.d739.s12.e1	DDI-DrugBank.d739.s12.e3
DDI-DrugBank.d739.s12	false	DDI-DrugBank.d739.s12.e1	DDI-DrugBank.d739.s12.e4
DDI-DrugBank.d739.s12	false	DDI-DrugBank.d739.s12.e2	DDI-DrugBank.d739.s12.e3
DDI-DrugBank.d739.s12	false	DDI-DrugBank.d739.s12.e2	DDI-DrugBank.d739.s12.e4
DDI-DrugBank.d739.s12	false	DDI-DrugBank.d739.s12.e3	DDI-DrugBank.d739.s12.e4
DDI-DrugBank.d739.s13|a|Phenobarbital, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of montelukast. 
DDI-DrugBank.d739.s13	0	12	Phenobarbital	drug	DDI-DrugBank.d739.s13.e0
DDI-DrugBank.d739.s13	70	80	montelukast	drug	DDI-DrugBank.d739.s13.e1
DDI-DrugBank.d739.s13	133	143	montelukast	drug	DDI-DrugBank.d739.s13.e2
DDI-DrugBank.d739.s13	false	DDI-DrugBank.d739.s13.e0	DDI-DrugBank.d739.s13.e1
DDI-DrugBank.d739.s13	false	DDI-DrugBank.d739.s13.e0	DDI-DrugBank.d739.s13.e2
DDI-DrugBank.d739.s13	false	DDI-DrugBank.d739.s13.e1	DDI-DrugBank.d739.s13.e2
DDI-DrugBank.d739.s14|a|No dosage adjustment for montelukast is recommended. 
DDI-DrugBank.d739.s14	25	35	montelukast	drug	DDI-DrugBank.d739.s14.e0
DDI-DrugBank.d739.s15|a|It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.
DDI-DrugBank.d739.s15	112	124	phenobarbital	drug	DDI-DrugBank.d739.s15.e0
DDI-DrugBank.d739.s15	129	136	rifampin	drug	DDI-DrugBank.d739.s15.e1
DDI-DrugBank.d739.s15	164	174	montelukast	drug	DDI-DrugBank.d739.s15.e2
DDI-DrugBank.d739.s15	false	DDI-DrugBank.d739.s15.e0	DDI-DrugBank.d739.s15.e1
DDI-DrugBank.d739.s15	true	DDI-DrugBank.d739.s15.e0	DDI-DrugBank.d739.s15.e2
DDI-DrugBank.d739.s15	true	DDI-DrugBank.d739.s15.e1	DDI-DrugBank.d739.s15.e2
DDI-DrugBank.d637.s0|a|Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. 
DDI-DrugBank.d637.s0	15	48	Central Nervous System Depressants	group	DDI-DrugBank.d637.s0.e0
DDI-DrugBank.d637.s0	77	84	morphine	drug	DDI-DrugBank.d637.s0.e1
DDI-DrugBank.d637.s0	127	141	CNS depressants	group	DDI-DrugBank.d637.s0.e2
DDI-DrugBank.d637.s0	151	157	alcohol	drug	DDI-DrugBank.d637.s0.e3
DDI-DrugBank.d637.s0	160	168	sedatives	group	DDI-DrugBank.d637.s0.e4
DDI-DrugBank.d637.s0	171	185	antihistaminics	group	DDI-DrugBank.d637.s0.e5
DDI-DrugBank.d637.s0	191	208	psychotropic drugs	group	DDI-DrugBank.d637.s0.e6
DDI-DrugBank.d637.s0	false	DDI-DrugBank.d637.s0.e0	DDI-DrugBank.d637.s0.e1
DDI-DrugBank.d637.s0	false	DDI-DrugBank.d637.s0.e0	DDI-DrugBank.d637.s0.e2
DDI-DrugBank.d637.s0	false	DDI-DrugBank.d637.s0.e0	DDI-DrugBank.d637.s0.e3
DDI-DrugBank.d637.s0	false	DDI-DrugBank.d637.s0.e0	DDI-DrugBank.d637.s0.e4
DDI-DrugBank.d637.s0	false	DDI-DrugBank.d637.s0.e0	DDI-DrugBank.d637.s0.e5
DDI-DrugBank.d637.s0	false	DDI-DrugBank.d637.s0.e0	DDI-DrugBank.d637.s0.e6
DDI-DrugBank.d637.s0	true	DDI-DrugBank.d637.s0.e1	DDI-DrugBank.d637.s0.e2
DDI-DrugBank.d637.s0	true	DDI-DrugBank.d637.s0.e1	DDI-DrugBank.d637.s0.e3
DDI-DrugBank.d637.s0	true	DDI-DrugBank.d637.s0.e1	DDI-DrugBank.d637.s0.e4
DDI-DrugBank.d637.s0	true	DDI-DrugBank.d637.s0.e1	DDI-DrugBank.d637.s0.e5
DDI-DrugBank.d637.s1|a|Use of neuroleptics in conjunction with oral morphine may increase the risk of respiratory depression, hypotension and profound sedation or coma. 
DDI-DrugBank.d637.s1	7	18	neuroleptics	group	DDI-DrugBank.d637.s1.e0
DDI-DrugBank.d637.s1	45	52	morphine	drug	DDI-DrugBank.d637.s1.e1
DDI-DrugBank.d637.s1	true	DDI-DrugBank.d637.s1.e0	DDI-DrugBank.d637.s1.e1
DDI-DrugBank.d637.s2|a|Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. 
DDI-DrugBank.d637.s2	17	58	Mixed Agonist/Antagonist Opioid Analgesics	group	DDI-DrugBank.d637.s2.e0
DDI-DrugBank.d637.s2	61	89	Agonist/antagonist analgesics	group	DDI-DrugBank.d637.s2.e1
DDI-DrugBank.d637.s2	98	108	pentazocine	drug	DDI-DrugBank.d637.s2.e2
DDI-DrugBank.d637.s2	111	120	nalbuphine	drug	DDI-DrugBank.d637.s2.e3
DDI-DrugBank.d637.s2	123	133	butorphanol	drug	DDI-DrugBank.d637.s2.e4
DDI-DrugBank.d637.s2	139	151	buprenorphine	drug	DDI-DrugBank.d637.s2.e5
DDI-DrugBank.d637.s2	261	284	opioid agonist analgesic	group	DDI-DrugBank.d637.s2.e6
DDI-DrugBank.d637.s2	false	DDI-DrugBank.d637.s2.e0	DDI-DrugBank.d637.s2.e1
DDI-DrugBank.d637.s2	false	DDI-DrugBank.d637.s2.e0	DDI-DrugBank.d637.s2.e2
DDI-DrugBank.d637.s2	false	DDI-DrugBank.d637.s2.e0	DDI-DrugBank.d637.s2.e3
DDI-DrugBank.d637.s2	false	DDI-DrugBank.d637.s2.e0	DDI-DrugBank.d637.s2.e4
DDI-DrugBank.d637.s2	false	DDI-DrugBank.d637.s2.e0	DDI-DrugBank.d637.s2.e5
DDI-DrugBank.d637.s2	false	DDI-DrugBank.d637.s2.e0	DDI-DrugBank.d637.s2.e6
DDI-DrugBank.d637.s2	false	DDI-DrugBank.d637.s2.e1	DDI-DrugBank.d637.s2.e2
DDI-DrugBank.d637.s2	false	DDI-DrugBank.d637.s2.e1	DDI-DrugBank.d637.s2.e3
DDI-DrugBank.d637.s2	false	DDI-DrugBank.d637.s2.e1	DDI-DrugBank.d637.s2.e4
DDI-DrugBank.d637.s2	false	DDI-DrugBank.d637.s2.e1	DDI-DrugBank.d637.s2.e5
DDI-DrugBank.d637.s3|a|In these patients, the mixed agonist/antagonist may alter the analgesic effect or may precipitate withdrawal symptoms.
DDI-DrugBank.d700.s0|a|Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. 
DDI-DrugBank.d700.s0	0	7	Antacids	group	DDI-DrugBank.d700.s0.e0
DDI-DrugBank.d700.s0	41	48	Myfortic	brand	DDI-DrugBank.d700.s0.e1
DDI-DrugBank.d700.s0	133	141	magnesium	drug	DDI-DrugBank.d700.s0.e2
DDI-DrugBank.d700.s0	143	150	aluminum	drug	DDI-DrugBank.d700.s0.e3
DDI-DrugBank.d700.s0	163	170	antacids	group	DDI-DrugBank.d700.s0.e4
DDI-DrugBank.d700.s0	271	278	Myfortic	brand	DDI-DrugBank.d700.s0.e5
DDI-DrugBank.d700.s0	false	DDI-DrugBank.d700.s0.e0	DDI-DrugBank.d700.s0.e1
DDI-DrugBank.d700.s0	false	DDI-DrugBank.d700.s0.e0	DDI-DrugBank.d700.s0.e2
DDI-DrugBank.d700.s0	false	DDI-DrugBank.d700.s0.e0	DDI-DrugBank.d700.s0.e3
DDI-DrugBank.d700.s0	false	DDI-DrugBank.d700.s0.e0	DDI-DrugBank.d700.s0.e4
DDI-DrugBank.d700.s0	false	DDI-DrugBank.d700.s0.e0	DDI-DrugBank.d700.s0.e5
DDI-DrugBank.d700.s0	true	DDI-DrugBank.d700.s0.e1	DDI-DrugBank.d700.s0.e2
DDI-DrugBank.d700.s0	true	DDI-DrugBank.d700.s0.e1	DDI-DrugBank.d700.s0.e3
DDI-DrugBank.d700.s0	false	DDI-DrugBank.d700.s0.e1	DDI-DrugBank.d700.s0.e4
DDI-DrugBank.d700.s0	false	DDI-DrugBank.d700.s0.e1	DDI-DrugBank.d700.s0.e5
DDI-DrugBank.d700.s0	false	DDI-DrugBank.d700.s0.e2	DDI-DrugBank.d700.s0.e3
DDI-DrugBank.d700.s1|a|It is recommended that Myfortic and antacids not be administered simultaneously. 
DDI-DrugBank.d700.s1	23	30	Myfortic	drug	DDI-DrugBank.d700.s1.e0
DDI-DrugBank.d700.s1	36	43	antacids	group	DDI-DrugBank.d700.s1.e1
DDI-DrugBank.d700.s1	true	DDI-DrugBank.d700.s1.e0	DDI-DrugBank.d700.s1.e1
DDI-DrugBank.d700.s2|a|Cyclosporine: When studied in stable renal transplant patients, cyclosporine, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of Myfortic. 
DDI-DrugBank.d700.s2	0	11	Cyclosporine	drug	DDI-DrugBank.d700.s2.e0
DDI-DrugBank.d700.s2	64	75	cyclosporine	drug	DDI-DrugBank.d700.s2.e1
DDI-DrugBank.d700.s2	152	159	Myfortic	brand	DDI-DrugBank.d700.s2.e2
DDI-DrugBank.d700.s2	false	DDI-DrugBank.d700.s2.e0	DDI-DrugBank.d700.s2.e1
DDI-DrugBank.d700.s2	false	DDI-DrugBank.d700.s2.e0	DDI-DrugBank.d700.s2.e2
DDI-DrugBank.d700.s2	false	DDI-DrugBank.d700.s2.e1	DDI-DrugBank.d700.s2.e2
DDI-DrugBank.d700.s3|a|Acyclovir/Ganciclovir: may be taken with Myfortic; 
DDI-DrugBank.d700.s3	0	8	Acyclovir	drug	DDI-DrugBank.d700.s3.e0
DDI-DrugBank.d700.s3	10	20	Ganciclovir	drug	DDI-DrugBank.d700.s3.e1
DDI-DrugBank.d700.s3	41	48	Myfortic	brand	DDI-DrugBank.d700.s3.e2
DDI-DrugBank.d700.s3	false	DDI-DrugBank.d700.s3.e0	DDI-DrugBank.d700.s3.e1
DDI-DrugBank.d700.s3	false	DDI-DrugBank.d700.s3.e0	DDI-DrugBank.d700.s3.e2
DDI-DrugBank.d700.s3	false	DDI-DrugBank.d700.s3.e1	DDI-DrugBank.d700.s3.e2
DDI-DrugBank.d700.s4|a|however, during the period of treatment, physicians should monitor blood cell counts. 
DDI-DrugBank.d700.s5|a|Both acyclovir/ganciclovir and MPAG concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two. 
DDI-DrugBank.d700.s5	5	13	acyclovir	drug	DDI-DrugBank.d700.s5.e0
DDI-DrugBank.d700.s5	15	25	ganciclovir	drug	DDI-DrugBank.d700.s5.e1
DDI-DrugBank.d700.s5	31	34	MPAG	drug_n	DDI-DrugBank.d700.s5.e2
DDI-DrugBank.d700.s5	false	DDI-DrugBank.d700.s5.e0	DDI-DrugBank.d700.s5.e1
DDI-DrugBank.d700.s5	false	DDI-DrugBank.d700.s5.e0	DDI-DrugBank.d700.s5.e2
DDI-DrugBank.d700.s5	false	DDI-DrugBank.d700.s5.e1	DDI-DrugBank.d700.s5.e2
DDI-DrugBank.d700.s6|a|Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. 
DDI-DrugBank.d700.s6	0	11	Azathioprine	drug	DDI-DrugBank.d700.s6.e0
DDI-DrugBank.d700.s6	13	33	Mycophenolate Mofetil	drug	DDI-DrugBank.d700.s6.e1
DDI-DrugBank.d700.s6	47	58	azathioprine	drug	DDI-DrugBank.d700.s6.e2
DDI-DrugBank.d700.s6	64	84	mycophenolate mofetil	drug	DDI-DrugBank.d700.s6.e3
DDI-DrugBank.d700.s6	136	143	Myfortic	brand	DDI-DrugBank.d700.s6.e4
DDI-DrugBank.d700.s6	184	195	azathioprine	drug	DDI-DrugBank.d700.s6.e5
DDI-DrugBank.d700.s6	200	220	mycophenolate mofetil	drug	DDI-DrugBank.d700.s6.e6
DDI-DrugBank.d700.s6	false	DDI-DrugBank.d700.s6.e0	DDI-DrugBank.d700.s6.e1
DDI-DrugBank.d700.s6	false	DDI-DrugBank.d700.s6.e0	DDI-DrugBank.d700.s6.e2
DDI-DrugBank.d700.s6	false	DDI-DrugBank.d700.s6.e0	DDI-DrugBank.d700.s6.e3
DDI-DrugBank.d700.s6	false	DDI-DrugBank.d700.s6.e0	DDI-DrugBank.d700.s6.e4
DDI-DrugBank.d700.s6	false	DDI-DrugBank.d700.s6.e0	DDI-DrugBank.d700.s6.e5
DDI-DrugBank.d700.s6	false	DDI-DrugBank.d700.s6.e0	DDI-DrugBank.d700.s6.e6
DDI-DrugBank.d700.s6	false	DDI-DrugBank.d700.s6.e1	DDI-DrugBank.d700.s6.e2
DDI-DrugBank.d700.s6	false	DDI-DrugBank.d700.s6.e1	DDI-DrugBank.d700.s6.e3
DDI-DrugBank.d700.s6	false	DDI-DrugBank.d700.s6.e1	DDI-DrugBank.d700.s6.e4
DDI-DrugBank.d700.s6	false	DDI-DrugBank.d700.s6.e1	DDI-DrugBank.d700.s6.e5
DDI-DrugBank.d700.s7|a|Cholestyramine and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce MPA exposure when coadministered with mycophenolate mofetil. 
DDI-DrugBank.d700.s7	0	13	Cholestyramine	drug	DDI-DrugBank.d700.s7.e0
DDI-DrugBank.d700.s7	108	110	MPA	drug_n	DDI-DrugBank.d700.s7.e1
DDI-DrugBank.d700.s7	146	166	mycophenolate mofetil	drug	DDI-DrugBank.d700.s7.e2
DDI-DrugBank.d700.s7	false	DDI-DrugBank.d700.s7.e0	DDI-DrugBank.d700.s7.e1
DDI-DrugBank.d700.s7	false	DDI-DrugBank.d700.s7.e0	DDI-DrugBank.d700.s7.e2
DDI-DrugBank.d700.s7	false	DDI-DrugBank.d700.s7.e1	DDI-DrugBank.d700.s7.e2
DDI-DrugBank.d700.s8|a|Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. 
DDI-DrugBank.d700.s8	29	36	Myfortic	drug	DDI-DrugBank.d700.s8.e0
DDI-DrugBank.d700.s8	43	56	cholestyramine	drug	DDI-DrugBank.d700.s8.e1
DDI-DrugBank.d700.s8	204	221	activated charcoal	drug	DDI-DrugBank.d700.s8.e2
DDI-DrugBank.d700.s8	275	282	Myfortic	brand	DDI-DrugBank.d700.s8.e3
DDI-DrugBank.d700.s8	true	DDI-DrugBank.d700.s8.e0	DDI-DrugBank.d700.s8.e1
DDI-DrugBank.d700.s8	true	DDI-DrugBank.d700.s8.e0	DDI-DrugBank.d700.s8.e2
DDI-DrugBank.d700.s8	false	DDI-DrugBank.d700.s8.e0	DDI-DrugBank.d700.s8.e3
DDI-DrugBank.d700.s8	false	DDI-DrugBank.d700.s8.e1	DDI-DrugBank.d700.s8.e2
DDI-DrugBank.d700.s8	false	DDI-DrugBank.d700.s8.e1	DDI-DrugBank.d700.s8.e3
DDI-DrugBank.d700.s8	false	DDI-DrugBank.d700.s8.e2	DDI-DrugBank.d700.s8.e3
DDI-DrugBank.d700.s9|a|Oral Contraceptives: Given the different metabolism of Myfortic and oral contraceptives, no drug interaction between these two classes of drug is expected. 
DDI-DrugBank.d700.s9	5	18	Contraceptives	group	DDI-DrugBank.d700.s9.e0
DDI-DrugBank.d700.s9	55	62	Myfortic	brand	DDI-DrugBank.d700.s9.e1
DDI-DrugBank.d700.s9	73	86	contraceptives	group	DDI-DrugBank.d700.s9.e2
DDI-DrugBank.d700.s9	false	DDI-DrugBank.d700.s9.e0	DDI-DrugBank.d700.s9.e1
DDI-DrugBank.d700.s9	false	DDI-DrugBank.d700.s9.e0	DDI-DrugBank.d700.s9.e2
DDI-DrugBank.d700.s9	false	DDI-DrugBank.d700.s9.e1	DDI-DrugBank.d700.s9.e2
DDI-DrugBank.d700.s10|a|However, in a drug-drug interaction study, mean levonorgesterol AUC was decreased by 15% when coadministered with mycophenolate mofetil. 
DDI-DrugBank.d700.s10	48	62	levonorgesterol	drug	DDI-DrugBank.d700.s10.e0
DDI-DrugBank.d700.s10	114	134	mycophenolate mofetil	drug	DDI-DrugBank.d700.s10.e1
DDI-DrugBank.d700.s10	true	DDI-DrugBank.d700.s10.e0	DDI-DrugBank.d700.s10.e1
DDI-DrugBank.d700.s11|a|Therefore, it is recommended that oral contraceptives are co- administered with Myfortic with caution and additional birth control methods be considered. 
DDI-DrugBank.d700.s11	39	52	contraceptives	group	DDI-DrugBank.d700.s11.e0
DDI-DrugBank.d700.s11	80	87	Myfortic	brand	DDI-DrugBank.d700.s11.e1
DDI-DrugBank.d700.s11	true	DDI-DrugBank.d700.s11.e0	DDI-DrugBank.d700.s11.e1
DDI-DrugBank.d700.s12|a|Live Vaccines: During treatment with Myfortic, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective. 
DDI-DrugBank.d700.s12	0	12	Live Vaccines	group	DDI-DrugBank.d700.s12.e0
DDI-DrugBank.d700.s12	37	44	Myfortic	drug	DDI-DrugBank.d700.s12.e1
DDI-DrugBank.d700.s12	58	81	live attenuated vaccines	group	DDI-DrugBank.d700.s12.e2
DDI-DrugBank.d700.s12	false	DDI-DrugBank.d700.s12.e0	DDI-DrugBank.d700.s12.e1
DDI-DrugBank.d700.s12	false	DDI-DrugBank.d700.s12.e0	DDI-DrugBank.d700.s12.e2
DDI-DrugBank.d700.s12	true	DDI-DrugBank.d700.s12.e1	DDI-DrugBank.d700.s12.e2
DDI-DrugBank.d700.s13|a|Influenza vaccination may be of value. 
DDI-DrugBank.d700.s14|a|Prescribers should refer to national guidelines for influenza vaccination. 
DDI-DrugBank.d700.s15|a|Drugs that alter the gastrointestinal flora may interact with Myfortic by disrupting enterohepatic recirculation. 
DDI-DrugBank.d700.s15	62	69	Myfortic	brand	DDI-DrugBank.d700.s15.e0
DDI-DrugBank.d700.s16|a|Interference of MPAG hydrolysis may lead to less MPA available for absorption.
DDI-DrugBank.d700.s16	16	19	MPAG	drug_n	DDI-DrugBank.d700.s16.e0
DDI-DrugBank.d700.s16	49	51	MPA	drug_n	DDI-DrugBank.d700.s16.e1
DDI-DrugBank.d700.s16	false	DDI-DrugBank.d700.s16.e0	DDI-DrugBank.d700.s16.e1
DDI-DrugBank.d763.s0|a|Ondansetron does not itself appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the liver. 
DDI-DrugBank.d763.s0	0	10	Ondansetron	drug	DDI-DrugBank.d763.s0.e0
DDI-DrugBank.d763.s1|a|Because ondansetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of ondansetron. 
DDI-DrugBank.d763.s1	8	18	ondansetron	drug	DDI-DrugBank.d763.s1.e0
DDI-DrugBank.d763.s1	209	219	ondansetron	drug	DDI-DrugBank.d763.s1.e1
DDI-DrugBank.d763.s1	false	DDI-DrugBank.d763.s1.e0	DDI-DrugBank.d763.s1.e1
DDI-DrugBank.d763.s2|a|On the basis of limited available data, no dosage adjustment is recommended for patients on these drugs.  
DDI-DrugBank.d763.s3|a|Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 
DDI-DrugBank.d763.s3	0	8	Phenytoin	drug	DDI-DrugBank.d763.s3.e0
DDI-DrugBank.d763.s3	11	23	Carbamazepine	drug	DDI-DrugBank.d763.s3.e1
DDI-DrugBank.d763.s3	30	39	Rifampicin	drug	DDI-DrugBank.d763.s3.e2
DDI-DrugBank.d763.s3	100	108	phenytoin	drug	DDI-DrugBank.d763.s3.e3
DDI-DrugBank.d763.s3	111	123	carbamazepine	drug	DDI-DrugBank.d763.s3.e4
DDI-DrugBank.d763.s3	130	139	rifampicin	drug	DDI-DrugBank.d763.s3.e5
DDI-DrugBank.d763.s3	160	170	ondansetron	drug	DDI-DrugBank.d763.s3.e6
DDI-DrugBank.d763.s3	204	214	ondansetron	drug	DDI-DrugBank.d763.s3.e7
DDI-DrugBank.d763.s3	false	DDI-DrugBank.d763.s3.e0	DDI-DrugBank.d763.s3.e1
DDI-DrugBank.d763.s3	false	DDI-DrugBank.d763.s3.e0	DDI-DrugBank.d763.s3.e2
DDI-DrugBank.d763.s3	false	DDI-DrugBank.d763.s3.e0	DDI-DrugBank.d763.s3.e3
DDI-DrugBank.d763.s3	false	DDI-DrugBank.d763.s3.e0	DDI-DrugBank.d763.s3.e4
DDI-DrugBank.d763.s3	false	DDI-DrugBank.d763.s3.e0	DDI-DrugBank.d763.s3.e5
DDI-DrugBank.d763.s3	false	DDI-DrugBank.d763.s3.e0	DDI-DrugBank.d763.s3.e6
DDI-DrugBank.d763.s3	false	DDI-DrugBank.d763.s3.e0	DDI-DrugBank.d763.s3.e7
DDI-DrugBank.d763.s3	false	DDI-DrugBank.d763.s3.e1	DDI-DrugBank.d763.s3.e2
DDI-DrugBank.d763.s3	false	DDI-DrugBank.d763.s3.e1	DDI-DrugBank.d763.s3.e3
DDI-DrugBank.d763.s3	false	DDI-DrugBank.d763.s3.e1	DDI-DrugBank.d763.s3.e4
DDI-DrugBank.d763.s4|a|However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. 
DDI-DrugBank.d763.s4	66	76	ondansetron	drug	DDI-DrugBank.d763.s4.e0
DDI-DrugBank.d763.s4	126	133	Tramadol	drug	DDI-DrugBank.d763.s4.e1
DDI-DrugBank.d763.s4	189	199	ondansetron	drug	DDI-DrugBank.d763.s4.e2
DDI-DrugBank.d763.s4	205	212	tramadol	drug	DDI-DrugBank.d763.s4.e3
DDI-DrugBank.d763.s4	273	283	ondansetron	drug	DDI-DrugBank.d763.s4.e4
DDI-DrugBank.d763.s4	360	367	tramadol	drug	DDI-DrugBank.d763.s4.e5
DDI-DrugBank.d763.s4	472	482	ondansetron	drug	DDI-DrugBank.d763.s4.e6
DDI-DrugBank.d763.s4	false	DDI-DrugBank.d763.s4.e0	DDI-DrugBank.d763.s4.e1
DDI-DrugBank.d763.s4	false	DDI-DrugBank.d763.s4.e0	DDI-DrugBank.d763.s4.e2
DDI-DrugBank.d763.s4	false	DDI-DrugBank.d763.s4.e0	DDI-DrugBank.d763.s4.e3
DDI-DrugBank.d763.s4	false	DDI-DrugBank.d763.s4.e0	DDI-DrugBank.d763.s4.e4
DDI-DrugBank.d763.s4	false	DDI-DrugBank.d763.s4.e0	DDI-DrugBank.d763.s4.e5
DDI-DrugBank.d763.s4	false	DDI-DrugBank.d763.s4.e0	DDI-DrugBank.d763.s4.e6
DDI-DrugBank.d763.s4	false	DDI-DrugBank.d763.s4.e1	DDI-DrugBank.d763.s4.e2
DDI-DrugBank.d763.s4	false	DDI-DrugBank.d763.s4.e1	DDI-DrugBank.d763.s4.e3
DDI-DrugBank.d763.s4	false	DDI-DrugBank.d763.s4.e1	DDI-DrugBank.d763.s4.e4
DDI-DrugBank.d763.s4	false	DDI-DrugBank.d763.s4.e1	DDI-DrugBank.d763.s4.e5
DDI-DrugBank.d763.s5|a|In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.  
DDI-DrugBank.d763.s5	11	20	carmustine	drug	DDI-DrugBank.d763.s5.e0
DDI-DrugBank.d763.s5	23	31	etoposide	drug	DDI-DrugBank.d763.s5.e1
DDI-DrugBank.d763.s5	38	46	cisplatin	drug	DDI-DrugBank.d763.s5.e2
DDI-DrugBank.d763.s5	86	96	ondansetron	drug	DDI-DrugBank.d763.s5.e3
DDI-DrugBank.d763.s5	false	DDI-DrugBank.d763.s5.e0	DDI-DrugBank.d763.s5.e1
DDI-DrugBank.d763.s5	false	DDI-DrugBank.d763.s5.e0	DDI-DrugBank.d763.s5.e2
DDI-DrugBank.d763.s5	false	DDI-DrugBank.d763.s5.e0	DDI-DrugBank.d763.s5.e3
DDI-DrugBank.d763.s5	false	DDI-DrugBank.d763.s5.e1	DDI-DrugBank.d763.s5.e2
DDI-DrugBank.d763.s5	false	DDI-DrugBank.d763.s5.e1	DDI-DrugBank.d763.s5.e3
DDI-DrugBank.d763.s5	false	DDI-DrugBank.d763.s5.e2	DDI-DrugBank.d763.s5.e3
DDI-DrugBank.d763.s6|a|In a crossover study in 76 pediatric patients, I.V. 
DDI-DrugBank.d763.s7|a|ondansetron did not increase blood levels of high-dose methotrexate.
DDI-DrugBank.d763.s7	0	10	ondansetron	drug	DDI-DrugBank.d763.s7.e0
DDI-DrugBank.d763.s7	55	66	methotrexate	drug	DDI-DrugBank.d763.s7.e1
DDI-DrugBank.d763.s7	false	DDI-DrugBank.d763.s7.e0	DDI-DrugBank.d763.s7.e1
DDI-DrugBank.d611.s0|a|Other beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent    (metaproterenol sulfate USP) because they may have additive effects. 
DDI-DrugBank.d611.s0	6	44	beta adrenergic aerosol bronchodilators	group	DDI-DrugBank.d611.s0.e0
DDI-DrugBank.d611.s0	84	90	Alupent	brand	DDI-DrugBank.d611.s0.e1
DDI-DrugBank.d611.s0	96	117	metaproterenol sulfate	drug	DDI-DrugBank.d611.s0.e2
DDI-DrugBank.d611.s0	true	DDI-DrugBank.d611.s0.e0	DDI-DrugBank.d611.s0.e1
DDI-DrugBank.d611.s0	true	DDI-DrugBank.d611.s0.e0	DDI-DrugBank.d611.s0.e2
DDI-DrugBank.d611.s0	false	DDI-DrugBank.d611.s0.e1	DDI-DrugBank.d611.s0.e2
DDI-DrugBank.d611.s1|a|Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.
DDI-DrugBank.d611.s1	0	23	Beta adrenergic agonists	group	DDI-DrugBank.d611.s1.e0
DDI-DrugBank.d611.s1	92	119	monoamine oxidase inhibitors	group	DDI-DrugBank.d611.s1.e1
DDI-DrugBank.d611.s1	124	148	tricyclic antidepressants	group	DDI-DrugBank.d611.s1.e2
DDI-DrugBank.d611.s1	171	194	beta adrenergic agonists	group	DDI-DrugBank.d611.s1.e3
DDI-DrugBank.d611.s1	true	DDI-DrugBank.d611.s1.e0	DDI-DrugBank.d611.s1.e1
DDI-DrugBank.d611.s1	true	DDI-DrugBank.d611.s1.e0	DDI-DrugBank.d611.s1.e2
DDI-DrugBank.d611.s1	false	DDI-DrugBank.d611.s1.e0	DDI-DrugBank.d611.s1.e3
DDI-DrugBank.d611.s1	false	DDI-DrugBank.d611.s1.e1	DDI-DrugBank.d611.s1.e2
DDI-DrugBank.d611.s1	false	DDI-DrugBank.d611.s1.e1	DDI-DrugBank.d611.s1.e3
DDI-DrugBank.d611.s1	false	DDI-DrugBank.d611.s1.e2	DDI-DrugBank.d611.s1.e3
DDI-DrugBank.d761.s0|a|Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. 
DDI-DrugBank.d761.s0	0	6	Alcohol	drug	DDI-DrugBank.d761.s0.e0
DDI-DrugBank.d761.s0	84	90	XENICAL	brand	DDI-DrugBank.d761.s0.e1
DDI-DrugBank.d761.s0	108	114	alcohol	drug	DDI-DrugBank.d761.s0.e2
DDI-DrugBank.d761.s0	188	194	alcohol	drug	DDI-DrugBank.d761.s0.e3
DDI-DrugBank.d761.s0	214	221	orlistat	drug	DDI-DrugBank.d761.s0.e4
DDI-DrugBank.d761.s0	287	294	orlistat	drug	DDI-DrugBank.d761.s0.e5
DDI-DrugBank.d761.s0	false	DDI-DrugBank.d761.s0.e0	DDI-DrugBank.d761.s0.e1
DDI-DrugBank.d761.s0	false	DDI-DrugBank.d761.s0.e0	DDI-DrugBank.d761.s0.e2
DDI-DrugBank.d761.s0	false	DDI-DrugBank.d761.s0.e0	DDI-DrugBank.d761.s0.e3
DDI-DrugBank.d761.s0	false	DDI-DrugBank.d761.s0.e0	DDI-DrugBank.d761.s0.e4
DDI-DrugBank.d761.s0	false	DDI-DrugBank.d761.s0.e0	DDI-DrugBank.d761.s0.e5
DDI-DrugBank.d761.s0	false	DDI-DrugBank.d761.s0.e1	DDI-DrugBank.d761.s0.e2
DDI-DrugBank.d761.s0	false	DDI-DrugBank.d761.s0.e1	DDI-DrugBank.d761.s0.e3
DDI-DrugBank.d761.s0	false	DDI-DrugBank.d761.s0.e1	DDI-DrugBank.d761.s0.e4
DDI-DrugBank.d761.s0	false	DDI-DrugBank.d761.s0.e1	DDI-DrugBank.d761.s0.e5
DDI-DrugBank.d761.s0	false	DDI-DrugBank.d761.s0.e2	DDI-DrugBank.d761.s0.e3
DDI-DrugBank.d761.s1|a|Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. 
DDI-DrugBank.d761.s1	0	11	Cyclosporine	drug	DDI-DrugBank.d761.s1.e0
DDI-DrugBank.d761.s1	38	44	XENICAL	brand	DDI-DrugBank.d761.s1.e1
DDI-DrugBank.d761.s1	50	61	cyclosporine	drug	DDI-DrugBank.d761.s1.e2
DDI-DrugBank.d761.s1	110	121	cyclosporine	drug	DDI-DrugBank.d761.s1.e3
DDI-DrugBank.d761.s1	142	148	XENICAL	brand	DDI-DrugBank.d761.s1.e4
DDI-DrugBank.d761.s1	174	185	cyclosporine	drug	DDI-DrugBank.d761.s1.e5
DDI-DrugBank.d761.s1	false	DDI-DrugBank.d761.s1.e0	DDI-DrugBank.d761.s1.e1
DDI-DrugBank.d761.s1	false	DDI-DrugBank.d761.s1.e0	DDI-DrugBank.d761.s1.e2
DDI-DrugBank.d761.s1	false	DDI-DrugBank.d761.s1.e0	DDI-DrugBank.d761.s1.e3
DDI-DrugBank.d761.s1	false	DDI-DrugBank.d761.s1.e0	DDI-DrugBank.d761.s1.e4
DDI-DrugBank.d761.s1	false	DDI-DrugBank.d761.s1.e0	DDI-DrugBank.d761.s1.e5
DDI-DrugBank.d761.s1	false	DDI-DrugBank.d761.s1.e1	DDI-DrugBank.d761.s1.e2
DDI-DrugBank.d761.s1	false	DDI-DrugBank.d761.s1.e1	DDI-DrugBank.d761.s1.e3
DDI-DrugBank.d761.s1	false	DDI-DrugBank.d761.s1.e1	DDI-DrugBank.d761.s1.e4
DDI-DrugBank.d761.s1	false	DDI-DrugBank.d761.s1.e1	DDI-DrugBank.d761.s1.e5
DDI-DrugBank.d761.s1	false	DDI-DrugBank.d761.s1.e2	DDI-DrugBank.d761.s1.e3
DDI-DrugBank.d761.s2|a|Digoxin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of digoxin. 
DDI-DrugBank.d761.s2	0	6	Digoxin	drug	DDI-DrugBank.d761.s2.e0
DDI-DrugBank.d761.s2	48	54	XENICAL	brand	DDI-DrugBank.d761.s2.e1
DDI-DrugBank.d761.s2	93	99	XENICAL	brand	DDI-DrugBank.d761.s2.e2
DDI-DrugBank.d761.s2	156	162	digoxin	drug	DDI-DrugBank.d761.s2.e3
DDI-DrugBank.d761.s2	false	DDI-DrugBank.d761.s2.e0	DDI-DrugBank.d761.s2.e1
DDI-DrugBank.d761.s2	false	DDI-DrugBank.d761.s2.e0	DDI-DrugBank.d761.s2.e2
DDI-DrugBank.d761.s2	false	DDI-DrugBank.d761.s2.e0	DDI-DrugBank.d761.s2.e3
DDI-DrugBank.d761.s2	false	DDI-DrugBank.d761.s2.e1	DDI-DrugBank.d761.s2.e2
DDI-DrugBank.d761.s2	false	DDI-DrugBank.d761.s2.e1	DDI-DrugBank.d761.s2.e3
DDI-DrugBank.d761.s2	false	DDI-DrugBank.d761.s2.e2	DDI-DrugBank.d761.s2.e3
DDI-DrugBank.d761.s3|a|Fat-soluble Vitamin Supplements and Analogues: A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with XENICAL. 
DDI-DrugBank.d761.s3	0	30	Fat-soluble Vitamin Supplements	group	DDI-DrugBank.d761.s3.e0
DDI-DrugBank.d761.s3	109	121	beta-carotene	drug	DDI-DrugBank.d761.s3.e1
DDI-DrugBank.d761.s3	182	188	XENICAL	brand	DDI-DrugBank.d761.s3.e2
DDI-DrugBank.d761.s3	false	DDI-DrugBank.d761.s3.e0	DDI-DrugBank.d761.s3.e1
DDI-DrugBank.d761.s3	false	DDI-DrugBank.d761.s3.e0	DDI-DrugBank.d761.s3.e2
DDI-DrugBank.d761.s3	true	DDI-DrugBank.d761.s3.e1	DDI-DrugBank.d761.s3.e2
DDI-DrugBank.d761.s4|a|XENICAL inhibited absorption of a vitamin E acetate supplement by approximately 60%. 
DDI-DrugBank.d761.s4	0	6	XENICAL	brand	DDI-DrugBank.d761.s4.e0
DDI-DrugBank.d761.s4	34	50	vitamin E acetate	drug	DDI-DrugBank.d761.s4.e1
DDI-DrugBank.d761.s4	true	DDI-DrugBank.d761.s4.e0	DDI-DrugBank.d761.s4.e1
DDI-DrugBank.d761.s5|a|The effect of orlistat on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time. 
DDI-DrugBank.d761.s5	14	21	orlistat	drug	DDI-DrugBank.d761.s5.e0
DDI-DrugBank.d761.s5	57	65	vitamin D	group	DDI-DrugBank.d761.s5.e1
DDI-DrugBank.d761.s5	68	76	vitamin A	group	DDI-DrugBank.d761.s5.e2
DDI-DrugBank.d761.s5	105	113	vitamin K	group	DDI-DrugBank.d761.s5.e3
DDI-DrugBank.d761.s5	false	DDI-DrugBank.d761.s5.e0	DDI-DrugBank.d761.s5.e1
DDI-DrugBank.d761.s5	false	DDI-DrugBank.d761.s5.e0	DDI-DrugBank.d761.s5.e2
DDI-DrugBank.d761.s5	false	DDI-DrugBank.d761.s5.e0	DDI-DrugBank.d761.s5.e3
DDI-DrugBank.d761.s5	false	DDI-DrugBank.d761.s5.e1	DDI-DrugBank.d761.s5.e2
DDI-DrugBank.d761.s5	false	DDI-DrugBank.d761.s5.e1	DDI-DrugBank.d761.s5.e3
DDI-DrugBank.d761.s5	false	DDI-DrugBank.d761.s5.e2	DDI-DrugBank.d761.s5.e3
DDI-DrugBank.d761.s6|a|Glyburide: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide. 
DDI-DrugBank.d761.s6	0	8	Glyburide	drug	DDI-DrugBank.d761.s6.e0
DDI-DrugBank.d761.s6	50	57	orlistat	drug	DDI-DrugBank.d761.s6.e1
DDI-DrugBank.d761.s6	95	102	orlistat	drug	DDI-DrugBank.d761.s6.e2
DDI-DrugBank.d761.s6	187	195	glyburide	drug	DDI-DrugBank.d761.s6.e3
DDI-DrugBank.d761.s6	false	DDI-DrugBank.d761.s6.e0	DDI-DrugBank.d761.s6.e1
DDI-DrugBank.d761.s6	false	DDI-DrugBank.d761.s6.e0	DDI-DrugBank.d761.s6.e2
DDI-DrugBank.d761.s6	false	DDI-DrugBank.d761.s6.e0	DDI-DrugBank.d761.s6.e3
DDI-DrugBank.d761.s6	false	DDI-DrugBank.d761.s6.e1	DDI-DrugBank.d761.s6.e2
DDI-DrugBank.d761.s6	false	DDI-DrugBank.d761.s6.e1	DDI-DrugBank.d761.s6.e3
DDI-DrugBank.d761.s6	false	DDI-DrugBank.d761.s6.e2	DDI-DrugBank.d761.s6.e3
DDI-DrugBank.d761.s7|a|Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of nifedipine (extended-release tablets). 
DDI-DrugBank.d761.s7	0	9	Nifedipine	drug	DDI-DrugBank.d761.s7.e0
DDI-DrugBank.d761.s7	78	84	XENICAL	brand	DDI-DrugBank.d761.s7.e1
DDI-DrugBank.d761.s7	123	129	XENICAL	brand	DDI-DrugBank.d761.s7.e2
DDI-DrugBank.d761.s7	168	177	nifedipine	drug	DDI-DrugBank.d761.s7.e3
DDI-DrugBank.d761.s7	false	DDI-DrugBank.d761.s7.e0	DDI-DrugBank.d761.s7.e1
DDI-DrugBank.d761.s7	false	DDI-DrugBank.d761.s7.e0	DDI-DrugBank.d761.s7.e2
DDI-DrugBank.d761.s7	false	DDI-DrugBank.d761.s7.e0	DDI-DrugBank.d761.s7.e3
DDI-DrugBank.d761.s7	false	DDI-DrugBank.d761.s7.e1	DDI-DrugBank.d761.s7.e2
DDI-DrugBank.d761.s7	false	DDI-DrugBank.d761.s7.e1	DDI-DrugBank.d761.s7.e3
DDI-DrugBank.d761.s7	false	DDI-DrugBank.d761.s7.e2	DDI-DrugBank.d761.s7.e3
DDI-DrugBank.d761.s8|a|Oral Contraceptives: In 20 normal-weight female subjects, the treatment of XENICAL 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral contraceptives. 
DDI-DrugBank.d761.s8	5	18	Contraceptives	group	DDI-DrugBank.d761.s8.e0
DDI-DrugBank.d761.s8	75	81	XENICAL	brand	DDI-DrugBank.d761.s8.e1
DDI-DrugBank.d761.s8	187	200	contraceptives	group	DDI-DrugBank.d761.s8.e2
DDI-DrugBank.d761.s8	false	DDI-DrugBank.d761.s8.e0	DDI-DrugBank.d761.s8.e1
DDI-DrugBank.d761.s8	false	DDI-DrugBank.d761.s8.e0	DDI-DrugBank.d761.s8.e2
DDI-DrugBank.d761.s8	false	DDI-DrugBank.d761.s8.e1	DDI-DrugBank.d761.s8.e2
DDI-DrugBank.d761.s9|a|Phenytoin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin. 
DDI-DrugBank.d761.s9	0	8	Phenytoin	drug	DDI-DrugBank.d761.s9.e0
DDI-DrugBank.d761.s9	50	56	XENICAL	brand	DDI-DrugBank.d761.s9.e1
DDI-DrugBank.d761.s9	95	101	XENICAL	brand	DDI-DrugBank.d761.s9.e2
DDI-DrugBank.d761.s9	165	173	phenytoin	drug	DDI-DrugBank.d761.s9.e3
DDI-DrugBank.d761.s9	false	DDI-DrugBank.d761.s9.e0	DDI-DrugBank.d761.s9.e1
DDI-DrugBank.d761.s9	false	DDI-DrugBank.d761.s9.e0	DDI-DrugBank.d761.s9.e2
DDI-DrugBank.d761.s9	false	DDI-DrugBank.d761.s9.e0	DDI-DrugBank.d761.s9.e3
DDI-DrugBank.d761.s9	false	DDI-DrugBank.d761.s9.e1	DDI-DrugBank.d761.s9.e2
DDI-DrugBank.d761.s9	false	DDI-DrugBank.d761.s9.e1	DDI-DrugBank.d761.s9.e3
DDI-DrugBank.d761.s9	false	DDI-DrugBank.d761.s9.e2	DDI-DrugBank.d761.s9.e3
DDI-DrugBank.d761.s10|a|Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of pravastatin. 
DDI-DrugBank.d761.s10	0	10	Pravastatin	drug	DDI-DrugBank.d761.s10.e0
DDI-DrugBank.d761.s10	108	114	XENICAL	brand	DDI-DrugBank.d761.s10.e1
DDI-DrugBank.d761.s10	153	159	XENICAL	brand	DDI-DrugBank.d761.s10.e2
DDI-DrugBank.d761.s10	200	210	pravastatin	drug	DDI-DrugBank.d761.s10.e3
DDI-DrugBank.d761.s10	false	DDI-DrugBank.d761.s10.e0	DDI-DrugBank.d761.s10.e1
DDI-DrugBank.d761.s10	false	DDI-DrugBank.d761.s10.e0	DDI-DrugBank.d761.s10.e2
DDI-DrugBank.d761.s10	false	DDI-DrugBank.d761.s10.e0	DDI-DrugBank.d761.s10.e3
DDI-DrugBank.d761.s10	false	DDI-DrugBank.d761.s10.e1	DDI-DrugBank.d761.s10.e2
DDI-DrugBank.d761.s10	false	DDI-DrugBank.d761.s10.e1	DDI-DrugBank.d761.s10.e3
DDI-DrugBank.d761.s10	false	DDI-DrugBank.d761.s10.e2	DDI-DrugBank.d761.s10.e3
DDI-DrugBank.d761.s11|a|Warfarin: In 12 normal-weight subjects, administration of XENICAL 120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). 
DDI-DrugBank.d761.s11	0	7	Warfarin	drug	DDI-DrugBank.d761.s11.e0
DDI-DrugBank.d761.s11	58	64	XENICAL	brand	DDI-DrugBank.d761.s11.e1
DDI-DrugBank.d761.s11	142	149	warfarin	drug	DDI-DrugBank.d761.s11.e2
DDI-DrugBank.d761.s11	false	DDI-DrugBank.d761.s11.e0	DDI-DrugBank.d761.s11.e1
DDI-DrugBank.d761.s11	false	DDI-DrugBank.d761.s11.e0	DDI-DrugBank.d761.s11.e2
DDI-DrugBank.d761.s11	false	DDI-DrugBank.d761.s11.e1	DDI-DrugBank.d761.s11.e2
DDI-DrugBank.d761.s12|a|Although undercarboxylated osteocalcin, a marker of vitamin K nutritional status, was unaltered with XENICAL administration, vitamin K levels tended to decline in subjects taking XENICAL. 
DDI-DrugBank.d761.s12	101	107	XENICAL	brand	DDI-DrugBank.d761.s12.e0
DDI-DrugBank.d761.s12	179	185	XENICAL	brand	DDI-DrugBank.d761.s12.e1
DDI-DrugBank.d761.s12	false	DDI-DrugBank.d761.s12.e0	DDI-DrugBank.d761.s12.e1
DDI-DrugBank.d761.s13|a|Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.
DDI-DrugBank.d761.s13	14	22	vitamin K	group	DDI-DrugBank.d761.s13.e0
DDI-DrugBank.d761.s13	57	63	XENICAL	brand	DDI-DrugBank.d761.s13.e1
DDI-DrugBank.d761.s13	102	109	warfarin	drug	DDI-DrugBank.d761.s13.e2
DDI-DrugBank.d761.s13	130	136	XENICAL	brand	DDI-DrugBank.d761.s13.e3
DDI-DrugBank.d761.s13	true	DDI-DrugBank.d761.s13.e0	DDI-DrugBank.d761.s13.e1
DDI-DrugBank.d761.s13	false	DDI-DrugBank.d761.s13.e0	DDI-DrugBank.d761.s13.e2
DDI-DrugBank.d761.s13	false	DDI-DrugBank.d761.s13.e0	DDI-DrugBank.d761.s13.e3
DDI-DrugBank.d761.s13	false	DDI-DrugBank.d761.s13.e1	DDI-DrugBank.d761.s13.e2
DDI-DrugBank.d761.s13	false	DDI-DrugBank.d761.s13.e1	DDI-DrugBank.d761.s13.e3
DDI-DrugBank.d761.s13	true	DDI-DrugBank.d761.s13.e2	DDI-DrugBank.d761.s13.e3
DDI-DrugBank.d747.s0|a|Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.
DDI-DrugBank.d747.s0	0	11	Tetracycline	group	DDI-DrugBank.d747.s0.e0
DDI-DrugBank.d747.s0	31	40	antibiotic	group	DDI-DrugBank.d747.s0.e1
DDI-DrugBank.d747.s0	85	94	penicillin	drug	DDI-DrugBank.d747.s0.e2
DDI-DrugBank.d747.s0	false	DDI-DrugBank.d747.s0.e0	DDI-DrugBank.d747.s0.e1
DDI-DrugBank.d747.s0	true	DDI-DrugBank.d747.s0.e0	DDI-DrugBank.d747.s0.e2
DDI-DrugBank.d747.s0	false	DDI-DrugBank.d747.s0.e1	DDI-DrugBank.d747.s0.e2
DDI-DrugBank.d728.s0|a|No specific cytochrome P450-based drug interaction studies have been conducted. 
DDI-DrugBank.d728.s1|a|No pharmacokinetic interaction between 85 mg/m2 ELOXATIN and infusional 5-FU has been observed in patients treated every 2 weeks. 
DDI-DrugBank.d728.s1	48	55	ELOXATIN	brand	DDI-DrugBank.d728.s1.e0
DDI-DrugBank.d728.s1	72	75	5-FU	drug	DDI-DrugBank.d728.s1.e1
DDI-DrugBank.d728.s1	false	DDI-DrugBank.d728.s1.e0	DDI-DrugBank.d728.s1.e1
DDI-DrugBank.d728.s2|a|Increases of 5-FU plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 ELOXATIN dosed every 3 weeks. 
DDI-DrugBank.d728.s2	13	16	5-FU	drug	DDI-DrugBank.d728.s2.e0
DDI-DrugBank.d728.s2	104	111	ELOXATIN	brand	DDI-DrugBank.d728.s2.e1
DDI-DrugBank.d728.s2	true	DDI-DrugBank.d728.s2.e0	DDI-DrugBank.d728.s2.e1
DDI-DrugBank.d728.s3|a|Since platinum containing species are eliminated primarily through the kidney, clearance of these products may be decreased by coadministration of potentially nephrotoxic compounds; 
DDI-DrugBank.d728.s4|a|although, this has not been specifically studied.
DDI-DrugBank.d584.s0|a|Anticoagulants Anabolic steroids may increase sensitivity to oral anticoagulants. 
DDI-DrugBank.d584.s0	0	13	Anticoagulants	group	DDI-DrugBank.d584.s0.e0
DDI-DrugBank.d584.s0	15	31	Anabolic steroids	group	DDI-DrugBank.d584.s0.e1
DDI-DrugBank.d584.s0	66	79	anticoagulants	group	DDI-DrugBank.d584.s0.e2
DDI-DrugBank.d584.s0	false	DDI-DrugBank.d584.s0.e0	DDI-DrugBank.d584.s0.e1
DDI-DrugBank.d584.s0	false	DDI-DrugBank.d584.s0.e0	DDI-DrugBank.d584.s0.e2
DDI-DrugBank.d584.s0	true	DDI-DrugBank.d584.s0.e1	DDI-DrugBank.d584.s0.e2
DDI-DrugBank.d584.s1|a|Dosage of the anticoagulant may have to be decreased in order to maintain desired prothrombin time. 
DDI-DrugBank.d584.s1	14	26	anticoagulant	group	DDI-DrugBank.d584.s1.e0
DDI-DrugBank.d584.s2|a|Patients receiving oral anticoagulant therapy require close monitoring, especially when anabolic steroids are started or stopped. 
DDI-DrugBank.d584.s2	88	104	anabolic steroids	group	DDI-DrugBank.d584.s2.e0
DDI-DrugBank.d584.s3|a|Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. 
DDI-DrugBank.d584.s3	0	7	Warfarin	drug	DDI-DrugBank.d584.s3.e0
DDI-DrugBank.d584.s3	31	41	oxandrolone	drug	DDI-DrugBank.d584.s3.e1
DDI-DrugBank.d584.s3	117	124	warfarin	drug	DDI-DrugBank.d584.s3.e2
DDI-DrugBank.d584.s3	158	167	S-warfarin	drug	DDI-DrugBank.d584.s3.e3
DDI-DrugBank.d584.s3	257	266	R-warfarin	drug	DDI-DrugBank.d584.s3.e4
DDI-DrugBank.d584.s3	false	DDI-DrugBank.d584.s3.e0	DDI-DrugBank.d584.s3.e1
DDI-DrugBank.d584.s3	false	DDI-DrugBank.d584.s3.e0	DDI-DrugBank.d584.s3.e2
DDI-DrugBank.d584.s3	false	DDI-DrugBank.d584.s3.e0	DDI-DrugBank.d584.s3.e3
DDI-DrugBank.d584.s3	false	DDI-DrugBank.d584.s3.e0	DDI-DrugBank.d584.s3.e4
DDI-DrugBank.d584.s3	true	DDI-DrugBank.d584.s3.e1	DDI-DrugBank.d584.s3.e2
DDI-DrugBank.d584.s3	false	DDI-DrugBank.d584.s3.e1	DDI-DrugBank.d584.s3.e3
DDI-DrugBank.d584.s3	false	DDI-DrugBank.d584.s3.e1	DDI-DrugBank.d584.s3.e4
DDI-DrugBank.d584.s3	false	DDI-DrugBank.d584.s3.e2	DDI-DrugBank.d584.s3.e3
DDI-DrugBank.d584.s3	false	DDI-DrugBank.d584.s3.e2	DDI-DrugBank.d584.s3.e4
DDI-DrugBank.d584.s3	false	DDI-DrugBank.d584.s3.e3	DDI-DrugBank.d584.s3.e4
DDI-DrugBank.d584.s4|a|Microscopic hematuria (9/15) and gingival bleeding (1/15) were also observed. 
DDI-DrugBank.d584.s5|a|A 5.5-fold decrease in the mean warfarin dose from 6.13 mg/day to 1.13 mg/day (approximately 80-85% reduction of warfarin dose), was necessary to maintain a target INR of 1.5. 
DDI-DrugBank.d584.s5	32	39	warfarin	drug	DDI-DrugBank.d584.s5.e0
DDI-DrugBank.d584.s5	113	120	warfarin	drug	DDI-DrugBank.d584.s5.e1
DDI-DrugBank.d584.s5	false	DDI-DrugBank.d584.s5.e0	DDI-DrugBank.d584.s5.e1
DDI-DrugBank.d584.s6|a|When oxandrolone therapy is initiated in a patient already receiving treatment with warfarin, the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved. 
DDI-DrugBank.d584.s6	5	15	oxandrolone	drug	DDI-DrugBank.d584.s6.e0
DDI-DrugBank.d584.s6	84	91	warfarin	drug	DDI-DrugBank.d584.s6.e1
DDI-DrugBank.d584.s6	171	178	warfarin	drug	DDI-DrugBank.d584.s6.e2
DDI-DrugBank.d584.s6	true	DDI-DrugBank.d584.s6.e0	DDI-DrugBank.d584.s6.e1
DDI-DrugBank.d584.s6	false	DDI-DrugBank.d584.s6.e0	DDI-DrugBank.d584.s6.e2
DDI-DrugBank.d584.s6	false	DDI-DrugBank.d584.s6.e1	DDI-DrugBank.d584.s6.e2
DDI-DrugBank.d584.s7|a|Furthermore, in patients receiving both drugs, careful monitoring of the INR or PT, and adjustment of the warfarin dosage if indicated are recommended when the oxandrolone dose is changed or discontinued. 
DDI-DrugBank.d584.s7	106	113	warfarin	drug	DDI-DrugBank.d584.s7.e0
DDI-DrugBank.d584.s7	160	170	oxandrolone	drug	DDI-DrugBank.d584.s7.e1
DDI-DrugBank.d584.s7	true	DDI-DrugBank.d584.s7.e0	DDI-DrugBank.d584.s7.e1
DDI-DrugBank.d584.s8|a|Patients should be closely monitored for signs and symptoms of occult bleeding. 
DDI-DrugBank.d584.s9|a|Oral hypoglycemic agents Oxandrolone may inhibit the metabolism of oral hypoglycemic agents. 
DDI-DrugBank.d584.s9	5	23	hypoglycemic agents	group	DDI-DrugBank.d584.s9.e0
DDI-DrugBank.d584.s9	25	35	Oxandrolone	drug	DDI-DrugBank.d584.s9.e1
DDI-DrugBank.d584.s9	72	90	hypoglycemic agents	group	DDI-DrugBank.d584.s9.e2
DDI-DrugBank.d584.s9	false	DDI-DrugBank.d584.s9.e0	DDI-DrugBank.d584.s9.e1
DDI-DrugBank.d584.s9	false	DDI-DrugBank.d584.s9.e0	DDI-DrugBank.d584.s9.e2
DDI-DrugBank.d584.s9	true	DDI-DrugBank.d584.s9.e1	DDI-DrugBank.d584.s9.e2
DDI-DrugBank.d584.s10|a|Adrenal steroids or ACTH In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema. 
DDI-DrugBank.d584.s10	0	15	Adrenal steroids	group	DDI-DrugBank.d584.s10.e0
DDI-DrugBank.d584.s10	20	23	ACTH	drug	DDI-DrugBank.d584.s10.e1
DDI-DrugBank.d584.s10	81	105	adrenal cortical steroids	group	DDI-DrugBank.d584.s10.e2
DDI-DrugBank.d584.s10	110	113	ACTH	drug	DDI-DrugBank.d584.s10.e3
DDI-DrugBank.d584.s10	false	DDI-DrugBank.d584.s10.e0	DDI-DrugBank.d584.s10.e1
DDI-DrugBank.d584.s10	false	DDI-DrugBank.d584.s10.e0	DDI-DrugBank.d584.s10.e2
DDI-DrugBank.d584.s10	false	DDI-DrugBank.d584.s10.e0	DDI-DrugBank.d584.s10.e3
DDI-DrugBank.d584.s10	false	DDI-DrugBank.d584.s10.e1	DDI-DrugBank.d584.s10.e2
DDI-DrugBank.d584.s10	false	DDI-DrugBank.d584.s10.e1	DDI-DrugBank.d584.s10.e3
DDI-DrugBank.d584.s10	false	DDI-DrugBank.d584.s10.e2	DDI-DrugBank.d584.s10.e3
DDI-DrugBank.d584.s11|a|Drug/Laboratory test interactions Anabolic steroids may decrease levels of thyroxine-binding globulin, resulting in decreased total T4 serum levels and increased resin uptake of T3 and T4. 
DDI-DrugBank.d584.s11	34	50	Anabolic steroids	drug	DDI-DrugBank.d584.s11.e0
DDI-DrugBank.d584.s12|a|Free thyroid hormone levels remain unchanged. 
DDI-DrugBank.d584.s13|a|In addition, a decrease in PBI and radioactive iodine uptake may occur.    
DDI-DrugBank.d784.s0|a|The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. 
DDI-DrugBank.d784.s0	23	32	oxybutynin	drug	DDI-DrugBank.d784.s0.e0
DDI-DrugBank.d784.s0	45	65	anticholinergic drugs	group	DDI-DrugBank.d784.s0.e1
DDI-DrugBank.d784.s0	true	DDI-DrugBank.d784.s0.e0	DDI-DrugBank.d784.s0.e1
DDI-DrugBank.d784.s1|a|Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. 
DDI-DrugBank.d784.s1	0	21	Anticholinergic agents	group	DDI-DrugBank.d784.s1.e0
DDI-DrugBank.d784.s2|a|This may be of concern for drugs with a narrow therapeutic index. 
DDI-DrugBank.d784.s3|a|Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with ketoconazole, a potent CYP3A4 inhibitor. 
DDI-DrugBank.d784.s3	5	23	oxybutynin chloride	drug	DDI-DrugBank.d784.s3.e0
DDI-DrugBank.d784.s3	85	95	DITROPAN XL	brand	DDI-DrugBank.d784.s3.e1
DDI-DrugBank.d784.s3	119	130	ketoconazole	drug	DDI-DrugBank.d784.s3.e2
DDI-DrugBank.d784.s3	false	DDI-DrugBank.d784.s3.e0	DDI-DrugBank.d784.s3.e1
DDI-DrugBank.d784.s3	false	DDI-DrugBank.d784.s3.e0	DDI-DrugBank.d784.s3.e2
DDI-DrugBank.d784.s3	true	DDI-DrugBank.d784.s3.e1	DDI-DrugBank.d784.s3.e2
DDI-DrugBank.d784.s4|a|Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). 
DDI-DrugBank.d784.s4	67	84	antimycotic agents	group	DDI-DrugBank.d784.s4.e0
DDI-DrugBank.d784.s4	93	104	itraconazole	drug	DDI-DrugBank.d784.s4.e1
DDI-DrugBank.d784.s4	110	119	miconazole	drug	DDI-DrugBank.d784.s4.e2
DDI-DrugBank.d784.s4	125	145	macrolide antibiotics	group	DDI-DrugBank.d784.s4.e3
DDI-DrugBank.d784.s4	154	165	erythromycin	drug	DDI-DrugBank.d784.s4.e4
DDI-DrugBank.d784.s4	171	184	clarithromycin	drug	DDI-DrugBank.d784.s4.e5
DDI-DrugBank.d784.s4	198	207	oxybutynin	drug	DDI-DrugBank.d784.s4.e6
DDI-DrugBank.d784.s4	false	DDI-DrugBank.d784.s4.e0	DDI-DrugBank.d784.s4.e1
DDI-DrugBank.d784.s4	false	DDI-DrugBank.d784.s4.e0	DDI-DrugBank.d784.s4.e2
DDI-DrugBank.d784.s4	false	DDI-DrugBank.d784.s4.e0	DDI-DrugBank.d784.s4.e3
DDI-DrugBank.d784.s4	false	DDI-DrugBank.d784.s4.e0	DDI-DrugBank.d784.s4.e4
DDI-DrugBank.d784.s4	false	DDI-DrugBank.d784.s4.e0	DDI-DrugBank.d784.s4.e5
DDI-DrugBank.d784.s4	true	DDI-DrugBank.d784.s4.e0	DDI-DrugBank.d784.s4.e6
DDI-DrugBank.d784.s4	false	DDI-DrugBank.d784.s4.e1	DDI-DrugBank.d784.s4.e2
DDI-DrugBank.d784.s4	false	DDI-DrugBank.d784.s4.e1	DDI-DrugBank.d784.s4.e3
DDI-DrugBank.d784.s4	false	DDI-DrugBank.d784.s4.e1	DDI-DrugBank.d784.s4.e4
DDI-DrugBank.d784.s4	false	DDI-DrugBank.d784.s4.e1	DDI-DrugBank.d784.s4.e5
DDI-DrugBank.d784.s5|a|The clinical relevance of such potential interactions is not known. 
DDI-DrugBank.d784.s6|a|Caution should be used when such drugs are co-administered. 
DDI-DrugBank.d784.s7|a|Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    
DDI-DrugBank.d784.s7	24	30	antacid	group	DDI-DrugBank.d784.s7.e0
DDI-DrugBank.d784.s7	42	48	antacid	group	DDI-DrugBank.d784.s7.e1
DDI-DrugBank.d784.s7	61	78	aluminum hydroxide	drug	DDI-DrugBank.d784.s7.e2
DDI-DrugBank.d784.s7	81	99	magnesium hydroxide	drug	DDI-DrugBank.d784.s7.e3
DDI-DrugBank.d784.s7	106	116	simethicone	drug	DDI-DrugBank.d784.s7.e4
DDI-DrugBank.d784.s7	164	173	oxybutynin	drug	DDI-DrugBank.d784.s7.e5
DDI-DrugBank.d784.s7	178	195	desethyloxybutynin	drug_n	DDI-DrugBank.d784.s7.e6
DDI-DrugBank.d784.s7	false	DDI-DrugBank.d784.s7.e0	DDI-DrugBank.d784.s7.e1
DDI-DrugBank.d784.s7	false	DDI-DrugBank.d784.s7.e0	DDI-DrugBank.d784.s7.e2
DDI-DrugBank.d784.s7	false	DDI-DrugBank.d784.s7.e0	DDI-DrugBank.d784.s7.e3
DDI-DrugBank.d784.s7	false	DDI-DrugBank.d784.s7.e0	DDI-DrugBank.d784.s7.e4
DDI-DrugBank.d784.s7	false	DDI-DrugBank.d784.s7.e0	DDI-DrugBank.d784.s7.e5
DDI-DrugBank.d784.s7	false	DDI-DrugBank.d784.s7.e0	DDI-DrugBank.d784.s7.e6
DDI-DrugBank.d784.s7	false	DDI-DrugBank.d784.s7.e1	DDI-DrugBank.d784.s7.e2
DDI-DrugBank.d784.s7	false	DDI-DrugBank.d784.s7.e1	DDI-DrugBank.d784.s7.e3
DDI-DrugBank.d784.s7	false	DDI-DrugBank.d784.s7.e1	DDI-DrugBank.d784.s7.e4
DDI-DrugBank.d784.s7	false	DDI-DrugBank.d784.s7.e1	DDI-DrugBank.d784.s7.e5
DDI-DrugBank.d758.s0|a|The CNS depressant effects of oxycodone hydrochloride may be additive with that of other CNS depressants..
DDI-DrugBank.d758.s0	30	52	oxycodone hydrochloride	drug	DDI-DrugBank.d758.s0.e0
DDI-DrugBank.d758.s0	89	103	CNS depressants	group	DDI-DrugBank.d758.s0.e1
DDI-DrugBank.d758.s0	true	DDI-DrugBank.d758.s0.e0	DDI-DrugBank.d758.s0.e1
DDI-DrugBank.d753.s0|a|The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 
DDI-DrugBank.d753.s0	29	43	CNS depressants	group	DDI-DrugBank.d753.s0.e0
DDI-DrugBank.d753.s0	55	63	sedatives	group	DDI-DrugBank.d753.s0.e1
DDI-DrugBank.d753.s0	66	74	hypnotics	group	DDI-DrugBank.d753.s0.e2
DDI-DrugBank.d753.s0	77	89	tranquilizers	group	DDI-DrugBank.d753.s0.e3
DDI-DrugBank.d753.s0	100	110	anesthetics	group	DDI-DrugBank.d753.s0.e4
DDI-DrugBank.d753.s0	113	126	phenothiazines	group	DDI-DrugBank.d753.s0.e5
DDI-DrugBank.d753.s0	135	141	opioids	group	DDI-DrugBank.d753.s0.e6
DDI-DrugBank.d753.s0	144	168	tricyclic antidepressants	group	DDI-DrugBank.d753.s0.e7
DDI-DrugBank.d753.s0	171	204	monoamine oxidase (MAO) inhibitors	group	DDI-DrugBank.d753.s0.e8
DDI-DrugBank.d753.s0	211	217	alcohol	drug	DDI-DrugBank.d753.s0.e9
DDI-DrugBank.d753.s0	false	DDI-DrugBank.d753.s0.e0	DDI-DrugBank.d753.s0.e1
DDI-DrugBank.d753.s0	false	DDI-DrugBank.d753.s0.e0	DDI-DrugBank.d753.s0.e2
DDI-DrugBank.d753.s0	false	DDI-DrugBank.d753.s0.e0	DDI-DrugBank.d753.s0.e3
DDI-DrugBank.d753.s0	false	DDI-DrugBank.d753.s0.e0	DDI-DrugBank.d753.s0.e4
DDI-DrugBank.d753.s0	false	DDI-DrugBank.d753.s0.e0	DDI-DrugBank.d753.s0.e5
DDI-DrugBank.d753.s0	false	DDI-DrugBank.d753.s0.e0	DDI-DrugBank.d753.s0.e6
DDI-DrugBank.d753.s0	false	DDI-DrugBank.d753.s0.e0	DDI-DrugBank.d753.s0.e7
DDI-DrugBank.d753.s0	false	DDI-DrugBank.d753.s0.e0	DDI-DrugBank.d753.s0.e8
DDI-DrugBank.d753.s0	false	DDI-DrugBank.d753.s0.e0	DDI-DrugBank.d753.s0.e9
DDI-DrugBank.d753.s0	false	DDI-DrugBank.d753.s0.e1	DDI-DrugBank.d753.s0.e2
DDI-DrugBank.d753.s1|a|When such combined therapy is contemplated, the dose of one or both agents should be reduced. 
DDI-DrugBank.d753.s2|a|Anticholinergics or other medications with anticholinergic activity when used concurrently with opioid analgesics may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. 
DDI-DrugBank.d753.s2	0	15	Anticholinergics	group	DDI-DrugBank.d753.s2.e0
DDI-DrugBank.d753.s2	96	112	opioid analgesics	group	DDI-DrugBank.d753.s2.e1
DDI-DrugBank.d753.s2	true	DDI-DrugBank.d753.s2.e0	DDI-DrugBank.d753.s2.e1
DDI-DrugBank.d753.s3|a|It has been reported that the incidence of bradycardia was increased when oxymorphone was combined with propofol for induction of anesthesia. 
DDI-DrugBank.d753.s3	74	84	oxymorphone	drug	DDI-DrugBank.d753.s3.e0
DDI-DrugBank.d753.s3	104	111	propofol	drug	DDI-DrugBank.d753.s3.e1
DDI-DrugBank.d753.s3	true	DDI-DrugBank.d753.s3.e0	DDI-DrugBank.d753.s3.e1
DDI-DrugBank.d753.s4|a|In addition, CNS toxicity has been reported (confusion, disorientation, respiratory depression, apnea, seizures) following coadministration of cimetidine with opioid analgesics; 
DDI-DrugBank.d753.s4	143	152	cimetidine	drug	DDI-DrugBank.d753.s4.e0
DDI-DrugBank.d753.s4	159	175	opioid analgesics	group	DDI-DrugBank.d753.s4.e1
DDI-DrugBank.d753.s4	true	DDI-DrugBank.d753.s4.e0	DDI-DrugBank.d753.s4.e1
DDI-DrugBank.d753.s5|a|no clear-cut cause and effect relationship was established.
DDI-DrugBank.d670.s0|a|Potential for INVEGA    to Affect Other Drugs Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. 
DDI-DrugBank.d670.s0	14	19	INVEGA	brand	DDI-DrugBank.d670.s0.e0
DDI-DrugBank.d670.s0	46	57	Paliperidone	drug	DDI-DrugBank.d670.s0.e1
DDI-DrugBank.d670.s0	false	DDI-DrugBank.d670.s0.e0	DDI-DrugBank.d670.s0.e1
DDI-DrugBank.d670.s1|a|In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. 
DDI-DrugBank.d670.s1	55	66	paliperidone	drug	DDI-DrugBank.d670.s1.e0
DDI-DrugBank.d670.s2|a|Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. 
DDI-DrugBank.d670.s2	11	22	paliperidone	drug	DDI-DrugBank.d670.s2.e0
DDI-DrugBank.d670.s3|a|Paliperidone is also not expected to have enzyme inducing properties. 
DDI-DrugBank.d670.s3	0	11	Paliperidone	drug	DDI-DrugBank.d670.s3.e0
DDI-DrugBank.d670.s4|a|At therapeutic concentrations, paliperidone did not inhibit P-glycoprotein. 
DDI-DrugBank.d670.s4	31	42	paliperidone	drug	DDI-DrugBank.d670.s4.e0
DDI-DrugBank.d670.s5|a|Paliperidone is therefore not expected to inhibit P-glycoprotein-mediated transport of other drugs in a clinically relevant manner. 
DDI-DrugBank.d670.s5	0	11	Paliperidone	drug	DDI-DrugBank.d670.s5.e0
DDI-DrugBank.d670.s6|a|Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. 
DDI-DrugBank.d670.s6	33	44	paliperidone	drug	DDI-DrugBank.d670.s6.e0
DDI-DrugBank.d670.s6	47	52	INVEGA	brand	DDI-DrugBank.d670.s6.e1
DDI-DrugBank.d670.s6	111	132	centrally acting drugs	group	DDI-DrugBank.d670.s6.e2
DDI-DrugBank.d670.s6	138	144	alcohol	drug	DDI-DrugBank.d670.s6.e3
DDI-DrugBank.d670.s6	false	DDI-DrugBank.d670.s6.e0	DDI-DrugBank.d670.s6.e1
DDI-DrugBank.d670.s6	true	DDI-DrugBank.d670.s6.e0	DDI-DrugBank.d670.s6.e2
DDI-DrugBank.d670.s6	true	DDI-DrugBank.d670.s6.e0	DDI-DrugBank.d670.s6.e3
DDI-DrugBank.d670.s6	true	DDI-DrugBank.d670.s6.e1	DDI-DrugBank.d670.s6.e2
DDI-DrugBank.d670.s6	true	DDI-DrugBank.d670.s6.e1	DDI-DrugBank.d670.s6.e3
DDI-DrugBank.d670.s6	false	DDI-DrugBank.d670.s6.e2	DDI-DrugBank.d670.s6.e3
DDI-DrugBank.d670.s7|a|Paliperidone may antagonize the effect of levodopa and other dopamine agonists. 
DDI-DrugBank.d670.s7	0	11	Paliperidone	drug	DDI-DrugBank.d670.s7.e0
DDI-DrugBank.d670.s7	42	49	levodopa	drug	DDI-DrugBank.d670.s7.e1
DDI-DrugBank.d670.s7	61	77	dopamine agonists	group	DDI-DrugBank.d670.s7.e2
DDI-DrugBank.d670.s7	true	DDI-DrugBank.d670.s7.e0	DDI-DrugBank.d670.s7.e1
DDI-DrugBank.d670.s7	true	DDI-DrugBank.d670.s7.e0	DDI-DrugBank.d670.s7.e2
DDI-DrugBank.d670.s7	false	DDI-DrugBank.d670.s7.e1	DDI-DrugBank.d670.s7.e2
DDI-DrugBank.d670.s8|a|Because of its potential for inducing orthostatic hypotension, an additive effect may be observed when INVEGA    is administered with other therapeutic agents that have this potential. 
DDI-DrugBank.d670.s8	103	108	INVEGA	brand	DDI-DrugBank.d670.s8.e0
DDI-DrugBank.d670.s9|a|Potential for Other Drugs to Affect INVEGA    Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. 
DDI-DrugBank.d670.s9	36	41	INVEGA	brand	DDI-DrugBank.d670.s9.e0
DDI-DrugBank.d670.s9	46	57	Paliperidone	drug	DDI-DrugBank.d670.s9.e1
DDI-DrugBank.d670.s9	false	DDI-DrugBank.d670.s9.e0	DDI-DrugBank.d670.s9.e1
DDI-DrugBank.d670.s10|a|While in vitro studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, in vivo studies do not show decreased elimination by these isozymes and they contribute to only a small fraction of total body clearance.
DDI-DrugBank.d670.s10	84	95	paliperidone	drug	DDI-DrugBank.d670.s10.e0
DDI-DrugBank.d680.s0|a|Pantoprazole is metabolized through the cytochrome P450 system, primarily the CYP2C19 and CYP3A4 isozymes, and subsequently undergoes Phase II conjugation. 
DDI-DrugBank.d680.s0	0	11	Pantoprazole	drug	DDI-DrugBank.d680.s0.e0
DDI-DrugBank.d680.s1|a|Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
DDI-DrugBank.d680.s1	53	64	pantoprazole	drug	DDI-DrugBank.d680.s1.e0
DDI-DrugBank.d680.s1	154	165	theophylline	drug	DDI-DrugBank.d680.s1.e1
DDI-DrugBank.d680.s1	168	176	cisapride	drug	DDI-DrugBank.d680.s1.e2
DDI-DrugBank.d680.s1	179	188	antipyrine	drug	DDI-DrugBank.d680.s1.e3
DDI-DrugBank.d680.s1	191	198	caffeine	drug	DDI-DrugBank.d680.s1.e4
DDI-DrugBank.d680.s1	201	213	carbamazepine	drug	DDI-DrugBank.d680.s1.e5
DDI-DrugBank.d680.s1	216	223	diazepam	drug	DDI-DrugBank.d680.s1.e6
DDI-DrugBank.d680.s1	253	269	desmethyldiazepam	drug_n	DDI-DrugBank.d680.s1.e7
DDI-DrugBank.d680.s1	273	282	diclofenac	drug	DDI-DrugBank.d680.s1.e8
DDI-DrugBank.d680.s1	285	292	naproxen	drug	DDI-DrugBank.d680.s1.e9
DDI-DrugBank.d680.s1	false	DDI-DrugBank.d680.s1.e0	DDI-DrugBank.d680.s1.e1
DDI-DrugBank.d680.s1	false	DDI-DrugBank.d680.s1.e0	DDI-DrugBank.d680.s1.e2
DDI-DrugBank.d680.s1	false	DDI-DrugBank.d680.s1.e0	DDI-DrugBank.d680.s1.e3
DDI-DrugBank.d680.s1	false	DDI-DrugBank.d680.s1.e0	DDI-DrugBank.d680.s1.e4
DDI-DrugBank.d680.s1	false	DDI-DrugBank.d680.s1.e0	DDI-DrugBank.d680.s1.e5
DDI-DrugBank.d680.s1	false	DDI-DrugBank.d680.s1.e0	DDI-DrugBank.d680.s1.e6
DDI-DrugBank.d680.s1	false	DDI-DrugBank.d680.s1.e0	DDI-DrugBank.d680.s1.e7
DDI-DrugBank.d680.s1	false	DDI-DrugBank.d680.s1.e0	DDI-DrugBank.d680.s1.e8
DDI-DrugBank.d680.s1	false	DDI-DrugBank.d680.s1.e0	DDI-DrugBank.d680.s1.e9
DDI-DrugBank.d680.s1	false	DDI-DrugBank.d680.s1.e0	DDI-DrugBank.d680.s1.e10
DDI-DrugBank.d680.s2|a|Clinically relevant interactions of pantoprazole with other drugs with the same metabolic pathways are not expected. 
DDI-DrugBank.d680.s2	36	47	pantoprazole	drug	DDI-DrugBank.d680.s2.e0
DDI-DrugBank.d680.s3|a|Therefore, when coadministered with pantoprazole, adjustment of the dosage of pantoprazole or of such drugs may not be necessary. 
DDI-DrugBank.d680.s3	36	47	pantoprazole	drug	DDI-DrugBank.d680.s3.e0
DDI-DrugBank.d680.s3	78	89	pantoprazole	drug	DDI-DrugBank.d680.s3.e1
DDI-DrugBank.d680.s3	false	DDI-DrugBank.d680.s3.e0	DDI-DrugBank.d680.s3.e1
DDI-DrugBank.d680.s4|a|There was also no interaction with concomitantly administered antacids. 
DDI-DrugBank.d680.s4	62	69	antacids	group	DDI-DrugBank.d680.s4.e0
DDI-DrugBank.d680.s5|a|There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly. 
DDI-DrugBank.d680.s5	98	119	proton pump inhibitors	group	DDI-DrugBank.d680.s5.e0
DDI-DrugBank.d680.s5	132	143	pantoprazole	drug	DDI-DrugBank.d680.s5.e1
DDI-DrugBank.d680.s5	150	157	warfarin	drug	DDI-DrugBank.d680.s5.e2
DDI-DrugBank.d680.s5	false	DDI-DrugBank.d680.s5.e0	DDI-DrugBank.d680.s5.e1
DDI-DrugBank.d680.s5	true	DDI-DrugBank.d680.s5.e0	DDI-DrugBank.d680.s5.e2
DDI-DrugBank.d680.s5	true	DDI-DrugBank.d680.s5.e1	DDI-DrugBank.d680.s5.e2
DDI-DrugBank.d680.s6|a|Increases in INR and prothrombin time may lead to abnormal bleeding and even death. 
DDI-DrugBank.d680.s7|a|Patients treated with proton pump inhibitors and warfarin concomitantly should be monitored for increases in INR and prothrombin time. 
DDI-DrugBank.d680.s7	22	43	proton pump inhibitors	group	DDI-DrugBank.d680.s7.e0
DDI-DrugBank.d680.s7	49	56	warfarin	drug	DDI-DrugBank.d680.s7.e1
DDI-DrugBank.d680.s7	true	DDI-DrugBank.d680.s7.e0	DDI-DrugBank.d680.s7.e1
DDI-DrugBank.d680.s8|a|Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). 
DDI-DrugBank.d680.s8	75	86	pantoprazole	drug	DDI-DrugBank.d680.s8.e0
DDI-DrugBank.d680.s8	202	213	ketoconazole	drug	DDI-DrugBank.d680.s8.e1
DDI-DrugBank.d680.s8	216	225	ampicillin	drug	DDI-DrugBank.d680.s8.e2
DDI-DrugBank.d680.s8	239	242	iron	drug	DDI-DrugBank.d680.s8.e3
DDI-DrugBank.d680.s8	true	DDI-DrugBank.d680.s8.e0	DDI-DrugBank.d680.s8.e1
DDI-DrugBank.d680.s8	true	DDI-DrugBank.d680.s8.e0	DDI-DrugBank.d680.s8.e2
DDI-DrugBank.d680.s8	true	DDI-DrugBank.d680.s8.e0	DDI-DrugBank.d680.s8.e3
DDI-DrugBank.d680.s8	false	DDI-DrugBank.d680.s8.e1	DDI-DrugBank.d680.s8.e2
DDI-DrugBank.d680.s8	false	DDI-DrugBank.d680.s8.e1	DDI-DrugBank.d680.s8.e3
DDI-DrugBank.d680.s8	false	DDI-DrugBank.d680.s8.e2	DDI-DrugBank.d680.s8.e3
DDI-DrugBank.d680.s9|a|Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving most proton pump inhibitors, including pantoprazole. 
DDI-DrugBank.d680.s9	85	104	tetrahydrocannabinol	drug	DDI-DrugBank.d680.s9.e0
DDI-DrugBank.d680.s9	107	109	THC	drug	DDI-DrugBank.d680.s9.e1
DDI-DrugBank.d680.s9	139	160	proton pump inhibitors	group	DDI-DrugBank.d680.s9.e2
DDI-DrugBank.d680.s9	173	184	pantoprazole	drug	DDI-DrugBank.d680.s9.e3
DDI-DrugBank.d680.s9	false	DDI-DrugBank.d680.s9.e0	DDI-DrugBank.d680.s9.e1
DDI-DrugBank.d680.s9	false	DDI-DrugBank.d680.s9.e0	DDI-DrugBank.d680.s9.e2
DDI-DrugBank.d680.s9	false	DDI-DrugBank.d680.s9.e0	DDI-DrugBank.d680.s9.e3
DDI-DrugBank.d680.s9	false	DDI-DrugBank.d680.s9.e1	DDI-DrugBank.d680.s9.e2
DDI-DrugBank.d680.s9	false	DDI-DrugBank.d680.s9.e1	DDI-DrugBank.d680.s9.e3
DDI-DrugBank.d680.s9	false	DDI-DrugBank.d680.s9.e2	DDI-DrugBank.d680.s9.e3
DDI-DrugBank.d680.s10|a|An alternative confirmatory method should be considered to verify positive results.
DDI-DrugBank.d726.s0|a|Paricalcitol is not expected to inhibit the clearance of drugs metabolized by cytochrome P450 enzymes CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 CYP2E1 or CYP3A nor induce the clearance of drugs metabolized by CYP2B6, CYP2C9 or CYP3A. 
DDI-DrugBank.d726.s0	0	11	Paricalcitol	drug_n	DDI-DrugBank.d726.s0.e0
DDI-DrugBank.d726.s1|a|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
DDI-DrugBank.d726.s1	62	73	ketoconazole	drug	DDI-DrugBank.d726.s1.e0
DDI-DrugBank.d726.s1	97	108	paricalcitol	drug	DDI-DrugBank.d726.s1.e1
DDI-DrugBank.d726.s1	126	137	paricalcitol	drug	DDI-DrugBank.d726.s1.e2
DDI-DrugBank.d726.s1	177	188	ketoconazole	drug	DDI-DrugBank.d726.s1.e3
DDI-DrugBank.d726.s1	291	302	paricalcitol	drug	DDI-DrugBank.d726.s1.e4
DDI-DrugBank.d726.s1	309	320	ketoconazole	drug	DDI-DrugBank.d726.s1.e5
DDI-DrugBank.d726.s1	368	377	atazanavir	drug	DDI-DrugBank.d726.s1.e6
DDI-DrugBank.d726.s1	380	393	clarithromycin	drug	DDI-DrugBank.d726.s1.e7
DDI-DrugBank.d726.s1	396	404	indinavir	drug	DDI-DrugBank.d726.s1.e8
DDI-DrugBank.d726.s1	407	418	itraconazole	drug	DDI-DrugBank.d726.s1.e9
DDI-DrugBank.d726.s1	true	DDI-DrugBank.d726.s1.e0	DDI-DrugBank.d726.s1.e1
DDI-DrugBank.d726.s1	false	DDI-DrugBank.d726.s1.e0	DDI-DrugBank.d726.s1.e2
DDI-DrugBank.d726.s1	false	DDI-DrugBank.d726.s1.e0	DDI-DrugBank.d726.s1.e3
DDI-DrugBank.d726.s1	false	DDI-DrugBank.d726.s1.e0	DDI-DrugBank.d726.s1.e4
DDI-DrugBank.d726.s1	false	DDI-DrugBank.d726.s1.e0	DDI-DrugBank.d726.s1.e5
DDI-DrugBank.d726.s1	false	DDI-DrugBank.d726.s1.e0	DDI-DrugBank.d726.s1.e6
DDI-DrugBank.d726.s1	false	DDI-DrugBank.d726.s1.e0	DDI-DrugBank.d726.s1.e7
DDI-DrugBank.d726.s1	false	DDI-DrugBank.d726.s1.e0	DDI-DrugBank.d726.s1.e8
DDI-DrugBank.d726.s1	false	DDI-DrugBank.d726.s1.e0	DDI-DrugBank.d726.s1.e9
DDI-DrugBank.d726.s1	false	DDI-DrugBank.d726.s1.e0	DDI-DrugBank.d726.s1.e10
DDI-DrugBank.d726.s2|a|Dose adjustment of Zemplar Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as ketoconazole. 
DDI-DrugBank.d726.s2	19	25	Zemplar	brand	DDI-DrugBank.d726.s2.e0
DDI-DrugBank.d726.s2	209	220	ketoconazole	drug	DDI-DrugBank.d726.s2.e1
DDI-DrugBank.d726.s2	true	DDI-DrugBank.d726.s2.e0	DDI-DrugBank.d726.s2.e1
DDI-DrugBank.d726.s3|a|Drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of Zemplar Capsules.
DDI-DrugBank.d726.s3	43	62	fat-soluble vitamins	group	DDI-DrugBank.d726.s3.e0
DDI-DrugBank.d726.s3	73	86	cholestyramine	drug	DDI-DrugBank.d726.s3.e1
DDI-DrugBank.d726.s3	126	132	Zemplar	brand	DDI-DrugBank.d726.s3.e2
DDI-DrugBank.d726.s3	true	DDI-DrugBank.d726.s3.e0	DDI-DrugBank.d726.s3.e1
DDI-DrugBank.d726.s3	false	DDI-DrugBank.d726.s3.e0	DDI-DrugBank.d726.s3.e2
DDI-DrugBank.d726.s3	true	DDI-DrugBank.d726.s3.e1	DDI-DrugBank.d726.s3.e2
DDI-DrugBank.d581.s0|a|No formal drug interaction studies between Neulasta and other drugs have been performed. 
DDI-DrugBank.d581.s0	43	50	Neulasta	brand	DDI-DrugBank.d581.s0.e0
DDI-DrugBank.d581.s1|a|Drugs such as lithium may potentiate the release of neutrophils; 
DDI-DrugBank.d581.s1	14	20	lithium	drug	DDI-DrugBank.d581.s1.e0
DDI-DrugBank.d581.s2|a|patients receiving lithium and Neulasta should have more frequent monitoring of neutrophil counts.
DDI-DrugBank.d581.s2	19	25	lithium	drug	DDI-DrugBank.d581.s2.e0
DDI-DrugBank.d581.s2	31	38	Neulasta	brand	DDI-DrugBank.d581.s2.e1
DDI-DrugBank.d581.s2	true	DDI-DrugBank.d581.s2.e0	DDI-DrugBank.d581.s2.e1
DDI-DrugBank.d741.s0|a|In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving methadone, treatment with PEG-Intron once weekly for 4 weeks was associated with a mean increase of 16% in methadone AUC; 
DDI-DrugBank.d741.s0	86	94	methadone	drug	DDI-DrugBank.d741.s0.e0
DDI-DrugBank.d741.s0	112	121	PEG-Intron	brand	DDI-DrugBank.d741.s0.e1
DDI-DrugBank.d741.s0	193	201	methadone	drug	DDI-DrugBank.d741.s0.e2
DDI-DrugBank.d741.s0	true	DDI-DrugBank.d741.s0.e0	DDI-DrugBank.d741.s0.e1
DDI-DrugBank.d741.s0	false	DDI-DrugBank.d741.s0.e0	DDI-DrugBank.d741.s0.e2
DDI-DrugBank.d741.s0	false	DDI-DrugBank.d741.s0.e1	DDI-DrugBank.d741.s0.e2
DDI-DrugBank.d741.s1|a|in 2 out of 18 patients, methadone AUC doubled. 
DDI-DrugBank.d741.s1	25	33	methadone	drug	DDI-DrugBank.d741.s1.e0
DDI-DrugBank.d741.s2|a|The clinical significance of this finding is unknown; 
DDI-DrugBank.d741.s3|a|however, patients should be monitored for the signs and symptoms of increased narcotic effect.
DDI-DrugBank.d744.s0|a|Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT. 
DDI-DrugBank.d744.s0	63	69	insulin	drug	DDI-DrugBank.d744.s0.e0
DDI-DrugBank.d744.s0	83	94	hypoglycemic	group	DDI-DrugBank.d744.s0.e1
DDI-DrugBank.d744.s0	196	203	SOMAVERT	brand	DDI-DrugBank.d744.s0.e2
DDI-DrugBank.d744.s0	false	DDI-DrugBank.d744.s0.e0	DDI-DrugBank.d744.s0.e1
DDI-DrugBank.d744.s0	true	DDI-DrugBank.d744.s0.e0	DDI-DrugBank.d744.s0.e2
DDI-DrugBank.d744.s0	true	DDI-DrugBank.d744.s0.e1	DDI-DrugBank.d744.s0.e2
DDI-DrugBank.d744.s1|a|In clinical studies, patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids. 
DDI-DrugBank.d744.s1	33	39	opioids	group	DDI-DrugBank.d744.s1.e0
DDI-DrugBank.d744.s1	67	77	pegvisomant	drug	DDI-DrugBank.d744.s1.e1
DDI-DrugBank.d744.s1	172	178	opioids	group	DDI-DrugBank.d744.s1.e2
DDI-DrugBank.d744.s1	true	DDI-DrugBank.d744.s1.e0	DDI-DrugBank.d744.s1.e1
DDI-DrugBank.d744.s1	false	DDI-DrugBank.d744.s1.e0	DDI-DrugBank.d744.s1.e2
DDI-DrugBank.d744.s1	false	DDI-DrugBank.d744.s1.e1	DDI-DrugBank.d744.s1.e2
DDI-DrugBank.d744.s2|a|The mechanism of this interaction is not known.
DDI-DrugBank.d641.s0|a|ALIMTA is primarily eliminated unchanged renally as a result of glomerular filtration and tubular secretion. 
DDI-DrugBank.d641.s0	0	5	ALIMTA	brand	DDI-DrugBank.d641.s0.e0
DDI-DrugBank.d641.s1|a|Concomitant administration of nephrotoxic drugs could result in delayed clearance of ALIMTA. 
DDI-DrugBank.d641.s1	85	90	ALIMTA	brand	DDI-DrugBank.d641.s1.e0
DDI-DrugBank.d641.s2|a|Concomitant administration of substances that are also tubularly secreted (e.g., probenecid) could potentially result in delayed clearance of ALIMTA. 
DDI-DrugBank.d641.s2	81	90	probenecid	drug	DDI-DrugBank.d641.s2.e0
DDI-DrugBank.d641.s2	142	147	ALIMTA	brand	DDI-DrugBank.d641.s2.e1
DDI-DrugBank.d641.s2	true	DDI-DrugBank.d641.s2.e0	DDI-DrugBank.d641.s2.e1
DDI-DrugBank.d641.s3|a|Although ibuprofen (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). 
DDI-DrugBank.d641.s3	9	17	ibuprofen	drug	DDI-DrugBank.d641.s3.e0
DDI-DrugBank.d641.s3	57	62	ALIMTA	brand	DDI-DrugBank.d641.s3.e1
DDI-DrugBank.d641.s3	182	190	ibuprofen	drug	DDI-DrugBank.d641.s3.e2
DDI-DrugBank.d641.s3	210	215	ALIMTA	brand	DDI-DrugBank.d641.s3.e3
DDI-DrugBank.d641.s3	false	DDI-DrugBank.d641.s3.e0	DDI-DrugBank.d641.s3.e1
DDI-DrugBank.d641.s3	false	DDI-DrugBank.d641.s3.e0	DDI-DrugBank.d641.s3.e2
DDI-DrugBank.d641.s3	false	DDI-DrugBank.d641.s3.e0	DDI-DrugBank.d641.s3.e3
DDI-DrugBank.d641.s3	false	DDI-DrugBank.d641.s3.e1	DDI-DrugBank.d641.s3.e2
DDI-DrugBank.d641.s3	false	DDI-DrugBank.d641.s3.e1	DDI-DrugBank.d641.s3.e3
DDI-DrugBank.d641.s3	true	DDI-DrugBank.d641.s3.e2	DDI-DrugBank.d641.s3.e3
DDI-DrugBank.d641.s4|a|Patients with mild to moderate renal insufficiency should avoid taking NSAIDs with short elimination half-lives for a period of 2 days before, the day of, and 2 days following administration of ALIMTA. 
DDI-DrugBank.d641.s4	71	76	NSAIDs	group	DDI-DrugBank.d641.s4.e0
DDI-DrugBank.d641.s4	194	199	ALIMTA	brand	DDI-DrugBank.d641.s4.e1
DDI-DrugBank.d641.s4	true	DDI-DrugBank.d641.s4.e0	DDI-DrugBank.d641.s4.e1
DDI-DrugBank.d641.s5|a|In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration. 
DDI-DrugBank.d641.s5	63	68	ALIMTA	brand	DDI-DrugBank.d641.s5.e0
DDI-DrugBank.d641.s5	74	79	NSAIDs	group	DDI-DrugBank.d641.s5.e1
DDI-DrugBank.d641.s5	131	136	NSAIDs	group	DDI-DrugBank.d641.s5.e2
DDI-DrugBank.d641.s5	223	228	ALIMTA	brand	DDI-DrugBank.d641.s5.e3
DDI-DrugBank.d641.s5	false	DDI-DrugBank.d641.s5.e0	DDI-DrugBank.d641.s5.e1
DDI-DrugBank.d641.s5	false	DDI-DrugBank.d641.s5.e0	DDI-DrugBank.d641.s5.e2
DDI-DrugBank.d641.s5	false	DDI-DrugBank.d641.s5.e0	DDI-DrugBank.d641.s5.e3
DDI-DrugBank.d641.s5	false	DDI-DrugBank.d641.s5.e1	DDI-DrugBank.d641.s5.e2
DDI-DrugBank.d641.s5	false	DDI-DrugBank.d641.s5.e1	DDI-DrugBank.d641.s5.e3
DDI-DrugBank.d641.s5	true	DDI-DrugBank.d641.s5.e2	DDI-DrugBank.d641.s5.e3
DDI-DrugBank.d641.s6|a|If concomitant administration of an NSAID is necessary, patients should be monitored closely for toxicity, especially myelosuppression, renal, and gastrointestinal toxicity. 
DDI-DrugBank.d641.s6	36	40	NSAID	group	DDI-DrugBank.d641.s6.e0
DDI-DrugBank.d641.s7|a|Drug/Laboratory Test Interactions None known.
DDI-DrugBank.d671.s0|a|The interaction of CYLERT (pemoline) with other drugs has not been studied in humans. 
DDI-DrugBank.d671.s0	19	24	CYLERT	brand	DDI-DrugBank.d671.s0.e0
DDI-DrugBank.d671.s0	27	34	pemoline	drug	DDI-DrugBank.d671.s0.e1
DDI-DrugBank.d671.s0	false	DDI-DrugBank.d671.s0.e0	DDI-DrugBank.d671.s0.e1
DDI-DrugBank.d671.s1|a|Patients who are receiving CYLERT concurrently with other drugs, especially drugs with CNS activity, should be monitored carefully. 
DDI-DrugBank.d671.s1	27	32	CYLERT	brand	DDI-DrugBank.d671.s1.e0
DDI-DrugBank.d671.s2|a|Decreased seizure threshold has been reported in patients receiving CYLERT concomitantly with antiepileptic medications.
DDI-DrugBank.d671.s2	68	73	CYLERT	brand	DDI-DrugBank.d671.s2.e0
DDI-DrugBank.d671.s2	94	118	antiepileptic medications	group	DDI-DrugBank.d671.s2.e1
DDI-DrugBank.d671.s2	true	DDI-DrugBank.d671.s2.e0	DDI-DrugBank.d671.s2.e1
DDI-DrugBank.d665.s0|a|Concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth. 
DDI-DrugBank.d665.s0	29	54	bacteriostatic antibiotics	group	DDI-DrugBank.d665.s0.e0
DDI-DrugBank.d665.s0	63	74	erythromycin	drug	DDI-DrugBank.d665.s0.e1
DDI-DrugBank.d665.s0	77	88	tetracycline	drug	DDI-DrugBank.d665.s0.e2
DDI-DrugBank.d665.s0	132	142	penicillins	group	DDI-DrugBank.d665.s0.e3
DDI-DrugBank.d665.s0	false	DDI-DrugBank.d665.s0.e0	DDI-DrugBank.d665.s0.e1
DDI-DrugBank.d665.s0	false	DDI-DrugBank.d665.s0.e0	DDI-DrugBank.d665.s0.e2
DDI-DrugBank.d665.s0	true	DDI-DrugBank.d665.s0.e0	DDI-DrugBank.d665.s0.e3
DDI-DrugBank.d665.s0	false	DDI-DrugBank.d665.s0.e1	DDI-DrugBank.d665.s0.e2
DDI-DrugBank.d665.s0	true	DDI-DrugBank.d665.s0.e1	DDI-DrugBank.d665.s0.e3
DDI-DrugBank.d665.s0	true	DDI-DrugBank.d665.s0.e2	DDI-DrugBank.d665.s0.e3
DDI-DrugBank.d665.s1|a|Bactericidal agents work most effectively against the immature cell wall of rapidly proliferating microorganisms. 
DDI-DrugBank.d665.s2|a|This has been demonstrated in vitro; 
DDI-DrugBank.d665.s3|a|however, the clinical significance of this interaction is not well documented. 
DDI-DrugBank.d665.s4|a|There are few clinical situations in which the concurrent use of ''static'' and ''cidal '' antibiotics are indicated. 
DDI-DrugBank.d665.s4	91	101	antibiotics	group	DDI-DrugBank.d665.s4.e0
DDI-DrugBank.d665.s5|a|However, in selected circumstances in which such therapy is appropriate, using adequate doses of antibacterial agents and beginning penicillin therapy first, should minimize the potential for interaction. 
DDI-DrugBank.d665.s5	97	109	antibacterial	group	DDI-DrugBank.d665.s5.e0
DDI-DrugBank.d665.s6|a|Penicillin blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of penicillins. 
DDI-DrugBank.d665.s6	0	9	Penicillin	group	DDI-DrugBank.d665.s6.e0
DDI-DrugBank.d665.s6	73	82	probenecid	drug	DDI-DrugBank.d665.s6.e1
DDI-DrugBank.d665.s6	128	138	penicillins	group	DDI-DrugBank.d665.s6.e2
DDI-DrugBank.d665.s6	true	DDI-DrugBank.d665.s6.e0	DDI-DrugBank.d665.s6.e1
DDI-DrugBank.d665.s6	false	DDI-DrugBank.d665.s6.e0	DDI-DrugBank.d665.s6.e2
DDI-DrugBank.d665.s6	false	DDI-DrugBank.d665.s6.e1	DDI-DrugBank.d665.s6.e2
DDI-DrugBank.d665.s7|a|Displacement of penicillin from plasma protein binding sites will elevate the level of free penicillin in the serum.
DDI-DrugBank.d665.s7	16	25	penicillin	group	DDI-DrugBank.d665.s7.e0
DDI-DrugBank.d665.s7	92	101	penicillin	group	DDI-DrugBank.d665.s7.e1
DDI-DrugBank.d665.s7	false	DDI-DrugBank.d665.s7.e0	DDI-DrugBank.d665.s7.e1
DDI-DrugBank.d757.s0|a|Usage with Alcohol: Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving pentazocine.
DDI-DrugBank.d757.s0	11	17	Alcohol	drug	DDI-DrugBank.d757.s0.e0
DDI-DrugBank.d757.s0	80	86	alcohol	drug	DDI-DrugBank.d757.s0.e1
DDI-DrugBank.d757.s0	156	166	pentazocine	drug	DDI-DrugBank.d757.s0.e2
DDI-DrugBank.d757.s0	false	DDI-DrugBank.d757.s0.e0	DDI-DrugBank.d757.s0.e1
DDI-DrugBank.d757.s0	false	DDI-DrugBank.d757.s0.e0	DDI-DrugBank.d757.s0.e2
DDI-DrugBank.d757.s0	true	DDI-DrugBank.d757.s0.e1	DDI-DrugBank.d757.s0.e2
DDI-DrugBank.d659.s0|a|Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors. 
DDI-DrugBank.d659.s0	152	158	TRENTAL	brand	DDI-DrugBank.d659.s0.e0
DDI-DrugBank.d659.s0	177	190	anticoagulants	group	DDI-DrugBank.d659.s0.e1
DDI-DrugBank.d659.s0	195	225	platelet aggregation inhibitors	group	DDI-DrugBank.d659.s0.e2
DDI-DrugBank.d659.s0	true	DDI-DrugBank.d659.s0.e0	DDI-DrugBank.d659.s0.e1
DDI-DrugBank.d659.s0	true	DDI-DrugBank.d659.s0.e0	DDI-DrugBank.d659.s0.e2
DDI-DrugBank.d659.s0	false	DDI-DrugBank.d659.s0.e1	DDI-DrugBank.d659.s0.e2
DDI-DrugBank.d659.s1|a|Patients on Warfarin should have more frequent monitoring of prothrombin times, while patients with other risk factors complicated by hemorrhage (e.g., recent surgery, peptic ulceration) should have periodic examinations for bleeding including hematocrit and/or hemoglobin. 
DDI-DrugBank.d659.s1	12	19	Warfarin	drug	DDI-DrugBank.d659.s1.e0
DDI-DrugBank.d659.s2|a|Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. 
DDI-DrugBank.d659.s2	30	36	TRENTAL	brand	DDI-DrugBank.d659.s2.e0
DDI-DrugBank.d659.s2	42	53	theophylline	drug	DDI-DrugBank.d659.s2.e1
DDI-DrugBank.d659.s2	91	102	theophylline	drug	DDI-DrugBank.d659.s2.e2
DDI-DrugBank.d659.s2	115	126	theophylline	drug	DDI-DrugBank.d659.s2.e3
DDI-DrugBank.d659.s2	true	DDI-DrugBank.d659.s2.e0	DDI-DrugBank.d659.s2.e1
DDI-DrugBank.d659.s2	false	DDI-DrugBank.d659.s2.e0	DDI-DrugBank.d659.s2.e2
DDI-DrugBank.d659.s2	false	DDI-DrugBank.d659.s2.e0	DDI-DrugBank.d659.s2.e3
DDI-DrugBank.d659.s2	false	DDI-DrugBank.d659.s2.e1	DDI-DrugBank.d659.s2.e2
DDI-DrugBank.d659.s2	false	DDI-DrugBank.d659.s2.e1	DDI-DrugBank.d659.s2.e3
DDI-DrugBank.d659.s2	false	DDI-DrugBank.d659.s2.e2	DDI-DrugBank.d659.s2.e3
DDI-DrugBank.d659.s3|a|Such patients should be closely monitored for signs of toxicity and have their theophylline dosage adjusted as necessary. 
DDI-DrugBank.d659.s3	79	90	theophylline	drug	DDI-DrugBank.d659.s3.e0
DDI-DrugBank.d659.s4|a|TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. 
DDI-DrugBank.d659.s4	0	6	TRENTAL	brand	DDI-DrugBank.d659.s4.e0
DDI-DrugBank.d659.s4	40	61	antihypertensive drugs	group	DDI-DrugBank.d659.s4.e1
DDI-DrugBank.d659.s4	64	76	beta blockers	group	DDI-DrugBank.d659.s4.e2
DDI-DrugBank.d659.s4	79	87	digitalis	group	DDI-DrugBank.d659.s4.e3
DDI-DrugBank.d659.s4	90	98	diuretics	group	DDI-DrugBank.d659.s4.e4
DDI-DrugBank.d659.s4	101	119	antidiabetic agents	group	DDI-DrugBank.d659.s4.e5
DDI-DrugBank.d659.s4	126	140	antiarrhythmics	group	DDI-DrugBank.d659.s4.e6
DDI-DrugBank.d659.s4	false	DDI-DrugBank.d659.s4.e0	DDI-DrugBank.d659.s4.e1
DDI-DrugBank.d659.s4	false	DDI-DrugBank.d659.s4.e0	DDI-DrugBank.d659.s4.e2
DDI-DrugBank.d659.s4	false	DDI-DrugBank.d659.s4.e0	DDI-DrugBank.d659.s4.e3
DDI-DrugBank.d659.s4	false	DDI-DrugBank.d659.s4.e0	DDI-DrugBank.d659.s4.e4
DDI-DrugBank.d659.s4	false	DDI-DrugBank.d659.s4.e0	DDI-DrugBank.d659.s4.e5
DDI-DrugBank.d659.s4	false	DDI-DrugBank.d659.s4.e0	DDI-DrugBank.d659.s4.e6
DDI-DrugBank.d659.s4	false	DDI-DrugBank.d659.s4.e1	DDI-DrugBank.d659.s4.e2
DDI-DrugBank.d659.s4	false	DDI-DrugBank.d659.s4.e1	DDI-DrugBank.d659.s4.e3
DDI-DrugBank.d659.s4	false	DDI-DrugBank.d659.s4.e1	DDI-DrugBank.d659.s4.e4
DDI-DrugBank.d659.s4	false	DDI-DrugBank.d659.s4.e1	DDI-DrugBank.d659.s4.e5
DDI-DrugBank.d659.s5|a|Small decreases in blood pressure have been observed in some patients treated with TRENTAL; 
DDI-DrugBank.d659.s5	83	89	TRENTAL	brand	DDI-DrugBank.d659.s5.e0
DDI-DrugBank.d659.s6|a|periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. 
DDI-DrugBank.d659.s7|a|If indicated, dosage of the antihypertensive agents should be reduced.
DDI-DrugBank.d659.s7	28	50	antihypertensive agents	group	DDI-DrugBank.d659.s7.e0
DDI-DrugBank.d650.s0|a|Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 
DDI-DrugBank.d650.s0	0	19	Dopamine antagonists	group	DDI-DrugBank.d650.s0.e0
DDI-DrugBank.d650.s0	34	45	neuroleptics	group	DDI-DrugBank.d650.s0.e1
DDI-DrugBank.d650.s0	48	61	phenothiazines	group	DDI-DrugBank.d650.s0.e2
DDI-DrugBank.d650.s0	64	77	butyrophenones	group	DDI-DrugBank.d650.s0.e3
DDI-DrugBank.d650.s0	80	92	thioxanthines	group	DDI-DrugBank.d650.s0.e4
DDI-DrugBank.d650.s0	99	112	metoclopramide	drug	DDI-DrugBank.d650.s0.e5
DDI-DrugBank.d650.s0	171	176	Permax	brand	DDI-DrugBank.d650.s0.e6
DDI-DrugBank.d650.s0	181	196	dopamine agonist	group	DDI-DrugBank.d650.s0.e7
DDI-DrugBank.d650.s0	false	DDI-DrugBank.d650.s0.e0	DDI-DrugBank.d650.s0.e1
DDI-DrugBank.d650.s0	false	DDI-DrugBank.d650.s0.e0	DDI-DrugBank.d650.s0.e2
DDI-DrugBank.d650.s0	false	DDI-DrugBank.d650.s0.e0	DDI-DrugBank.d650.s0.e3
DDI-DrugBank.d650.s0	false	DDI-DrugBank.d650.s0.e0	DDI-DrugBank.d650.s0.e4
DDI-DrugBank.d650.s0	false	DDI-DrugBank.d650.s0.e0	DDI-DrugBank.d650.s0.e5
DDI-DrugBank.d650.s0	true	DDI-DrugBank.d650.s0.e0	DDI-DrugBank.d650.s0.e6
DDI-DrugBank.d650.s0	false	DDI-DrugBank.d650.s0.e0	DDI-DrugBank.d650.s0.e7
DDI-DrugBank.d650.s0	false	DDI-DrugBank.d650.s0.e1	DDI-DrugBank.d650.s0.e2
DDI-DrugBank.d650.s0	false	DDI-DrugBank.d650.s0.e1	DDI-DrugBank.d650.s0.e3
DDI-DrugBank.d650.s0	false	DDI-DrugBank.d650.s0.e1	DDI-DrugBank.d650.s0.e4
DDI-DrugBank.d650.s1|a|these agents may diminish the effectiveness of Permax. 
DDI-DrugBank.d650.s1	47	52	Permax	brand	DDI-DrugBank.d650.s1.e0
DDI-DrugBank.d650.s2|a|Because pergolide mesylate is approximately 90% bound to plasma proteins, caution should be exercised if pergolide mesylate is coadministered with other drugs known to affect protein binding.
DDI-DrugBank.d650.s2	8	25	pergolide mesylate	drug	DDI-DrugBank.d650.s2.e0
DDI-DrugBank.d650.s2	105	122	pergolide mesylate	drug	DDI-DrugBank.d650.s2.e1
DDI-DrugBank.d650.s2	false	DDI-DrugBank.d650.s2.e0	DDI-DrugBank.d650.s2.e1
DDI-DrugBank.d781.s0|a|Diuretics: Patients on diuretics, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of ACEON    Tablets therapy. 
DDI-DrugBank.d781.s0	0	8	Diuretics	group	DDI-DrugBank.d781.s0.e0
DDI-DrugBank.d781.s0	23	31	diuretics	group	DDI-DrugBank.d781.s0.e1
DDI-DrugBank.d781.s0	162	166	ACEON	brand	DDI-DrugBank.d781.s0.e2
DDI-DrugBank.d781.s0	false	DDI-DrugBank.d781.s0.e0	DDI-DrugBank.d781.s0.e1
DDI-DrugBank.d781.s0	false	DDI-DrugBank.d781.s0.e0	DDI-DrugBank.d781.s0.e2
DDI-DrugBank.d781.s0	true	DDI-DrugBank.d781.s0.e1	DDI-DrugBank.d781.s0.e2
DDI-DrugBank.d781.s1|a|The possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with perindopril. 
DDI-DrugBank.d781.s1	84	91	diuretic	group	DDI-DrugBank.d781.s1.e0
DDI-DrugBank.d781.s1	161	171	perindopril	drug	DDI-DrugBank.d781.s1.e1
DDI-DrugBank.d781.s1	true	DDI-DrugBank.d781.s1.e0	DDI-DrugBank.d781.s1.e1
DDI-DrugBank.d781.s2|a|If diuretics cannot be interrupted, close medical supervision should be provided with the first dose of ACEON    Tablets, for at least two hours and until blood pressure has stabilized for another hour. 
DDI-DrugBank.d781.s2	3	11	diuretics	group	DDI-DrugBank.d781.s2.e0
DDI-DrugBank.d781.s2	104	108	ACEON	brand	DDI-DrugBank.d781.s2.e1
DDI-DrugBank.d781.s2	true	DDI-DrugBank.d781.s2.e0	DDI-DrugBank.d781.s2.e1
DDI-DrugBank.d781.s3|a|The rate and extent of perindopril absorption and elimination are not affected by concomitant diuretics. 
DDI-DrugBank.d781.s3	23	33	perindopril	drug	DDI-DrugBank.d781.s3.e0
DDI-DrugBank.d781.s3	94	102	diuretics	group	DDI-DrugBank.d781.s3.e1
DDI-DrugBank.d781.s3	false	DDI-DrugBank.d781.s3.e0	DDI-DrugBank.d781.s3.e1
DDI-DrugBank.d781.s4|a|The bioavailability of perindoprilat was reduced by diuretics, however, and this was associated with a decrease in plasma ACE inhibition. 
DDI-DrugBank.d781.s4	23	35	perindoprilat	drug_n	DDI-DrugBank.d781.s4.e0
DDI-DrugBank.d781.s4	52	60	diuretics	group	DDI-DrugBank.d781.s4.e1
DDI-DrugBank.d781.s4	false	DDI-DrugBank.d781.s4.e0	DDI-DrugBank.d781.s4.e1
DDI-DrugBank.d781.s5|a|Potassium Supplements and Potassium-Sparing Diuretics: ACEON    Tablets may increase serum potassium because of its potential to decrease aldosterone production. 
DDI-DrugBank.d781.s5	0	8	Potassium	drug	DDI-DrugBank.d781.s5.e0
DDI-DrugBank.d781.s5	26	52	Potassium-Sparing Diuretics	group	DDI-DrugBank.d781.s5.e1
DDI-DrugBank.d781.s5	55	59	ACEON	brand	DDI-DrugBank.d781.s5.e2
DDI-DrugBank.d781.s5	false	DDI-DrugBank.d781.s5.e0	DDI-DrugBank.d781.s5.e1
DDI-DrugBank.d781.s5	false	DDI-DrugBank.d781.s5.e0	DDI-DrugBank.d781.s5.e2
DDI-DrugBank.d781.s5	false	DDI-DrugBank.d781.s5.e1	DDI-DrugBank.d781.s5.e2
DDI-DrugBank.d781.s6|a|Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 
DDI-DrugBank.d781.s6	7	33	potassium-sparing diuretics	group	DDI-DrugBank.d781.s6.e0
DDI-DrugBank.d781.s6	36	49	spironolactone	drug	DDI-DrugBank.d781.s6.e1
DDI-DrugBank.d781.s6	52	60	amiloride	drug	DDI-DrugBank.d781.s6.e2
DDI-DrugBank.d781.s6	63	73	triamterene	drug	DDI-DrugBank.d781.s6.e3
DDI-DrugBank.d781.s6	88	96	potassium	drug	DDI-DrugBank.d781.s6.e4
DDI-DrugBank.d781.s6	164	175	indomethacin	drug	DDI-DrugBank.d781.s6.e5
DDI-DrugBank.d781.s6	178	184	heparin	drug	DDI-DrugBank.d781.s6.e6
DDI-DrugBank.d781.s6	187	198	cyclosporine	drug	DDI-DrugBank.d781.s6.e7
DDI-DrugBank.d781.s6	false	DDI-DrugBank.d781.s6.e0	DDI-DrugBank.d781.s6.e1
DDI-DrugBank.d781.s6	false	DDI-DrugBank.d781.s6.e0	DDI-DrugBank.d781.s6.e2
DDI-DrugBank.d781.s6	false	DDI-DrugBank.d781.s6.e0	DDI-DrugBank.d781.s6.e3
DDI-DrugBank.d781.s6	false	DDI-DrugBank.d781.s6.e0	DDI-DrugBank.d781.s6.e4
DDI-DrugBank.d781.s6	false	DDI-DrugBank.d781.s6.e0	DDI-DrugBank.d781.s6.e5
DDI-DrugBank.d781.s6	false	DDI-DrugBank.d781.s6.e0	DDI-DrugBank.d781.s6.e6
DDI-DrugBank.d781.s6	false	DDI-DrugBank.d781.s6.e0	DDI-DrugBank.d781.s6.e7
DDI-DrugBank.d781.s6	false	DDI-DrugBank.d781.s6.e1	DDI-DrugBank.d781.s6.e2
DDI-DrugBank.d781.s6	false	DDI-DrugBank.d781.s6.e1	DDI-DrugBank.d781.s6.e3
DDI-DrugBank.d781.s6	false	DDI-DrugBank.d781.s6.e1	DDI-DrugBank.d781.s6.e4
DDI-DrugBank.d781.s7|a|Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patient's serum potassium should be monitored frequently. 
DDI-DrugBank.d781.s8|a|Lithium: Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. 
DDI-DrugBank.d781.s8	0	6	Lithium	drug	DDI-DrugBank.d781.s8.e0
DDI-DrugBank.d781.s8	25	31	lithium	drug	DDI-DrugBank.d781.s8.e1
DDI-DrugBank.d781.s8	49	55	lithium	drug	DDI-DrugBank.d781.s8.e2
DDI-DrugBank.d781.s8	119	125	lithium	drug	DDI-DrugBank.d781.s8.e3
DDI-DrugBank.d781.s8	false	DDI-DrugBank.d781.s8.e0	DDI-DrugBank.d781.s8.e1
DDI-DrugBank.d781.s8	false	DDI-DrugBank.d781.s8.e0	DDI-DrugBank.d781.s8.e2
DDI-DrugBank.d781.s8	false	DDI-DrugBank.d781.s8.e0	DDI-DrugBank.d781.s8.e3
DDI-DrugBank.d781.s8	false	DDI-DrugBank.d781.s8.e1	DDI-DrugBank.d781.s8.e2
DDI-DrugBank.d781.s8	false	DDI-DrugBank.d781.s8.e1	DDI-DrugBank.d781.s8.e3
DDI-DrugBank.d781.s8	false	DDI-DrugBank.d781.s8.e2	DDI-DrugBank.d781.s8.e3
DDI-DrugBank.d781.s9|a|These drugs should be coadministered with caution and frequent monitoring of serum lithium concentration is recommended. 
DDI-DrugBank.d781.s9	83	89	lithium	drug	DDI-DrugBank.d781.s9.e0
DDI-DrugBank.d781.s10|a|Use of a diuretic may further increase the risk of lithium toxicity. 
DDI-DrugBank.d781.s10	9	16	diuretic	group	DDI-DrugBank.d781.s10.e0
DDI-DrugBank.d781.s10	51	57	lithium	drug	DDI-DrugBank.d781.s10.e1
DDI-DrugBank.d781.s10	false	DDI-DrugBank.d781.s10.e0	DDI-DrugBank.d781.s10.e1
DDI-DrugBank.d781.s11|a|Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. 
DDI-DrugBank.d781.s11	0	6	Digoxin	drug	DDI-DrugBank.d781.s11.e0
DDI-DrugBank.d781.s11	74	80	digoxin	drug	DDI-DrugBank.d781.s11.e1
DDI-DrugBank.d781.s11	122	126	ACEON	brand	DDI-DrugBank.d781.s11.e2
DDI-DrugBank.d781.s11	157	163	digoxin	drug	DDI-DrugBank.d781.s11.e3
DDI-DrugBank.d781.s11	196	206	perindopril	drug	DDI-DrugBank.d781.s11.e4
DDI-DrugBank.d781.s11	208	220	perindoprilat	drug_n	DDI-DrugBank.d781.s11.e5
DDI-DrugBank.d781.s11	false	DDI-DrugBank.d781.s11.e0	DDI-DrugBank.d781.s11.e1
DDI-DrugBank.d781.s11	false	DDI-DrugBank.d781.s11.e0	DDI-DrugBank.d781.s11.e2
DDI-DrugBank.d781.s11	false	DDI-DrugBank.d781.s11.e0	DDI-DrugBank.d781.s11.e3
DDI-DrugBank.d781.s11	false	DDI-DrugBank.d781.s11.e0	DDI-DrugBank.d781.s11.e4
DDI-DrugBank.d781.s11	false	DDI-DrugBank.d781.s11.e0	DDI-DrugBank.d781.s11.e5
DDI-DrugBank.d781.s11	false	DDI-DrugBank.d781.s11.e1	DDI-DrugBank.d781.s11.e2
DDI-DrugBank.d781.s11	false	DDI-DrugBank.d781.s11.e1	DDI-DrugBank.d781.s11.e3
DDI-DrugBank.d781.s11	false	DDI-DrugBank.d781.s11.e1	DDI-DrugBank.d781.s11.e4
DDI-DrugBank.d781.s11	false	DDI-DrugBank.d781.s11.e1	DDI-DrugBank.d781.s11.e5
DDI-DrugBank.d781.s11	false	DDI-DrugBank.d781.s11.e2	DDI-DrugBank.d781.s11.e3
DDI-DrugBank.d781.s12|a|Gentamicin: Animal data have suggested the possibility of interaction between perindopril and gentamicin. 
DDI-DrugBank.d781.s12	0	9	Gentamicin	drug	DDI-DrugBank.d781.s12.e0
DDI-DrugBank.d781.s12	78	88	perindopril	drug	DDI-DrugBank.d781.s12.e1
DDI-DrugBank.d781.s12	94	103	gentamicin	drug	DDI-DrugBank.d781.s12.e2
DDI-DrugBank.d781.s12	false	DDI-DrugBank.d781.s12.e0	DDI-DrugBank.d781.s12.e1
DDI-DrugBank.d781.s12	false	DDI-DrugBank.d781.s12.e0	DDI-DrugBank.d781.s12.e2
DDI-DrugBank.d781.s12	true	DDI-DrugBank.d781.s12.e1	DDI-DrugBank.d781.s12.e2
DDI-DrugBank.d781.s13|a|However, this has not been investigated in human studies. 
DDI-DrugBank.d781.s14|a|Coadministration of both drugs should proceed with caution. 
DDI-DrugBank.d781.s15|a|Food Interaction: Oral administration of ACEON    Tablets with food does not significantly lower the rate or extent of perindopril absorption relative to the fasted state. 
DDI-DrugBank.d781.s15	41	45	ACEON	brand	DDI-DrugBank.d781.s15.e0
DDI-DrugBank.d781.s15	119	129	perindopril	drug	DDI-DrugBank.d781.s15.e1
DDI-DrugBank.d781.s15	false	DDI-DrugBank.d781.s15.e0	DDI-DrugBank.d781.s15.e1
DDI-DrugBank.d781.s16|a|However, the extent of biotransformation of perindopril to the active metabolite, perindoprilat, is reduced approximately 43%, resulting in a reduction in the plasma ACE inhibition curve of approximately 20%, probably clinically insignificant. 
DDI-DrugBank.d781.s16	44	54	perindopril	drug	DDI-DrugBank.d781.s16.e0
DDI-DrugBank.d781.s16	82	94	perindoprilat	drug_n	DDI-DrugBank.d781.s16.e1
DDI-DrugBank.d781.s16	false	DDI-DrugBank.d781.s16.e0	DDI-DrugBank.d781.s16.e1
DDI-DrugBank.d781.s17|a|In clinical trials, perindopril was generally administered in a non-fasting state.        
DDI-DrugBank.d781.s17	20	30	perindopril	drug	DDI-DrugBank.d781.s17.e0
DDI-DrugBank.d750.s0|a|Concomitant use of alcohol with phentermine hydrochloride may result in an adverse drug interaction.
DDI-DrugBank.d750.s0	19	25	alcohol	drug	DDI-DrugBank.d750.s0.e0
DDI-DrugBank.d750.s0	32	56	phentermine hydrochloride	drug	DDI-DrugBank.d750.s0.e1
DDI-DrugBank.d750.s0	true	DDI-DrugBank.d750.s0.e0	DDI-DrugBank.d750.s0.e1
DDI-DrugBank.d725.s0|a|Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. 
DDI-DrugBank.d725.s0	0	11	Vasopressors	group	DDI-DrugBank.d725.s0.e0
DDI-DrugBank.d725.s0	27	37	metaraminol	drug	DDI-DrugBank.d725.s0.e1
DDI-DrugBank.d725.s0	85	93	halothane	drug	DDI-DrugBank.d725.s0.e2
DDI-DrugBank.d725.s0	false	DDI-DrugBank.d725.s0.e0	DDI-DrugBank.d725.s0.e1
DDI-DrugBank.d725.s0	true	DDI-DrugBank.d725.s0.e0	DDI-DrugBank.d725.s0.e2
DDI-DrugBank.d725.s0	true	DDI-DrugBank.d725.s0.e1	DDI-DrugBank.d725.s0.e2
DDI-DrugBank.d725.s1|a|MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). 
DDI-DrugBank.d725.s1	0	13	MAO Inhibitors	group	DDI-DrugBank.d725.s1.e0
DDI-DrugBank.d725.s1	38	67	sympathomimetic pressor amines	group	DDI-DrugBank.d725.s1.e1
DDI-DrugBank.d725.s1	115	142	monoamine oxidase inhibitors	group	DDI-DrugBank.d725.s1.e2
DDI-DrugBank.d725.s1	145	148	MAOI	group	DDI-DrugBank.d725.s1.e3
DDI-DrugBank.d725.s1	false	DDI-DrugBank.d725.s1.e0	DDI-DrugBank.d725.s1.e1
DDI-DrugBank.d725.s1	false	DDI-DrugBank.d725.s1.e0	DDI-DrugBank.d725.s1.e2
DDI-DrugBank.d725.s1	false	DDI-DrugBank.d725.s1.e0	DDI-DrugBank.d725.s1.e3
DDI-DrugBank.d725.s1	true	DDI-DrugBank.d725.s1.e1	DDI-DrugBank.d725.s1.e2
DDI-DrugBank.d725.s1	true	DDI-DrugBank.d725.s1.e1	DDI-DrugBank.d725.s1.e3
DDI-DrugBank.d725.s1	false	DDI-DrugBank.d725.s1.e2	DDI-DrugBank.d725.s1.e3
DDI-DrugBank.d725.s2|a|Therefore, when initiating pressor therapy in these patients, the initial dose should be small and used with due caution. 
DDI-DrugBank.d725.s3|a|The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants.
DDI-DrugBank.d725.s3	24	40	adrenergic agents	group	DDI-DrugBank.d725.s3.e0
DDI-DrugBank.d725.s3	69	93	tricyclic antidepressants	group	DDI-DrugBank.d725.s3.e1
DDI-DrugBank.d725.s3	true	DDI-DrugBank.d725.s3.e0	DDI-DrugBank.d725.s3.e1
DDI-DrugBank.d689.s0|a|Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. 
DDI-DrugBank.d689.s0	0	11	Vasopressors	group	DDI-DrugBank.d689.s0.e0
DDI-DrugBank.d689.s0	27	37	metaraminol	drug	DDI-DrugBank.d689.s0.e1
DDI-DrugBank.d689.s0	85	93	halothane	drug	DDI-DrugBank.d689.s0.e2
DDI-DrugBank.d689.s0	false	DDI-DrugBank.d689.s0.e0	DDI-DrugBank.d689.s0.e1
DDI-DrugBank.d689.s0	true	DDI-DrugBank.d689.s0.e0	DDI-DrugBank.d689.s0.e2
DDI-DrugBank.d689.s0	true	DDI-DrugBank.d689.s0.e1	DDI-DrugBank.d689.s0.e2
DDI-DrugBank.d689.s1|a|MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). 
DDI-DrugBank.d689.s1	0	13	MAO Inhibitors	group	DDI-DrugBank.d689.s1.e0
DDI-DrugBank.d689.s1	39	68	sympathomimetic pressor amines	group	DDI-DrugBank.d689.s1.e1
DDI-DrugBank.d689.s1	116	143	monoamine oxidase inhibitors	group	DDI-DrugBank.d689.s1.e2
DDI-DrugBank.d689.s1	146	149	MAOI	group	DDI-DrugBank.d689.s1.e3
DDI-DrugBank.d689.s1	false	DDI-DrugBank.d689.s1.e0	DDI-DrugBank.d689.s1.e1
DDI-DrugBank.d689.s1	false	DDI-DrugBank.d689.s1.e0	DDI-DrugBank.d689.s1.e2
DDI-DrugBank.d689.s1	false	DDI-DrugBank.d689.s1.e0	DDI-DrugBank.d689.s1.e3
DDI-DrugBank.d689.s1	true	DDI-DrugBank.d689.s1.e1	DDI-DrugBank.d689.s1.e2
DDI-DrugBank.d689.s1	true	DDI-DrugBank.d689.s1.e1	DDI-DrugBank.d689.s1.e3
DDI-DrugBank.d689.s1	false	DDI-DrugBank.d689.s1.e2	DDI-DrugBank.d689.s1.e3
DDI-DrugBank.d689.s2|a|Therefore, when initiating pressor therapy in these patients, the initial dose should be small and used with due caution. 
DDI-DrugBank.d689.s3|a|The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants.
DDI-DrugBank.d689.s3	24	40	adrenergic agents	group	DDI-DrugBank.d689.s3.e0
DDI-DrugBank.d689.s3	69	93	tricyclic antidepressants	group	DDI-DrugBank.d689.s3.e1
DDI-DrugBank.d689.s3	true	DDI-DrugBank.d689.s3.e0	DDI-DrugBank.d689.s3.e1
DDI-DrugBank.d627.s0|a|Pilocarpine should be administered with caution to patients taking beta adrenergic antagonists because of the possibility of conduction disturbances. 
DDI-DrugBank.d627.s0	0	10	Pilocarpine	drug	DDI-DrugBank.d627.s0.e0
DDI-DrugBank.d627.s0	67	93	beta adrenergic antagonists	group	DDI-DrugBank.d627.s0.e1
DDI-DrugBank.d627.s0	true	DDI-DrugBank.d627.s0.e0	DDI-DrugBank.d627.s0.e1
DDI-DrugBank.d627.s1|a|Drugs with parasympathomimetic effects administered concurrently with pilocarpine would be expected to result in additive pharmacologic effects. 
DDI-DrugBank.d627.s1	70	80	pilocarpine	drug	DDI-DrugBank.d627.s1.e0
DDI-DrugBank.d627.s2|a|Pilocarpine might antagonize the anticholinergic effects of drugs used concomitantly. 
DDI-DrugBank.d627.s2	0	10	Pilocarpine	drug	DDI-DrugBank.d627.s2.e0
DDI-DrugBank.d627.s3|a|These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication (e.g., atropine, inhaled ipratropium). 
DDI-DrugBank.d627.s3	146	153	atropine	drug	DDI-DrugBank.d627.s3.e0
DDI-DrugBank.d627.s3	164	174	ipratropium	drug	DDI-DrugBank.d627.s3.e1
DDI-DrugBank.d627.s3	false	DDI-DrugBank.d627.s3.e0	DDI-DrugBank.d627.s3.e1
DDI-DrugBank.d627.s4|a|While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
DDI-DrugBank.d627.s4	179	198	acetylsalicylic acid	drug	DDI-DrugBank.d627.s4.e0
DDI-DrugBank.d627.s4	219	225	calcium	drug	DDI-DrugBank.d627.s4.e1
DDI-DrugBank.d627.s4	228	247	conjugated estrogens	drug	DDI-DrugBank.d627.s4.e2
DDI-DrugBank.d627.s4	250	275	hydroxychloroquine sulfate	drug	DDI-DrugBank.d627.s4.e3
DDI-DrugBank.d627.s4	278	286	ibuprofen	drug	DDI-DrugBank.d627.s4.e4
DDI-DrugBank.d627.s4	289	308	levothyroxine sodium	drug	DDI-DrugBank.d627.s4.e5
DDI-DrugBank.d627.s4	311	337	medroxyprogesterone acetate	drug	DDI-DrugBank.d627.s4.e6
DDI-DrugBank.d627.s4	340	351	methotrexate	drug	DDI-DrugBank.d627.s4.e7
DDI-DrugBank.d627.s4	354	366	multivitamins	group	DDI-DrugBank.d627.s4.e8
DDI-DrugBank.d627.s4	369	376	naproxen	drug	DDI-DrugBank.d627.s4.e9
DDI-DrugBank.d627.s4	false	DDI-DrugBank.d627.s4.e0	DDI-DrugBank.d627.s4.e1
DDI-DrugBank.d627.s4	false	DDI-DrugBank.d627.s4.e0	DDI-DrugBank.d627.s4.e2
DDI-DrugBank.d627.s4	false	DDI-DrugBank.d627.s4.e0	DDI-DrugBank.d627.s4.e3
DDI-DrugBank.d627.s4	false	DDI-DrugBank.d627.s4.e0	DDI-DrugBank.d627.s4.e4
DDI-DrugBank.d627.s4	false	DDI-DrugBank.d627.s4.e0	DDI-DrugBank.d627.s4.e5
DDI-DrugBank.d627.s4	false	DDI-DrugBank.d627.s4.e0	DDI-DrugBank.d627.s4.e6
DDI-DrugBank.d627.s4	false	DDI-DrugBank.d627.s4.e0	DDI-DrugBank.d627.s4.e7
DDI-DrugBank.d627.s4	false	DDI-DrugBank.d627.s4.e0	DDI-DrugBank.d627.s4.e8
DDI-DrugBank.d627.s4	false	DDI-DrugBank.d627.s4.e0	DDI-DrugBank.d627.s4.e9
DDI-DrugBank.d627.s4	false	DDI-DrugBank.d627.s4.e0	DDI-DrugBank.d627.s4.e10
DDI-DrugBank.d666.s0|a|Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. 
DDI-DrugBank.d666.s0	37	45	reserpine	drug	DDI-DrugBank.d666.s0.e0
DDI-DrugBank.d666.s0	92	111	beta-blocking agents	group	DDI-DrugBank.d666.s0.e1
DDI-DrugBank.d666.s0	true	DDI-DrugBank.d666.s0.e0	DDI-DrugBank.d666.s0.e1
DDI-DrugBank.d666.s1|a|Patients receiving pindolol plus a catecholamine-depleting agent should, therefore, be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension. 
DDI-DrugBank.d666.s1	19	26	pindolol	drug	DDI-DrugBank.d666.s1.e0
DDI-DrugBank.d666.s2|a|Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. 
DDI-DrugBank.d666.s2	0	7	Pindolol	drug	DDI-DrugBank.d666.s2.e0
DDI-DrugBank.d666.s2	41	63	antihypertensive agents	group	DDI-DrugBank.d666.s2.e1
DDI-DrugBank.d666.s2	76	94	hydrochlorothiazide	drug	DDI-DrugBank.d666.s2.e2
DDI-DrugBank.d666.s2	97	107	hydralazine	drug	DDI-DrugBank.d666.s2.e3
DDI-DrugBank.d666.s2	114	125	guanethidine	drug	DDI-DrugBank.d666.s2.e4
DDI-DrugBank.d666.s2	false	DDI-DrugBank.d666.s2.e0	DDI-DrugBank.d666.s2.e1
DDI-DrugBank.d666.s2	false	DDI-DrugBank.d666.s2.e0	DDI-DrugBank.d666.s2.e2
DDI-DrugBank.d666.s2	false	DDI-DrugBank.d666.s2.e0	DDI-DrugBank.d666.s2.e3
DDI-DrugBank.d666.s2	false	DDI-DrugBank.d666.s2.e0	DDI-DrugBank.d666.s2.e4
DDI-DrugBank.d666.s2	false	DDI-DrugBank.d666.s2.e1	DDI-DrugBank.d666.s2.e2
DDI-DrugBank.d666.s2	false	DDI-DrugBank.d666.s2.e1	DDI-DrugBank.d666.s2.e3
DDI-DrugBank.d666.s2	false	DDI-DrugBank.d666.s2.e1	DDI-DrugBank.d666.s2.e4
DDI-DrugBank.d666.s2	false	DDI-DrugBank.d666.s2.e2	DDI-DrugBank.d666.s2.e3
DDI-DrugBank.d666.s2	false	DDI-DrugBank.d666.s2.e2	DDI-DrugBank.d666.s2.e4
DDI-DrugBank.d666.s2	false	DDI-DrugBank.d666.s2.e3	DDI-DrugBank.d666.s2.e4
DDI-DrugBank.d666.s3|a|Pindolol has been shown to increase serum thioridazine levels when both drugs are co-administered. 
DDI-DrugBank.d666.s3	0	7	Pindolol	drug	DDI-DrugBank.d666.s3.e0
DDI-DrugBank.d666.s3	42	53	thioridazine	drug	DDI-DrugBank.d666.s3.e1
DDI-DrugBank.d666.s3	true	DDI-DrugBank.d666.s3.e0	DDI-DrugBank.d666.s3.e1
DDI-DrugBank.d666.s4|a|Pindolol levels may also be increased with this combination. 
DDI-DrugBank.d666.s4	0	7	Pindolol	drug	DDI-DrugBank.d666.s4.e0
DDI-DrugBank.d666.s5|a|Risk of anaphylactic reaction: While taking beta blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. 
DDI-DrugBank.d666.s5	44	56	beta blockers	group	DDI-DrugBank.d666.s5.e0
DDI-DrugBank.d666.s6|a|Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reactions.
DDI-DrugBank.d666.s6	56	66	epinephrine	drug	DDI-DrugBank.d666.s6.e0
DDI-DrugBank.d635.s0|a|Other short-acting beta adrenergic aerosol bronchodilators should not be used concomitantly with MAXAIR AUTOHALER because they may have additive effects.
DDI-DrugBank.d635.s0	6	57	short-acting beta adrenergic aerosol bronchodilators	group	DDI-DrugBank.d635.s0.e0
DDI-DrugBank.d635.s0	97	112	MAXAIR AUTOHALER	brand	DDI-DrugBank.d635.s0.e1
DDI-DrugBank.d635.s0	true	DDI-DrugBank.d635.s0.e0	DDI-DrugBank.d635.s0.e1
DDI-DrugBank.d656.s0|a|FELDENE is highly protein bound, and therefore, might be expected to displace other protein-bound drugs. 
DDI-DrugBank.d656.s0	0	6	FELDENE	brand	DDI-DrugBank.d656.s0.e0
DDI-DrugBank.d656.s1|a|Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. 
DDI-DrugBank.d656.s1	56	83	coumarin-type anticoagulants	group	DDI-DrugBank.d656.s1.e0
DDI-DrugBank.d656.s1	104	131	coumarin-type anticoagulants	group	DDI-DrugBank.d656.s1.e1
DDI-DrugBank.d656.s1	157	163	FELDENE	brand	DDI-DrugBank.d656.s1.e2
DDI-DrugBank.d656.s1	291	297	FELDENE	brand	DDI-DrugBank.d656.s1.e3
DDI-DrugBank.d656.s1	314	341	coumarin-type anticoagulants	group	DDI-DrugBank.d656.s1.e4
DDI-DrugBank.d656.s1	false	DDI-DrugBank.d656.s1.e0	DDI-DrugBank.d656.s1.e1
DDI-DrugBank.d656.s1	false	DDI-DrugBank.d656.s1.e0	DDI-DrugBank.d656.s1.e2
DDI-DrugBank.d656.s1	false	DDI-DrugBank.d656.s1.e0	DDI-DrugBank.d656.s1.e3
DDI-DrugBank.d656.s1	false	DDI-DrugBank.d656.s1.e0	DDI-DrugBank.d656.s1.e4
DDI-DrugBank.d656.s1	true	DDI-DrugBank.d656.s1.e1	DDI-DrugBank.d656.s1.e2
DDI-DrugBank.d656.s1	false	DDI-DrugBank.d656.s1.e1	DDI-DrugBank.d656.s1.e3
DDI-DrugBank.d656.s1	false	DDI-DrugBank.d656.s1.e1	DDI-DrugBank.d656.s1.e4
DDI-DrugBank.d656.s1	false	DDI-DrugBank.d656.s1.e2	DDI-DrugBank.d656.s1.e3
DDI-DrugBank.d656.s1	false	DDI-DrugBank.d656.s1.e2	DDI-DrugBank.d656.s1.e4
DDI-DrugBank.d656.s1	true	DDI-DrugBank.d656.s1.e3	DDI-DrugBank.d656.s1.e4
DDI-DrugBank.d656.s2|a|Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 
DDI-DrugBank.d656.s2	17	25	piroxicam	drug	DDI-DrugBank.d656.s2.e0
DDI-DrugBank.d656.s2	90	96	FELDENE	brand	DDI-DrugBank.d656.s2.e1
DDI-DrugBank.d656.s2	134	140	aspirin	brand	DDI-DrugBank.d656.s2.e2
DDI-DrugBank.d656.s2	191	198	antacids	group	DDI-DrugBank.d656.s2.e3
DDI-DrugBank.d656.s2	217	225	piroxicam	drug	DDI-DrugBank.d656.s2.e4
DDI-DrugBank.d656.s2	243	279	Nonsteroidal anti-inflammatory agents	group	DDI-DrugBank.d656.s2.e5
DDI-DrugBank.d656.s2	292	298	FELDENE	brand	DDI-DrugBank.d656.s2.e6
DDI-DrugBank.d656.s2	352	358	lithium	drug	DDI-DrugBank.d656.s2.e7
DDI-DrugBank.d656.s2	false	DDI-DrugBank.d656.s2.e0	DDI-DrugBank.d656.s2.e1
DDI-DrugBank.d656.s2	false	DDI-DrugBank.d656.s2.e0	DDI-DrugBank.d656.s2.e2
DDI-DrugBank.d656.s2	false	DDI-DrugBank.d656.s2.e0	DDI-DrugBank.d656.s2.e3
DDI-DrugBank.d656.s2	false	DDI-DrugBank.d656.s2.e0	DDI-DrugBank.d656.s2.e4
DDI-DrugBank.d656.s2	false	DDI-DrugBank.d656.s2.e0	DDI-DrugBank.d656.s2.e5
DDI-DrugBank.d656.s2	false	DDI-DrugBank.d656.s2.e0	DDI-DrugBank.d656.s2.e6
DDI-DrugBank.d656.s2	false	DDI-DrugBank.d656.s2.e0	DDI-DrugBank.d656.s2.e7
DDI-DrugBank.d656.s2	true	DDI-DrugBank.d656.s2.e1	DDI-DrugBank.d656.s2.e2
DDI-DrugBank.d656.s2	false	DDI-DrugBank.d656.s2.e1	DDI-DrugBank.d656.s2.e3
DDI-DrugBank.d656.s2	false	DDI-DrugBank.d656.s2.e1	DDI-DrugBank.d656.s2.e4
DDI-DrugBank.d656.s3|a|It is recommended that plasma lithium levels be monitored when initiating, adjusting and discontinuing FELDENE.
DDI-DrugBank.d656.s3	30	36	lithium	drug	DDI-DrugBank.d656.s3.e0
DDI-DrugBank.d656.s3	103	109	FELDENE	brand	DDI-DrugBank.d656.s3.e1
DDI-DrugBank.d656.s3	true	DDI-DrugBank.d656.s3.e0	DDI-DrugBank.d656.s3.e1
DDI-DrugBank.d622.s0|a|When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. 
DDI-DrugBank.d622.s0	5	12	atropine	drug	DDI-DrugBank.d622.s0.e0
DDI-DrugBank.d622.s0	18	28	pralidoxime	drug	DDI-DrugBank.d622.s0.e1
DDI-DrugBank.d622.s0	189	196	atropine	drug	DDI-DrugBank.d622.s0.e2
DDI-DrugBank.d622.s0	true	DDI-DrugBank.d622.s0.e0	DDI-DrugBank.d622.s0.e1
DDI-DrugBank.d622.s0	false	DDI-DrugBank.d622.s0.e0	DDI-DrugBank.d622.s0.e2
DDI-DrugBank.d622.s0	false	DDI-DrugBank.d622.s0.e1	DDI-DrugBank.d622.s0.e2
DDI-DrugBank.d622.s1|a|This is especially true if the total dose of atropine has been large and the administration of pralidoxime has been delayed. 
DDI-DrugBank.d622.s1	45	52	atropine	drug	DDI-DrugBank.d622.s1.e0
DDI-DrugBank.d622.s1	95	105	pralidoxime	drug	DDI-DrugBank.d622.s1.e1
DDI-DrugBank.d622.s1	false	DDI-DrugBank.d622.s1.e0	DDI-DrugBank.d622.s1.e1
DDI-DrugBank.d622.s2|a|2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime: since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions; 
DDI-DrugBank.d622.s2	154	164	pralidoxime	drug	DDI-DrugBank.d622.s2.e0
DDI-DrugBank.d622.s2	173	184	barbiturates	group	DDI-DrugBank.d622.s2.e1
DDI-DrugBank.d622.s2	209	227	anticholinesterases	group	DDI-DrugBank.d622.s2.e2
DDI-DrugBank.d622.s2	false	DDI-DrugBank.d622.s2.e0	DDI-DrugBank.d622.s2.e1
DDI-DrugBank.d622.s2	false	DDI-DrugBank.d622.s2.e0	DDI-DrugBank.d622.s2.e2
DDI-DrugBank.d622.s2	true	DDI-DrugBank.d622.s2.e1	DDI-DrugBank.d622.s2.e2
DDI-DrugBank.d622.s3|a|morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.
DDI-DrugBank.d622.s3	0	7	morphine	drug	DDI-DrugBank.d622.s3.e0
DDI-DrugBank.d622.s3	10	21	theophylline	drug	DDI-DrugBank.d622.s3.e1
DDI-DrugBank.d622.s3	24	36	aminophylline	drug	DDI-DrugBank.d622.s3.e2
DDI-DrugBank.d622.s3	39	53	succinylcholine	drug	DDI-DrugBank.d622.s3.e3
DDI-DrugBank.d622.s3	56	64	reserpine	drug	DDI-DrugBank.d622.s3.e4
DDI-DrugBank.d622.s3	71	102	phenothiazine-type tranquilizers	group	DDI-DrugBank.d622.s3.e5
DDI-DrugBank.d622.s3	false	DDI-DrugBank.d622.s3.e0	DDI-DrugBank.d622.s3.e1
DDI-DrugBank.d622.s3	false	DDI-DrugBank.d622.s3.e0	DDI-DrugBank.d622.s3.e2
DDI-DrugBank.d622.s3	false	DDI-DrugBank.d622.s3.e0	DDI-DrugBank.d622.s3.e3
DDI-DrugBank.d622.s3	false	DDI-DrugBank.d622.s3.e0	DDI-DrugBank.d622.s3.e4
DDI-DrugBank.d622.s3	false	DDI-DrugBank.d622.s3.e0	DDI-DrugBank.d622.s3.e5
DDI-DrugBank.d622.s3	false	DDI-DrugBank.d622.s3.e1	DDI-DrugBank.d622.s3.e2
DDI-DrugBank.d622.s3	false	DDI-DrugBank.d622.s3.e1	DDI-DrugBank.d622.s3.e3
DDI-DrugBank.d622.s3	false	DDI-DrugBank.d622.s3.e1	DDI-DrugBank.d622.s3.e4
DDI-DrugBank.d622.s3	false	DDI-DrugBank.d622.s3.e1	DDI-DrugBank.d622.s3.e5
DDI-DrugBank.d622.s3	false	DDI-DrugBank.d622.s3.e2	DDI-DrugBank.d622.s3.e3
DDI-DrugBank.d737.s0|a|Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). 
DDI-DrugBank.d737.s0	0	8	Carbidopa	drug	DDI-DrugBank.d737.s0.e0
DDI-DrugBank.d737.s0	10	17	Levodopa	drug	DDI-DrugBank.d737.s0.e1
DDI-DrugBank.d737.s0	20	28	Carbidopa	drug	DDI-DrugBank.d737.s0.e2
DDI-DrugBank.d737.s0	30	37	Levodopa	drug	DDI-DrugBank.d737.s0.e3
DDI-DrugBank.d737.s0	82	92	pramipexole	drug	DDI-DrugBank.d737.s0.e4
DDI-DrugBank.d737.s0	false	DDI-DrugBank.d737.s0.e0	DDI-DrugBank.d737.s0.e1
DDI-DrugBank.d737.s0	false	DDI-DrugBank.d737.s0.e0	DDI-DrugBank.d737.s0.e2
DDI-DrugBank.d737.s0	false	DDI-DrugBank.d737.s0.e0	DDI-DrugBank.d737.s0.e3
DDI-DrugBank.d737.s0	false	DDI-DrugBank.d737.s0.e0	DDI-DrugBank.d737.s0.e4
DDI-DrugBank.d737.s0	false	DDI-DrugBank.d737.s0.e1	DDI-DrugBank.d737.s0.e2
DDI-DrugBank.d737.s0	false	DDI-DrugBank.d737.s0.e1	DDI-DrugBank.d737.s0.e3
DDI-DrugBank.d737.s0	false	DDI-DrugBank.d737.s0.e1	DDI-DrugBank.d737.s0.e4
DDI-DrugBank.d737.s0	false	DDI-DrugBank.d737.s0.e2	DDI-DrugBank.d737.s0.e3
DDI-DrugBank.d737.s0	false	DDI-DrugBank.d737.s0.e2	DDI-DrugBank.d737.s0.e4
DDI-DrugBank.d737.s0	false	DDI-DrugBank.d737.s0.e3	DDI-DrugBank.d737.s0.e4
DDI-DrugBank.d737.s1|a|5 hours. 
DDI-DrugBank.d737.s2|a|Selegiline: In healthy volunteers (N= 11), selegiline did not influence the pharmacokinetics of pramipexole. 
DDI-DrugBank.d737.s2	0	9	Selegiline	drug	DDI-DrugBank.d737.s2.e0
DDI-DrugBank.d737.s2	43	52	selegiline	drug	DDI-DrugBank.d737.s2.e1
DDI-DrugBank.d737.s2	96	106	pramipexole	drug	DDI-DrugBank.d737.s2.e2
DDI-DrugBank.d737.s2	false	DDI-DrugBank.d737.s2.e0	DDI-DrugBank.d737.s2.e1
DDI-DrugBank.d737.s2	false	DDI-DrugBank.d737.s2.e0	DDI-DrugBank.d737.s2.e2
DDI-DrugBank.d737.s2	false	DDI-DrugBank.d737.s2.e1	DDI-DrugBank.d737.s2.e2
DDI-DrugBank.d737.s3|a|Amantadine: Population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of pramipexole (N= 54). 
DDI-DrugBank.d737.s3	0	9	Amantadine	drug	DDI-DrugBank.d737.s3.e0
DDI-DrugBank.d737.s3	62	71	amantadine	drug	DDI-DrugBank.d737.s3.e1
DDI-DrugBank.d737.s3	116	126	pramipexole	drug	DDI-DrugBank.d737.s3.e2
DDI-DrugBank.d737.s3	false	DDI-DrugBank.d737.s3.e0	DDI-DrugBank.d737.s3.e1
DDI-DrugBank.d737.s3	false	DDI-DrugBank.d737.s3.e0	DDI-DrugBank.d737.s3.e2
DDI-DrugBank.d737.s3	false	DDI-DrugBank.d737.s3.e1	DDI-DrugBank.d737.s3.e2
DDI-DrugBank.d737.s4|a|Cimetidine: Cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole AUC and a 40% increase in half-life (N= 12). 
DDI-DrugBank.d737.s4	0	9	Cimetidine	drug	DDI-DrugBank.d737.s4.e0
DDI-DrugBank.d737.s4	12	21	Cimetidine	drug	DDI-DrugBank.d737.s4.e1
DDI-DrugBank.d737.s4	146	156	pramipexole	drug	DDI-DrugBank.d737.s4.e2
DDI-DrugBank.d737.s4	false	DDI-DrugBank.d737.s4.e0	DDI-DrugBank.d737.s4.e1
DDI-DrugBank.d737.s4	false	DDI-DrugBank.d737.s4.e0	DDI-DrugBank.d737.s4.e2
DDI-DrugBank.d737.s4	true	DDI-DrugBank.d737.s4.e1	DDI-DrugBank.d737.s4.e2
DDI-DrugBank.d737.s5|a|Probenecid: Probenecid, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence pramipexole pharmacokinetics (N= 12). 
DDI-DrugBank.d737.s5	0	9	Probenecid	drug	DDI-DrugBank.d737.s5.e0
DDI-DrugBank.d737.s5	12	21	Probenecid	drug	DDI-DrugBank.d737.s5.e1
DDI-DrugBank.d737.s5	144	154	pramipexole	drug	DDI-DrugBank.d737.s5.e2
DDI-DrugBank.d737.s5	false	DDI-DrugBank.d737.s5.e0	DDI-DrugBank.d737.s5.e1
DDI-DrugBank.d737.s5	false	DDI-DrugBank.d737.s5.e0	DDI-DrugBank.d737.s5.e2
DDI-DrugBank.d737.s5	false	DDI-DrugBank.d737.s5.e1	DDI-DrugBank.d737.s5.e2
DDI-DrugBank.d737.s6|a|Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
DDI-DrugBank.d737.s6	178	187	cimetidine	drug	DDI-DrugBank.d737.s6.e0
DDI-DrugBank.d737.s6	190	199	ranitidine	drug	DDI-DrugBank.d737.s6.e1
DDI-DrugBank.d737.s6	202	210	diltiazem	drug	DDI-DrugBank.d737.s6.e2
DDI-DrugBank.d737.s6	213	223	triamterene	drug	DDI-DrugBank.d737.s6.e3
DDI-DrugBank.d737.s6	226	234	verapamil	drug	DDI-DrugBank.d737.s6.e4
DDI-DrugBank.d737.s6	237	245	quinidine	drug	DDI-DrugBank.d737.s6.e5
DDI-DrugBank.d737.s6	252	258	quinine	drug	DDI-DrugBank.d737.s6.e6
DDI-DrugBank.d737.s6	293	303	pramipexole	drug	DDI-DrugBank.d737.s6.e7
DDI-DrugBank.d737.s6	379	392	cephalosporins	group	DDI-DrugBank.d737.s6.e8
DDI-DrugBank.d737.s6	395	405	penicillins	group	DDI-DrugBank.d737.s6.e9
DDI-DrugBank.d737.s6	false	DDI-DrugBank.d737.s6.e0	DDI-DrugBank.d737.s6.e1
DDI-DrugBank.d737.s6	false	DDI-DrugBank.d737.s6.e0	DDI-DrugBank.d737.s6.e2
DDI-DrugBank.d737.s6	false	DDI-DrugBank.d737.s6.e0	DDI-DrugBank.d737.s6.e3
DDI-DrugBank.d737.s6	false	DDI-DrugBank.d737.s6.e0	DDI-DrugBank.d737.s6.e4
DDI-DrugBank.d737.s6	false	DDI-DrugBank.d737.s6.e0	DDI-DrugBank.d737.s6.e5
DDI-DrugBank.d737.s6	false	DDI-DrugBank.d737.s6.e0	DDI-DrugBank.d737.s6.e6
DDI-DrugBank.d737.s6	true	DDI-DrugBank.d737.s6.e0	DDI-DrugBank.d737.s6.e7
DDI-DrugBank.d737.s6	false	DDI-DrugBank.d737.s6.e0	DDI-DrugBank.d737.s6.e8
DDI-DrugBank.d737.s6	false	DDI-DrugBank.d737.s6.e0	DDI-DrugBank.d737.s6.e9
DDI-DrugBank.d737.s6	false	DDI-DrugBank.d737.s6.e0	DDI-DrugBank.d737.s6.e10
DDI-DrugBank.d737.s7|a|CYP interactions: Inhibitors of cytochrome P450 enzymes would not be expected to affect pramipexole elimination because pramipexole is not appreciably metabolized by these enzymes in vivo or in vitro. 
DDI-DrugBank.d737.s7	88	98	pramipexole	drug	DDI-DrugBank.d737.s7.e0
DDI-DrugBank.d737.s7	120	130	pramipexole	drug	DDI-DrugBank.d737.s7.e1
DDI-DrugBank.d737.s7	false	DDI-DrugBank.d737.s7.e0	DDI-DrugBank.d737.s7.e1
DDI-DrugBank.d737.s8|a|Pramipexole does not inhibit CYP enzymes CYPIA2, CYP2C9, CYP2CI9, CYP2EI, and CYP3A4. 
DDI-DrugBank.d737.s8	0	10	Pramipexole	drug	DDI-DrugBank.d737.s8.e0
DDI-DrugBank.d737.s9|a|Inhibition of CYP2D6 was observed with an apparent Ki of 30 uM, indicating that pramipexole will not inhibit CYP enzymes at plasma concentrations observed following the highest recommended clinical dose (1.5 mg tid). 
DDI-DrugBank.d737.s9	80	90	pramipexole	drug	DDI-DrugBank.d737.s9.e0
DDI-DrugBank.d737.s10|a|Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 
DDI-DrugBank.d737.s10	0	19	Dopamine antagonists	group	DDI-DrugBank.d737.s10.e0
DDI-DrugBank.d737.s10	28	38	pramipexole	drug	DDI-DrugBank.d737.s10.e1
DDI-DrugBank.d737.s10	45	60	dopamine agonist	group	DDI-DrugBank.d737.s10.e2
DDI-DrugBank.d737.s10	83	102	dopamine antagonists	group	DDI-DrugBank.d737.s10.e3
DDI-DrugBank.d737.s10	117	128	neuroleptics	group	DDI-DrugBank.d737.s10.e4
DDI-DrugBank.d737.s10	131	144	phenothiazines	group	DDI-DrugBank.d737.s10.e5
DDI-DrugBank.d737.s10	147	160	butyrophenones	group	DDI-DrugBank.d737.s10.e6
DDI-DrugBank.d737.s10	163	175	thioxanthenes	group	DDI-DrugBank.d737.s10.e7
DDI-DrugBank.d737.s10	181	194	metoclopramide	group	DDI-DrugBank.d737.s10.e8
DDI-DrugBank.d737.s10	231	237	MIRAPEX	brand	DDI-DrugBank.d737.s10.e9
DDI-DrugBank.d737.s10	false	DDI-DrugBank.d737.s10.e0	DDI-DrugBank.d737.s10.e1
DDI-DrugBank.d737.s10	false	DDI-DrugBank.d737.s10.e0	DDI-DrugBank.d737.s10.e2
DDI-DrugBank.d737.s10	false	DDI-DrugBank.d737.s10.e0	DDI-DrugBank.d737.s10.e3
DDI-DrugBank.d737.s10	false	DDI-DrugBank.d737.s10.e0	DDI-DrugBank.d737.s10.e4
DDI-DrugBank.d737.s10	false	DDI-DrugBank.d737.s10.e0	DDI-DrugBank.d737.s10.e5
DDI-DrugBank.d737.s10	false	DDI-DrugBank.d737.s10.e0	DDI-DrugBank.d737.s10.e6
DDI-DrugBank.d737.s10	false	DDI-DrugBank.d737.s10.e0	DDI-DrugBank.d737.s10.e7
DDI-DrugBank.d737.s10	false	DDI-DrugBank.d737.s10.e0	DDI-DrugBank.d737.s10.e8
DDI-DrugBank.d737.s10	false	DDI-DrugBank.d737.s10.e0	DDI-DrugBank.d737.s10.e9
DDI-DrugBank.d737.s10	false	DDI-DrugBank.d737.s10.e1	DDI-DrugBank.d737.s10.e2
DDI-DrugBank.d737.s11|a|Drug/ Laboratory Test Interactions There are no known interactions between MIRAPEX and laboratory tests.
DDI-DrugBank.d737.s11	75	81	MIRAPEX	brand	DDI-DrugBank.d737.s11.e0
DDI-DrugBank.d632.s0|a|Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). 
DDI-DrugBank.d632.s0	40	45	SYMLIN	brand	DDI-DrugBank.d632.s0.e0
DDI-DrugBank.d632.s0	150	171	anticholinergic agents	group	DDI-DrugBank.d632.s0.e1
DDI-DrugBank.d632.s0	181	188	atropine	drug	DDI-DrugBank.d632.s0.e2
DDI-DrugBank.d632.s0	258	285	alpha glucosidase inhibitors	group	DDI-DrugBank.d632.s0.e3
DDI-DrugBank.d632.s0	true	DDI-DrugBank.d632.s0.e0	DDI-DrugBank.d632.s0.e1
DDI-DrugBank.d632.s0	true	DDI-DrugBank.d632.s0.e0	DDI-DrugBank.d632.s0.e2
DDI-DrugBank.d632.s0	true	DDI-DrugBank.d632.s0.e0	DDI-DrugBank.d632.s0.e3
DDI-DrugBank.d632.s0	false	DDI-DrugBank.d632.s0.e1	DDI-DrugBank.d632.s0.e2
DDI-DrugBank.d632.s0	false	DDI-DrugBank.d632.s0.e1	DDI-DrugBank.d632.s0.e3
DDI-DrugBank.d632.s0	false	DDI-DrugBank.d632.s0.e2	DDI-DrugBank.d632.s0.e3
DDI-DrugBank.d632.s1|a|Patients using these drugs have not been studied in clinical trials. 
DDI-DrugBank.d632.s2|a|SYMLIN has the potential to delay the absorption of concomitantly administered oral medications. 
DDI-DrugBank.d632.s2	0	5	SYMLIN	brand	DDI-DrugBank.d632.s2.e0
DDI-DrugBank.d632.s3|a|When the rapid onset of a concomitant orally administered agent is a critical determinant of effectiveness (such as analgesics), the agent should be administered at least 1 hour prior to or 2 hours after SYMLIN injection. 
DDI-DrugBank.d632.s3	116	125	analgesics	group	DDI-DrugBank.d632.s3.e0
DDI-DrugBank.d632.s3	204	209	SYMLIN	brand	DDI-DrugBank.d632.s3.e1
DDI-DrugBank.d632.s3	true	DDI-DrugBank.d632.s3.e0	DDI-DrugBank.d632.s3.e1
DDI-DrugBank.d632.s4|a|In clinical trials, the concomitant use of sulfonylureas or biguanides did not alter the adverse event profile of SYMLIN. 
DDI-DrugBank.d632.s4	43	55	sulfonylureas	group	DDI-DrugBank.d632.s4.e0
DDI-DrugBank.d632.s4	60	69	biguanides	group	DDI-DrugBank.d632.s4.e1
DDI-DrugBank.d632.s4	114	119	SYMLIN	brand	DDI-DrugBank.d632.s4.e2
DDI-DrugBank.d632.s4	false	DDI-DrugBank.d632.s4.e0	DDI-DrugBank.d632.s4.e1
DDI-DrugBank.d632.s4	false	DDI-DrugBank.d632.s4.e0	DDI-DrugBank.d632.s4.e2
DDI-DrugBank.d632.s4	false	DDI-DrugBank.d632.s4.e1	DDI-DrugBank.d632.s4.e2
DDI-DrugBank.d632.s5|a|No formal interaction studies have been performed to assess the effect of SYMLIN on the kinetics of oral antidiabetic agents. 
DDI-DrugBank.d632.s5	74	79	SYMLIN	brand	DDI-DrugBank.d632.s5.e0
DDI-DrugBank.d632.s5	105	123	antidiabetic agents	group	DDI-DrugBank.d632.s5.e1
DDI-DrugBank.d632.s5	false	DDI-DrugBank.d632.s5.e0	DDI-DrugBank.d632.s5.e1
DDI-DrugBank.d632.s6|a|Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection. 
DDI-DrugBank.d632.s6	7	12	SYMLIN	brand	DDI-DrugBank.d632.s6.e0
DDI-DrugBank.d632.s6	18	24	Insulin	drug	DDI-DrugBank.d632.s6.e1
DDI-DrugBank.d632.s6	60	65	SYMLIN	brand	DDI-DrugBank.d632.s6.e2
DDI-DrugBank.d632.s6	157	169	human insulin	drug	DDI-DrugBank.d632.s6.e3
DDI-DrugBank.d632.s6	false	DDI-DrugBank.d632.s6.e0	DDI-DrugBank.d632.s6.e1
DDI-DrugBank.d632.s6	false	DDI-DrugBank.d632.s6.e0	DDI-DrugBank.d632.s6.e2
DDI-DrugBank.d632.s6	false	DDI-DrugBank.d632.s6.e0	DDI-DrugBank.d632.s6.e3
DDI-DrugBank.d632.s6	false	DDI-DrugBank.d632.s6.e1	DDI-DrugBank.d632.s6.e2
DDI-DrugBank.d632.s6	false	DDI-DrugBank.d632.s6.e1	DDI-DrugBank.d632.s6.e3
DDI-DrugBank.d632.s6	true	DDI-DrugBank.d632.s6.e2	DDI-DrugBank.d632.s6.e3
DDI-DrugBank.d632.s7|a|Thus, SYMLIN and insulin should not be mixed and must be administered separately.
DDI-DrugBank.d632.s7	6	11	SYMLIN	brand	DDI-DrugBank.d632.s7.e0
DDI-DrugBank.d632.s7	17	23	insulin	drug	DDI-DrugBank.d632.s7.e1
DDI-DrugBank.d632.s7	false	DDI-DrugBank.d632.s7.e0	DDI-DrugBank.d632.s7.e1
DDI-DrugBank.d653.s0|a|The pharmacokinetic interactions listed below are potentially clinically important. 
DDI-DrugBank.d653.s1|a|Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. 
DDI-DrugBank.d653.s1	42	54	phenobarbital	drug	DDI-DrugBank.d653.s1.e0
DDI-DrugBank.d653.s1	57	65	phenytoin	drug	DDI-DrugBank.d653.s1.e1
DDI-DrugBank.d653.s1	71	78	rifampin	drug	DDI-DrugBank.d653.s1.e2
DDI-DrugBank.d653.s1	110	124	corticosteroids	group	DDI-DrugBank.d653.s1.e3
DDI-DrugBank.d653.s1	155	168	corticosteroid	group	DDI-DrugBank.d653.s1.e4
DDI-DrugBank.d653.s1	false	DDI-DrugBank.d653.s1.e0	DDI-DrugBank.d653.s1.e1
DDI-DrugBank.d653.s1	false	DDI-DrugBank.d653.s1.e0	DDI-DrugBank.d653.s1.e2
DDI-DrugBank.d653.s1	true	DDI-DrugBank.d653.s1.e0	DDI-DrugBank.d653.s1.e3
DDI-DrugBank.d653.s1	true	DDI-DrugBank.d653.s1.e0	DDI-DrugBank.d653.s1.e4
DDI-DrugBank.d653.s1	false	DDI-DrugBank.d653.s1.e1	DDI-DrugBank.d653.s1.e2
DDI-DrugBank.d653.s1	true	DDI-DrugBank.d653.s1.e1	DDI-DrugBank.d653.s1.e3
DDI-DrugBank.d653.s1	true	DDI-DrugBank.d653.s1.e1	DDI-DrugBank.d653.s1.e4
DDI-DrugBank.d653.s1	true	DDI-DrugBank.d653.s1.e2	DDI-DrugBank.d653.s1.e3
DDI-DrugBank.d653.s1	true	DDI-DrugBank.d653.s1.e2	DDI-DrugBank.d653.s1.e4
DDI-DrugBank.d653.s1	false	DDI-DrugBank.d653.s1.e3	DDI-DrugBank.d653.s1.e4
DDI-DrugBank.d653.s2|a|Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. 
DDI-DrugBank.d653.s2	14	27	troleandomycin	drug	DDI-DrugBank.d653.s2.e0
DDI-DrugBank.d653.s2	33	44	ketoconazole	drug	DDI-DrugBank.d653.s2.e1
DDI-DrugBank.d653.s2	76	90	corticosteroids	group	DDI-DrugBank.d653.s2.e2
DDI-DrugBank.d653.s2	false	DDI-DrugBank.d653.s2.e0	DDI-DrugBank.d653.s2.e1
DDI-DrugBank.d653.s2	true	DDI-DrugBank.d653.s2.e0	DDI-DrugBank.d653.s2.e2
DDI-DrugBank.d653.s2	true	DDI-DrugBank.d653.s2.e1	DDI-DrugBank.d653.s2.e2
DDI-DrugBank.d653.s3|a|Therefore, the dose of corticosteroid should be titrated to avoid steroid toxicity. 
DDI-DrugBank.d653.s3	23	36	corticosteroid	group	DDI-DrugBank.d653.s3.e0
DDI-DrugBank.d653.s4|a|Corticosteroids may increase the clearance of chronic high dose aspirin. 
DDI-DrugBank.d653.s4	0	14	Corticosteroids	group	DDI-DrugBank.d653.s4.e0
DDI-DrugBank.d653.s4	64	70	aspirin	brand	DDI-DrugBank.d653.s4.e1
DDI-DrugBank.d653.s4	true	DDI-DrugBank.d653.s4.e0	DDI-DrugBank.d653.s4.e1
DDI-DrugBank.d653.s5|a|This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn. 
DDI-DrugBank.d653.s5	29	38	salicylate	group	DDI-DrugBank.d653.s5.e0
DDI-DrugBank.d653.s5	77	86	salicylate	group	DDI-DrugBank.d653.s5.e1
DDI-DrugBank.d653.s5	102	115	corticosteroid	group	DDI-DrugBank.d653.s5.e2
DDI-DrugBank.d653.s5	false	DDI-DrugBank.d653.s5.e0	DDI-DrugBank.d653.s5.e1
DDI-DrugBank.d653.s5	false	DDI-DrugBank.d653.s5.e0	DDI-DrugBank.d653.s5.e2
DDI-DrugBank.d653.s5	true	DDI-DrugBank.d653.s5.e1	DDI-DrugBank.d653.s5.e2
DDI-DrugBank.d653.s6|a|Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia. 
DDI-DrugBank.d653.s6	0	6	Aspirin	brand	DDI-DrugBank.d653.s6.e0
DDI-DrugBank.d653.s6	54	68	corticosteroids	group	DDI-DrugBank.d653.s6.e1
DDI-DrugBank.d653.s6	true	DDI-DrugBank.d653.s6.e0	DDI-DrugBank.d653.s6.e1
DDI-DrugBank.d653.s7|a|The effect of corticosteroids on oral anticoagulants is variable. 
DDI-DrugBank.d653.s7	14	28	corticosteroids	group	DDI-DrugBank.d653.s7.e0
DDI-DrugBank.d653.s7	38	51	anticoagulants	group	DDI-DrugBank.d653.s7.e1
DDI-DrugBank.d653.s7	true	DDI-DrugBank.d653.s7.e0	DDI-DrugBank.d653.s7.e1
DDI-DrugBank.d653.s8|a|There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids. 
DDI-DrugBank.d653.s8	63	76	anticoagulants	group	DDI-DrugBank.d653.s8.e0
DDI-DrugBank.d653.s8	107	121	corticosteroids	group	DDI-DrugBank.d653.s8.e1
DDI-DrugBank.d653.s8	true	DDI-DrugBank.d653.s8.e0	DDI-DrugBank.d653.s8.e1
DDI-DrugBank.d653.s9|a|Therefore, coagulation indices should be monitored to maintain the desired anticoagulant effect.
DDI-DrugBank.d780.s0|a|Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. 
DDI-DrugBank.d780.s0	0	18	Anticholinesterases	group	DDI-DrugBank.d780.s0.e0
DDI-DrugBank.d780.s0	39	60	procaine hydrochloride	drug	DDI-DrugBank.d780.s0.e1
DDI-DrugBank.d780.s0	66	90	anticholinesterase agents	group	DDI-DrugBank.d780.s0.e2
DDI-DrugBank.d780.s0	140	158	anticholinesterases	group	DDI-DrugBank.d780.s0.e3
DDI-DrugBank.d780.s0	185	206	procaine hydrochloride	drug	DDI-DrugBank.d780.s0.e4
DDI-DrugBank.d780.s0	false	DDI-DrugBank.d780.s0.e0	DDI-DrugBank.d780.s0.e1
DDI-DrugBank.d780.s0	false	DDI-DrugBank.d780.s0.e0	DDI-DrugBank.d780.s0.e2
DDI-DrugBank.d780.s0	false	DDI-DrugBank.d780.s0.e0	DDI-DrugBank.d780.s0.e3
DDI-DrugBank.d780.s0	false	DDI-DrugBank.d780.s0.e0	DDI-DrugBank.d780.s0.e4
DDI-DrugBank.d780.s0	true	DDI-DrugBank.d780.s0.e1	DDI-DrugBank.d780.s0.e2
DDI-DrugBank.d780.s0	false	DDI-DrugBank.d780.s0.e1	DDI-DrugBank.d780.s0.e3
DDI-DrugBank.d780.s0	false	DDI-DrugBank.d780.s0.e1	DDI-DrugBank.d780.s0.e4
DDI-DrugBank.d780.s0	false	DDI-DrugBank.d780.s0.e2	DDI-DrugBank.d780.s0.e3
DDI-DrugBank.d780.s0	false	DDI-DrugBank.d780.s0.e2	DDI-DrugBank.d780.s0.e4
DDI-DrugBank.d780.s0	true	DDI-DrugBank.d780.s0.e3	DDI-DrugBank.d780.s0.e4
DDI-DrugBank.d780.s1|a|Antimyasthenics Concurrent use of procaine hydrochloride and antimyasthenics may result in loss of control of symptoms of myasthenia gravis due to antagonism of the effects of antimyasthenics on skeletal muscle. 
DDI-DrugBank.d780.s1	34	55	procaine hydrochloride	drug	DDI-DrugBank.d780.s1.e0
DDI-DrugBank.d780.s2|a|Temporary dosage adjustment of antimyasthenics may be required. 
DDI-DrugBank.d780.s3|a|Also antimyasthenics may have anticholinesterase activity. 
DDI-DrugBank.d780.s4|a|CNS depressant medications: Concurrent use of procaine hydrochloride and CNS depressant medications may result in additive depressant effects. 
DDI-DrugBank.d780.s4	0	13	CNS depressant	group	DDI-DrugBank.d780.s4.e0
DDI-DrugBank.d780.s4	46	67	procaine hydrochloride	drug	DDI-DrugBank.d780.s4.e1
DDI-DrugBank.d780.s4	73	98	CNS depressant medications	group	DDI-DrugBank.d780.s4.e2
DDI-DrugBank.d780.s4	false	DDI-DrugBank.d780.s4.e0	DDI-DrugBank.d780.s4.e1
DDI-DrugBank.d780.s4	false	DDI-DrugBank.d780.s4.e0	DDI-DrugBank.d780.s4.e2
DDI-DrugBank.d780.s4	true	DDI-DrugBank.d780.s4.e1	DDI-DrugBank.d780.s4.e2
DDI-DrugBank.d780.s5|a|Hyaluronidase: Hyaluronidase may increase the diffusion rate of procaine hydrochloride, resulting in a decreased time of onset, but an increase in systemic toxicity. 
DDI-DrugBank.d780.s5	0	12	Hyaluronidase	drug	DDI-DrugBank.d780.s5.e0
DDI-DrugBank.d780.s5	15	27	Hyaluronidase	drug	DDI-DrugBank.d780.s5.e1
DDI-DrugBank.d780.s5	64	85	procaine hydrochloride	drug	DDI-DrugBank.d780.s5.e2
DDI-DrugBank.d780.s5	false	DDI-DrugBank.d780.s5.e0	DDI-DrugBank.d780.s5.e1
DDI-DrugBank.d780.s5	false	DDI-DrugBank.d780.s5.e0	DDI-DrugBank.d780.s5.e2
DDI-DrugBank.d780.s5	true	DDI-DrugBank.d780.s5.e1	DDI-DrugBank.d780.s5.e2
DDI-DrugBank.d780.s6|a|Neuromuscular blocking agents (such as suxamethonium chloride): Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade. 
DDI-DrugBank.d780.s6	0	28	Neuromuscular blocking agents	group	DDI-DrugBank.d780.s6.e0
DDI-DrugBank.d780.s6	39	60	suxamethonium chloride	drug	DDI-DrugBank.d780.s6.e1
DDI-DrugBank.d780.s6	82	103	procaine hydrochloride	drug	DDI-DrugBank.d780.s6.e2
DDI-DrugBank.d780.s6	109	137	neuromuscular blocking agents	group	DDI-DrugBank.d780.s6.e3
DDI-DrugBank.d780.s6	false	DDI-DrugBank.d780.s6.e0	DDI-DrugBank.d780.s6.e1
DDI-DrugBank.d780.s6	false	DDI-DrugBank.d780.s6.e0	DDI-DrugBank.d780.s6.e2
DDI-DrugBank.d780.s6	false	DDI-DrugBank.d780.s6.e0	DDI-DrugBank.d780.s6.e3
DDI-DrugBank.d780.s6	false	DDI-DrugBank.d780.s6.e1	DDI-DrugBank.d780.s6.e2
DDI-DrugBank.d780.s6	false	DDI-DrugBank.d780.s6.e1	DDI-DrugBank.d780.s6.e3
DDI-DrugBank.d780.s6	true	DDI-DrugBank.d780.s6.e2	DDI-DrugBank.d780.s6.e3
DDI-DrugBank.d780.s7|a|Sulfonamides: Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide. 
DDI-DrugBank.d780.s7	0	11	Sulfonamides	group	DDI-DrugBank.d780.s7.e0
DDI-DrugBank.d780.s7	32	53	procaine hydrochloride	drug	DDI-DrugBank.d780.s7.e1
DDI-DrugBank.d780.s7	59	70	sulfonamides	group	DDI-DrugBank.d780.s7.e2
DDI-DrugBank.d780.s7	133	143	sulfonamide	group	DDI-DrugBank.d780.s7.e3
DDI-DrugBank.d780.s7	false	DDI-DrugBank.d780.s7.e0	DDI-DrugBank.d780.s7.e1
DDI-DrugBank.d780.s7	false	DDI-DrugBank.d780.s7.e0	DDI-DrugBank.d780.s7.e2
DDI-DrugBank.d780.s7	false	DDI-DrugBank.d780.s7.e0	DDI-DrugBank.d780.s7.e3
DDI-DrugBank.d780.s7	true	DDI-DrugBank.d780.s7.e1	DDI-DrugBank.d780.s7.e2
DDI-DrugBank.d780.s7	false	DDI-DrugBank.d780.s7.e1	DDI-DrugBank.d780.s7.e3
DDI-DrugBank.d780.s7	false	DDI-DrugBank.d780.s7.e2	DDI-DrugBank.d780.s7.e3
DDI-DrugBank.d780.s8|a|Acetazolamide: Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine.
DDI-DrugBank.d780.s8	0	12	Acetazolamide	drug	DDI-DrugBank.d780.s8.e0
DDI-DrugBank.d780.s8	33	45	acetazolamide	drug	DDI-DrugBank.d780.s8.e1
DDI-DrugBank.d780.s8	51	72	procaine hydrochloride	drug	DDI-DrugBank.d780.s8.e2
DDI-DrugBank.d780.s8	109	116	procaine	drug	DDI-DrugBank.d780.s8.e3
DDI-DrugBank.d780.s8	false	DDI-DrugBank.d780.s8.e0	DDI-DrugBank.d780.s8.e1
DDI-DrugBank.d780.s8	false	DDI-DrugBank.d780.s8.e0	DDI-DrugBank.d780.s8.e2
DDI-DrugBank.d780.s8	false	DDI-DrugBank.d780.s8.e0	DDI-DrugBank.d780.s8.e3
DDI-DrugBank.d780.s8	true	DDI-DrugBank.d780.s8.e1	DDI-DrugBank.d780.s8.e2
DDI-DrugBank.d780.s8	false	DDI-DrugBank.d780.s8.e1	DDI-DrugBank.d780.s8.e3
DDI-DrugBank.d780.s8	false	DDI-DrugBank.d780.s8.e2	DDI-DrugBank.d780.s8.e3
DDI-DrugBank.d676.s0|a|To minimize CNS depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution. 
DDI-DrugBank.d676.s0	54	65	barbiturates	group	DDI-DrugBank.d676.s0.e0
DDI-DrugBank.d676.s0	68	81	antihistamines	group	DDI-DrugBank.d676.s0.e1
DDI-DrugBank.d676.s0	84	92	narcotics	group	DDI-DrugBank.d676.s0.e2
DDI-DrugBank.d676.s0	95	112	hypotensive agents	group	DDI-DrugBank.d676.s0.e3
DDI-DrugBank.d676.s0	117	130	phenothiazines	group	DDI-DrugBank.d676.s0.e4
DDI-DrugBank.d676.s0	false	DDI-DrugBank.d676.s0.e0	DDI-DrugBank.d676.s0.e1
DDI-DrugBank.d676.s0	false	DDI-DrugBank.d676.s0.e0	DDI-DrugBank.d676.s0.e2
DDI-DrugBank.d676.s0	false	DDI-DrugBank.d676.s0.e0	DDI-DrugBank.d676.s0.e3
DDI-DrugBank.d676.s0	false	DDI-DrugBank.d676.s0.e0	DDI-DrugBank.d676.s0.e4
DDI-DrugBank.d676.s0	false	DDI-DrugBank.d676.s0.e1	DDI-DrugBank.d676.s0.e2
DDI-DrugBank.d676.s0	false	DDI-DrugBank.d676.s0.e1	DDI-DrugBank.d676.s0.e3
DDI-DrugBank.d676.s0	false	DDI-DrugBank.d676.s0.e1	DDI-DrugBank.d676.s0.e4
DDI-DrugBank.d676.s0	false	DDI-DrugBank.d676.s0.e2	DDI-DrugBank.d676.s0.e3
DDI-DrugBank.d676.s0	false	DDI-DrugBank.d676.s0.e2	DDI-DrugBank.d676.s0.e4
DDI-DrugBank.d676.s0	false	DDI-DrugBank.d676.s0.e3	DDI-DrugBank.d676.s0.e4
DDI-DrugBank.d676.s1|a|Ethyl alcohol should not be used since there may be an Antabuse (disulfiram)-like reaction. 
DDI-DrugBank.d676.s1	0	12	Ethyl alcohol	drug	DDI-DrugBank.d676.s1.e0
DDI-DrugBank.d676.s2|a|Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. 
DDI-DrugBank.d676.s2	8	15	Matulane	brand	DDI-DrugBank.d676.s2.e0
DDI-DrugBank.d676.s2	70	90	sympathomimetic drugs	group	DDI-DrugBank.d676.s2.e1
DDI-DrugBank.d676.s2	93	116	tricyclic antidepressant	group	DDI-DrugBank.d676.s2.e2
DDI-DrugBank.d676.s2	131	147	amitriptyline HCl	drug	DDI-DrugBank.d676.s2.e3
DDI-DrugBank.d676.s2	150	163	imipramine HCl	drug	DDI-DrugBank.d676.s2.e4
DDI-DrugBank.d676.s2	208	215	tyramine	drug_n	DDI-DrugBank.d676.s2.e5
DDI-DrugBank.d676.s2	true	DDI-DrugBank.d676.s2.e0	DDI-DrugBank.d676.s2.e1
DDI-DrugBank.d676.s2	true	DDI-DrugBank.d676.s2.e0	DDI-DrugBank.d676.s2.e2
DDI-DrugBank.d676.s2	true	DDI-DrugBank.d676.s2.e0	DDI-DrugBank.d676.s2.e3
DDI-DrugBank.d676.s2	true	DDI-DrugBank.d676.s2.e0	DDI-DrugBank.d676.s2.e4
DDI-DrugBank.d676.s2	true	DDI-DrugBank.d676.s2.e0	DDI-DrugBank.d676.s2.e5
DDI-DrugBank.d676.s2	false	DDI-DrugBank.d676.s2.e1	DDI-DrugBank.d676.s2.e2
DDI-DrugBank.d676.s2	false	DDI-DrugBank.d676.s2.e1	DDI-DrugBank.d676.s2.e3
DDI-DrugBank.d676.s2	false	DDI-DrugBank.d676.s2.e1	DDI-DrugBank.d676.s2.e4
DDI-DrugBank.d676.s2	false	DDI-DrugBank.d676.s2.e1	DDI-DrugBank.d676.s2.e5
DDI-DrugBank.d676.s2	false	DDI-DrugBank.d676.s2.e2	DDI-DrugBank.d676.s2.e3
DDI-DrugBank.d676.s3|a|A further phenomenon of toxicity common to many hydrazine derivatives is hemolysis and the appearance of Heinz-Ehrlich inclusion bodies in erythrocytes.  
DDI-DrugBank.d676.s3	48	68	hydrazine derivatives	group	DDI-DrugBank.d676.s3.e0
DDI-DrugBank.d676.s4|a|No cross-resistance with other chemotherapeutic agents, radiotherapy or steroids has been demonstrated.
DDI-DrugBank.d676.s4	31	53	chemotherapeutic agents	group	DDI-DrugBank.d676.s4.e0
DDI-DrugBank.d676.s4	72	79	steroids	group	DDI-DrugBank.d676.s4.e1
DDI-DrugBank.d676.s4	false	DDI-DrugBank.d676.s4.e0	DDI-DrugBank.d676.s4.e1
DDI-DrugBank.d734.s0|a|Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. 
DDI-DrugBank.d734.s0	0	17	Thiazide diuretics	group	DDI-DrugBank.d734.s0.e0
DDI-DrugBank.d734.s0	82	95	phenothiazines	group	DDI-DrugBank.d734.s0.e1
DDI-DrugBank.d734.s0	true	DDI-DrugBank.d734.s0.e0	DDI-DrugBank.d734.s0.e1
DDI-DrugBank.d734.s1|a|Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly. 
DDI-DrugBank.d734.s1	28	39	guanethidine	drug	DDI-DrugBank.d734.s1.e0
DDI-DrugBank.d734.s1	88	101	phenothiazines	group	DDI-DrugBank.d734.s1.e1
DDI-DrugBank.d734.s1	true	DDI-DrugBank.d734.s1.e0	DDI-DrugBank.d734.s1.e1
DDI-DrugBank.d734.s2|a|Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs.
DDI-DrugBank.d734.s2	30	40	propranolol	drug	DDI-DrugBank.d734.s2.e0
DDI-DrugBank.d734.s2	47	60	phenothiazines	group	DDI-DrugBank.d734.s2.e1
DDI-DrugBank.d734.s2	true	DDI-DrugBank.d734.s2.e0	DDI-DrugBank.d734.s2.e1
DDI-DrugBank.d628.s0|a|The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) 
DDI-DrugBank.d628.s0	35	42	DIPRIVAN	brand	DDI-DrugBank.d628.s0.e0
DDI-DrugBank.d628.s0	158	166	narcotics	group	DDI-DrugBank.d628.s0.e1
DDI-DrugBank.d628.s0	173	180	morphine	drug	DDI-DrugBank.d628.s0.e2
DDI-DrugBank.d628.s0	183	192	meperidine	drug	DDI-DrugBank.d628.s0.e3
DDI-DrugBank.d628.s0	199	206	fentanyl	drug	DDI-DrugBank.d628.s0.e4
DDI-DrugBank.d628.s0	true	DDI-DrugBank.d628.s0.e0	DDI-DrugBank.d628.s0.e1
DDI-DrugBank.d628.s0	true	DDI-DrugBank.d628.s0.e0	DDI-DrugBank.d628.s0.e2
DDI-DrugBank.d628.s0	true	DDI-DrugBank.d628.s0.e0	DDI-DrugBank.d628.s0.e3
DDI-DrugBank.d628.s0	true	DDI-DrugBank.d628.s0.e0	DDI-DrugBank.d628.s0.e4
DDI-DrugBank.d628.s0	false	DDI-DrugBank.d628.s0.e1	DDI-DrugBank.d628.s0.e2
DDI-DrugBank.d628.s0	false	DDI-DrugBank.d628.s0.e1	DDI-DrugBank.d628.s0.e3
DDI-DrugBank.d628.s0	false	DDI-DrugBank.d628.s0.e1	DDI-DrugBank.d628.s0.e4
DDI-DrugBank.d628.s0	false	DDI-DrugBank.d628.s0.e2	DDI-DrugBank.d628.s0.e3
DDI-DrugBank.d628.s0	false	DDI-DrugBank.d628.s0.e2	DDI-DrugBank.d628.s0.e4
DDI-DrugBank.d628.s0	false	DDI-DrugBank.d628.s0.e3	DDI-DrugBank.d628.s0.e4
DDI-DrugBank.d628.s1|a|and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). 
DDI-DrugBank.d628.s1	20	26	opioids	group	DDI-DrugBank.d628.s1.e0
DDI-DrugBank.d628.s1	32	40	sedatives	group	DDI-DrugBank.d628.s1.e1
DDI-DrugBank.d628.s1	47	61	benzodiazepines	group	DDI-DrugBank.d628.s1.e2
DDI-DrugBank.d628.s1	64	75	barbiturates	group	DDI-DrugBank.d628.s1.e3
DDI-DrugBank.d628.s1	78	92	chloral hydrate	drug	DDI-DrugBank.d628.s1.e4
DDI-DrugBank.d628.s1	95	104	droperidol	drug	DDI-DrugBank.d628.s1.e5
DDI-DrugBank.d628.s1	false	DDI-DrugBank.d628.s1.e0	DDI-DrugBank.d628.s1.e1
DDI-DrugBank.d628.s1	false	DDI-DrugBank.d628.s1.e0	DDI-DrugBank.d628.s1.e2
DDI-DrugBank.d628.s1	false	DDI-DrugBank.d628.s1.e0	DDI-DrugBank.d628.s1.e3
DDI-DrugBank.d628.s1	false	DDI-DrugBank.d628.s1.e0	DDI-DrugBank.d628.s1.e4
DDI-DrugBank.d628.s1	false	DDI-DrugBank.d628.s1.e0	DDI-DrugBank.d628.s1.e5
DDI-DrugBank.d628.s1	false	DDI-DrugBank.d628.s1.e1	DDI-DrugBank.d628.s1.e2
DDI-DrugBank.d628.s1	false	DDI-DrugBank.d628.s1.e1	DDI-DrugBank.d628.s1.e3
DDI-DrugBank.d628.s1	false	DDI-DrugBank.d628.s1.e1	DDI-DrugBank.d628.s1.e4
DDI-DrugBank.d628.s1	false	DDI-DrugBank.d628.s1.e1	DDI-DrugBank.d628.s1.e5
DDI-DrugBank.d628.s1	false	DDI-DrugBank.d628.s1.e2	DDI-DrugBank.d628.s1.e3
DDI-DrugBank.d628.s2|a|These agents may increase the anesthetic or sedative effects of DIPRIVAN Injectable Emulsion and may also result in more pronounced decreases in systolic, diastolic, and mean arterial pressures and cardiac output. 
DDI-DrugBank.d628.s2	64	71	DIPRIVAN	brand	DDI-DrugBank.d628.s2.e0
DDI-DrugBank.d628.s3|a|During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). 
DDI-DrugBank.d628.s3	58	65	DIPRIVAN	brand	DDI-DrugBank.d628.s3.e0
DDI-DrugBank.d628.s3	229	244	analgesic agents	group	DDI-DrugBank.d628.s3.e1
DDI-DrugBank.d628.s3	251	263	nitrous oxide	drug	DDI-DrugBank.d628.s3.e2
DDI-DrugBank.d628.s3	268	274	opioids	group	DDI-DrugBank.d628.s3.e3
DDI-DrugBank.d628.s3	true	DDI-DrugBank.d628.s3.e0	DDI-DrugBank.d628.s3.e1
DDI-DrugBank.d628.s3	true	DDI-DrugBank.d628.s3.e0	DDI-DrugBank.d628.s3.e2
DDI-DrugBank.d628.s3	true	DDI-DrugBank.d628.s3.e0	DDI-DrugBank.d628.s3.e3
DDI-DrugBank.d628.s3	false	DDI-DrugBank.d628.s3.e1	DDI-DrugBank.d628.s3.e2
DDI-DrugBank.d628.s3	false	DDI-DrugBank.d628.s3.e1	DDI-DrugBank.d628.s3.e3
DDI-DrugBank.d628.s3	false	DDI-DrugBank.d628.s3.e2	DDI-DrugBank.d628.s3.e3
DDI-DrugBank.d628.s4|a|The concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated. 
DDI-DrugBank.d628.s4	65	74	isoflurane	drug	DDI-DrugBank.d628.s4.e0
DDI-DrugBank.d628.s4	77	85	enflurane	drug	DDI-DrugBank.d628.s4.e1
DDI-DrugBank.d628.s4	92	100	halothane	drug	DDI-DrugBank.d628.s4.e2
DDI-DrugBank.d628.s4	127	134	DIPRIVAN	brand	DDI-DrugBank.d628.s4.e3
DDI-DrugBank.d628.s4	false	DDI-DrugBank.d628.s4.e0	DDI-DrugBank.d628.s4.e1
DDI-DrugBank.d628.s4	false	DDI-DrugBank.d628.s4.e0	DDI-DrugBank.d628.s4.e2
DDI-DrugBank.d628.s4	false	DDI-DrugBank.d628.s4.e0	DDI-DrugBank.d628.s4.e3
DDI-DrugBank.d628.s4	false	DDI-DrugBank.d628.s4.e1	DDI-DrugBank.d628.s4.e2
DDI-DrugBank.d628.s4	false	DDI-DrugBank.d628.s4.e1	DDI-DrugBank.d628.s4.e3
DDI-DrugBank.d628.s4	false	DDI-DrugBank.d628.s4.e2	DDI-DrugBank.d628.s4.e3
DDI-DrugBank.d628.s5|a|These inhalational agents can also be expected to increase the anesthetic or sedative and cardiorespiratory effects of DIPRIVAN Injectable Emulsion. 
DDI-DrugBank.d628.s5	119	126	DIPRIVAN	brand	DDI-DrugBank.d628.s5.e0
DDI-DrugBank.d628.s6|a|DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and nondepolarizing muscle relaxants). 
DDI-DrugBank.d628.s6	0	7	DIPRIVAN	brand	DDI-DrugBank.d628.s6.e0
DDI-DrugBank.d628.s6	140	168	neuromuscular blocking agents	group	DDI-DrugBank.d628.s6.e1
DDI-DrugBank.d628.s6	175	189	succinylcholine	drug	DDI-DrugBank.d628.s6.e2
DDI-DrugBank.d628.s6	195	226	nondepolarizing muscle relaxants	group	DDI-DrugBank.d628.s6.e3
DDI-DrugBank.d628.s6	false	DDI-DrugBank.d628.s6.e0	DDI-DrugBank.d628.s6.e1
DDI-DrugBank.d628.s6	false	DDI-DrugBank.d628.s6.e0	DDI-DrugBank.d628.s6.e2
DDI-DrugBank.d628.s6	false	DDI-DrugBank.d628.s6.e0	DDI-DrugBank.d628.s6.e3
DDI-DrugBank.d628.s6	false	DDI-DrugBank.d628.s6.e1	DDI-DrugBank.d628.s6.e2
DDI-DrugBank.d628.s6	false	DDI-DrugBank.d628.s6.e1	DDI-DrugBank.d628.s6.e3
DDI-DrugBank.d628.s6	false	DDI-DrugBank.d628.s6.e2	DDI-DrugBank.d628.s6.e3
DDI-DrugBank.d628.s7|a|No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of muscle relaxants, inhalational agents, analgesic agents, and local anesthetic agents) have been observed.
DDI-DrugBank.d628.s7	136	151	muscle relaxants	group	DDI-DrugBank.d628.s7.e0
DDI-DrugBank.d628.s7	175	190	analgesic agents	group	DDI-DrugBank.d628.s7.e1
DDI-DrugBank.d628.s7	203	219	anesthetic agents	group	DDI-DrugBank.d628.s7.e2
DDI-DrugBank.d628.s7	false	DDI-DrugBank.d628.s7.e0	DDI-DrugBank.d628.s7.e1
DDI-DrugBank.d628.s7	false	DDI-DrugBank.d628.s7.e0	DDI-DrugBank.d628.s7.e2
DDI-DrugBank.d628.s7	false	DDI-DrugBank.d628.s7.e1	DDI-DrugBank.d628.s7.e2
DDI-DrugBank.d690.s0|a|The CNS-depressant effect of propoxyphene is additive with that of other CNS depressants, including alcohol. 
DDI-DrugBank.d690.s0	29	40	propoxyphene	drug	DDI-DrugBank.d690.s0.e0
DDI-DrugBank.d690.s0	73	87	CNS depressants	group	DDI-DrugBank.d690.s0.e1
DDI-DrugBank.d690.s0	100	106	alcohol	drug	DDI-DrugBank.d690.s0.e2
DDI-DrugBank.d690.s0	true	DDI-DrugBank.d690.s0.e0	DDI-DrugBank.d690.s0.e1
DDI-DrugBank.d690.s0	true	DDI-DrugBank.d690.s0.e0	DDI-DrugBank.d690.s0.e2
DDI-DrugBank.d690.s0	false	DDI-DrugBank.d690.s0.e1	DDI-DrugBank.d690.s0.e2
DDI-DrugBank.d690.s1|a|As is the case with many medicinal agents, propoxyphene may slow the metabolism of a concomitantly administered drug. 
DDI-DrugBank.d690.s1	43	54	propoxyphene	drug	DDI-DrugBank.d690.s1.e0
DDI-DrugBank.d690.s2|a|Should this occur, the higher serum concentrations of that drug may result in increased pharmacologic or adverse effects of that drug. 
DDI-DrugBank.d690.s3|a|Such occurrences have been reported when propoxyphene was administered to patients on antidepressants, anticonvulsants, or warfarin-like drugs. 
DDI-DrugBank.d690.s3	41	52	propoxyphene	drug	DDI-DrugBank.d690.s3.e0
DDI-DrugBank.d690.s3	86	100	antidepressants	group	DDI-DrugBank.d690.s3.e1
DDI-DrugBank.d690.s3	103	117	anticonvulsants	group	DDI-DrugBank.d690.s3.e2
DDI-DrugBank.d690.s3	123	130	warfarin	drug	DDI-DrugBank.d690.s3.e3
DDI-DrugBank.d690.s3	false	DDI-DrugBank.d690.s3.e0	DDI-DrugBank.d690.s3.e1
DDI-DrugBank.d690.s3	false	DDI-DrugBank.d690.s3.e0	DDI-DrugBank.d690.s3.e2
DDI-DrugBank.d690.s3	false	DDI-DrugBank.d690.s3.e0	DDI-DrugBank.d690.s3.e3
DDI-DrugBank.d690.s3	false	DDI-DrugBank.d690.s3.e1	DDI-DrugBank.d690.s3.e2
DDI-DrugBank.d690.s3	false	DDI-DrugBank.d690.s3.e1	DDI-DrugBank.d690.s3.e3
DDI-DrugBank.d690.s3	false	DDI-DrugBank.d690.s3.e2	DDI-DrugBank.d690.s3.e3
DDI-DrugBank.d690.s4|a|Sever neurologic signs, including coma, have occurred with concurrent use of carbamazepine.
DDI-DrugBank.d690.s4	77	89	carbamazepine	drug	DDI-DrugBank.d690.s4.e0
DDI-DrugBank.d606.s0|a|MAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine. 
DDI-DrugBank.d606.s0	0	13	MAO inhibitors	group	DDI-DrugBank.d606.s0.e0
DDI-DrugBank.d606.s0	19	42	beta adrenergic blockers	group	DDI-DrugBank.d606.s0.e1
DDI-DrugBank.d606.s0	68	82	pseudoephedrine	drug	DDI-DrugBank.d606.s0.e2
DDI-DrugBank.d606.s0	false	DDI-DrugBank.d606.s0.e0	DDI-DrugBank.d606.s0.e1
DDI-DrugBank.d606.s0	true	DDI-DrugBank.d606.s0.e0	DDI-DrugBank.d606.s0.e2
DDI-DrugBank.d606.s0	true	DDI-DrugBank.d606.s0.e1	DDI-DrugBank.d606.s0.e2
DDI-DrugBank.d606.s1|a|Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.
DDI-DrugBank.d606.s1	0	15	Sympathomimetics	group	DDI-DrugBank.d606.s1.e0
DDI-DrugBank.d606.s1	60	69	methyldopa	drug	DDI-DrugBank.d606.s1.e1
DDI-DrugBank.d606.s1	72	83	mecamylamine	drug	DDI-DrugBank.d606.s1.e2
DDI-DrugBank.d606.s1	86	94	reserpine	drug	DDI-DrugBank.d606.s1.e3
DDI-DrugBank.d606.s1	100	117	veratrum alkaloids	group	DDI-DrugBank.d606.s1.e4
DDI-DrugBank.d606.s1	true	DDI-DrugBank.d606.s1.e0	DDI-DrugBank.d606.s1.e1
DDI-DrugBank.d606.s1	true	DDI-DrugBank.d606.s1.e0	DDI-DrugBank.d606.s1.e2
DDI-DrugBank.d606.s1	true	DDI-DrugBank.d606.s1.e0	DDI-DrugBank.d606.s1.e3
DDI-DrugBank.d606.s1	true	DDI-DrugBank.d606.s1.e0	DDI-DrugBank.d606.s1.e4
DDI-DrugBank.d606.s1	false	DDI-DrugBank.d606.s1.e1	DDI-DrugBank.d606.s1.e2
DDI-DrugBank.d606.s1	false	DDI-DrugBank.d606.s1.e1	DDI-DrugBank.d606.s1.e3
DDI-DrugBank.d606.s1	false	DDI-DrugBank.d606.s1.e1	DDI-DrugBank.d606.s1.e4
DDI-DrugBank.d606.s1	false	DDI-DrugBank.d606.s1.e2	DDI-DrugBank.d606.s1.e3
DDI-DrugBank.d606.s1	false	DDI-DrugBank.d606.s1.e2	DDI-DrugBank.d606.s1.e4
DDI-DrugBank.d606.s1	false	DDI-DrugBank.d606.s1.e3	DDI-DrugBank.d606.s1.e4
DDI-DrugBank.d631.s0|a|Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. 
DDI-DrugBank.d631.s0	0	12	Pyrimethamine	drug	DDI-DrugBank.d631.s0.e0
DDI-DrugBank.d631.s0	31	42	sulfonamides	group	DDI-DrugBank.d631.s0.e1
DDI-DrugBank.d631.s0	45	51	quinine	drug	DDI-DrugBank.d631.s0.e2
DDI-DrugBank.d631.s0	63	75	antimalarials	group	DDI-DrugBank.d631.s0.e3
DDI-DrugBank.d631.s0	93	103	antibiotics	group	DDI-DrugBank.d631.s0.e4
DDI-DrugBank.d631.s0	false	DDI-DrugBank.d631.s0.e0	DDI-DrugBank.d631.s0.e1
DDI-DrugBank.d631.s0	false	DDI-DrugBank.d631.s0.e0	DDI-DrugBank.d631.s0.e2
DDI-DrugBank.d631.s0	false	DDI-DrugBank.d631.s0.e0	DDI-DrugBank.d631.s0.e3
DDI-DrugBank.d631.s0	false	DDI-DrugBank.d631.s0.e0	DDI-DrugBank.d631.s0.e4
DDI-DrugBank.d631.s0	false	DDI-DrugBank.d631.s0.e1	DDI-DrugBank.d631.s0.e2
DDI-DrugBank.d631.s0	false	DDI-DrugBank.d631.s0.e1	DDI-DrugBank.d631.s0.e3
DDI-DrugBank.d631.s0	false	DDI-DrugBank.d631.s0.e1	DDI-DrugBank.d631.s0.e4
DDI-DrugBank.d631.s0	false	DDI-DrugBank.d631.s0.e2	DDI-DrugBank.d631.s0.e3
DDI-DrugBank.d631.s0	false	DDI-DrugBank.d631.s0.e2	DDI-DrugBank.d631.s0.e4
DDI-DrugBank.d631.s0	false	DDI-DrugBank.d631.s0.e3	DDI-DrugBank.d631.s0.e4
DDI-DrugBank.d631.s1|a|If signs of folate deficiency develop, pyrimethamine should be discontinued. 
DDI-DrugBank.d631.s1	39	51	pyrimethamine	drug	DDI-DrugBank.d631.s1.e0
DDI-DrugBank.d631.s2|a|Folinic acid (leucovorin) should be administered until normal hematopoiesis is restored. 
DDI-DrugBank.d631.s2	0	11	Folinic acid	drug	DDI-DrugBank.d631.s2.e0
DDI-DrugBank.d631.s2	14	23	leucovorin	drug	DDI-DrugBank.d631.s2.e1
DDI-DrugBank.d631.s2	false	DDI-DrugBank.d631.s2.e0	DDI-DrugBank.d631.s2.e1
DDI-DrugBank.d631.s3|a|Mild hepatotoxicity has been reported in some patients when lorazepam and pyrimethamine were administered concomitantly.
DDI-DrugBank.d631.s3	60	68	lorazepam	drug	DDI-DrugBank.d631.s3.e0
DDI-DrugBank.d631.s3	74	86	pyrimethamine	drug	DDI-DrugBank.d631.s3.e1
DDI-DrugBank.d631.s3	true	DDI-DrugBank.d631.s3.e0	DDI-DrugBank.d631.s3.e1
DDI-DrugBank.d648.s0|a|Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. 
DDI-DrugBank.d648.s0	0	13	Cholestyramine	drug	DDI-DrugBank.d648.s0.e0
DDI-DrugBank.d648.s0	16	29	Cholestyramine	drug	DDI-DrugBank.d648.s0.e1
DDI-DrugBank.d648.s0	101	110	raloxifene	drug	DDI-DrugBank.d648.s0.e2
DDI-DrugBank.d648.s0	150	155	EVISTA	brand	DDI-DrugBank.d648.s0.e3
DDI-DrugBank.d648.s0	false	DDI-DrugBank.d648.s0.e0	DDI-DrugBank.d648.s0.e1
DDI-DrugBank.d648.s0	false	DDI-DrugBank.d648.s0.e0	DDI-DrugBank.d648.s0.e2
DDI-DrugBank.d648.s0	false	DDI-DrugBank.d648.s0.e0	DDI-DrugBank.d648.s0.e3
DDI-DrugBank.d648.s0	true	DDI-DrugBank.d648.s0.e1	DDI-DrugBank.d648.s0.e2
DDI-DrugBank.d648.s0	true	DDI-DrugBank.d648.s0.e1	DDI-DrugBank.d648.s0.e3
DDI-DrugBank.d648.s0	false	DDI-DrugBank.d648.s0.e2	DDI-DrugBank.d648.s0.e3
DDI-DrugBank.d648.s1|a|Warfarin: The coadministration of EVISTA and warfarin has not been assessed under chronic conditions. 
DDI-DrugBank.d648.s1	0	7	Warfarin	drug	DDI-DrugBank.d648.s1.e0
DDI-DrugBank.d648.s1	34	39	EVISTA	brand	DDI-DrugBank.d648.s1.e1
DDI-DrugBank.d648.s1	45	52	warfarin	drug	DDI-DrugBank.d648.s1.e2
DDI-DrugBank.d648.s1	false	DDI-DrugBank.d648.s1.e0	DDI-DrugBank.d648.s1.e1
DDI-DrugBank.d648.s1	false	DDI-DrugBank.d648.s1.e0	DDI-DrugBank.d648.s1.e2
DDI-DrugBank.d648.s1	false	DDI-DrugBank.d648.s1.e1	DDI-DrugBank.d648.s1.e2
DDI-DrugBank.d648.s2|a|However, 10% decreases in prothrombin time have been observed in single-dose studies. 
DDI-DrugBank.d648.s3|a|If EVISTA is given concurrently with warfarin, prothrombin time should be monitored. 
DDI-DrugBank.d648.s3	3	8	EVISTA	brand	DDI-DrugBank.d648.s3.e0
DDI-DrugBank.d648.s3	37	44	warfarin	drug	DDI-DrugBank.d648.s3.e1
DDI-DrugBank.d648.s3	true	DDI-DrugBank.d648.s3.e0	DDI-DrugBank.d648.s3.e1
DDI-DrugBank.d648.s4|a|Other Highly Protein-Bound Drugs: Raloxifene is more than 95% bound to plasma proteins. 
DDI-DrugBank.d648.s4	34	43	Raloxifene	drug	DDI-DrugBank.d648.s4.e0
DDI-DrugBank.d648.s5|a|In vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen. 
DDI-DrugBank.d648.s5	10	19	raloxifene	drug	DDI-DrugBank.d648.s5.e0
DDI-DrugBank.d648.s5	51	58	warfarin	drug	DDI-DrugBank.d648.s5.e1
DDI-DrugBank.d648.s5	61	69	phenytoin	drug	DDI-DrugBank.d648.s5.e2
DDI-DrugBank.d648.s5	75	83	tamoxifen	drug	DDI-DrugBank.d648.s5.e3
DDI-DrugBank.d648.s5	false	DDI-DrugBank.d648.s5.e0	DDI-DrugBank.d648.s5.e1
DDI-DrugBank.d648.s5	false	DDI-DrugBank.d648.s5.e0	DDI-DrugBank.d648.s5.e2
DDI-DrugBank.d648.s5	false	DDI-DrugBank.d648.s5.e0	DDI-DrugBank.d648.s5.e3
DDI-DrugBank.d648.s5	false	DDI-DrugBank.d648.s5.e1	DDI-DrugBank.d648.s5.e2
DDI-DrugBank.d648.s5	false	DDI-DrugBank.d648.s5.e1	DDI-DrugBank.d648.s5.e3
DDI-DrugBank.d648.s5	false	DDI-DrugBank.d648.s5.e2	DDI-DrugBank.d648.s5.e3
DDI-DrugBank.d648.s6|a|Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. 
DDI-DrugBank.d648.s6	28	33	EVISTA	brand	DDI-DrugBank.d648.s6.e0
DDI-DrugBank.d648.s6	100	109	clofibrate	drug	DDI-DrugBank.d648.s6.e1
DDI-DrugBank.d648.s6	112	123	indomethacin	drug	DDI-DrugBank.d648.s6.e2
DDI-DrugBank.d648.s6	126	133	naproxen	drug	DDI-DrugBank.d648.s6.e3
DDI-DrugBank.d648.s6	136	144	ibuprofen	drug	DDI-DrugBank.d648.s6.e4
DDI-DrugBank.d648.s6	147	154	diazepam	drug	DDI-DrugBank.d648.s6.e5
DDI-DrugBank.d648.s6	161	169	diazoxide	drug	DDI-DrugBank.d648.s6.e6
DDI-DrugBank.d648.s6	true	DDI-DrugBank.d648.s6.e0	DDI-DrugBank.d648.s6.e1
DDI-DrugBank.d648.s6	true	DDI-DrugBank.d648.s6.e0	DDI-DrugBank.d648.s6.e2
DDI-DrugBank.d648.s6	true	DDI-DrugBank.d648.s6.e0	DDI-DrugBank.d648.s6.e3
DDI-DrugBank.d648.s6	true	DDI-DrugBank.d648.s6.e0	DDI-DrugBank.d648.s6.e4
DDI-DrugBank.d648.s6	true	DDI-DrugBank.d648.s6.e0	DDI-DrugBank.d648.s6.e5
DDI-DrugBank.d648.s6	true	DDI-DrugBank.d648.s6.e0	DDI-DrugBank.d648.s6.e6
DDI-DrugBank.d648.s6	false	DDI-DrugBank.d648.s6.e1	DDI-DrugBank.d648.s6.e2
DDI-DrugBank.d648.s6	false	DDI-DrugBank.d648.s6.e1	DDI-DrugBank.d648.s6.e3
DDI-DrugBank.d648.s6	false	DDI-DrugBank.d648.s6.e1	DDI-DrugBank.d648.s6.e4
DDI-DrugBank.d648.s6	false	DDI-DrugBank.d648.s6.e1	DDI-DrugBank.d648.s6.e5
DDI-DrugBank.d648.s7|a|See also CLINICAL PHARMACOLOGY, Drug-Drug Interactions
DDI-DrugBank.d590.s0|a|Coadministration of TRITEC with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%). 
DDI-DrugBank.d590.s0	20	25	TRITEC	brand	DDI-DrugBank.d590.s0.e0
DDI-DrugBank.d590.s0	32	45	clarithromycin	drug	DDI-DrugBank.d590.s0.e1
DDI-DrugBank.d590.s0	76	85	ranitidine	drug	DDI-DrugBank.d590.s0.e2
DDI-DrugBank.d590.s0	177	203	14- hydroxy- clarithromycin	drug_n	DDI-DrugBank.d590.s0.e3
DDI-DrugBank.d590.s0	true	DDI-DrugBank.d590.s0.e0	DDI-DrugBank.d590.s0.e1
DDI-DrugBank.d590.s0	false	DDI-DrugBank.d590.s0.e0	DDI-DrugBank.d590.s0.e2
DDI-DrugBank.d590.s0	false	DDI-DrugBank.d590.s0.e0	DDI-DrugBank.d590.s0.e3
DDI-DrugBank.d590.s0	false	DDI-DrugBank.d590.s0.e1	DDI-DrugBank.d590.s0.e2
DDI-DrugBank.d590.s0	false	DDI-DrugBank.d590.s0.e1	DDI-DrugBank.d590.s0.e3
DDI-DrugBank.d590.s0	false	DDI-DrugBank.d590.s0.e2	DDI-DrugBank.d590.s0.e3
DDI-DrugBank.d590.s1|a|Coadministration with aspirin results in a slight decrease in the rate of salicylate absorption that is clinically unimportant. 
DDI-DrugBank.d590.s1	22	28	aspirin	brand	DDI-DrugBank.d590.s1.e0
DDI-DrugBank.d590.s1	74	83	salicylate	group	DDI-DrugBank.d590.s1.e1
DDI-DrugBank.d590.s1	false	DDI-DrugBank.d590.s1.e0	DDI-DrugBank.d590.s1.e1
DDI-DrugBank.d590.s2|a|Coadministration with a high dose of antacid (170 mEq) results in a 28% decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from TRITEC. 
DDI-DrugBank.d590.s2	37	43	antacid	group	DDI-DrugBank.d590.s2.e0
DDI-DrugBank.d590.s2	109	118	ranitidine	drug	DDI-DrugBank.d590.s2.e1
DDI-DrugBank.d590.s2	175	180	TRITEC	brand	DDI-DrugBank.d590.s2.e2
DDI-DrugBank.d590.s2	true	DDI-DrugBank.d590.s2.e0	DDI-DrugBank.d590.s2.e1
DDI-DrugBank.d590.s2	true	DDI-DrugBank.d590.s2.e0	DDI-DrugBank.d590.s2.e2
DDI-DrugBank.d590.s2	false	DDI-DrugBank.d590.s2.e1	DDI-DrugBank.d590.s2.e2
DDI-DrugBank.d590.s3|a|These effects are clinically insignificant. 
DDI-DrugBank.d590.s4|a|For information on drug interactions associated with ranitidine, refer to the ZANTAC     package insert.
DDI-DrugBank.d590.s4	53	62	ranitidine	drug	DDI-DrugBank.d590.s4.e0
DDI-DrugBank.d590.s4	78	83	ZANTAC	brand	DDI-DrugBank.d590.s4.e1
DDI-DrugBank.d590.s4	false	DDI-DrugBank.d590.s4.e0	DDI-DrugBank.d590.s4.e1
DDI-DrugBank.d654.s0|a|Co-administration of oral ketoconazole 200 mg twice daily increased retapamulin geometric mean AUC(0-24) and Cmax by 81% after topical application of retapamulin ointment, 1% on the abraded skin of healthy adult males. 
DDI-DrugBank.d654.s0	26	37	ketoconazole	drug	DDI-DrugBank.d654.s0.e0
DDI-DrugBank.d654.s0	68	78	retapamulin	drug	DDI-DrugBank.d654.s0.e1
DDI-DrugBank.d654.s0	150	160	retapamulin	drug	DDI-DrugBank.d654.s0.e2
DDI-DrugBank.d654.s0	false	DDI-DrugBank.d654.s0.e0	DDI-DrugBank.d654.s0.e1
DDI-DrugBank.d654.s0	true	DDI-DrugBank.d654.s0.e0	DDI-DrugBank.d654.s0.e2
DDI-DrugBank.d654.s0	false	DDI-DrugBank.d654.s0.e1	DDI-DrugBank.d654.s0.e2
DDI-DrugBank.d654.s1|a|Due to low systemic exposure to retapamulin following topical application in patients, dosage adjustments for retapamulin are unnecessary when co-administered with CYP3A4 inhibitors, such as ketoconazole. 
DDI-DrugBank.d654.s1	32	42	retapamulin	drug	DDI-DrugBank.d654.s1.e0
DDI-DrugBank.d654.s1	110	120	retapamulin	drug	DDI-DrugBank.d654.s1.e1
DDI-DrugBank.d654.s1	191	202	ketoconazole	drug	DDI-DrugBank.d654.s1.e2
DDI-DrugBank.d654.s1	false	DDI-DrugBank.d654.s1.e0	DDI-DrugBank.d654.s1.e1
DDI-DrugBank.d654.s1	false	DDI-DrugBank.d654.s1.e0	DDI-DrugBank.d654.s1.e2
DDI-DrugBank.d654.s1	false	DDI-DrugBank.d654.s1.e1	DDI-DrugBank.d654.s1.e2
DDI-DrugBank.d654.s2|a|Based on in vitro P450 inhibition studies and the low systemic exposure observed following topical application of ALTABAX, retapamulin is unlikely to affect the metabolism of other P450 substrates. 
DDI-DrugBank.d654.s2	114	120	ALTABAX	brand	DDI-DrugBank.d654.s2.e0
DDI-DrugBank.d654.s2	123	133	retapamulin	drug	DDI-DrugBank.d654.s2.e1
DDI-DrugBank.d654.s2	false	DDI-DrugBank.d654.s2.e0	DDI-DrugBank.d654.s2.e1
DDI-DrugBank.d654.s3|a|The effect of concurrent application of ALTABAX and other topical products to the same area of skin has not been studied.
DDI-DrugBank.d654.s3	40	46	ALTABAX	brand	DDI-DrugBank.d654.s3.e0
DDI-DrugBank.d618.s0|a|The interaction of Retavase    with other cardioactive drugs has not been studied. 
DDI-DrugBank.d618.s0	19	26	Retavase	brand	DDI-DrugBank.d618.s0.e0
DDI-DrugBank.d618.s1|a|In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.
DDI-DrugBank.d618.s1	40	46	heparin	drug	DDI-DrugBank.d618.s1.e0
DDI-DrugBank.d618.s1	52	72	vitamin K antagonists	group	DDI-DrugBank.d618.s1.e1
DDI-DrugBank.d618.s1	119	125	aspirin	brand	DDI-DrugBank.d618.s1.e2
DDI-DrugBank.d618.s1	128	139	dipyridamole	drug	DDI-DrugBank.d618.s1.e3
DDI-DrugBank.d618.s1	146	154	abciximab	drug	DDI-DrugBank.d618.s1.e4
DDI-DrugBank.d618.s1	225	232	Retavase	brand	DDI-DrugBank.d618.s1.e5
DDI-DrugBank.d618.s1	false	DDI-DrugBank.d618.s1.e0	DDI-DrugBank.d618.s1.e1
DDI-DrugBank.d618.s1	false	DDI-DrugBank.d618.s1.e0	DDI-DrugBank.d618.s1.e2
DDI-DrugBank.d618.s1	false	DDI-DrugBank.d618.s1.e0	DDI-DrugBank.d618.s1.e3
DDI-DrugBank.d618.s1	false	DDI-DrugBank.d618.s1.e0	DDI-DrugBank.d618.s1.e4
DDI-DrugBank.d618.s1	true	DDI-DrugBank.d618.s1.e0	DDI-DrugBank.d618.s1.e5
DDI-DrugBank.d618.s1	false	DDI-DrugBank.d618.s1.e1	DDI-DrugBank.d618.s1.e2
DDI-DrugBank.d618.s1	false	DDI-DrugBank.d618.s1.e1	DDI-DrugBank.d618.s1.e3
DDI-DrugBank.d618.s1	false	DDI-DrugBank.d618.s1.e1	DDI-DrugBank.d618.s1.e4
DDI-DrugBank.d618.s1	true	DDI-DrugBank.d618.s1.e1	DDI-DrugBank.d618.s1.e5
DDI-DrugBank.d618.s1	false	DDI-DrugBank.d618.s1.e2	DDI-DrugBank.d618.s1.e3
DDI-DrugBank.d698.s0|a|Interactions for Vitamin B2 (Riboflavin):  Alcohol - impairs the intestinal absorption of riboflavin
DDI-DrugBank.d698.s0	17	26	Vitamin B2	drug	DDI-DrugBank.d698.s0.e0
DDI-DrugBank.d698.s0	29	38	Riboflavin	drug	DDI-DrugBank.d698.s0.e1
DDI-DrugBank.d698.s0	43	49	Alcohol	drug	DDI-DrugBank.d698.s0.e2
DDI-DrugBank.d698.s0	90	99	riboflavin	drug	DDI-DrugBank.d698.s0.e3
DDI-DrugBank.d698.s0	false	DDI-DrugBank.d698.s0.e0	DDI-DrugBank.d698.s0.e1
DDI-DrugBank.d698.s0	false	DDI-DrugBank.d698.s0.e0	DDI-DrugBank.d698.s0.e2
DDI-DrugBank.d698.s0	false	DDI-DrugBank.d698.s0.e0	DDI-DrugBank.d698.s0.e3
DDI-DrugBank.d698.s0	false	DDI-DrugBank.d698.s0.e1	DDI-DrugBank.d698.s0.e2
DDI-DrugBank.d698.s0	false	DDI-DrugBank.d698.s0.e1	DDI-DrugBank.d698.s0.e3
DDI-DrugBank.d698.s0	true	DDI-DrugBank.d698.s0.e2	DDI-DrugBank.d698.s0.e3
DDI-DrugBank.d698.s1|a|Probenecid - concurrent use decreases gastrointestinal absorption of riboflavin; 
DDI-DrugBank.d698.s1	0	9	Probenecid	drug	DDI-DrugBank.d698.s1.e0
DDI-DrugBank.d698.s1	69	78	riboflavin	drug	DDI-DrugBank.d698.s1.e1
DDI-DrugBank.d698.s1	true	DDI-DrugBank.d698.s1.e0	DDI-DrugBank.d698.s1.e1
DDI-DrugBank.d698.s2|a|requirements for riboflavin may be increased in patients receiving probenecid.
DDI-DrugBank.d698.s2	17	26	riboflavin	drug	DDI-DrugBank.d698.s2.e0
DDI-DrugBank.d698.s2	67	76	probenecid	drug	DDI-DrugBank.d698.s2.e1
DDI-DrugBank.d698.s2	true	DDI-DrugBank.d698.s2.e0	DDI-DrugBank.d698.s2.e1
DDI-DrugBank.d710.s0|a|Cimetidine: The effects of chronic cimetidine use on the metabolism of rimantadine are not known. 
DDI-DrugBank.d710.s0	0	9	Cimetidine	drug	DDI-DrugBank.d710.s0.e0
DDI-DrugBank.d710.s0	35	44	cimetidine	drug	DDI-DrugBank.d710.s0.e1
DDI-DrugBank.d710.s0	71	81	rimantadine	drug	DDI-DrugBank.d710.s0.e2
DDI-DrugBank.d710.s0	false	DDI-DrugBank.d710.s0.e0	DDI-DrugBank.d710.s0.e1
DDI-DrugBank.d710.s0	false	DDI-DrugBank.d710.s0.e0	DDI-DrugBank.d710.s0.e2
DDI-DrugBank.d710.s0	false	DDI-DrugBank.d710.s0.e1	DDI-DrugBank.d710.s0.e2
DDI-DrugBank.d710.s1|a|When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). 
DDI-DrugBank.d710.s1	29	43	rimantadine HCl	drug	DDI-DrugBank.d710.s1.e0
DDI-DrugBank.d710.s1	95	104	Cimetidine	drug	DDI-DrugBank.d710.s1.e1
DDI-DrugBank.d710.s1	152	162	rimantadine	drug	DDI-DrugBank.d710.s1.e2
DDI-DrugBank.d710.s1	270	280	rimantadine	drug	DDI-DrugBank.d710.s1.e3
DDI-DrugBank.d710.s1	331	340	cimetidine	drug	DDI-DrugBank.d710.s1.e4
DDI-DrugBank.d710.s1	true	DDI-DrugBank.d710.s1.e0	DDI-DrugBank.d710.s1.e1
DDI-DrugBank.d710.s1	false	DDI-DrugBank.d710.s1.e0	DDI-DrugBank.d710.s1.e2
DDI-DrugBank.d710.s1	false	DDI-DrugBank.d710.s1.e0	DDI-DrugBank.d710.s1.e3
DDI-DrugBank.d710.s1	false	DDI-DrugBank.d710.s1.e0	DDI-DrugBank.d710.s1.e4
DDI-DrugBank.d710.s1	false	DDI-DrugBank.d710.s1.e1	DDI-DrugBank.d710.s1.e2
DDI-DrugBank.d710.s1	false	DDI-DrugBank.d710.s1.e1	DDI-DrugBank.d710.s1.e3
DDI-DrugBank.d710.s1	false	DDI-DrugBank.d710.s1.e1	DDI-DrugBank.d710.s1.e4
DDI-DrugBank.d710.s1	false	DDI-DrugBank.d710.s1.e2	DDI-DrugBank.d710.s1.e3
DDI-DrugBank.d710.s1	false	DDI-DrugBank.d710.s1.e2	DDI-DrugBank.d710.s1.e4
DDI-DrugBank.d710.s1	false	DDI-DrugBank.d710.s1.e3	DDI-DrugBank.d710.s1.e4
DDI-DrugBank.d710.s2|a|Acetaminophen: Rimantadine HCl, 100 mg, was given twice daily for 13 days to 12 healthy volunteers. 
DDI-DrugBank.d710.s2	0	12	Acetaminophen	drug	DDI-DrugBank.d710.s2.e0
DDI-DrugBank.d710.s2	15	29	Rimantadine HCl	drug	DDI-DrugBank.d710.s2.e1
DDI-DrugBank.d710.s2	false	DDI-DrugBank.d710.s2.e0	DDI-DrugBank.d710.s2.e1
DDI-DrugBank.d710.s3|a|On day 11, acetaminophen (650 mg four times daily) was started and continued for 8 days. 
DDI-DrugBank.d710.s3	11	23	acetaminophen	drug	DDI-DrugBank.d710.s3.e0
DDI-DrugBank.d710.s4|a|The pharmacokinetics of rimantadine were assessed on days 11 and 13. 
DDI-DrugBank.d710.s4	24	34	rimantadine	drug	DDI-DrugBank.d710.s4.e0
DDI-DrugBank.d710.s5|a|Coadministration with acetaminophen reduced the peak concentration and AUC values for rimantadine by approximately 11%. 
DDI-DrugBank.d710.s5	22	34	acetaminophen	drug	DDI-DrugBank.d710.s5.e0
DDI-DrugBank.d710.s5	86	96	rimantadine	drug	DDI-DrugBank.d710.s5.e1
DDI-DrugBank.d710.s5	true	DDI-DrugBank.d710.s5.e0	DDI-DrugBank.d710.s5.e1
DDI-DrugBank.d710.s6|a|Aspirin: Rimantadine HCl, 100 mg, was given twice daily fro 13 days to 12 healthy volunteers. 
DDI-DrugBank.d710.s6	0	6	Aspirin	brand	DDI-DrugBank.d710.s6.e0
DDI-DrugBank.d710.s6	9	23	Rimantadine HCl	drug	DDI-DrugBank.d710.s6.e1
DDI-DrugBank.d710.s6	false	DDI-DrugBank.d710.s6.e0	DDI-DrugBank.d710.s6.e1
DDI-DrugBank.d710.s7|a|On day 11, aspirin (650 mg, four times daily) was started and continued for 8 days. 
DDI-DrugBank.d710.s7	11	17	aspirin	brand	DDI-DrugBank.d710.s7.e0
DDI-DrugBank.d710.s8|a|The pharmacokinetics of rimantadine were assessed on days 11 and 13. 
DDI-DrugBank.d710.s8	24	34	rimantadine	drug	DDI-DrugBank.d710.s8.e0
DDI-DrugBank.d710.s9|a|Peak plasma concentrations and AUC of rimantadine were reduced approximately 10% in the presence of aspirin.
DDI-DrugBank.d710.s9	38	48	rimantadine	drug	DDI-DrugBank.d710.s9.e0
DDI-DrugBank.d710.s9	100	106	aspirin	brand	DDI-DrugBank.d710.s9.e1
DDI-DrugBank.d710.s9	true	DDI-DrugBank.d710.s9.e0	DDI-DrugBank.d710.s9.e1
DDI-DrugBank.d596.s0|a|Drug-Drug Interactions Effect of Exelon    (rivastigmine tartrate) on the Metabolism of Other Drugs: Rivastigmine is primarily metabolized through hydrolysis by esterases. 
DDI-DrugBank.d596.s0	33	38	Exelon	brand	DDI-DrugBank.d596.s0.e0
DDI-DrugBank.d596.s0	44	64	rivastigmine tartrate	drug	DDI-DrugBank.d596.s0.e1
DDI-DrugBank.d596.s0	101	112	Rivastigmine	drug	DDI-DrugBank.d596.s0.e2
DDI-DrugBank.d596.s0	false	DDI-DrugBank.d596.s0.e0	DDI-DrugBank.d596.s0.e1
DDI-DrugBank.d596.s0	false	DDI-DrugBank.d596.s0.e0	DDI-DrugBank.d596.s0.e2
DDI-DrugBank.d596.s0	false	DDI-DrugBank.d596.s0.e1	DDI-DrugBank.d596.s0.e2
DDI-DrugBank.d596.s1|a|Minimal metabolism occurs via the major cytochrome P450 isoenzymes. 
DDI-DrugBank.d596.s2|a|Based on in vitro studies, no pharmacokinetic drug interactions with drugs metabolized by the following isoenzyme systems are expected: CYP1A2, CYP2D6, CYP3A4/5, CYP2E1, CYP2C9, CYP2C8, or CYP2C19. 
DDI-DrugBank.d596.s3|a|No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. 
DDI-DrugBank.d596.s3	52	63	rivastigmine	drug	DDI-DrugBank.d596.s3.e0
DDI-DrugBank.d596.s3	69	75	digoxin	drug	DDI-DrugBank.d596.s3.e1
DDI-DrugBank.d596.s3	78	85	warfarin	drug	DDI-DrugBank.d596.s3.e2
DDI-DrugBank.d596.s3	88	95	diazepam	drug	DDI-DrugBank.d596.s3.e3
DDI-DrugBank.d596.s3	101	110	fluoxetine	drug	DDI-DrugBank.d596.s3.e4
DDI-DrugBank.d596.s3	false	DDI-DrugBank.d596.s3.e0	DDI-DrugBank.d596.s3.e1
DDI-DrugBank.d596.s3	false	DDI-DrugBank.d596.s3.e0	DDI-DrugBank.d596.s3.e2
DDI-DrugBank.d596.s3	false	DDI-DrugBank.d596.s3.e0	DDI-DrugBank.d596.s3.e3
DDI-DrugBank.d596.s3	false	DDI-DrugBank.d596.s3.e0	DDI-DrugBank.d596.s3.e4
DDI-DrugBank.d596.s3	false	DDI-DrugBank.d596.s3.e1	DDI-DrugBank.d596.s3.e2
DDI-DrugBank.d596.s3	false	DDI-DrugBank.d596.s3.e1	DDI-DrugBank.d596.s3.e3
DDI-DrugBank.d596.s3	false	DDI-DrugBank.d596.s3.e1	DDI-DrugBank.d596.s3.e4
DDI-DrugBank.d596.s3	false	DDI-DrugBank.d596.s3.e2	DDI-DrugBank.d596.s3.e3
DDI-DrugBank.d596.s3	false	DDI-DrugBank.d596.s3.e2	DDI-DrugBank.d596.s3.e4
DDI-DrugBank.d596.s3	false	DDI-DrugBank.d596.s3.e3	DDI-DrugBank.d596.s3.e4
DDI-DrugBank.d596.s4|a|The elevation of prothrombin time induced by warfarin is not affected by administration of Exelon. 
DDI-DrugBank.d596.s4	45	52	warfarin	drug	DDI-DrugBank.d596.s4.e0
DDI-DrugBank.d596.s4	91	96	Exelon	brand	DDI-DrugBank.d596.s4.e1
DDI-DrugBank.d596.s4	false	DDI-DrugBank.d596.s4.e0	DDI-DrugBank.d596.s4.e1
DDI-DrugBank.d596.s5|a|Effect of Other Drugs on the Metabolism of Exelon: Drugs that induce or inhibit CYP450 metabolism are not expected to alter the metabolism of rivastigmine. 
DDI-DrugBank.d596.s5	43	48	Exelon	brand	DDI-DrugBank.d596.s5.e0
DDI-DrugBank.d596.s5	142	153	rivastigmine	drug	DDI-DrugBank.d596.s5.e1
DDI-DrugBank.d596.s5	false	DDI-DrugBank.d596.s5.e0	DDI-DrugBank.d596.s5.e1
DDI-DrugBank.d596.s6|a|Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. 
DDI-DrugBank.d596.s6	72	83	rivastigmine	drug	DDI-DrugBank.d596.s6.e0
DDI-DrugBank.d596.s6	147	153	digoxin	drug	DDI-DrugBank.d596.s6.e1
DDI-DrugBank.d596.s6	156	163	warfarin	drug	DDI-DrugBank.d596.s6.e2
DDI-DrugBank.d596.s6	166	173	diazepam	drug	DDI-DrugBank.d596.s6.e3
DDI-DrugBank.d596.s6	179	188	fluoxetine	drug	DDI-DrugBank.d596.s6.e4
DDI-DrugBank.d596.s6	false	DDI-DrugBank.d596.s6.e0	DDI-DrugBank.d596.s6.e1
DDI-DrugBank.d596.s6	false	DDI-DrugBank.d596.s6.e0	DDI-DrugBank.d596.s6.e2
DDI-DrugBank.d596.s6	false	DDI-DrugBank.d596.s6.e0	DDI-DrugBank.d596.s6.e3
DDI-DrugBank.d596.s6	false	DDI-DrugBank.d596.s6.e0	DDI-DrugBank.d596.s6.e4
DDI-DrugBank.d596.s6	false	DDI-DrugBank.d596.s6.e1	DDI-DrugBank.d596.s6.e2
DDI-DrugBank.d596.s6	false	DDI-DrugBank.d596.s6.e1	DDI-DrugBank.d596.s6.e3
DDI-DrugBank.d596.s6	false	DDI-DrugBank.d596.s6.e1	DDI-DrugBank.d596.s6.e4
DDI-DrugBank.d596.s6	false	DDI-DrugBank.d596.s6.e2	DDI-DrugBank.d596.s6.e3
DDI-DrugBank.d596.s6	false	DDI-DrugBank.d596.s6.e2	DDI-DrugBank.d596.s6.e4
DDI-DrugBank.d596.s6	false	DDI-DrugBank.d596.s6.e3	DDI-DrugBank.d596.s6.e4
DDI-DrugBank.d596.s7|a|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 
DDI-DrugBank.d596.s7	91	102	rivastigmine	drug	DDI-DrugBank.d596.s7.e0
DDI-DrugBank.d596.s7	167	174	antacids	group	DDI-DrugBank.d596.s7.e1
DDI-DrugBank.d596.s7	184	200	antihypertensives	group	DDI-DrugBank.d596.s7.e2
DDI-DrugBank.d596.s7	210	233	calcium channel blockers	group	DDI-DrugBank.d596.s7.e3
DDI-DrugBank.d596.s7	243	255	antidiabetics	group	DDI-DrugBank.d596.s7.e4
DDI-DrugBank.d596.s7	265	300	nonsteroidal anti-inflammatory drugs	group	DDI-DrugBank.d596.s7.e5
DDI-DrugBank.d596.s7	310	318	estrogens	group	DDI-DrugBank.d596.s7.e6
DDI-DrugBank.d596.s7	328	348	salicylate analgesics	group	DDI-DrugBank.d596.s7.e7
DDI-DrugBank.d596.s7	359	370	antianginals	group	DDI-DrugBank.d596.s7.e8
DDI-DrugBank.d596.s7	384	397	antihistamines	group	DDI-DrugBank.d596.s7.e9
DDI-DrugBank.d596.s7	false	DDI-DrugBank.d596.s7.e0	DDI-DrugBank.d596.s7.e1
DDI-DrugBank.d596.s7	false	DDI-DrugBank.d596.s7.e0	DDI-DrugBank.d596.s7.e2
DDI-DrugBank.d596.s7	false	DDI-DrugBank.d596.s7.e0	DDI-DrugBank.d596.s7.e3
DDI-DrugBank.d596.s7	false	DDI-DrugBank.d596.s7.e0	DDI-DrugBank.d596.s7.e4
DDI-DrugBank.d596.s7	false	DDI-DrugBank.d596.s7.e0	DDI-DrugBank.d596.s7.e5
DDI-DrugBank.d596.s7	false	DDI-DrugBank.d596.s7.e0	DDI-DrugBank.d596.s7.e6
DDI-DrugBank.d596.s7	false	DDI-DrugBank.d596.s7.e0	DDI-DrugBank.d596.s7.e7
DDI-DrugBank.d596.s7	false	DDI-DrugBank.d596.s7.e0	DDI-DrugBank.d596.s7.e8
DDI-DrugBank.d596.s7	false	DDI-DrugBank.d596.s7.e0	DDI-DrugBank.d596.s7.e9
DDI-DrugBank.d596.s7	false	DDI-DrugBank.d596.s7.e1	DDI-DrugBank.d596.s7.e2
DDI-DrugBank.d596.s8|a|Use with Anticholinergics: Because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications. 
DDI-DrugBank.d596.s8	9	24	Anticholinergics	group	DDI-DrugBank.d596.s8.e0
DDI-DrugBank.d596.s8	65	89	cholinesterase inhibitors	group	DDI-DrugBank.d596.s8.e1
DDI-DrugBank.d596.s8	144	170	anticholinergic medications	group	DDI-DrugBank.d596.s8.e2
DDI-DrugBank.d596.s8	false	DDI-DrugBank.d596.s8.e0	DDI-DrugBank.d596.s8.e1
DDI-DrugBank.d596.s8	false	DDI-DrugBank.d596.s8.e0	DDI-DrugBank.d596.s8.e2
DDI-DrugBank.d596.s8	true	DDI-DrugBank.d596.s8.e1	DDI-DrugBank.d596.s8.e2
DDI-DrugBank.d596.s9|a|Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.
DDI-DrugBank.d596.s9	9	23	Cholinomimetics	group	DDI-DrugBank.d596.s9.e0
DDI-DrugBank.d596.s9	35	59	Cholinesterase Inhibitors	group	DDI-DrugBank.d596.s9.e1
DDI-DrugBank.d596.s9	104	128	cholinesterase inhibitors	group	DDI-DrugBank.d596.s9.e2
DDI-DrugBank.d596.s9	158	172	succinylcholine	drug	DDI-DrugBank.d596.s9.e3
DDI-DrugBank.d596.s9	183	211	neuromuscular blocking agents	group	DDI-DrugBank.d596.s9.e4
DDI-DrugBank.d596.s9	216	235	cholinergic agonists	group	DDI-DrugBank.d596.s9.e5
DDI-DrugBank.d596.s9	245	255	bethanechol	drug	DDI-DrugBank.d596.s9.e6
DDI-DrugBank.d596.s9	false	DDI-DrugBank.d596.s9.e0	DDI-DrugBank.d596.s9.e1
DDI-DrugBank.d596.s9	false	DDI-DrugBank.d596.s9.e0	DDI-DrugBank.d596.s9.e2
DDI-DrugBank.d596.s9	false	DDI-DrugBank.d596.s9.e0	DDI-DrugBank.d596.s9.e3
DDI-DrugBank.d596.s9	false	DDI-DrugBank.d596.s9.e0	DDI-DrugBank.d596.s9.e4
DDI-DrugBank.d596.s9	false	DDI-DrugBank.d596.s9.e0	DDI-DrugBank.d596.s9.e5
DDI-DrugBank.d596.s9	false	DDI-DrugBank.d596.s9.e0	DDI-DrugBank.d596.s9.e6
DDI-DrugBank.d596.s9	false	DDI-DrugBank.d596.s9.e1	DDI-DrugBank.d596.s9.e2
DDI-DrugBank.d596.s9	false	DDI-DrugBank.d596.s9.e1	DDI-DrugBank.d596.s9.e3
DDI-DrugBank.d596.s9	false	DDI-DrugBank.d596.s9.e1	DDI-DrugBank.d596.s9.e4
DDI-DrugBank.d596.s9	false	DDI-DrugBank.d596.s9.e1	DDI-DrugBank.d596.s9.e5
DDI-DrugBank.d661.s0|a|Drug Interactions: The use of ZEMURON    (rocuronium bromide) Injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied. 
DDI-DrugBank.d661.s0	30	36	ZEMURON	brand	DDI-DrugBank.d661.s0.e0
DDI-DrugBank.d661.s0	42	59	rocuronium bromide	drug	DDI-DrugBank.d661.s0.e1
DDI-DrugBank.d661.s0	79	93	succinylcholine	drug	DDI-DrugBank.d661.s0.e2
DDI-DrugBank.d661.s0	155	169	succinylcholine	drug	DDI-DrugBank.d661.s0.e3
DDI-DrugBank.d661.s0	false	DDI-DrugBank.d661.s0.e0	DDI-DrugBank.d661.s0.e1
DDI-DrugBank.d661.s0	false	DDI-DrugBank.d661.s0.e0	DDI-DrugBank.d661.s0.e2
DDI-DrugBank.d661.s0	false	DDI-DrugBank.d661.s0.e0	DDI-DrugBank.d661.s0.e3
DDI-DrugBank.d661.s0	false	DDI-DrugBank.d661.s0.e1	DDI-DrugBank.d661.s0.e2
DDI-DrugBank.d661.s0	false	DDI-DrugBank.d661.s0.e1	DDI-DrugBank.d661.s0.e3
DDI-DrugBank.d661.s0	false	DDI-DrugBank.d661.s0.e2	DDI-DrugBank.d661.s0.e3
DDI-DrugBank.d661.s1|a|If ZEMURON    is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed. 
DDI-DrugBank.d661.s1	3	9	ZEMURON	brand	DDI-DrugBank.d661.s1.e0
DDI-DrugBank.d661.s1	58	72	succinylcholine	drug	DDI-DrugBank.d661.s1.e1
DDI-DrugBank.d661.s1	118	132	succinylcholine	drug	DDI-DrugBank.d661.s1.e2
DDI-DrugBank.d661.s1	true	DDI-DrugBank.d661.s1.e0	DDI-DrugBank.d661.s1.e1
DDI-DrugBank.d661.s1	false	DDI-DrugBank.d661.s1.e0	DDI-DrugBank.d661.s1.e2
DDI-DrugBank.d661.s1	false	DDI-DrugBank.d661.s1.e1	DDI-DrugBank.d661.s1.e2
DDI-DrugBank.d661.s2|a|The median duration of action of ZEMURON    0.6 mg/kg administered after a 1 mg/kg dose of succinylcholine when T 1 returned to 75% of control was 36 minutes (range 14-57, n=12) vs. 
DDI-DrugBank.d661.s2	33	39	ZEMURON	brand	DDI-DrugBank.d661.s2.e0
DDI-DrugBank.d661.s2	91	105	succinylcholine	drug	DDI-DrugBank.d661.s2.e1
DDI-DrugBank.d661.s2	false	DDI-DrugBank.d661.s2.e0	DDI-DrugBank.d661.s2.e1
DDI-DrugBank.d661.s3|a|28 minutes (17-51, n=12) without succinylcholine. 
DDI-DrugBank.d661.s3	33	47	succinylcholine	drug	DDI-DrugBank.d661.s3.e0
DDI-DrugBank.d661.s4|a|There are no controlled studies documenting the use of ZEMURON    before or after other nondepolarizing muscle relaxants. 
DDI-DrugBank.d661.s4	55	61	ZEMURON	brand	DDI-DrugBank.d661.s4.e0
DDI-DrugBank.d661.s4	88	119	nondepolarizing muscle relaxants	group	DDI-DrugBank.d661.s4.e1
DDI-DrugBank.d661.s4	false	DDI-DrugBank.d661.s4.e0	DDI-DrugBank.d661.s4.e1
DDI-DrugBank.d661.s5|a|Interactions have been observed when other nondepolarizing muscle relaxants have been administered in succession. 
DDI-DrugBank.d661.s5	43	74	nondepolarizing muscle relaxants	group	DDI-DrugBank.d661.s5.e0
DDI-DrugBank.d661.s6|a|Drug/Laboratory Test Interactions:       None known.
DDI-DrugBank.d591.s0|a|Ropivacaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive. 
DDI-DrugBank.d591.s0	0	10	Ropivacaine	drug	DDI-DrugBank.d591.s0.e0
DDI-DrugBank.d591.s0	74	84	anesthetics	group	DDI-DrugBank.d591.s0.e1
DDI-DrugBank.d591.s0	120	147	amide-type local anesthetics	group	DDI-DrugBank.d591.s0.e2
DDI-DrugBank.d591.s0	true	DDI-DrugBank.d591.s0.e0	DDI-DrugBank.d591.s0.e1
DDI-DrugBank.d591.s0	false	DDI-DrugBank.d591.s0.e0	DDI-DrugBank.d591.s0.e2
DDI-DrugBank.d591.s0	false	DDI-DrugBank.d591.s0.e1	DDI-DrugBank.d591.s0.e2
DDI-DrugBank.d591.s1|a|Cytochrome P4501A2 is involved in the formation of 3-hydroxy ropivacaine, the major metabolite. 
DDI-DrugBank.d591.s1	51	71	3-hydroxy ropivacaine	drug_n	DDI-DrugBank.d591.s1.e0
DDI-DrugBank.d591.s2|a|In vivo, the plasma clearance of ropivacaine was reduced by 70% during coadministration of fluvoxamine (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor. 
DDI-DrugBank.d591.s2	33	43	ropivacaine	drug	DDI-DrugBank.d591.s2.e0
DDI-DrugBank.d591.s2	91	101	fluvoxamine	drug	DDI-DrugBank.d591.s2.e1
DDI-DrugBank.d591.s2	true	DDI-DrugBank.d591.s2.e0	DDI-DrugBank.d591.s2.e1
DDI-DrugBank.d591.s3|a|Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. 
DDI-DrugBank.d591.s3	54	64	fluvoxamine	drug	DDI-DrugBank.d591.s3.e0
DDI-DrugBank.d591.s3	112	122	Ropivacaine	drug	DDI-DrugBank.d591.s3.e1
DDI-DrugBank.d591.s3	143	153	Ropivacaine	drug	DDI-DrugBank.d591.s3.e2
DDI-DrugBank.d591.s3	176	186	ropivacaine	drug	DDI-DrugBank.d591.s3.e3
DDI-DrugBank.d591.s3	true	DDI-DrugBank.d591.s3.e0	DDI-DrugBank.d591.s3.e1
DDI-DrugBank.d591.s3	false	DDI-DrugBank.d591.s3.e0	DDI-DrugBank.d591.s3.e2
DDI-DrugBank.d591.s3	false	DDI-DrugBank.d591.s3.e0	DDI-DrugBank.d591.s3.e3
DDI-DrugBank.d591.s3	false	DDI-DrugBank.d591.s3.e1	DDI-DrugBank.d591.s3.e2
DDI-DrugBank.d591.s3	false	DDI-DrugBank.d591.s3.e1	DDI-DrugBank.d591.s3.e3
DDI-DrugBank.d591.s3	false	DDI-DrugBank.d591.s3.e2	DDI-DrugBank.d591.s3.e3
DDI-DrugBank.d591.s4|a|Caution should be exercised when CYP1A2 inhibitors are coadministered. 
DDI-DrugBank.d591.s5|a|Possible interactions with drugs known to be metabolized by CYP1A2 via competitive inhibition such as theophylline and imipramine may also occur. 
DDI-DrugBank.d591.s5	102	113	theophylline	drug	DDI-DrugBank.d591.s5.e0
DDI-DrugBank.d591.s5	119	128	imipramine	drug	DDI-DrugBank.d591.s5.e1
DDI-DrugBank.d591.s5	false	DDI-DrugBank.d591.s5.e0	DDI-DrugBank.d591.s5.e1
DDI-DrugBank.d591.s6|a|Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.
DDI-DrugBank.d591.s6	64	75	ketoconazole	drug	DDI-DrugBank.d591.s6.e0
DDI-DrugBank.d591.s6	105	115	ropivacaine	drug	DDI-DrugBank.d591.s6.e1
DDI-DrugBank.d591.s6	152	163	ketoconazole	drug	DDI-DrugBank.d591.s6.e2
DDI-DrugBank.d591.s6	220	230	ropivacaine	drug	DDI-DrugBank.d591.s6.e3
DDI-DrugBank.d591.s6	false	DDI-DrugBank.d591.s6.e0	DDI-DrugBank.d591.s6.e1
DDI-DrugBank.d591.s6	false	DDI-DrugBank.d591.s6.e0	DDI-DrugBank.d591.s6.e2
DDI-DrugBank.d591.s6	true	DDI-DrugBank.d591.s6.e0	DDI-DrugBank.d591.s6.e3
DDI-DrugBank.d591.s6	false	DDI-DrugBank.d591.s6.e1	DDI-DrugBank.d591.s6.e2
DDI-DrugBank.d591.s6	false	DDI-DrugBank.d591.s6.e1	DDI-DrugBank.d591.s6.e3
DDI-DrugBank.d591.s6	false	DDI-DrugBank.d591.s6.e2	DDI-DrugBank.d591.s6.e3
DDI-DrugBank.d609.s0|a|An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. 
DDI-DrugBank.d609.s0	32	42	gemfibrozil	drug	DDI-DrugBank.d609.s0.e0
DDI-DrugBank.d609.s0	69	81	rosiglitazone	drug	DDI-DrugBank.d609.s0.e1
DDI-DrugBank.d609.s0	117	124	rifampin	drug	DDI-DrugBank.d609.s0.e2
DDI-DrugBank.d609.s0	151	163	rosiglitazone	drug	DDI-DrugBank.d609.s0.e3
DDI-DrugBank.d609.s0	true	DDI-DrugBank.d609.s0.e0	DDI-DrugBank.d609.s0.e1
DDI-DrugBank.d609.s0	false	DDI-DrugBank.d609.s0.e0	DDI-DrugBank.d609.s0.e2
DDI-DrugBank.d609.s0	false	DDI-DrugBank.d609.s0.e0	DDI-DrugBank.d609.s0.e3
DDI-DrugBank.d609.s0	false	DDI-DrugBank.d609.s0.e1	DDI-DrugBank.d609.s0.e2
DDI-DrugBank.d609.s0	false	DDI-DrugBank.d609.s0.e1	DDI-DrugBank.d609.s0.e3
DDI-DrugBank.d609.s0	true	DDI-DrugBank.d609.s0.e2	DDI-DrugBank.d609.s0.e3
DDI-DrugBank.d609.s1|a|Therefore, if an inhibitor or an inducer of CYP2C8 is started or stopped during treatment with rosiglitazone, changes in diabetes treatment may be needed based upon clinical response.
DDI-DrugBank.d609.s1	95	107	rosiglitazone	drug	DDI-DrugBank.d609.s1.e0
DDI-DrugBank.d709.s0|a|Concomitant administration contra-indicated:  - Vasoconstrictive ergot alkaloids.  
DDI-DrugBank.d709.s0	65	79	ergot alkaloids	group	DDI-DrugBank.d709.s0.e0
DDI-DrugBank.d709.s1|a|Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. 
DDI-DrugBank.d709.s1	48	58	Terfenadine	drug	DDI-DrugBank.d709.s1.e0
DDI-DrugBank.d709.s1	64	73	astemizole	drug	DDI-DrugBank.d709.s1.e1
DDI-DrugBank.d709.s1	84	93	macrolides	group	DDI-DrugBank.d709.s1.e2
DDI-DrugBank.d709.s1	109	119	terfenadine	drug	DDI-DrugBank.d709.s1.e3
DDI-DrugBank.d709.s1	125	134	astemizole	drug	DDI-DrugBank.d709.s1.e4
DDI-DrugBank.d709.s1	false	DDI-DrugBank.d709.s1.e0	DDI-DrugBank.d709.s1.e1
DDI-DrugBank.d709.s1	false	DDI-DrugBank.d709.s1.e0	DDI-DrugBank.d709.s1.e2
DDI-DrugBank.d709.s1	false	DDI-DrugBank.d709.s1.e0	DDI-DrugBank.d709.s1.e3
DDI-DrugBank.d709.s1	false	DDI-DrugBank.d709.s1.e0	DDI-DrugBank.d709.s1.e4
DDI-DrugBank.d709.s1	false	DDI-DrugBank.d709.s1.e1	DDI-DrugBank.d709.s1.e2
DDI-DrugBank.d709.s1	false	DDI-DrugBank.d709.s1.e1	DDI-DrugBank.d709.s1.e3
DDI-DrugBank.d709.s1	false	DDI-DrugBank.d709.s1.e1	DDI-DrugBank.d709.s1.e4
DDI-DrugBank.d709.s1	true	DDI-DrugBank.d709.s1.e2	DDI-DrugBank.d709.s1.e3
DDI-DrugBank.d709.s1	true	DDI-DrugBank.d709.s1.e2	DDI-DrugBank.d709.s1.e4
DDI-DrugBank.d709.s1	false	DDI-DrugBank.d709.s1.e3	DDI-DrugBank.d709.s1.e4
DDI-DrugBank.d709.s2|a|This may result in severe ventricular arrhythmia, typically torsades de pointe. 
DDI-DrugBank.d709.s3|a|Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. 
DDI-DrugBank.d709.s3	56	68	roxithromycin	drug	DDI-DrugBank.d709.s3.e0
DDI-DrugBank.d709.s3	101	113	roxithromycin	drug	DDI-DrugBank.d709.s3.e1
DDI-DrugBank.d709.s3	120	130	terfenadine	drug	DDI-DrugBank.d709.s3.e2
DDI-DrugBank.d709.s3	135	144	astemizole	drug	DDI-DrugBank.d709.s3.e3
DDI-DrugBank.d709.s3	false	DDI-DrugBank.d709.s3.e0	DDI-DrugBank.d709.s3.e1
DDI-DrugBank.d709.s3	false	DDI-DrugBank.d709.s3.e0	DDI-DrugBank.d709.s3.e2
DDI-DrugBank.d709.s3	false	DDI-DrugBank.d709.s3.e0	DDI-DrugBank.d709.s3.e3
DDI-DrugBank.d709.s3	true	DDI-DrugBank.d709.s3.e1	DDI-DrugBank.d709.s3.e2
DDI-DrugBank.d709.s3	true	DDI-DrugBank.d709.s3.e1	DDI-DrugBank.d709.s3.e3
DDI-DrugBank.d709.s3	false	DDI-DrugBank.d709.s3.e2	DDI-DrugBank.d709.s3.e3
DDI-DrugBank.d709.s4|a|- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. 
DDI-DrugBank.d709.s4	2	10	Cisapride	drug	DDI-DrugBank.d709.s4.e0
DDI-DrugBank.d709.s4	13	20	pimozide	drug	DDI-DrugBank.d709.s4.e1
DDI-DrugBank.d709.s4	43	51	cisapride	drug	DDI-DrugBank.d709.s4.e2
DDI-DrugBank.d709.s4	56	63	pimozide	drug	DDI-DrugBank.d709.s4.e3
DDI-DrugBank.d709.s4	352	375	macrolide antibacterials	group	DDI-DrugBank.d709.s4.e4
DDI-DrugBank.d709.s4	false	DDI-DrugBank.d709.s4.e0	DDI-DrugBank.d709.s4.e1
DDI-DrugBank.d709.s4	false	DDI-DrugBank.d709.s4.e0	DDI-DrugBank.d709.s4.e2
DDI-DrugBank.d709.s4	false	DDI-DrugBank.d709.s4.e0	DDI-DrugBank.d709.s4.e3
DDI-DrugBank.d709.s4	false	DDI-DrugBank.d709.s4.e0	DDI-DrugBank.d709.s4.e4
DDI-DrugBank.d709.s4	false	DDI-DrugBank.d709.s4.e1	DDI-DrugBank.d709.s4.e2
DDI-DrugBank.d709.s4	false	DDI-DrugBank.d709.s4.e1	DDI-DrugBank.d709.s4.e3
DDI-DrugBank.d709.s4	true	DDI-DrugBank.d709.s4.e1	DDI-DrugBank.d709.s4.e4
DDI-DrugBank.d709.s4	false	DDI-DrugBank.d709.s4.e2	DDI-DrugBank.d709.s4.e3
DDI-DrugBank.d709.s4	true	DDI-DrugBank.d709.s4.e2	DDI-DrugBank.d709.s4.e4
DDI-DrugBank.d709.s4	false	DDI-DrugBank.d709.s4.e3	DDI-DrugBank.d709.s4.e4
DDI-DrugBank.d709.s5|a|Although such a risk is not verified for roxithromycin, combination of roxithromycin with such drugs is not recommended.
DDI-DrugBank.d709.s5	41	53	roxithromycin	drug	DDI-DrugBank.d709.s5.e0
DDI-DrugBank.d709.s5	71	83	roxithromycin	drug	DDI-DrugBank.d709.s5.e1
DDI-DrugBank.d709.s5	false	DDI-DrugBank.d709.s5.e0	DDI-DrugBank.d709.s5.e1
DDI-DrugBank.d770.s0|a|Nasal Spray: Formal studies designed to evaluate drug interactions with Calcitonin (salmon) have not been done. 
DDI-DrugBank.d770.s0	72	90	Calcitonin (salmon)	drug	DDI-DrugBank.d770.s0.e0
DDI-DrugBank.d770.s1|a|No drug interaction studies have been performed with Calcitonin (salmon) nasal spray ingredients. 
DDI-DrugBank.d770.s1	53	71	Calcitonin (salmon)	drug	DDI-DrugBank.d770.s1.e0
DDI-DrugBank.d770.s2|a|Currently, no drug interactions with Calcitonin (salmon) have been observed. 
DDI-DrugBank.d770.s2	37	55	Calcitonin (salmon)	drug	DDI-DrugBank.d770.s2.e0
DDI-DrugBank.d770.s3|a|The effects of prior use of diphosphonates in postmenopausal osteoporosis patients have not been assessed; 
DDI-DrugBank.d770.s3	28	41	diphosphonates	group	DDI-DrugBank.d770.s3.e0
DDI-DrugBank.d770.s4|a|however, in patients with Paget's Disease prior diphosphonate use appears to reduce the anti-resorptive response to Calcitonin (salmon) nasal spray.
DDI-DrugBank.d770.s4	48	60	diphosphonate	group	DDI-DrugBank.d770.s4.e0
DDI-DrugBank.d770.s4	116	134	Calcitonin (salmon)	drug	DDI-DrugBank.d770.s4.e1
DDI-DrugBank.d770.s4	true	DDI-DrugBank.d770.s4.e0	DDI-DrugBank.d770.s4.e1
DDI-DrugBank.d576.s0|a|Salicylates antagonize the uricosuric action of . drugs used to treat gout. 
DDI-DrugBank.d576.s0	0	10	Salicylates	group	DDI-DrugBank.d576.s0.e0
DDI-DrugBank.d576.s1|a|ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. 
DDI-DrugBank.d576.s1	0	6	ASPIRIN	brand	DDI-DrugBank.d576.s1.e0
DDI-DrugBank.d576.s1	18	33	SALICYLATE DRUGS	group	DDI-DrugBank.d576.s1.e1
DDI-DrugBank.d576.s1	55	62	DISALCID	brand	DDI-DrugBank.d576.s1.e2
DDI-DrugBank.d576.s1	106	119	SALICYLIC ACID	drug	DDI-DrugBank.d576.s1.e3
DDI-DrugBank.d576.s1	false	DDI-DrugBank.d576.s1.e0	DDI-DrugBank.d576.s1.e1
DDI-DrugBank.d576.s1	true	DDI-DrugBank.d576.s1.e0	DDI-DrugBank.d576.s1.e2
DDI-DrugBank.d576.s1	false	DDI-DrugBank.d576.s1.e0	DDI-DrugBank.d576.s1.e3
DDI-DrugBank.d576.s1	true	DDI-DrugBank.d576.s1.e1	DDI-DrugBank.d576.s1.e2
DDI-DrugBank.d576.s1	false	DDI-DrugBank.d576.s1.e1	DDI-DrugBank.d576.s1.e3
DDI-DrugBank.d576.s1	false	DDI-DrugBank.d576.s1.e2	DDI-DrugBank.d576.s1.e3
DDI-DrugBank.d576.s2|a|Drugs and foods that raise urine pH will increase renal clearance and urinary excretion of salicylic acid, thus lowering plasma levels; 
DDI-DrugBank.d576.s2	91	104	salicylic acid	drug	DDI-DrugBank.d576.s2.e0
DDI-DrugBank.d576.s3|a|acidifying drugs or foods will decrease urinary excretion and increase plasma levels. 
DDI-DrugBank.d576.s4|a|Salicylates given concomitantly with anticoagulant drugs may predispose to systemic bleeding. 
DDI-DrugBank.d576.s4	0	10	Salicylates	group	DDI-DrugBank.d576.s4.e0
DDI-DrugBank.d576.s4	37	55	anticoagulant drugs	group	DDI-DrugBank.d576.s4.e1
DDI-DrugBank.d576.s4	true	DDI-DrugBank.d576.s4.e0	DDI-DrugBank.d576.s4.e1
DDI-DrugBank.d576.s5|a|Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. 
DDI-DrugBank.d576.s5	0	10	Salicylates	group	DDI-DrugBank.d576.s5.e0
DDI-DrugBank.d576.s5	56	73	antidiabetic drugs	group	DDI-DrugBank.d576.s5.e1
DDI-DrugBank.d576.s5	true	DDI-DrugBank.d576.s5.e0	DDI-DrugBank.d576.s5.e1
DDI-DrugBank.d576.s6|a|Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 
DDI-DrugBank.d576.s6	0	9	Salicylate	group	DDI-DrugBank.d576.s6.e0
DDI-DrugBank.d576.s6	78	87	penicillin	drug	DDI-DrugBank.d576.s6.e1
DDI-DrugBank.d576.s6	90	99	thiopental	drug	DDI-DrugBank.d576.s6.e2
DDI-DrugBank.d576.s6	102	110	thyroxine	drug	DDI-DrugBank.d576.s6.e3
DDI-DrugBank.d576.s6	113	128	triiodothyronine	drug	DDI-DrugBank.d576.s6.e4
DDI-DrugBank.d576.s6	131	139	phenytoin	drug	DDI-DrugBank.d576.s6.e5
DDI-DrugBank.d576.s6	142	155	sulfinpyrazone	drug	DDI-DrugBank.d576.s6.e6
DDI-DrugBank.d576.s6	158	165	naproxen	drug	DDI-DrugBank.d576.s6.e7
DDI-DrugBank.d576.s6	168	175	warfarin	drug	DDI-DrugBank.d576.s6.e8
DDI-DrugBank.d576.s6	178	189	methotrexate	drug	DDI-DrugBank.d576.s6.e9
DDI-DrugBank.d576.s6	true	DDI-DrugBank.d576.s6.e0	DDI-DrugBank.d576.s6.e1
DDI-DrugBank.d576.s6	true	DDI-DrugBank.d576.s6.e0	DDI-DrugBank.d576.s6.e2
DDI-DrugBank.d576.s6	true	DDI-DrugBank.d576.s6.e0	DDI-DrugBank.d576.s6.e3
DDI-DrugBank.d576.s6	true	DDI-DrugBank.d576.s6.e0	DDI-DrugBank.d576.s6.e4
DDI-DrugBank.d576.s6	true	DDI-DrugBank.d576.s6.e0	DDI-DrugBank.d576.s6.e5
DDI-DrugBank.d576.s6	true	DDI-DrugBank.d576.s6.e0	DDI-DrugBank.d576.s6.e6
DDI-DrugBank.d576.s6	true	DDI-DrugBank.d576.s6.e0	DDI-DrugBank.d576.s6.e7
DDI-DrugBank.d576.s6	true	DDI-DrugBank.d576.s6.e0	DDI-DrugBank.d576.s6.e8
DDI-DrugBank.d576.s6	true	DDI-DrugBank.d576.s6.e0	DDI-DrugBank.d576.s6.e9
DDI-DrugBank.d576.s6	true	DDI-DrugBank.d576.s6.e0	DDI-DrugBank.d576.s6.e10
DDI-DrugBank.d576.s7|a|Drug/ Laboratory Test Interactions Salicylate competes with thyroid hormone for binding to plasma proteins, which may be reflected in a depressed plasma T4 value in some patients; 
DDI-DrugBank.d576.s7	35	44	Salicylate	group	DDI-DrugBank.d576.s7.e0
DDI-DrugBank.d576.s8|a|thyroid function and basal metabolism are unaffected.
DDI-DrugBank.d607.s0|a|Interactions between Leukine and other drugs have not been fully evaluated. 
DDI-DrugBank.d607.s0	21	27	Leukine	brand	DDI-DrugBank.d607.s0.e0
DDI-DrugBank.d607.s1|a|Drugs which may potentiate the myeloproliferative effects of Leukine, such as lithium and corticosteroids, should be used with caution.
DDI-DrugBank.d607.s1	61	67	Leukine	brand	DDI-DrugBank.d607.s1.e0
DDI-DrugBank.d607.s1	78	84	lithium	drug	DDI-DrugBank.d607.s1.e1
DDI-DrugBank.d607.s1	90	104	corticosteroids	group	DDI-DrugBank.d607.s1.e2
DDI-DrugBank.d607.s1	true	DDI-DrugBank.d607.s1.e0	DDI-DrugBank.d607.s1.e1
DDI-DrugBank.d607.s1	true	DDI-DrugBank.d607.s1.e0	DDI-DrugBank.d607.s1.e2
DDI-DrugBank.d607.s1	false	DDI-DrugBank.d607.s1.e1	DDI-DrugBank.d607.s1.e2
DDI-DrugBank.d771.s0|a|The absorption of oral medications may be decreased during the concurrent use of scopolamine because of decreased gastric motility and delayed gastric emptying. 
DDI-DrugBank.d771.s0	81	91	scopolamine	drug	DDI-DrugBank.d771.s0.e0
DDI-DrugBank.d771.s1|a|Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol. 
DDI-DrugBank.d771.s1	0	10	Scopolamine	drug	DDI-DrugBank.d771.s1.e0
DDI-DrugBank.d771.s1	116	124	sedatives	group	DDI-DrugBank.d771.s1.e1
DDI-DrugBank.d771.s1	127	139	tranquilizers	group	DDI-DrugBank.d771.s1.e2
DDI-DrugBank.d771.s1	145	151	alcohol	drug	DDI-DrugBank.d771.s1.e3
DDI-DrugBank.d771.s1	true	DDI-DrugBank.d771.s1.e0	DDI-DrugBank.d771.s1.e1
DDI-DrugBank.d771.s1	true	DDI-DrugBank.d771.s1.e0	DDI-DrugBank.d771.s1.e2
DDI-DrugBank.d771.s1	true	DDI-DrugBank.d771.s1.e0	DDI-DrugBank.d771.s1.e3
DDI-DrugBank.d771.s1	false	DDI-DrugBank.d771.s1.e1	DDI-DrugBank.d771.s1.e2
DDI-DrugBank.d771.s1	false	DDI-DrugBank.d771.s1.e1	DDI-DrugBank.d771.s1.e3
DDI-DrugBank.d771.s1	false	DDI-DrugBank.d771.s1.e2	DDI-DrugBank.d771.s1.e3
DDI-DrugBank.d771.s2|a|Special attention should be paid to potential interactions with drugs having anticholinergic properties; 
DDI-DrugBank.d771.s3|a|e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants. 
DDI-DrugBank.d771.s3	12	31	belladonna alkaloids	group	DDI-DrugBank.d771.s3.e0
DDI-DrugBank.d771.s3	34	47	antihistamines	group	DDI-DrugBank.d771.s3.e1
DDI-DrugBank.d771.s3	60	68	meclizine	drug	DDI-DrugBank.d771.s3.e2
DDI-DrugBank.d771.s3	72	96	tricyclic antidepressants	group	DDI-DrugBank.d771.s3.e3
DDI-DrugBank.d771.s3	103	118	muscle relaxants	group	DDI-DrugBank.d771.s3.e4
DDI-DrugBank.d771.s3	false	DDI-DrugBank.d771.s3.e0	DDI-DrugBank.d771.s3.e1
DDI-DrugBank.d771.s3	false	DDI-DrugBank.d771.s3.e0	DDI-DrugBank.d771.s3.e2
DDI-DrugBank.d771.s3	false	DDI-DrugBank.d771.s3.e0	DDI-DrugBank.d771.s3.e3
DDI-DrugBank.d771.s3	false	DDI-DrugBank.d771.s3.e0	DDI-DrugBank.d771.s3.e4
DDI-DrugBank.d771.s3	false	DDI-DrugBank.d771.s3.e1	DDI-DrugBank.d771.s3.e2
DDI-DrugBank.d771.s3	false	DDI-DrugBank.d771.s3.e1	DDI-DrugBank.d771.s3.e3
DDI-DrugBank.d771.s3	false	DDI-DrugBank.d771.s3.e1	DDI-DrugBank.d771.s3.e4
DDI-DrugBank.d771.s3	false	DDI-DrugBank.d771.s3.e2	DDI-DrugBank.d771.s3.e3
DDI-DrugBank.d771.s3	false	DDI-DrugBank.d771.s3.e2	DDI-DrugBank.d771.s3.e4
DDI-DrugBank.d771.s3	false	DDI-DrugBank.d771.s3.e3	DDI-DrugBank.d771.s3.e4
DDI-DrugBank.d771.s4|a|Laboratory Test Interactions Scopolamine will interfere with the gastric secretion test.
DDI-DrugBank.d771.s4	29	39	Scopolamine	drug	DDI-DrugBank.d771.s4.e0
DDI-DrugBank.d601.s0|a|Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.
DDI-DrugBank.d601.s0	0	11	Barbiturates	group	DDI-DrugBank.d601.s0.e0
DDI-DrugBank.d601.s0	52	65	contraceptives	group	DDI-DrugBank.d601.s0.e1
DDI-DrugBank.d601.s0	76	86	antibiotics	group	DDI-DrugBank.d601.s0.e2
DDI-DrugBank.d601.s0	89	97	quinidine	group	DDI-DrugBank.d601.s0.e3
DDI-DrugBank.d601.s0	100	111	theophylline	drug	DDI-DrugBank.d601.s0.e4
DDI-DrugBank.d601.s0	114	128	corticosteroids	group	DDI-DrugBank.d601.s0.e5
DDI-DrugBank.d601.s0	131	144	anticoagulants	group	DDI-DrugBank.d601.s0.e6
DDI-DrugBank.d601.s0	151	163	beta blockers	group	DDI-DrugBank.d601.s0.e7
DDI-DrugBank.d601.s0	true	DDI-DrugBank.d601.s0.e0	DDI-DrugBank.d601.s0.e1
DDI-DrugBank.d601.s0	true	DDI-DrugBank.d601.s0.e0	DDI-DrugBank.d601.s0.e2
DDI-DrugBank.d601.s0	true	DDI-DrugBank.d601.s0.e0	DDI-DrugBank.d601.s0.e3
DDI-DrugBank.d601.s0	true	DDI-DrugBank.d601.s0.e0	DDI-DrugBank.d601.s0.e4
DDI-DrugBank.d601.s0	true	DDI-DrugBank.d601.s0.e0	DDI-DrugBank.d601.s0.e5
DDI-DrugBank.d601.s0	true	DDI-DrugBank.d601.s0.e0	DDI-DrugBank.d601.s0.e6
DDI-DrugBank.d601.s0	true	DDI-DrugBank.d601.s0.e0	DDI-DrugBank.d601.s0.e7
DDI-DrugBank.d601.s0	false	DDI-DrugBank.d601.s0.e1	DDI-DrugBank.d601.s0.e2
DDI-DrugBank.d601.s0	false	DDI-DrugBank.d601.s0.e1	DDI-DrugBank.d601.s0.e3
DDI-DrugBank.d601.s0	false	DDI-DrugBank.d601.s0.e1	DDI-DrugBank.d601.s0.e4
DDI-DrugBank.d619.s0|a|The occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of selegiline and meperidine. 
DDI-DrugBank.d619.s0	152	161	selegiline	drug	DDI-DrugBank.d619.s0.e0
DDI-DrugBank.d619.s0	167	176	meperidine	drug	DDI-DrugBank.d619.s0.e1
DDI-DrugBank.d619.s0	true	DDI-DrugBank.d619.s0.e0	DDI-DrugBank.d619.s0.e1
DDI-DrugBank.d619.s1|a|Symptoms usually resolve over days when the combination is discontinued. 
DDI-DrugBank.d619.s2|a|This is typical of the interaction of meperidine and MAOIs. 
DDI-DrugBank.d619.s2	38	47	meperidine	drug	DDI-DrugBank.d619.s2.e0
DDI-DrugBank.d619.s2	53	57	MAOIs	group	DDI-DrugBank.d619.s2.e1
DDI-DrugBank.d619.s2	true	DDI-DrugBank.d619.s2.e0	DDI-DrugBank.d619.s2.e1
DDI-DrugBank.d619.s3|a|Other serious reactions (including severe agitation, hallucinations, and death) have been reported in patients receiving this combination. 
DDI-DrugBank.d619.s4|a|Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL. 
DDI-DrugBank.d619.s4	80	104	tricyclic antidepressants	group	DDI-DrugBank.d619.s4.e0
DDI-DrugBank.d619.s4	110	117	ELDEPRYL	brand	DDI-DrugBank.d619.s4.e1
DDI-DrugBank.d619.s4	123	161	selective serotonin reuptake inhibitors	group	DDI-DrugBank.d619.s4.e2
DDI-DrugBank.d619.s4	167	174	ELDEPRYL	brand	DDI-DrugBank.d619.s4.e3
DDI-DrugBank.d619.s4	true	DDI-DrugBank.d619.s4.e0	DDI-DrugBank.d619.s4.e1
DDI-DrugBank.d619.s4	false	DDI-DrugBank.d619.s4.e0	DDI-DrugBank.d619.s4.e2
DDI-DrugBank.d619.s4	false	DDI-DrugBank.d619.s4.e0	DDI-DrugBank.d619.s4.e3
DDI-DrugBank.d619.s4	false	DDI-DrugBank.d619.s4.e1	DDI-DrugBank.d619.s4.e2
DDI-DrugBank.d619.s4	false	DDI-DrugBank.d619.s4.e1	DDI-DrugBank.d619.s4.e3
DDI-DrugBank.d619.s4	true	DDI-DrugBank.d619.s4.e2	DDI-DrugBank.d619.s4.e3
DDI-DrugBank.d619.s5|a|One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication (ephedrine).
DDI-DrugBank.d619.s5	95	104	selegiline	drug	DDI-DrugBank.d619.s5.e0
DDI-DrugBank.d619.s5	112	137	sympathomimetic medication	group	DDI-DrugBank.d619.s5.e1
DDI-DrugBank.d619.s5	140	148	ephedrine	drug	DDI-DrugBank.d619.s5.e2
DDI-DrugBank.d619.s5	true	DDI-DrugBank.d619.s5.e0	DDI-DrugBank.d619.s5.e1
DDI-DrugBank.d619.s5	true	DDI-DrugBank.d619.s5.e0	DDI-DrugBank.d619.s5.e2
DDI-DrugBank.d619.s5	false	DDI-DrugBank.d619.s5.e1	DDI-DrugBank.d619.s5.e2
DDI-DrugBank.d694.s0|a|Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days. 
DDI-DrugBank.d694.s0	0	6	Digoxin	drug	DDI-DrugBank.d694.s0.e0
DDI-DrugBank.d694.s0	124	130	digoxin	drug	DDI-DrugBank.d694.s0.e1
DDI-DrugBank.d694.s0	169	179	sitagliptin	drug	DDI-DrugBank.d694.s0.e2
DDI-DrugBank.d694.s0	false	DDI-DrugBank.d694.s0.e0	DDI-DrugBank.d694.s0.e1
DDI-DrugBank.d694.s0	false	DDI-DrugBank.d694.s0.e0	DDI-DrugBank.d694.s0.e2
DDI-DrugBank.d694.s0	true	DDI-DrugBank.d694.s0.e1	DDI-DrugBank.d694.s0.e2
DDI-DrugBank.d694.s1|a|Patients receiving digoxin should be monitored appropriately. 
DDI-DrugBank.d694.s1	19	25	digoxin	drug	DDI-DrugBank.d694.s1.e0
DDI-DrugBank.d694.s2|a|No dosage adjustment of digoxin or JANUVIA is recommended.
DDI-DrugBank.d694.s2	24	30	digoxin	drug	DDI-DrugBank.d694.s2.e0
DDI-DrugBank.d694.s2	35	41	JANUVIA	brand	DDI-DrugBank.d694.s2.e1
DDI-DrugBank.d694.s2	false	DDI-DrugBank.d694.s2.e0	DDI-DrugBank.d694.s2.e1
DDI-DrugBank.d595.s0|a|Additives may be incompatible; 
DDI-DrugBank.d595.s1|a|norepinephrine and dobutamine are incompatible with sodium bicarbonate solution. 
DDI-DrugBank.d595.s1	0	13	norepinephrine	drug	DDI-DrugBank.d595.s1.e0
DDI-DrugBank.d595.s1	19	28	dobutamine	drug	DDI-DrugBank.d595.s1.e1
DDI-DrugBank.d595.s1	52	69	sodium bicarbonate	drug	DDI-DrugBank.d595.s1.e2
DDI-DrugBank.d595.s1	false	DDI-DrugBank.d595.s1.e0	DDI-DrugBank.d595.s1.e1
DDI-DrugBank.d595.s1	true	DDI-DrugBank.d595.s1.e0	DDI-DrugBank.d595.s1.e2
DDI-DrugBank.d595.s1	true	DDI-DrugBank.d595.s1.e1	DDI-DrugBank.d595.s1.e2
DDI-DrugBank.d595.s2|a|The addition of sodium bicarbonate to parenteral solutions containing calcium should be avoided, except where compatibility has been previously established. 
DDI-DrugBank.d595.s2	16	33	sodium bicarbonate	drug	DDI-DrugBank.d595.s2.e0
DDI-DrugBank.d595.s2	70	76	calcium	drug	DDI-DrugBank.d595.s2.e1
DDI-DrugBank.d595.s2	false	DDI-DrugBank.d595.s2.e0	DDI-DrugBank.d595.s2.e1
DDI-DrugBank.d595.s3|a|Precipitation or haze may result from sodium bicarbonate-calcium admixtures. 
DDI-DrugBank.d595.s4|a|NOTE: Do not use the injection if it contains precipitate. 
DDI-DrugBank.d595.s5|a|Additives may be incompatible. 
DDI-DrugBank.d595.s6|a|Consult with pharmacist, if available. 
DDI-DrugBank.d595.s7|a|When introducing additives, use aseptic technique, mix thoroughly and do not store.
DDI-DrugBank.d738.s0|a|Do not exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors. 
DDI-DrugBank.d738.s0	35	42	VESIcare	brand	DDI-DrugBank.d738.s0.e0
DDI-DrugBank.d738.s0	88	99	ketoconazole	drug	DDI-DrugBank.d738.s0.e1
DDI-DrugBank.d738.s0	true	DDI-DrugBank.d738.s0.e0	DDI-DrugBank.d738.s0.e1
DDI-DrugBank.d738.s1|a|Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose. 
DDI-DrugBank.d738.s1	81	91	solifenacin	drug	DDI-DrugBank.d738.s1.e0
DDI-DrugBank.d738.s1	177	187	solifenacin	drug	DDI-DrugBank.d738.s1.e1
DDI-DrugBank.d738.s1	273	283	solifenacin	drug	DDI-DrugBank.d738.s1.e2
DDI-DrugBank.d738.s1	347	358	moxifloxacin	drug	DDI-DrugBank.d738.s1.e3
DDI-DrugBank.d738.s1	false	DDI-DrugBank.d738.s1.e0	DDI-DrugBank.d738.s1.e1
DDI-DrugBank.d738.s1	false	DDI-DrugBank.d738.s1.e0	DDI-DrugBank.d738.s1.e2
DDI-DrugBank.d738.s1	false	DDI-DrugBank.d738.s1.e0	DDI-DrugBank.d738.s1.e3
DDI-DrugBank.d738.s1	false	DDI-DrugBank.d738.s1.e1	DDI-DrugBank.d738.s1.e2
DDI-DrugBank.d738.s1	false	DDI-DrugBank.d738.s1.e1	DDI-DrugBank.d738.s1.e3
DDI-DrugBank.d738.s1	false	DDI-DrugBank.d738.s1.e2	DDI-DrugBank.d738.s1.e3
DDI-DrugBank.d738.s2|a|This observation should be considered in clinical decisions to prescribe VESIcare for patients with a known history of QT prolongation or patients who are taking medications known to prolong the QT interval.
DDI-DrugBank.d738.s2	73	80	VESIcare	brand	DDI-DrugBank.d738.s2.e0
DDI-DrugBank.d599.s0|a|Excessive glucocorticoid therapy will inhibit the growth-promoting effect of human GH. 
DDI-DrugBank.d599.s0	77	84	human GH	drug	DDI-DrugBank.d599.s0.e0
DDI-DrugBank.d599.s1|a|Patients with ACTH deficiency should have their glucocorticoid-replacement dose carefully adjusted to avoid an inhibitory effect on growth. 
DDI-DrugBank.d599.s1	48	61	glucocorticoid	group	DDI-DrugBank.d599.s1.e0
DDI-DrugBank.d599.s2|a|The use of Nutropin in patients with chronic renal insufficiency receiving glucocorticoid therapy has not been evaluated. 
DDI-DrugBank.d599.s2	11	18	Nutropin	brand	DDI-DrugBank.d599.s2.e0
DDI-DrugBank.d599.s3|a|Concomitant glucocorticoid therapy may inhibit the growth-promoting effect of Nutropin. 
DDI-DrugBank.d599.s3	78	85	Nutropin	brand	DDI-DrugBank.d599.s3.e0
DDI-DrugBank.d599.s4|a|If glucocorticoid replacement is required, the glucocorticoid dose should be carefully adjusted. 
DDI-DrugBank.d599.s4	3	16	glucocorticoid	group	DDI-DrugBank.d599.s4.e0
DDI-DrugBank.d599.s4	47	60	glucocorticoid	group	DDI-DrugBank.d599.s4.e1
DDI-DrugBank.d599.s4	false	DDI-DrugBank.d599.s4.e0	DDI-DrugBank.d599.s4.e1
DDI-DrugBank.d599.s5|a|There was no evidence in the controlled studies of Nutropin   s interaction with drugs commonly used in chronic renal insufficiency patients. 
DDI-DrugBank.d599.s5	51	58	Nutropin	brand	DDI-DrugBank.d599.s5.e0
DDI-DrugBank.d599.s6|a|Limited published data indicate that GH treatment increases cytochrome P450 (CP450) mediated antipyrine clearance in man. 
DDI-DrugBank.d599.s6	37	38	GH	drug	DDI-DrugBank.d599.s6.e0
DDI-DrugBank.d599.s6	93	102	antipyrine	drug	DDI-DrugBank.d599.s6.e1
DDI-DrugBank.d599.s6	true	DDI-DrugBank.d599.s6.e0	DDI-DrugBank.d599.s6.e1
DDI-DrugBank.d599.s7|a|These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). 
DDI-DrugBank.d599.s7	24	25	GH	drug	DDI-DrugBank.d599.s7.e0
DDI-DrugBank.d599.s7	133	147	corticosteroids	group	DDI-DrugBank.d599.s7.e1
DDI-DrugBank.d599.s7	150	161	sex steroids	group	DDI-DrugBank.d599.s7.e2
DDI-DrugBank.d599.s7	164	178	anticonvulsants	group	DDI-DrugBank.d599.s7.e3
DDI-DrugBank.d599.s7	181	191	cyclosporin	drug	DDI-DrugBank.d599.s7.e4
DDI-DrugBank.d599.s7	true	DDI-DrugBank.d599.s7.e0	DDI-DrugBank.d599.s7.e1
DDI-DrugBank.d599.s7	true	DDI-DrugBank.d599.s7.e0	DDI-DrugBank.d599.s7.e2
DDI-DrugBank.d599.s7	true	DDI-DrugBank.d599.s7.e0	DDI-DrugBank.d599.s7.e3
DDI-DrugBank.d599.s7	true	DDI-DrugBank.d599.s7.e0	DDI-DrugBank.d599.s7.e4
DDI-DrugBank.d599.s7	false	DDI-DrugBank.d599.s7.e1	DDI-DrugBank.d599.s7.e2
DDI-DrugBank.d599.s7	false	DDI-DrugBank.d599.s7.e1	DDI-DrugBank.d599.s7.e3
DDI-DrugBank.d599.s7	false	DDI-DrugBank.d599.s7.e1	DDI-DrugBank.d599.s7.e4
DDI-DrugBank.d599.s7	false	DDI-DrugBank.d599.s7.e2	DDI-DrugBank.d599.s7.e3
DDI-DrugBank.d599.s7	false	DDI-DrugBank.d599.s7.e2	DDI-DrugBank.d599.s7.e4
DDI-DrugBank.d599.s7	false	DDI-DrugBank.d599.s7.e3	DDI-DrugBank.d599.s7.e4
DDI-DrugBank.d599.s8|a|Careful monitoring is advisable when GH is administered in combination with other drugs known to be metabolized by CP450 liver enzymes.
DDI-DrugBank.d599.s8	37	38	GH	drug	DDI-DrugBank.d599.s8.e0
DDI-DrugBank.d602.s0|a|Caution is recommended when administering NEXAVAR with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e.g. irinotecan). 
DDI-DrugBank.d602.s0	42	48	NEXAVAR	brand	DDI-DrugBank.d602.s0.e0
DDI-DrugBank.d602.s0	139	148	irinotecan	drug	DDI-DrugBank.d602.s0.e1
DDI-DrugBank.d602.s0	true	DDI-DrugBank.d602.s0.e0	DDI-DrugBank.d602.s0.e1
DDI-DrugBank.d602.s1|a|Concomitant treatment with NEXAVAR resulted in a 21% increase in the AUC of doxorubicin. 
DDI-DrugBank.d602.s1	27	33	NEXAVAR	brand	DDI-DrugBank.d602.s1.e0
DDI-DrugBank.d602.s1	76	86	doxorubicin	drug	DDI-DrugBank.d602.s1.e1
DDI-DrugBank.d602.s1	true	DDI-DrugBank.d602.s1.e0	DDI-DrugBank.d602.s1.e1
DDI-DrugBank.d602.s2|a|Caution is recommended when administering doxorubicin with NEXAVAR. 
DDI-DrugBank.d602.s2	42	52	doxorubicin	drug	DDI-DrugBank.d602.s2.e0
DDI-DrugBank.d602.s2	59	65	NEXAVAR	brand	DDI-DrugBank.d602.s2.e1
DDI-DrugBank.d602.s2	true	DDI-DrugBank.d602.s2.e0	DDI-DrugBank.d602.s2.e1
DDI-DrugBank.d602.s3|a|Sorafenib inhibits CYP2B6 and CYP2C8 in vitro with Ki values of 6 and 1-2 ?M, respectively. 
DDI-DrugBank.d602.s3	0	8	Sorafenib	drug	DDI-DrugBank.d602.s3.e0
DDI-DrugBank.d602.s4|a|Systemic exposure to substrates of CYP2B6 and CYP2C8 is expected to increase when co-administered with NEXAVAR. 
DDI-DrugBank.d602.s4	103	109	NEXAVAR	brand	DDI-DrugBank.d602.s4.e0
DDI-DrugBank.d602.s5|a|Caution is recommended when administering substrates of CYP2B6 and CYP2C8 with NEXAVAR.
DDI-DrugBank.d602.s5	79	85	NEXAVAR	brand	DDI-DrugBank.d602.s5.e0
DDI-DrugBank.d727.s0|a|Zidovudine competitively inhibits the intracellular phosphorylation of stavudine. 
DDI-DrugBank.d727.s0	0	9	Zidovudine	drug	DDI-DrugBank.d727.s0.e0
DDI-DrugBank.d727.s0	71	79	stavudine	drug	DDI-DrugBank.d727.s0.e1
DDI-DrugBank.d727.s0	true	DDI-DrugBank.d727.s0.e0	DDI-DrugBank.d727.s0.e1
DDI-DrugBank.d727.s1|a|Therefore, use of zidovudine in combination with ZERIT should be avoided. 
DDI-DrugBank.d727.s1	18	27	zidovudine	drug	DDI-DrugBank.d727.s1.e0
DDI-DrugBank.d727.s1	49	53	ZERIT	brand	DDI-DrugBank.d727.s1.e1
DDI-DrugBank.d727.s1	true	DDI-DrugBank.d727.s1.e0	DDI-DrugBank.d727.s1.e1
DDI-DrugBank.d727.s2|a|In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin. 
DDI-DrugBank.d727.s2	51	59	stavudine	drug	DDI-DrugBank.d727.s2.e0
DDI-DrugBank.d727.s2	109	119	doxorubicin	drug	DDI-DrugBank.d727.s2.e1
DDI-DrugBank.d727.s2	125	133	ribavirin	drug	DDI-DrugBank.d727.s2.e2
DDI-DrugBank.d727.s2	true	DDI-DrugBank.d727.s2.e0	DDI-DrugBank.d727.s2.e1
DDI-DrugBank.d727.s2	true	DDI-DrugBank.d727.s2.e0	DDI-DrugBank.d727.s2.e2
DDI-DrugBank.d727.s2	false	DDI-DrugBank.d727.s2.e1	DDI-DrugBank.d727.s2.e2
DDI-DrugBank.d727.s3|a|The clinical significance of these in vitro interactions is unknown; 
DDI-DrugBank.d727.s4|a|therefore, concomitant use of stavudine with either of these drugs should be undertaken with caution.
DDI-DrugBank.d727.s4	30	38	stavudine	drug	DDI-DrugBank.d727.s4.e0
DDI-DrugBank.d777.s0|a|The interaction of Streptase, Streptokinase, with other drugs has not been well studied. 
DDI-DrugBank.d777.s0	19	27	Streptase	brand	DDI-DrugBank.d777.s0.e0
DDI-DrugBank.d777.s0	30	42	Streptokinase	drug	DDI-DrugBank.d777.s0.e1
DDI-DrugBank.d777.s0	false	DDI-DrugBank.d777.s0.e0	DDI-DrugBank.d777.s0.e1
DDI-DrugBank.d777.s1|a|Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. 
DDI-DrugBank.d777.s1	7	20	Anticoagulants	group	DDI-DrugBank.d777.s1.e0
DDI-DrugBank.d777.s1	26	44	Antiplatelet Agents	group	DDI-DrugBank.d777.s1.e1
DDI-DrugBank.d777.s1	49	57	Streptase	brand	DDI-DrugBank.d777.s1.e2
DDI-DrugBank.d777.s1	60	72	Streptokinase	drug	DDI-DrugBank.d777.s1.e3
DDI-DrugBank.d777.s1	104	122	antiplatelet agents	group	DDI-DrugBank.d777.s1.e4
DDI-DrugBank.d777.s1	128	141	anticoagulants	group	DDI-DrugBank.d777.s1.e5
DDI-DrugBank.d777.s1	false	DDI-DrugBank.d777.s1.e0	DDI-DrugBank.d777.s1.e1
DDI-DrugBank.d777.s1	false	DDI-DrugBank.d777.s1.e0	DDI-DrugBank.d777.s1.e2
DDI-DrugBank.d777.s1	false	DDI-DrugBank.d777.s1.e0	DDI-DrugBank.d777.s1.e3
DDI-DrugBank.d777.s1	false	DDI-DrugBank.d777.s1.e0	DDI-DrugBank.d777.s1.e4
DDI-DrugBank.d777.s1	false	DDI-DrugBank.d777.s1.e0	DDI-DrugBank.d777.s1.e5
DDI-DrugBank.d777.s1	false	DDI-DrugBank.d777.s1.e1	DDI-DrugBank.d777.s1.e2
DDI-DrugBank.d777.s1	false	DDI-DrugBank.d777.s1.e1	DDI-DrugBank.d777.s1.e3
DDI-DrugBank.d777.s1	false	DDI-DrugBank.d777.s1.e1	DDI-DrugBank.d777.s1.e4
DDI-DrugBank.d777.s1	false	DDI-DrugBank.d777.s1.e1	DDI-DrugBank.d777.s1.e5
DDI-DrugBank.d777.s1	false	DDI-DrugBank.d777.s1.e2	DDI-DrugBank.d777.s1.e3
DDI-DrugBank.d777.s2|a|Therefore, careful monitoring is advised. 
DDI-DrugBank.d777.s3|a|In the treatment of acute MI, aspirin, when not otherwise contraindicated, should be administered with Streptokinase ( see below ). 
DDI-DrugBank.d777.s3	30	36	aspirin	brand	DDI-DrugBank.d777.s3.e0
DDI-DrugBank.d777.s3	103	115	Streptokinase	drug	DDI-DrugBank.d777.s3.e1
DDI-DrugBank.d777.s3	false	DDI-DrugBank.d777.s3.e0	DDI-DrugBank.d777.s3.e1
DDI-DrugBank.d777.s4|a|Anticoagulation and Antiplatelets After Treatment for Myocardial Infarction -- In the treatment of acute myocardial infarction, the use of aspirin has been shown to reduce the incidence of reinfarction and stroke. 
DDI-DrugBank.d777.s4	20	32	Antiplatelets	group	DDI-DrugBank.d777.s4.e0
DDI-DrugBank.d777.s4	139	145	aspirin	brand	DDI-DrugBank.d777.s4.e1
DDI-DrugBank.d777.s4	false	DDI-DrugBank.d777.s4.e0	DDI-DrugBank.d777.s4.e1
DDI-DrugBank.d777.s5|a|The addition of aspirin to Streptokinase causes a minimal increase in the risk of minor bleeding (3.9% vs. 3.1%), but does not appear to increase the incidence of major bleeding (see
DDI-DrugBank.d777.s5	16	22	aspirin	brand	DDI-DrugBank.d777.s5.e0
DDI-DrugBank.d777.s5	27	39	Streptokinase	drug	DDI-DrugBank.d777.s5.e1
DDI-DrugBank.d777.s5	true	DDI-DrugBank.d777.s5.e0	DDI-DrugBank.d777.s5.e1
DDI-DrugBank.d647.s0|a|ZANOSAR may demonstrate additive toxicity when used in combination with other cytotoxic drugs. 
DDI-DrugBank.d647.s0	0	6	ZANOSAR	brand	DDI-DrugBank.d647.s0.e0
DDI-DrugBank.d647.s1|a|Streptozocin has been reported to prolong the elimination half-life of doxorubicin and may lead to severe bone marrow suppression; 
DDI-DrugBank.d647.s1	0	11	Streptozocin	drug	DDI-DrugBank.d647.s1.e0
DDI-DrugBank.d647.s1	71	81	doxorubicin	drug	DDI-DrugBank.d647.s1.e1
DDI-DrugBank.d647.s1	true	DDI-DrugBank.d647.s1.e0	DDI-DrugBank.d647.s1.e1
DDI-DrugBank.d647.s2|a|a reduction of the doxorubicin dosage should be considered in patients receiving ZANOSAR concurrently. 
DDI-DrugBank.d647.s2	19	29	doxorubicin	drug	DDI-DrugBank.d647.s2.e0
DDI-DrugBank.d647.s2	81	87	ZANOSAR	brand	DDI-DrugBank.d647.s2.e1
DDI-DrugBank.d647.s2	true	DDI-DrugBank.d647.s2.e0	DDI-DrugBank.d647.s2.e1
DDI-DrugBank.d647.s3|a|The concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity.    
DDI-DrugBank.d647.s3	22	33	streptozocin	drug	DDI-DrugBank.d647.s3.e0
DDI-DrugBank.d647.s3	39	47	phenytoin	drug	DDI-DrugBank.d647.s3.e1
DDI-DrugBank.d647.s3	100	111	streptozocin	drug	DDI-DrugBank.d647.s3.e2
DDI-DrugBank.d647.s3	true	DDI-DrugBank.d647.s3.e0	DDI-DrugBank.d647.s3.e1
DDI-DrugBank.d647.s3	false	DDI-DrugBank.d647.s3.e0	DDI-DrugBank.d647.s3.e2
DDI-DrugBank.d647.s3	false	DDI-DrugBank.d647.s3.e1	DDI-DrugBank.d647.s3.e2
DDI-DrugBank.d732.s0|a|CHEMET is not known to interact with other drugs including iron supplements; 
DDI-DrugBank.d732.s0	0	5	CHEMET	brand	DDI-DrugBank.d732.s0.e0
DDI-DrugBank.d732.s0	59	62	iron	drug	DDI-DrugBank.d732.s0.e1
DDI-DrugBank.d732.s0	false	DDI-DrugBank.d732.s0.e0	DDI-DrugBank.d732.s0.e1
DDI-DrugBank.d732.s1|a|interactions have not been systematically studied. 
DDI-DrugBank.d732.s2|a|Concomitant administration of CHEMET with other chelation therapy, such as CaNa 2 EDTA is not recommended. 
DDI-DrugBank.d732.s2	30	35	CHEMET	brand	DDI-DrugBank.d732.s2.e0
DDI-DrugBank.d732.s2	75	85	CaNa 2 EDTA	drug	DDI-DrugBank.d732.s2.e1
DDI-DrugBank.d732.s2	true	DDI-DrugBank.d732.s2.e0	DDI-DrugBank.d732.s2.e1
DDI-DrugBank.d732.s3|a|Drug/Laboratory Tests Interaction: Succimer may interfere with serum and urinary laboratory tests. 
DDI-DrugBank.d732.s3	35	42	Succimer	drug	DDI-DrugBank.d732.s3.e0
DDI-DrugBank.d732.s4|a|In vitro studies have shown succimer to cause false positive results for ketones in urine using nitroprusside reagents such as Ketostix    and falsely decreased measurements of serum uric acid and CPK.
DDI-DrugBank.d732.s4	28	35	succimer	drug	DDI-DrugBank.d732.s4.e0
DDI-DrugBank.d649.s0|a|Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. 
DDI-DrugBank.d649.s0	0	13	Sulfamethizole	drug	DDI-DrugBank.d649.s0.e0
DDI-DrugBank.d649.s0	43	54	barbiturates	group	DDI-DrugBank.d649.s0.e1
DDI-DrugBank.d649.s0	57	67	tolbutamide	drug	DDI-DrugBank.d649.s0.e2
DDI-DrugBank.d649.s0	74	84	uricosurics	group	DDI-DrugBank.d649.s0.e3
DDI-DrugBank.d649.s0	true	DDI-DrugBank.d649.s0.e0	DDI-DrugBank.d649.s0.e1
DDI-DrugBank.d649.s0	true	DDI-DrugBank.d649.s0.e0	DDI-DrugBank.d649.s0.e2
DDI-DrugBank.d649.s0	true	DDI-DrugBank.d649.s0.e0	DDI-DrugBank.d649.s0.e3
DDI-DrugBank.d649.s0	false	DDI-DrugBank.d649.s0.e1	DDI-DrugBank.d649.s0.e2
DDI-DrugBank.d649.s0	false	DDI-DrugBank.d649.s0.e1	DDI-DrugBank.d649.s0.e3
DDI-DrugBank.d649.s0	false	DDI-DrugBank.d649.s0.e2	DDI-DrugBank.d649.s0.e3
DDI-DrugBank.d649.s1|a|It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
DDI-DrugBank.d649.s1	26	34	thiazides	group	DDI-DrugBank.d649.s1.e0
DDI-DrugBank.d649.s1	66	77	cyclosporine	drug	DDI-DrugBank.d649.s1.e1
DDI-DrugBank.d649.s1	107	125	sulfonylurea agents	group	DDI-DrugBank.d649.s1.e2
DDI-DrugBank.d649.s1	162	169	warfarin	drug	DDI-DrugBank.d649.s1.e3
DDI-DrugBank.d649.s1	205	216	methotrexate	drug	DDI-DrugBank.d649.s1.e4
DDI-DrugBank.d649.s1	248	259	methotrexate	drug	DDI-DrugBank.d649.s1.e5
DDI-DrugBank.d649.s1	263	271	phenytoin	drug	DDI-DrugBank.d649.s1.e6
DDI-DrugBank.d649.s1	305	313	phenytoin	drug	DDI-DrugBank.d649.s1.e7
DDI-DrugBank.d649.s1	false	DDI-DrugBank.d649.s1.e0	DDI-DrugBank.d649.s1.e1
DDI-DrugBank.d649.s1	false	DDI-DrugBank.d649.s1.e0	DDI-DrugBank.d649.s1.e2
DDI-DrugBank.d649.s1	false	DDI-DrugBank.d649.s1.e0	DDI-DrugBank.d649.s1.e3
DDI-DrugBank.d649.s1	false	DDI-DrugBank.d649.s1.e0	DDI-DrugBank.d649.s1.e4
DDI-DrugBank.d649.s1	false	DDI-DrugBank.d649.s1.e0	DDI-DrugBank.d649.s1.e5
DDI-DrugBank.d649.s1	false	DDI-DrugBank.d649.s1.e0	DDI-DrugBank.d649.s1.e6
DDI-DrugBank.d649.s1	false	DDI-DrugBank.d649.s1.e0	DDI-DrugBank.d649.s1.e7
DDI-DrugBank.d649.s1	false	DDI-DrugBank.d649.s1.e1	DDI-DrugBank.d649.s1.e2
DDI-DrugBank.d649.s1	false	DDI-DrugBank.d649.s1.e1	DDI-DrugBank.d649.s1.e3
DDI-DrugBank.d649.s1	false	DDI-DrugBank.d649.s1.e1	DDI-DrugBank.d649.s1.e4
DDI-DrugBank.d577.s0|a|In elderly patients concurrently receiving certain diuretics, primarily thiazides, an increased incidence of thrombopenia with purpura has been reported. 
DDI-DrugBank.d577.s0	51	59	diuretics	group	DDI-DrugBank.d577.s0.e0
DDI-DrugBank.d577.s0	72	80	thiazides	group	DDI-DrugBank.d577.s0.e1
DDI-DrugBank.d577.s0	false	DDI-DrugBank.d577.s0.e0	DDI-DrugBank.d577.s0.e1
DDI-DrugBank.d577.s1|a|It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin. 
DDI-DrugBank.d577.s1	26	41	sulfamethoxazole	drug	DDI-DrugBank.d577.s1.e0
DDI-DrugBank.d577.s1	110	122	anticoagulant	group	DDI-DrugBank.d577.s1.e1
DDI-DrugBank.d577.s1	124	131	warfarin	drug	DDI-DrugBank.d577.s1.e2
DDI-DrugBank.d577.s1	false	DDI-DrugBank.d577.s1.e0	DDI-DrugBank.d577.s1.e1
DDI-DrugBank.d577.s1	true	DDI-DrugBank.d577.s1.e0	DDI-DrugBank.d577.s1.e2
DDI-DrugBank.d577.s1	false	DDI-DrugBank.d577.s1.e1	DDI-DrugBank.d577.s1.e2
DDI-DrugBank.d577.s2|a|This interaction should be kept in mind when Gantanol is given to patients already on anticoagulant therapy, and the coagulation time should be reassessed. 
DDI-DrugBank.d577.s2	45	52	Gantanol	brand	DDI-DrugBank.d577.s2.e0
DDI-DrugBank.d577.s3|a|Sulfamethoxazole may inhibit the hepatic metabolism of phenytoin. 
DDI-DrugBank.d577.s3	0	15	Sulfamethoxazole	drug	DDI-DrugBank.d577.s3.e0
DDI-DrugBank.d577.s3	55	63	phenytoin	drug	DDI-DrugBank.d577.s3.e1
DDI-DrugBank.d577.s3	true	DDI-DrugBank.d577.s3.e0	DDI-DrugBank.d577.s3.e1
DDI-DrugBank.d577.s4|a|At a 1.6-g dose, sulfamethoxazole produced a slight but significant increase in the half-life of phenytoin but did not produce a corresponding decrease in the metabolic clearance rate. 
DDI-DrugBank.d577.s4	17	32	sulfamethoxazole	drug	DDI-DrugBank.d577.s4.e0
DDI-DrugBank.d577.s4	97	105	phenytoin	drug	DDI-DrugBank.d577.s4.e1
DDI-DrugBank.d577.s4	true	DDI-DrugBank.d577.s4.e0	DDI-DrugBank.d577.s4.e1
DDI-DrugBank.d577.s5|a|When administering these drugs concurrently, one should be alert for possible excessive phenytoin effect. 
DDI-DrugBank.d577.s5	88	96	phenytoin	drug	DDI-DrugBank.d577.s5.e0
DDI-DrugBank.d577.s6|a|Sulfonamides can also displace methotrexate from plasma protein-binding sites, thus increasing free methotrexate concentrations. 
DDI-DrugBank.d577.s6	0	11	Sulfonamides	group	DDI-DrugBank.d577.s6.e0
DDI-DrugBank.d577.s6	31	42	methotrexate	drug	DDI-DrugBank.d577.s6.e1
DDI-DrugBank.d577.s6	100	111	methotrexate	drug	DDI-DrugBank.d577.s6.e2
DDI-DrugBank.d577.s6	true	DDI-DrugBank.d577.s6.e0	DDI-DrugBank.d577.s6.e1
DDI-DrugBank.d577.s6	false	DDI-DrugBank.d577.s6.e0	DDI-DrugBank.d577.s6.e2
DDI-DrugBank.d577.s6	false	DDI-DrugBank.d577.s6.e1	DDI-DrugBank.d577.s6.e2
DDI-DrugBank.d577.s7|a|The presence of sulfamethoxazole may interfere with the Jaff    alkaline picrate reaction assay for creatinine, resulting in overestimations of about 10% in the range of normal values.
DDI-DrugBank.d577.s7	16	31	sulfamethoxazole	drug	DDI-DrugBank.d577.s7.e0
DDI-DrugBank.d693.s0|a|Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine. 
DDI-DrugBank.d693.s0	22	31	folic acid	drug	DDI-DrugBank.d693.s0.e0
DDI-DrugBank.d693.s0	37	43	digoxin	drug	DDI-DrugBank.d693.s0.e1
DDI-DrugBank.d693.s0	119	131	sulfasalazine	drug	DDI-DrugBank.d693.s0.e2
DDI-DrugBank.d693.s0	false	DDI-DrugBank.d693.s0.e0	DDI-DrugBank.d693.s0.e1
DDI-DrugBank.d693.s0	true	DDI-DrugBank.d693.s0.e0	DDI-DrugBank.d693.s0.e2
DDI-DrugBank.d693.s0	true	DDI-DrugBank.d693.s0.e1	DDI-DrugBank.d693.s0.e2
DDI-DrugBank.d693.s1|a|When daily doses of sulfasalazine 2 g and weekly doses of methotrexate 7.5 mg were coadministered to 15 rheumatoid arthritis patients in a drug-drug interaction study, the pharmacokinetic disposition of the drugs was not altered. 
DDI-DrugBank.d693.s1	20	32	sulfasalazine	drug	DDI-DrugBank.d693.s1.e0
DDI-DrugBank.d693.s1	58	69	methotrexate	drug	DDI-DrugBank.d693.s1.e1
DDI-DrugBank.d693.s1	false	DDI-DrugBank.d693.s1.e0	DDI-DrugBank.d693.s1.e1
DDI-DrugBank.d693.s2|a|Daily doses of sulfasalazine 2 g (maximum 3 g) and weekly doses of methotrexate 7.5 mg (maximum 15 mg) were administered alone or in combination to 310 rheumatoid arthritis patients in two controlled 52-week clinical studies. 
DDI-DrugBank.d693.s2	15	27	sulfasalazine	drug	DDI-DrugBank.d693.s2.e0
DDI-DrugBank.d693.s2	67	78	methotrexate	drug	DDI-DrugBank.d693.s2.e1
DDI-DrugBank.d693.s2	false	DDI-DrugBank.d693.s2.e0	DDI-DrugBank.d693.s2.e1
DDI-DrugBank.d693.s3|a|The overall toxicity profile of the combination revealed an increased incidence of gastrointestinal adverse events, especially nausea, when compared to the incidence associated with either drug administered alone. 
DDI-DrugBank.d693.s4|a|Drug/Laboratory Test Interactions: The presence of sulfasalazine or its metabolites in body fluids has not been reported to interfere with laboratory test procedures. 
DDI-DrugBank.d693.s4	51	63	sulfasalazine	drug	DDI-DrugBank.d693.s4.e0
DDI-DrugBank.d693.s5|a|REFERENCES 7.Farr M, et al. 
DDI-DrugBank.d693.s6|a|Immunodeficiencies associated with sulphasalazine therapy in inflammatory arthritis. 
DDI-DrugBank.d693.s6	35	48	sulphasalazine	drug	DDI-DrugBank.d693.s6.e0
DDI-DrugBank.d693.s7|a|British Jnl Rheum 1991;30:413-417.    
DDI-DrugBank.d682.s0|a|Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. 
DDI-DrugBank.d682.s0	0	8	Sulfoxone	drug	DDI-DrugBank.d682.s0.e0
DDI-DrugBank.d682.s0	38	49	barbiturates	group	DDI-DrugBank.d682.s0.e1
DDI-DrugBank.d682.s0	52	62	tolbutamide	drug	DDI-DrugBank.d682.s0.e2
DDI-DrugBank.d682.s0	69	79	uricosurics	group	DDI-DrugBank.d682.s0.e3
DDI-DrugBank.d682.s0	true	DDI-DrugBank.d682.s0.e0	DDI-DrugBank.d682.s0.e1
DDI-DrugBank.d682.s0	true	DDI-DrugBank.d682.s0.e0	DDI-DrugBank.d682.s0.e2
DDI-DrugBank.d682.s0	true	DDI-DrugBank.d682.s0.e0	DDI-DrugBank.d682.s0.e3
DDI-DrugBank.d682.s0	false	DDI-DrugBank.d682.s0.e1	DDI-DrugBank.d682.s0.e2
DDI-DrugBank.d682.s0	false	DDI-DrugBank.d682.s0.e1	DDI-DrugBank.d682.s0.e3
DDI-DrugBank.d682.s0	false	DDI-DrugBank.d682.s0.e2	DDI-DrugBank.d682.s0.e3
DDI-DrugBank.d682.s1|a|It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
DDI-DrugBank.d682.s1	26	34	thiazides	group	DDI-DrugBank.d682.s1.e0
DDI-DrugBank.d682.s1	66	77	cyclosporine	drug	DDI-DrugBank.d682.s1.e1
DDI-DrugBank.d682.s1	107	125	sulfonylurea agents	group	DDI-DrugBank.d682.s1.e2
DDI-DrugBank.d682.s1	162	169	warfarin	drug	DDI-DrugBank.d682.s1.e3
DDI-DrugBank.d682.s1	205	216	methotrexate	drug	DDI-DrugBank.d682.s1.e4
DDI-DrugBank.d682.s1	248	259	methotrexate	drug	DDI-DrugBank.d682.s1.e5
DDI-DrugBank.d682.s1	263	271	phenytoin	drug	DDI-DrugBank.d682.s1.e6
DDI-DrugBank.d682.s1	305	313	phenytoin	drug	DDI-DrugBank.d682.s1.e7
DDI-DrugBank.d682.s1	false	DDI-DrugBank.d682.s1.e0	DDI-DrugBank.d682.s1.e1
DDI-DrugBank.d682.s1	false	DDI-DrugBank.d682.s1.e0	DDI-DrugBank.d682.s1.e2
DDI-DrugBank.d682.s1	false	DDI-DrugBank.d682.s1.e0	DDI-DrugBank.d682.s1.e3
DDI-DrugBank.d682.s1	false	DDI-DrugBank.d682.s1.e0	DDI-DrugBank.d682.s1.e4
DDI-DrugBank.d682.s1	false	DDI-DrugBank.d682.s1.e0	DDI-DrugBank.d682.s1.e5
DDI-DrugBank.d682.s1	false	DDI-DrugBank.d682.s1.e0	DDI-DrugBank.d682.s1.e6
DDI-DrugBank.d682.s1	false	DDI-DrugBank.d682.s1.e0	DDI-DrugBank.d682.s1.e7
DDI-DrugBank.d682.s1	false	DDI-DrugBank.d682.s1.e1	DDI-DrugBank.d682.s1.e2
DDI-DrugBank.d682.s1	false	DDI-DrugBank.d682.s1.e1	DDI-DrugBank.d682.s1.e3
DDI-DrugBank.d682.s1	false	DDI-DrugBank.d682.s1.e1	DDI-DrugBank.d682.s1.e4
DDI-DrugBank.d720.s0|a|Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. 
DDI-DrugBank.d720.s0	0	4	Ergot	group	DDI-DrugBank.d720.s0.e0
DDI-DrugBank.d720.s1|a|Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. 
DDI-DrugBank.d720.s1	80	89	ergotamine	drug	DDI-DrugBank.d720.s1.e0
DDI-DrugBank.d720.s1	105	126	ergot-type medications	group	DDI-DrugBank.d720.s1.e1
DDI-DrugBank.d720.s1	134	150	dihydroergotamine	drug	DDI-DrugBank.d720.s1.e2
DDI-DrugBank.d720.s1	155	166	methysergide	drug	DDI-DrugBank.d720.s1.e3
DDI-DrugBank.d720.s1	173	183	sumatriptan	drug	DDI-DrugBank.d720.s1.e4
DDI-DrugBank.d720.s1	false	DDI-DrugBank.d720.s1.e0	DDI-DrugBank.d720.s1.e1
DDI-DrugBank.d720.s1	false	DDI-DrugBank.d720.s1.e0	DDI-DrugBank.d720.s1.e2
DDI-DrugBank.d720.s1	false	DDI-DrugBank.d720.s1.e0	DDI-DrugBank.d720.s1.e3
DDI-DrugBank.d720.s1	true	DDI-DrugBank.d720.s1.e0	DDI-DrugBank.d720.s1.e4
DDI-DrugBank.d720.s1	false	DDI-DrugBank.d720.s1.e1	DDI-DrugBank.d720.s1.e2
DDI-DrugBank.d720.s1	false	DDI-DrugBank.d720.s1.e1	DDI-DrugBank.d720.s1.e3
DDI-DrugBank.d720.s1	true	DDI-DrugBank.d720.s1.e1	DDI-DrugBank.d720.s1.e4
DDI-DrugBank.d720.s1	false	DDI-DrugBank.d720.s1.e2	DDI-DrugBank.d720.s1.e3
DDI-DrugBank.d720.s1	true	DDI-DrugBank.d720.s1.e2	DDI-DrugBank.d720.s1.e4
DDI-DrugBank.d720.s1	true	DDI-DrugBank.d720.s1.e3	DDI-DrugBank.d720.s1.e4
DDI-DrugBank.d720.s2|a|MAO-A inhibitors reduce sumatriptan clearance, significantly increasing systemic exposure. 
DDI-DrugBank.d720.s2	0	15	MAO-A inhibitors	group	DDI-DrugBank.d720.s2.e0
DDI-DrugBank.d720.s2	24	34	sumatriptan	drug	DDI-DrugBank.d720.s2.e1
DDI-DrugBank.d720.s2	true	DDI-DrugBank.d720.s2.e0	DDI-DrugBank.d720.s2.e1
DDI-DrugBank.d720.s3|a|Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 
DDI-DrugBank.d720.s3	22	42	sumatriptan succinate	drug	DDI-DrugBank.d720.s3.e0
DDI-DrugBank.d720.s3	74	89	MAO-A inhibitors	group	DDI-DrugBank.d720.s3.e1
DDI-DrugBank.d720.s3	112	150	Selective serotonin reuptake inhibitors	group	DDI-DrugBank.d720.s3.e2
DDI-DrugBank.d720.s3	153	157	SSRIs	group	DDI-DrugBank.d720.s3.e3
DDI-DrugBank.d720.s3	167	176	fluoxetine	drug	DDI-DrugBank.d720.s3.e4
DDI-DrugBank.d720.s3	179	189	fluvoxamine	drug	DDI-DrugBank.d720.s3.e5
DDI-DrugBank.d720.s3	192	201	paroxetine	drug	DDI-DrugBank.d720.s3.e6
DDI-DrugBank.d720.s3	204	213	sertraline	drug	DDI-DrugBank.d720.s3.e7
DDI-DrugBank.d720.s3	322	332	sumatriptan	drug	DDI-DrugBank.d720.s3.e8
DDI-DrugBank.d720.s3	true	DDI-DrugBank.d720.s3.e0	DDI-DrugBank.d720.s3.e1
DDI-DrugBank.d720.s3	false	DDI-DrugBank.d720.s3.e0	DDI-DrugBank.d720.s3.e2
DDI-DrugBank.d720.s3	false	DDI-DrugBank.d720.s3.e0	DDI-DrugBank.d720.s3.e3
DDI-DrugBank.d720.s3	false	DDI-DrugBank.d720.s3.e0	DDI-DrugBank.d720.s3.e4
DDI-DrugBank.d720.s3	false	DDI-DrugBank.d720.s3.e0	DDI-DrugBank.d720.s3.e5
DDI-DrugBank.d720.s3	false	DDI-DrugBank.d720.s3.e0	DDI-DrugBank.d720.s3.e6
DDI-DrugBank.d720.s3	false	DDI-DrugBank.d720.s3.e0	DDI-DrugBank.d720.s3.e7
DDI-DrugBank.d720.s3	false	DDI-DrugBank.d720.s3.e0	DDI-DrugBank.d720.s3.e8
DDI-DrugBank.d720.s3	false	DDI-DrugBank.d720.s3.e1	DDI-DrugBank.d720.s3.e2
DDI-DrugBank.d720.s3	false	DDI-DrugBank.d720.s3.e1	DDI-DrugBank.d720.s3.e3
DDI-DrugBank.d720.s4|a|If concomitant treatment with sumatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.
DDI-DrugBank.d720.s4	30	40	sumatriptan	drug	DDI-DrugBank.d720.s4.e0
DDI-DrugBank.d720.s4	49	52	SSRI	group	DDI-DrugBank.d720.s4.e1
DDI-DrugBank.d720.s4	true	DDI-DrugBank.d720.s4.e0	DDI-DrugBank.d720.s4.e1
DDI-DrugBank.d639.s0|a|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 
DDI-DrugBank.d639.s0	21	26	SUTENT	brand	DDI-DrugBank.d639.s0.e0
DDI-DrugBank.d639.s0	79	90	ketoconazole	drug	DDI-DrugBank.d639.s0.e1
DDI-DrugBank.d639.s0	93	104	itraconazole	drug	DDI-DrugBank.d639.s0.e2
DDI-DrugBank.d639.s0	107	120	clarithromycin	drug	DDI-DrugBank.d639.s0.e3
DDI-DrugBank.d639.s0	123	132	atazanavir	drug	DDI-DrugBank.d639.s0.e4
DDI-DrugBank.d639.s0	135	143	indinavir	drug	DDI-DrugBank.d639.s0.e5
DDI-DrugBank.d639.s0	146	155	nefazodone	drug	DDI-DrugBank.d639.s0.e6
DDI-DrugBank.d639.s0	158	167	nelfinavir	drug	DDI-DrugBank.d639.s0.e7
DDI-DrugBank.d639.s0	170	178	ritonavir	drug	DDI-DrugBank.d639.s0.e8
DDI-DrugBank.d639.s0	181	190	saquinavir	drug	DDI-DrugBank.d639.s0.e9
DDI-DrugBank.d639.s0	true	DDI-DrugBank.d639.s0.e0	DDI-DrugBank.d639.s0.e1
DDI-DrugBank.d639.s0	true	DDI-DrugBank.d639.s0.e0	DDI-DrugBank.d639.s0.e2
DDI-DrugBank.d639.s0	true	DDI-DrugBank.d639.s0.e0	DDI-DrugBank.d639.s0.e3
DDI-DrugBank.d639.s0	true	DDI-DrugBank.d639.s0.e0	DDI-DrugBank.d639.s0.e4
DDI-DrugBank.d639.s0	true	DDI-DrugBank.d639.s0.e0	DDI-DrugBank.d639.s0.e5
DDI-DrugBank.d639.s0	true	DDI-DrugBank.d639.s0.e0	DDI-DrugBank.d639.s0.e6
DDI-DrugBank.d639.s0	true	DDI-DrugBank.d639.s0.e0	DDI-DrugBank.d639.s0.e7
DDI-DrugBank.d639.s0	true	DDI-DrugBank.d639.s0.e0	DDI-DrugBank.d639.s0.e8
DDI-DrugBank.d639.s0	true	DDI-DrugBank.d639.s0.e0	DDI-DrugBank.d639.s0.e9
DDI-DrugBank.d639.s0	true	DDI-DrugBank.d639.s0.e0	DDI-DrugBank.d639.s0.e10
DDI-DrugBank.d639.s1|a|Grapefruit may also increase plasma concentrations of SUTENT. 
DDI-DrugBank.d639.s1	54	59	SUTENT	brand	DDI-DrugBank.d639.s1.e0
DDI-DrugBank.d639.s2|a|Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 
DDI-DrugBank.d639.s2	21	26	SUTENT	brand	DDI-DrugBank.d639.s2.e0
DDI-DrugBank.d639.s2	70	82	dexamethasone	drug	DDI-DrugBank.d639.s2.e1
DDI-DrugBank.d639.s2	85	93	phenytoin	drug	DDI-DrugBank.d639.s2.e2
DDI-DrugBank.d639.s2	96	108	carbamazepine	drug	DDI-DrugBank.d639.s2.e3
DDI-DrugBank.d639.s2	111	118	rifampin	drug	DDI-DrugBank.d639.s2.e4
DDI-DrugBank.d639.s2	121	129	rifabutin	drug	DDI-DrugBank.d639.s2.e5
DDI-DrugBank.d639.s2	132	141	rifapentin	drug	DDI-DrugBank.d639.s2.e6
DDI-DrugBank.d639.s2	144	156	phenobarbital	drug	DDI-DrugBank.d639.s2.e7
DDI-DrugBank.d639.s2	188	196	sunitinib	drug	DDI-DrugBank.d639.s2.e8
DDI-DrugBank.d639.s2	true	DDI-DrugBank.d639.s2.e0	DDI-DrugBank.d639.s2.e1
DDI-DrugBank.d639.s2	true	DDI-DrugBank.d639.s2.e0	DDI-DrugBank.d639.s2.e2
DDI-DrugBank.d639.s2	true	DDI-DrugBank.d639.s2.e0	DDI-DrugBank.d639.s2.e3
DDI-DrugBank.d639.s2	true	DDI-DrugBank.d639.s2.e0	DDI-DrugBank.d639.s2.e4
DDI-DrugBank.d639.s2	true	DDI-DrugBank.d639.s2.e0	DDI-DrugBank.d639.s2.e5
DDI-DrugBank.d639.s2	true	DDI-DrugBank.d639.s2.e0	DDI-DrugBank.d639.s2.e6
DDI-DrugBank.d639.s2	true	DDI-DrugBank.d639.s2.e0	DDI-DrugBank.d639.s2.e7
DDI-DrugBank.d639.s2	false	DDI-DrugBank.d639.s2.e0	DDI-DrugBank.d639.s2.e8
DDI-DrugBank.d639.s2	false	DDI-DrugBank.d639.s2.e1	DDI-DrugBank.d639.s2.e2
DDI-DrugBank.d639.s2	false	DDI-DrugBank.d639.s2.e1	DDI-DrugBank.d639.s2.e3
DDI-DrugBank.d639.s3|a|St. 
DDI-DrugBank.d639.s4|a|Johns Wort may decrease SUTENT plasma concentrations unpredictably. 
DDI-DrugBank.d639.s4	24	29	SUTENT	brand	DDI-DrugBank.d639.s4.e0
DDI-DrugBank.d639.s5|a|Patients receiving SUTENT should not take St. 
DDI-DrugBank.d639.s5	19	24	SUTENT	brand	DDI-DrugBank.d639.s5.e0
DDI-DrugBank.d639.s6|a|Johns Wort concomitantly. 
DDI-DrugBank.d639.s7|a|SUTENT dose modification is recommended in patients using concomitant CYP3A4 inhibitors or inducers.
DDI-DrugBank.d639.s7	0	5	SUTENT	brand	DDI-DrugBank.d639.s7.e0
DDI-DrugBank.d723.s0|a|Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.
DDI-DrugBank.d723.s0	39	60	acetylcholine chloride	drug	DDI-DrugBank.d723.s0.e0
DDI-DrugBank.d723.s0	63	69	Miochol	brand	DDI-DrugBank.d723.s0.e1
DDI-DrugBank.d723.s0	76	84	carbachol	drug	DDI-DrugBank.d723.s0.e2
DDI-DrugBank.d723.s0	87	95	Carboptic	brand	DDI-DrugBank.d723.s0.e3
DDI-DrugBank.d723.s0	98	113	Isopto Carbachol	brand	DDI-DrugBank.d723.s0.e4
DDI-DrugBank.d723.s0	144	151	suprofen	drug	DDI-DrugBank.d723.s0.e5
DDI-DrugBank.d723.s0	false	DDI-DrugBank.d723.s0.e0	DDI-DrugBank.d723.s0.e1
DDI-DrugBank.d723.s0	false	DDI-DrugBank.d723.s0.e0	DDI-DrugBank.d723.s0.e2
DDI-DrugBank.d723.s0	false	DDI-DrugBank.d723.s0.e0	DDI-DrugBank.d723.s0.e3
DDI-DrugBank.d723.s0	false	DDI-DrugBank.d723.s0.e0	DDI-DrugBank.d723.s0.e4
DDI-DrugBank.d723.s0	true	DDI-DrugBank.d723.s0.e0	DDI-DrugBank.d723.s0.e5
DDI-DrugBank.d723.s0	false	DDI-DrugBank.d723.s0.e1	DDI-DrugBank.d723.s0.e2
DDI-DrugBank.d723.s0	false	DDI-DrugBank.d723.s0.e1	DDI-DrugBank.d723.s0.e3
DDI-DrugBank.d723.s0	false	DDI-DrugBank.d723.s0.e1	DDI-DrugBank.d723.s0.e4
DDI-DrugBank.d723.s0	true	DDI-DrugBank.d723.s0.e1	DDI-DrugBank.d723.s0.e5
DDI-DrugBank.d723.s0	false	DDI-DrugBank.d723.s0.e2	DDI-DrugBank.d723.s0.e3
DDI-DrugBank.d704.s0|a|Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between FLOMAX capsules and other alpha-adrenergic blocking agents have not been determined. 
DDI-DrugBank.d704.s0	85	90	FLOMAX	brand	DDI-DrugBank.d704.s0.e0
DDI-DrugBank.d704.s0	111	142	alpha-adrenergic blocking agents	group	DDI-DrugBank.d704.s0.e1
DDI-DrugBank.d704.s0	false	DDI-DrugBank.d704.s0.e0	DDI-DrugBank.d704.s0.e1
DDI-DrugBank.d704.s1|a|However, interactions may be expected and FLOMAX capsules should NOT be used in combination with other alpha-adrenergic blocking agents. 
DDI-DrugBank.d704.s1	42	47	FLOMAX	brand	DDI-DrugBank.d704.s1.e0
DDI-DrugBank.d704.s1	103	134	alpha-adrenergic blocking agents	group	DDI-DrugBank.d704.s1.e1
DDI-DrugBank.d704.s1	true	DDI-DrugBank.d704.s1.e0	DDI-DrugBank.d704.s1.e1
DDI-DrugBank.d704.s2|a|The pharmacokinetic interaction between cimetidine and FLOMAX capsules was investigated. 
DDI-DrugBank.d704.s2	40	49	cimetidine	drug	DDI-DrugBank.d704.s2.e0
DDI-DrugBank.d704.s2	55	60	FLOMAX	brand	DDI-DrugBank.d704.s2.e1
DDI-DrugBank.d704.s2	false	DDI-DrugBank.d704.s2.e0	DDI-DrugBank.d704.s2.e1
DDI-DrugBank.d704.s3|a|The results indicate significant changes in tamsulosin HCI clearance (26% decrease) and AUC (44% increase). 
DDI-DrugBank.d704.s3	44	57	tamsulosin HCI	drug	DDI-DrugBank.d704.s3.e0
DDI-DrugBank.d704.s4|a|Therefore, FLOMAX capsules should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg. 
DDI-DrugBank.d704.s4	11	16	FLOMAX	brand	DDI-DrugBank.d704.s4.e0
DDI-DrugBank.d704.s4	75	84	cimetidine	drug	DDI-DrugBank.d704.s4.e1
DDI-DrugBank.d704.s4	true	DDI-DrugBank.d704.s4.e0	DDI-DrugBank.d704.s4.e1
DDI-DrugBank.d704.s5|a|Results from limited in vitro and in vivo drug-drug interaction studies between tamsulosin HCI and warfarin are inconclusive. 
DDI-DrugBank.d704.s5	80	93	tamsulosin HCI	drug	DDI-DrugBank.d704.s5.e0
DDI-DrugBank.d704.s5	99	106	warfarin	drug	DDI-DrugBank.d704.s5.e1
DDI-DrugBank.d704.s5	false	DDI-DrugBank.d704.s5.e0	DDI-DrugBank.d704.s5.e1
DDI-DrugBank.d704.s6|a|Therefore, caution should be exercised with concomitant administration of warfarin and FLOMAX capsules.        
DDI-DrugBank.d704.s6	74	81	warfarin	drug	DDI-DrugBank.d704.s6.e0
DDI-DrugBank.d704.s6	87	92	FLOMAX	brand	DDI-DrugBank.d704.s6.e1
DDI-DrugBank.d704.s6	true	DDI-DrugBank.d704.s6.e0	DDI-DrugBank.d704.s6.e1
DDI-DrugBank.d687.s0|a|Administration of valproic acid decreases oral clearance of temozolomide by about 5%. 
DDI-DrugBank.d687.s0	18	30	valproic acid	drug	DDI-DrugBank.d687.s0.e0
DDI-DrugBank.d687.s0	60	71	temozolomide	drug	DDI-DrugBank.d687.s0.e1
DDI-DrugBank.d687.s0	true	DDI-DrugBank.d687.s0.e0	DDI-DrugBank.d687.s0.e1
DDI-DrugBank.d687.s1|a|The clinical implication of this effect is not known. 
DDI-DrugBank.d687.s2|a|Patients with Severe Hepatic or Renal Impairment Caution should be exercised when TEMODAR Capsules are administered to patients with severe hepatic or renal impairment.
DDI-DrugBank.d687.s2	82	88	TEMODAR	brand	DDI-DrugBank.d687.s2.e0
DDI-DrugBank.d773.s0|a|Formal interaction studies of TNKase with other drugs have not been performed. 
DDI-DrugBank.d773.s0	30	35	TNKase	brand	DDI-DrugBank.d773.s0.e0
DDI-DrugBank.d773.s1|a|Patients studied in clinical trials of TNKase were routinely treated with heparin and aspirin. 
DDI-DrugBank.d773.s1	39	44	TNKase	brand	DDI-DrugBank.d773.s1.e0
DDI-DrugBank.d773.s1	74	80	heparin	drug	DDI-DrugBank.d773.s1.e1
DDI-DrugBank.d773.s1	86	92	aspirin	brand	DDI-DrugBank.d773.s1.e2
DDI-DrugBank.d773.s1	false	DDI-DrugBank.d773.s1.e0	DDI-DrugBank.d773.s1.e1
DDI-DrugBank.d773.s1	false	DDI-DrugBank.d773.s1.e0	DDI-DrugBank.d773.s1.e2
DDI-DrugBank.d773.s1	false	DDI-DrugBank.d773.s1.e1	DDI-DrugBank.d773.s1.e2
DDI-DrugBank.d773.s2|a|Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. 
DDI-DrugBank.d773.s2	0	13	Anticoagulants	group	DDI-DrugBank.d773.s2.e0
DDI-DrugBank.d773.s2	24	30	heparin	drug	DDI-DrugBank.d773.s2.e1
DDI-DrugBank.d773.s2	36	56	vitamin K antagonists	group	DDI-DrugBank.d773.s2.e2
DDI-DrugBank.d773.s2	107	126	acetylsalicylic acid	drug	DDI-DrugBank.d773.s2.e3
DDI-DrugBank.d773.s2	129	140	dipyridamole	drug	DDI-DrugBank.d773.s2.e4
DDI-DrugBank.d773.s2	248	253	TNKase	brand	DDI-DrugBank.d773.s2.e5
DDI-DrugBank.d773.s2	false	DDI-DrugBank.d773.s2.e0	DDI-DrugBank.d773.s2.e1
DDI-DrugBank.d773.s2	false	DDI-DrugBank.d773.s2.e0	DDI-DrugBank.d773.s2.e2
DDI-DrugBank.d773.s2	false	DDI-DrugBank.d773.s2.e0	DDI-DrugBank.d773.s2.e3
DDI-DrugBank.d773.s2	false	DDI-DrugBank.d773.s2.e0	DDI-DrugBank.d773.s2.e4
DDI-DrugBank.d773.s2	true	DDI-DrugBank.d773.s2.e0	DDI-DrugBank.d773.s2.e5
DDI-DrugBank.d773.s2	false	DDI-DrugBank.d773.s2.e1	DDI-DrugBank.d773.s2.e2
DDI-DrugBank.d773.s2	false	DDI-DrugBank.d773.s2.e1	DDI-DrugBank.d773.s2.e3
DDI-DrugBank.d773.s2	false	DDI-DrugBank.d773.s2.e1	DDI-DrugBank.d773.s2.e4
DDI-DrugBank.d773.s2	true	DDI-DrugBank.d773.s2.e1	DDI-DrugBank.d773.s2.e5
DDI-DrugBank.d773.s2	false	DDI-DrugBank.d773.s2.e2	DDI-DrugBank.d773.s2.e3
DDI-DrugBank.d773.s3|a|Drug/Laboratory Test Interactions During TNKase therapy, results of coagulation tests and/or measures of fibrinolytic activity may be unreliable unless specific precautions are taken to prevent in vitro artifacts. 
DDI-DrugBank.d773.s3	41	46	TNKase	brand	DDI-DrugBank.d773.s3.e0
DDI-DrugBank.d773.s4|a|Tenecteplase is an enzyme that, when present in blood in pharmacologic concentrations, remains active under in vitro conditions. 
DDI-DrugBank.d773.s4	0	11	Tenecteplase	drug	DDI-DrugBank.d773.s4.e0
DDI-DrugBank.d773.s5|a|This can lead to degradation of fibrinogen in blood samples removed for analysis.
DDI-DrugBank.d575.s0|a|In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. 
DDI-DrugBank.d575.s0	95	105	tolbutamide	drug	DDI-DrugBank.d575.s0.e0
DDI-DrugBank.d575.s0	108	124	sodium salicylate	drug	DDI-DrugBank.d575.s0.e1
DDI-DrugBank.d575.s0	130	143	sulfamethizole	drug	DDI-DrugBank.d575.s0.e2
DDI-DrugBank.d575.s0	169	178	teniposide	drug	DDI-DrugBank.d575.s0.e3
DDI-DrugBank.d575.s0	false	DDI-DrugBank.d575.s0.e0	DDI-DrugBank.d575.s0.e1
DDI-DrugBank.d575.s0	false	DDI-DrugBank.d575.s0.e0	DDI-DrugBank.d575.s0.e2
DDI-DrugBank.d575.s0	true	DDI-DrugBank.d575.s0.e0	DDI-DrugBank.d575.s0.e3
DDI-DrugBank.d575.s0	false	DDI-DrugBank.d575.s0.e1	DDI-DrugBank.d575.s0.e2
DDI-DrugBank.d575.s0	true	DDI-DrugBank.d575.s0.e1	DDI-DrugBank.d575.s0.e3
DDI-DrugBank.d575.s0	true	DDI-DrugBank.d575.s0.e2	DDI-DrugBank.d575.s0.e3
DDI-DrugBank.d575.s1|a|Because of the extremely high binding of teniposide to plasma proteins, these small decreases in binding could cause substantial increases in free drug levels in plasma which could result in potentiation of drug toxicity. 
DDI-DrugBank.d575.s1	41	50	teniposide	drug	DDI-DrugBank.d575.s1.e0
DDI-DrugBank.d575.s2|a|Therefore, caution should be used in administering VUMON (teniposide injection) to patients receiving these other agents. 
DDI-DrugBank.d575.s2	51	55	VUMON	brand	DDI-DrugBank.d575.s2.e0
DDI-DrugBank.d575.s2	58	67	teniposide	drug	DDI-DrugBank.d575.s2.e1
DDI-DrugBank.d575.s2	false	DDI-DrugBank.d575.s2.e0	DDI-DrugBank.d575.s2.e1
DDI-DrugBank.d575.s3|a|There was no change in the plasma kinetics of teniposide when coadministered with methotrexate. 
DDI-DrugBank.d575.s3	46	55	teniposide	drug	DDI-DrugBank.d575.s3.e0
DDI-DrugBank.d575.s3	82	93	methotrexate	drug	DDI-DrugBank.d575.s3.e1
DDI-DrugBank.d575.s3	false	DDI-DrugBank.d575.s3.e0	DDI-DrugBank.d575.s3.e1
DDI-DrugBank.d575.s4|a|However, the plasma clearance of methotrexate was slightly increased. 
DDI-DrugBank.d575.s4	33	44	methotrexate	drug	DDI-DrugBank.d575.s4.e0
DDI-DrugBank.d575.s5|a|An increase in intracellular levels of methotrexate was observed in vitro in the presence of teniposide.
DDI-DrugBank.d575.s5	39	50	methotrexate	drug	DDI-DrugBank.d575.s5.e0
DDI-DrugBank.d575.s5	93	102	teniposide	drug	DDI-DrugBank.d575.s5.e1
DDI-DrugBank.d575.s5	true	DDI-DrugBank.d575.s5.e0	DDI-DrugBank.d575.s5.e1
DDI-DrugBank.d645.s0|a|In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. 
DDI-DrugBank.d645.s0	57	67	terbinafine	drug	DDI-DrugBank.d645.s0.e0
DDI-DrugBank.d645.s0	104	114	tolbutamide	drug	DDI-DrugBank.d645.s0.e1
DDI-DrugBank.d645.s0	117	132	ethinylestradiol	drug	DDI-DrugBank.d645.s0.e2
DDI-DrugBank.d645.s0	135	148	ethoxycoumarin	drug_n	DDI-DrugBank.d645.s0.e3
DDI-DrugBank.d645.s0	155	166	cyclosporine	drug	DDI-DrugBank.d645.s0.e4
DDI-DrugBank.d645.s0	false	DDI-DrugBank.d645.s0.e0	DDI-DrugBank.d645.s0.e1
DDI-DrugBank.d645.s0	false	DDI-DrugBank.d645.s0.e0	DDI-DrugBank.d645.s0.e2
DDI-DrugBank.d645.s0	false	DDI-DrugBank.d645.s0.e0	DDI-DrugBank.d645.s0.e3
DDI-DrugBank.d645.s0	false	DDI-DrugBank.d645.s0.e0	DDI-DrugBank.d645.s0.e4
DDI-DrugBank.d645.s0	false	DDI-DrugBank.d645.s0.e1	DDI-DrugBank.d645.s0.e2
DDI-DrugBank.d645.s0	false	DDI-DrugBank.d645.s0.e1	DDI-DrugBank.d645.s0.e3
DDI-DrugBank.d645.s0	false	DDI-DrugBank.d645.s0.e1	DDI-DrugBank.d645.s0.e4
DDI-DrugBank.d645.s0	false	DDI-DrugBank.d645.s0.e2	DDI-DrugBank.d645.s0.e3
DDI-DrugBank.d645.s0	false	DDI-DrugBank.d645.s0.e2	DDI-DrugBank.d645.s0.e4
DDI-DrugBank.d645.s0	false	DDI-DrugBank.d645.s0.e3	DDI-DrugBank.d645.s0.e4
DDI-DrugBank.d645.s1|a|In vitro studies have also shown that terbinafine inhibits CYP2D6-mediated metabolism. 
DDI-DrugBank.d645.s1	38	48	terbinafine	drug	DDI-DrugBank.d645.s1.e0
DDI-DrugBank.d645.s2|a|This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (SSRIs), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window. 
DDI-DrugBank.d645.s2	98	122	tricyclic antidepressants	group	DDI-DrugBank.d645.s2.e0
DDI-DrugBank.d645.s2	139	177	selective serotonin reuptake inhibitors	group	DDI-DrugBank.d645.s2.e1
DDI-DrugBank.d645.s2	180	184	SSRIs	group	DDI-DrugBank.d645.s2.e2
DDI-DrugBank.d645.s2	192	235	monoamine oxidase inhibitors (MAO-Is) Type B	group	DDI-DrugBank.d645.s2.e3
DDI-DrugBank.d645.s2	false	DDI-DrugBank.d645.s2.e0	DDI-DrugBank.d645.s2.e1
DDI-DrugBank.d645.s2	false	DDI-DrugBank.d645.s2.e0	DDI-DrugBank.d645.s2.e2
DDI-DrugBank.d645.s2	false	DDI-DrugBank.d645.s2.e0	DDI-DrugBank.d645.s2.e3
DDI-DrugBank.d645.s2	false	DDI-DrugBank.d645.s2.e1	DDI-DrugBank.d645.s2.e2
DDI-DrugBank.d645.s2	false	DDI-DrugBank.d645.s2.e1	DDI-DrugBank.d645.s2.e3
DDI-DrugBank.d645.s2	false	DDI-DrugBank.d645.s2.e2	DDI-DrugBank.d645.s2.e3
DDI-DrugBank.d645.s3|a|In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of antipyrine or digoxin. 
DDI-DrugBank.d645.s3	89	99	terbinafine	drug	DDI-DrugBank.d645.s3.e0
DDI-DrugBank.d645.s3	134	143	antipyrine	drug	DDI-DrugBank.d645.s3.e1
DDI-DrugBank.d645.s3	148	154	digoxin	drug	DDI-DrugBank.d645.s3.e2
DDI-DrugBank.d645.s3	false	DDI-DrugBank.d645.s3.e0	DDI-DrugBank.d645.s3.e1
DDI-DrugBank.d645.s3	false	DDI-DrugBank.d645.s3.e0	DDI-DrugBank.d645.s3.e2
DDI-DrugBank.d645.s3	false	DDI-DrugBank.d645.s3.e1	DDI-DrugBank.d645.s3.e2
DDI-DrugBank.d645.s4|a|Terbinafine decreases the clearance of caffeine by 19%. 
DDI-DrugBank.d645.s4	0	10	Terbinafine	drug	DDI-DrugBank.d645.s4.e0
DDI-DrugBank.d645.s4	39	46	caffeine	drug	DDI-DrugBank.d645.s4.e1
DDI-DrugBank.d645.s4	true	DDI-DrugBank.d645.s4.e0	DDI-DrugBank.d645.s4.e1
DDI-DrugBank.d645.s5|a|Terbinafine increases the clearance of cyclosporine by 15%. 
DDI-DrugBank.d645.s5	0	10	Terbinafine	drug	DDI-DrugBank.d645.s5.e0
DDI-DrugBank.d645.s5	39	50	cyclosporine	drug	DDI-DrugBank.d645.s5.e1
DDI-DrugBank.d645.s5	true	DDI-DrugBank.d645.s5.e0	DDI-DrugBank.d645.s5.e1
DDI-DrugBank.d645.s6|a|There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin, however, a causal relationship between LAMISIL    Tablets and these changes has not been established. 
DDI-DrugBank.d645.s6	119	129	terbinafine	drug	DDI-DrugBank.d645.s6.e0
DDI-DrugBank.d645.s6	135	142	warfarin	drug	DDI-DrugBank.d645.s6.e1
DDI-DrugBank.d645.s6	184	190	LAMISIL	brand	DDI-DrugBank.d645.s6.e2
DDI-DrugBank.d645.s6	true	DDI-DrugBank.d645.s6.e0	DDI-DrugBank.d645.s6.e1
DDI-DrugBank.d645.s6	false	DDI-DrugBank.d645.s6.e0	DDI-DrugBank.d645.s6.e2
DDI-DrugBank.d645.s6	false	DDI-DrugBank.d645.s6.e1	DDI-DrugBank.d645.s6.e2
DDI-DrugBank.d645.s7|a|Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. 
DDI-DrugBank.d645.s7	0	10	Terbinafine	drug	DDI-DrugBank.d645.s7.e0
DDI-DrugBank.d645.s7	43	50	rifampin	drug	DDI-DrugBank.d645.s7.e1
DDI-DrugBank.d645.s7	99	108	cimetidine	drug	DDI-DrugBank.d645.s7.e2
DDI-DrugBank.d645.s7	true	DDI-DrugBank.d645.s7.e0	DDI-DrugBank.d645.s7.e1
DDI-DrugBank.d645.s7	true	DDI-DrugBank.d645.s7.e0	DDI-DrugBank.d645.s7.e2
DDI-DrugBank.d645.s7	false	DDI-DrugBank.d645.s7.e1	DDI-DrugBank.d645.s7.e2
DDI-DrugBank.d645.s8|a|Terbinafine clearance is unaffected by cyclosporine. 
DDI-DrugBank.d645.s8	0	10	Terbinafine	drug	DDI-DrugBank.d645.s8.e0
DDI-DrugBank.d645.s8	39	50	cyclosporine	drug	DDI-DrugBank.d645.s8.e1
DDI-DrugBank.d645.s8	false	DDI-DrugBank.d645.s8.e0	DDI-DrugBank.d645.s8.e1
DDI-DrugBank.d645.s9|a|There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.
DDI-DrugBank.d645.s9	120	133	contraceptives	group	DDI-DrugBank.d645.s9.e0
DDI-DrugBank.d645.s9	167	179	hypoglycemics	group	DDI-DrugBank.d645.s9.e1
DDI-DrugBank.d645.s9	182	194	theophyllines	drug	DDI-DrugBank.d645.s9.e2
DDI-DrugBank.d645.s9	197	206	phenytoins	drug	DDI-DrugBank.d645.s9.e3
DDI-DrugBank.d645.s9	209	226	thiazide diuretics	group	DDI-DrugBank.d645.s9.e4
DDI-DrugBank.d645.s9	229	241	beta blockers	group	DDI-DrugBank.d645.s9.e5
DDI-DrugBank.d645.s9	248	271	calcium channel blockers	group	DDI-DrugBank.d645.s9.e6
DDI-DrugBank.d645.s9	false	DDI-DrugBank.d645.s9.e0	DDI-DrugBank.d645.s9.e1
DDI-DrugBank.d645.s9	false	DDI-DrugBank.d645.s9.e0	DDI-DrugBank.d645.s9.e2
DDI-DrugBank.d645.s9	false	DDI-DrugBank.d645.s9.e0	DDI-DrugBank.d645.s9.e3
DDI-DrugBank.d645.s9	false	DDI-DrugBank.d645.s9.e0	DDI-DrugBank.d645.s9.e4
DDI-DrugBank.d645.s9	false	DDI-DrugBank.d645.s9.e0	DDI-DrugBank.d645.s9.e5
DDI-DrugBank.d645.s9	false	DDI-DrugBank.d645.s9.e0	DDI-DrugBank.d645.s9.e6
DDI-DrugBank.d645.s9	false	DDI-DrugBank.d645.s9.e1	DDI-DrugBank.d645.s9.e2
DDI-DrugBank.d645.s9	false	DDI-DrugBank.d645.s9.e1	DDI-DrugBank.d645.s9.e3
DDI-DrugBank.d645.s9	false	DDI-DrugBank.d645.s9.e1	DDI-DrugBank.d645.s9.e4
DDI-DrugBank.d645.s9	false	DDI-DrugBank.d645.s9.e1	DDI-DrugBank.d645.s9.e5
DDI-DrugBank.d743.s0|a|Ketoconazole: Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events, e.g. 
DDI-DrugBank.d743.s0	0	11	Ketoconazole	drug	DDI-DrugBank.d743.s0.e0
DDI-DrugBank.d743.s0	82	93	ketoconazole	drug	DDI-DrugBank.d743.s0.e1
DDI-DrugBank.d743.s0	121	131	terfenadine	drug	DDI-DrugBank.d743.s0.e2
DDI-DrugBank.d743.s0	false	DDI-DrugBank.d743.s0.e0	DDI-DrugBank.d743.s0.e1
DDI-DrugBank.d743.s0	false	DDI-DrugBank.d743.s0.e0	DDI-DrugBank.d743.s0.e2
DDI-DrugBank.d743.s0	true	DDI-DrugBank.d743.s0.e1	DDI-DrugBank.d743.s0.e2
DDI-DrugBank.d743.s1|a|death, cardiac arrest, and ventricular arrhythmia including torsades de pointes. 
DDI-DrugBank.d743.s2|a|Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine, resulting in elevated plasma terfenadine levels. 
DDI-DrugBank.d743.s2	35	46	ketoconazole	drug	DDI-DrugBank.d743.s2.e0
DDI-DrugBank.d743.s2	84	94	terfenadine	drug	DDI-DrugBank.d743.s2.e1
DDI-DrugBank.d743.s2	126	136	terfenadine	drug	DDI-DrugBank.d743.s2.e2
DDI-DrugBank.d743.s2	true	DDI-DrugBank.d743.s2.e0	DDI-DrugBank.d743.s2.e1
DDI-DrugBank.d743.s2	false	DDI-DrugBank.d743.s2.e0	DDI-DrugBank.d743.s2.e2
DDI-DrugBank.d743.s2	false	DDI-DrugBank.d743.s2.e1	DDI-DrugBank.d743.s2.e2
DDI-DrugBank.d743.s3|a|Presence of unchanged terfenadine is associated with statistically significant prolongation of the QT and QTc intervals.
DDI-DrugBank.d743.s3	22	32	terfenadine	drug	DDI-DrugBank.d743.s3.e0
DDI-DrugBank.d743.s4|a|Concomitant administration of ketoconazole and terfenadine is contraindicated. 
DDI-DrugBank.d743.s4	30	41	ketoconazole	drug	DDI-DrugBank.d743.s4.e0
DDI-DrugBank.d743.s4	47	57	terfenadine	drug	DDI-DrugBank.d743.s4.e1
DDI-DrugBank.d743.s4	true	DDI-DrugBank.d743.s4.e0	DDI-DrugBank.d743.s4.e1
DDI-DrugBank.d743.s5|a|Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. 
DDI-DrugBank.d743.s5	0	11	Itraconazole	drug	DDI-DrugBank.d743.s5.e0
DDI-DrugBank.d743.s5	54	64	terfenadine	drug	DDI-DrugBank.d743.s5.e1
DDI-DrugBank.d743.s5	118	128	terfenadine	drug	DDI-DrugBank.d743.s5.e2
DDI-DrugBank.d743.s5	134	145	itraconazole	drug	DDI-DrugBank.d743.s5.e3
DDI-DrugBank.d743.s5	169	180	itraconazole	drug	DDI-DrugBank.d743.s5.e4
DDI-DrugBank.d743.s5	false	DDI-DrugBank.d743.s5.e0	DDI-DrugBank.d743.s5.e1
DDI-DrugBank.d743.s5	false	DDI-DrugBank.d743.s5.e0	DDI-DrugBank.d743.s5.e2
DDI-DrugBank.d743.s5	false	DDI-DrugBank.d743.s5.e0	DDI-DrugBank.d743.s5.e3
DDI-DrugBank.d743.s5	false	DDI-DrugBank.d743.s5.e0	DDI-DrugBank.d743.s5.e4
DDI-DrugBank.d743.s5	false	DDI-DrugBank.d743.s5.e1	DDI-DrugBank.d743.s5.e2
DDI-DrugBank.d743.s5	false	DDI-DrugBank.d743.s5.e1	DDI-DrugBank.d743.s5.e3
DDI-DrugBank.d743.s5	false	DDI-DrugBank.d743.s5.e1	DDI-DrugBank.d743.s5.e4
DDI-DrugBank.d743.s5	true	DDI-DrugBank.d743.s5.e2	DDI-DrugBank.d743.s5.e3
DDI-DrugBank.d743.s5	false	DDI-DrugBank.d743.s5.e2	DDI-DrugBank.d743.s5.e4
DDI-DrugBank.d743.s5	false	DDI-DrugBank.d743.s5.e3	DDI-DrugBank.d743.s5.e4
DDI-DrugBank.d743.s6|a|One death has also been reported from foreign post- marketing sources. 
DDI-DrugBank.d743.s7|a|Concomitant administration of itraconazole and terfenadine is contraindicated. 
DDI-DrugBank.d743.s7	30	41	itraconazole	drug	DDI-DrugBank.d743.s7.e0
DDI-DrugBank.d743.s7	47	57	terfenadine	drug	DDI-DrugBank.d743.s7.e1
DDI-DrugBank.d743.s7	true	DDI-DrugBank.d743.s7.e0	DDI-DrugBank.d743.s7.e1
DDI-DrugBank.d743.s8|a|Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. 
DDI-DrugBank.d743.s8	40	67	azole-type antifungal agents	group	DDI-DrugBank.d743.s8.e0
DDI-DrugBank.d743.s8	80	90	fluconazole	drug	DDI-DrugBank.d743.s8.e1
DDI-DrugBank.d743.s8	93	105	metronidazole	drug	DDI-DrugBank.d743.s8.e2
DDI-DrugBank.d743.s8	112	121	miconazole	drug	DDI-DrugBank.d743.s8.e3
DDI-DrugBank.d743.s8	127	138	ketoconazole	drug	DDI-DrugBank.d743.s8.e4
DDI-DrugBank.d743.s8	145	156	itraconazole	drug	DDI-DrugBank.d743.s8.e5
DDI-DrugBank.d743.s8	198	208	terfenadine	drug	DDI-DrugBank.d743.s8.e6
DDI-DrugBank.d743.s8	false	DDI-DrugBank.d743.s8.e0	DDI-DrugBank.d743.s8.e1
DDI-DrugBank.d743.s8	false	DDI-DrugBank.d743.s8.e0	DDI-DrugBank.d743.s8.e2
DDI-DrugBank.d743.s8	false	DDI-DrugBank.d743.s8.e0	DDI-DrugBank.d743.s8.e3
DDI-DrugBank.d743.s8	false	DDI-DrugBank.d743.s8.e0	DDI-DrugBank.d743.s8.e4
DDI-DrugBank.d743.s8	false	DDI-DrugBank.d743.s8.e0	DDI-DrugBank.d743.s8.e5
DDI-DrugBank.d743.s8	true	DDI-DrugBank.d743.s8.e0	DDI-DrugBank.d743.s8.e6
DDI-DrugBank.d743.s8	false	DDI-DrugBank.d743.s8.e1	DDI-DrugBank.d743.s8.e2
DDI-DrugBank.d743.s8	false	DDI-DrugBank.d743.s8.e1	DDI-DrugBank.d743.s8.e3
DDI-DrugBank.d743.s8	false	DDI-DrugBank.d743.s8.e1	DDI-DrugBank.d743.s8.e4
DDI-DrugBank.d743.s8	false	DDI-DrugBank.d743.s8.e1	DDI-DrugBank.d743.s8.e5
DDI-DrugBank.d743.s9|a|Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. 
DDI-DrugBank.d743.s9	0	9	Macrolides	group	DDI-DrugBank.d743.s9.e0
DDI-DrugBank.d743.s9	60	71	erythromycin	drug	DDI-DrugBank.d743.s9.e1
DDI-DrugBank.d743.s9	77	90	clarithromycin	drug	DDI-DrugBank.d743.s9.e2
DDI-DrugBank.d743.s9	115	125	terfenadine	drug	DDI-DrugBank.d743.s9.e3
DDI-DrugBank.d743.s9	185	196	ketoconazole	drug	DDI-DrugBank.d743.s9.e4
DDI-DrugBank.d743.s9	false	DDI-DrugBank.d743.s9.e0	DDI-DrugBank.d743.s9.e1
DDI-DrugBank.d743.s9	false	DDI-DrugBank.d743.s9.e0	DDI-DrugBank.d743.s9.e2
DDI-DrugBank.d743.s9	false	DDI-DrugBank.d743.s9.e0	DDI-DrugBank.d743.s9.e3
DDI-DrugBank.d743.s9	false	DDI-DrugBank.d743.s9.e0	DDI-DrugBank.d743.s9.e4
DDI-DrugBank.d743.s9	false	DDI-DrugBank.d743.s9.e1	DDI-DrugBank.d743.s9.e2
DDI-DrugBank.d743.s9	true	DDI-DrugBank.d743.s9.e1	DDI-DrugBank.d743.s9.e3
DDI-DrugBank.d743.s9	false	DDI-DrugBank.d743.s9.e1	DDI-DrugBank.d743.s9.e4
DDI-DrugBank.d743.s9	true	DDI-DrugBank.d743.s9.e2	DDI-DrugBank.d743.s9.e3
DDI-DrugBank.d743.s9	false	DDI-DrugBank.d743.s9.e2	DDI-DrugBank.d743.s9.e4
DDI-DrugBank.d743.s9	false	DDI-DrugBank.d743.s9.e3	DDI-DrugBank.d743.s9.e4
DDI-DrugBank.d743.s10|a|Although erythromycin measurably decreases the clearance of the terfenadine acid metabolite, its influence on terfenadine plasma levels is still under investigation. 
DDI-DrugBank.d743.s10	64	74	terfenadine	drug	DDI-DrugBank.d743.s10.e0
DDI-DrugBank.d743.s11|a|A few spontaneous accounts of QT interval prolongation with ventricular arrhythmia including torsades de pointes, have been reported in patients receiving erythromycin or troleandomycin. 
DDI-DrugBank.d743.s11	155	166	erythromycin	drug	DDI-DrugBank.d743.s11.e0
DDI-DrugBank.d743.s11	171	184	troleandomycin	drug	DDI-DrugBank.d743.s11.e1
DDI-DrugBank.d743.s11	false	DDI-DrugBank.d743.s11.e0	DDI-DrugBank.d743.s11.e1
DDI-DrugBank.d743.s12|a|Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. 
DDI-DrugBank.d743.s12	30	40	terfenadine	drug	DDI-DrugBank.d743.s12.e0
DDI-DrugBank.d743.s12	47	60	clarithromycin	drug	DDI-DrugBank.d743.s12.e1
DDI-DrugBank.d743.s12	63	74	erythromycin	drug	DDI-DrugBank.d743.s12.e2
DDI-DrugBank.d743.s12	80	93	troleandomycin	drug	DDI-DrugBank.d743.s12.e3
DDI-DrugBank.d743.s12	202	212	terfenadine	drug	DDI-DrugBank.d743.s12.e4
DDI-DrugBank.d743.s12	225	245	macrolide antibiotics	group	DDI-DrugBank.d743.s12.e5
DDI-DrugBank.d743.s12	258	269	azithromycin	drug	DDI-DrugBank.d743.s12.e6
DDI-DrugBank.d743.s12	true	DDI-DrugBank.d743.s12.e0	DDI-DrugBank.d743.s12.e1
DDI-DrugBank.d743.s12	true	DDI-DrugBank.d743.s12.e0	DDI-DrugBank.d743.s12.e2
DDI-DrugBank.d743.s12	true	DDI-DrugBank.d743.s12.e0	DDI-DrugBank.d743.s12.e3
DDI-DrugBank.d743.s12	false	DDI-DrugBank.d743.s12.e0	DDI-DrugBank.d743.s12.e4
DDI-DrugBank.d743.s12	false	DDI-DrugBank.d743.s12.e0	DDI-DrugBank.d743.s12.e5
DDI-DrugBank.d743.s12	false	DDI-DrugBank.d743.s12.e0	DDI-DrugBank.d743.s12.e6
DDI-DrugBank.d743.s12	false	DDI-DrugBank.d743.s12.e1	DDI-DrugBank.d743.s12.e2
DDI-DrugBank.d743.s12	false	DDI-DrugBank.d743.s12.e1	DDI-DrugBank.d743.s12.e3
DDI-DrugBank.d743.s12	false	DDI-DrugBank.d743.s12.e1	DDI-DrugBank.d743.s12.e4
DDI-DrugBank.d743.s12	false	DDI-DrugBank.d743.s12.e1	DDI-DrugBank.d743.s12.e5
DDI-DrugBank.d743.s13|a|Studies to evaluate potential interactions of terfenadine with azithromycin are in progress.
DDI-DrugBank.d743.s13	46	56	terfenadine	drug	DDI-DrugBank.d743.s13.e0
DDI-DrugBank.d743.s13	63	74	azithromycin	drug	DDI-DrugBank.d743.s13.e1
DDI-DrugBank.d743.s13	false	DDI-DrugBank.d743.s13.e0	DDI-DrugBank.d743.s13.e1
DDI-DrugBank.d658.s0|a|When administered concurrently, testolactone may increase the effects of oral anticoagulants; 
DDI-DrugBank.d658.s0	32	43	testolactone	drug	DDI-DrugBank.d658.s0.e0
DDI-DrugBank.d658.s0	78	91	anticoagulants	group	DDI-DrugBank.d658.s0.e1
DDI-DrugBank.d658.s0	true	DDI-DrugBank.d658.s0.e0	DDI-DrugBank.d658.s0.e1
DDI-DrugBank.d658.s1|a|monitor and adjust anticoagulant dosage accordingly. 
DDI-DrugBank.d658.s1	19	31	anticoagulant	group	DDI-DrugBank.d658.s1.e0
DDI-DrugBank.d658.s2|a|Drug/Laboratory Test Interactions: Physiologic effects of testolactone may result in decreased estradiol concentrations with radioimmunoassays for estradiol, increased plasma calcium concentrations, and increased 24-hour urinary excretion of creatine and 17-ketosteroids.
DDI-DrugBank.d658.s2	58	69	testolactone	drug	DDI-DrugBank.d658.s2.e0
DDI-DrugBank.d604.s0|a|Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. 
DDI-DrugBank.d604.s0	0	10	Thalidomide	drug	DDI-DrugBank.d604.s0.e0
DDI-DrugBank.d604.s0	66	77	barbiturates	group	DDI-DrugBank.d604.s0.e1
DDI-DrugBank.d604.s0	80	86	alcohol	drug	DDI-DrugBank.d604.s0.e2
DDI-DrugBank.d604.s0	89	102	chlorpromazine	drug	DDI-DrugBank.d604.s0.e3
DDI-DrugBank.d604.s0	109	117	reserpine	drug	DDI-DrugBank.d604.s0.e4
DDI-DrugBank.d604.s0	true	DDI-DrugBank.d604.s0.e0	DDI-DrugBank.d604.s0.e1
DDI-DrugBank.d604.s0	false	DDI-DrugBank.d604.s0.e0	DDI-DrugBank.d604.s0.e2
DDI-DrugBank.d604.s0	false	DDI-DrugBank.d604.s0.e0	DDI-DrugBank.d604.s0.e3
DDI-DrugBank.d604.s0	false	DDI-DrugBank.d604.s0.e0	DDI-DrugBank.d604.s0.e4
DDI-DrugBank.d604.s0	false	DDI-DrugBank.d604.s0.e1	DDI-DrugBank.d604.s0.e2
DDI-DrugBank.d604.s0	false	DDI-DrugBank.d604.s0.e1	DDI-DrugBank.d604.s0.e3
DDI-DrugBank.d604.s0	false	DDI-DrugBank.d604.s0.e1	DDI-DrugBank.d604.s0.e4
DDI-DrugBank.d604.s0	false	DDI-DrugBank.d604.s0.e2	DDI-DrugBank.d604.s0.e3
DDI-DrugBank.d604.s0	false	DDI-DrugBank.d604.s0.e2	DDI-DrugBank.d604.s0.e4
DDI-DrugBank.d604.s0	false	DDI-DrugBank.d604.s0.e3	DDI-DrugBank.d604.s0.e4
DDI-DrugBank.d604.s1|a|Peripheral Neuropathy: Medications known to be associated with peripheral neuropathy should be used with caution in patients receiving thalidomide. 
DDI-DrugBank.d604.s1	135	145	thalidomide	drug	DDI-DrugBank.d604.s1.e0
DDI-DrugBank.d604.s2|a|Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. 
DDI-DrugBank.d604.s2	5	18	Contraceptives	group	DDI-DrugBank.d604.s2.e0
DDI-DrugBank.d604.s2	74	86	norethindrone	drug	DDI-DrugBank.d604.s2.e1
DDI-DrugBank.d604.s2	92	108	ethinyl estradiol	drug	DDI-DrugBank.d604.s2.e2
DDI-DrugBank.d604.s2	173	193	norethindrone acetate	drug	DDI-DrugBank.d604.s2.e3
DDI-DrugBank.d604.s2	210	226	ethinyl estradiol	drug	DDI-DrugBank.d604.s2.e4
DDI-DrugBank.d604.s2	false	DDI-DrugBank.d604.s2.e0	DDI-DrugBank.d604.s2.e1
DDI-DrugBank.d604.s2	false	DDI-DrugBank.d604.s2.e0	DDI-DrugBank.d604.s2.e2
DDI-DrugBank.d604.s2	false	DDI-DrugBank.d604.s2.e0	DDI-DrugBank.d604.s2.e3
DDI-DrugBank.d604.s2	false	DDI-DrugBank.d604.s2.e0	DDI-DrugBank.d604.s2.e4
DDI-DrugBank.d604.s2	false	DDI-DrugBank.d604.s2.e1	DDI-DrugBank.d604.s2.e2
DDI-DrugBank.d604.s2	false	DDI-DrugBank.d604.s2.e1	DDI-DrugBank.d604.s2.e3
DDI-DrugBank.d604.s2	false	DDI-DrugBank.d604.s2.e1	DDI-DrugBank.d604.s2.e4
DDI-DrugBank.d604.s2	false	DDI-DrugBank.d604.s2.e2	DDI-DrugBank.d604.s2.e3
DDI-DrugBank.d604.s2	false	DDI-DrugBank.d604.s2.e2	DDI-DrugBank.d604.s2.e4
DDI-DrugBank.d604.s2	false	DDI-DrugBank.d604.s2.e3	DDI-DrugBank.d604.s2.e4
DDI-DrugBank.d604.s3|a|The results were similar with and without coadministration of thalidomide 200 mg/day to steady-state levels. 
DDI-DrugBank.d604.s3	62	72	thalidomide	drug	DDI-DrugBank.d604.s3.e0
DDI-DrugBank.d604.s4|a|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 
DDI-DrugBank.d604.s4	14	24	Thalidomide	drug	DDI-DrugBank.d604.s4.e0
DDI-DrugBank.d604.s4	70	92	Hormonal Contraceptives	group	DDI-DrugBank.d604.s4.e1
DDI-DrugBank.d604.s4	114	136	HIV-protease inhibitors	group	DDI-DrugBank.d604.s4.e2
DDI-DrugBank.d604.s4	139	150	griseofulvin	drug	DDI-DrugBank.d604.s4.e3
DDI-DrugBank.d604.s4	153	161	modafinil	drug	DDI-DrugBank.d604.s4.e4
DDI-DrugBank.d604.s4	164	174	penicillins	group	DDI-DrugBank.d604.s4.e5
DDI-DrugBank.d604.s4	177	184	rifampin	drug	DDI-DrugBank.d604.s4.e6
DDI-DrugBank.d604.s4	187	195	rifabutin	drug	DDI-DrugBank.d604.s4.e7
DDI-DrugBank.d604.s4	198	206	phenytoin	drug	DDI-DrugBank.d604.s4.e8
DDI-DrugBank.d604.s4	209	221	carbamazepine	drug	DDI-DrugBank.d604.s4.e9
DDI-DrugBank.d604.s4	false	DDI-DrugBank.d604.s4.e0	DDI-DrugBank.d604.s4.e1
DDI-DrugBank.d604.s4	false	DDI-DrugBank.d604.s4.e0	DDI-DrugBank.d604.s4.e2
DDI-DrugBank.d604.s4	false	DDI-DrugBank.d604.s4.e0	DDI-DrugBank.d604.s4.e3
DDI-DrugBank.d604.s4	false	DDI-DrugBank.d604.s4.e0	DDI-DrugBank.d604.s4.e4
DDI-DrugBank.d604.s4	false	DDI-DrugBank.d604.s4.e0	DDI-DrugBank.d604.s4.e5
DDI-DrugBank.d604.s4	false	DDI-DrugBank.d604.s4.e0	DDI-DrugBank.d604.s4.e6
DDI-DrugBank.d604.s4	false	DDI-DrugBank.d604.s4.e0	DDI-DrugBank.d604.s4.e7
DDI-DrugBank.d604.s4	false	DDI-DrugBank.d604.s4.e0	DDI-DrugBank.d604.s4.e8
DDI-DrugBank.d604.s4	false	DDI-DrugBank.d604.s4.e0	DDI-DrugBank.d604.s4.e9
DDI-DrugBank.d604.s4	false	DDI-DrugBank.d604.s4.e1	DDI-DrugBank.d604.s4.e2
DDI-DrugBank.d604.s5|a|John's Wort with hormonal contraceptive agents may reduce the effectiveness of the contraception and up to one month after discontinuation of these concomitant therapies. 
DDI-DrugBank.d604.s5	0	10	John's Wort	drug_n	DDI-DrugBank.d604.s5.e0
DDI-DrugBank.d604.s5	17	45	hormonal contraceptive agents	group	DDI-DrugBank.d604.s5.e1
DDI-DrugBank.d604.s5	true	DDI-DrugBank.d604.s5.e0	DDI-DrugBank.d604.s5.e1
DDI-DrugBank.d604.s6|a|Therefore, women requiring treatment with one or more of these drugs must use two OTHER effective or highly effective methods of contraception or abstain from heterosexual sexual contact while taking thalidomide.    
DDI-DrugBank.d604.s6	200	210	thalidomide	drug	DDI-DrugBank.d604.s6.e0
DDI-DrugBank.d686.s0|a|Thiabendazole may compete with other drugs, such as theophylline, for sites of metabolism in the liver, thus elevating the serum levels of such compounds to potentially toxic levels. 
DDI-DrugBank.d686.s0	0	12	Thiabendazole	drug	DDI-DrugBank.d686.s0.e0
DDI-DrugBank.d686.s0	52	63	theophylline	drug	DDI-DrugBank.d686.s0.e1
DDI-DrugBank.d686.s0	true	DDI-DrugBank.d686.s0.e0	DDI-DrugBank.d686.s0.e1
DDI-DrugBank.d686.s1|a|Therefore, when concomitant use of thiabendazole and xanthine derivatives is anticipated, it may be necessary to monitor blood levels and/or reduce the dosage of such compounds. 
DDI-DrugBank.d686.s1	35	47	thiabendazole	drug	DDI-DrugBank.d686.s1.e0
DDI-DrugBank.d686.s1	53	72	xanthine derivatives	group	DDI-DrugBank.d686.s1.e1
DDI-DrugBank.d686.s1	true	DDI-DrugBank.d686.s1.e0	DDI-DrugBank.d686.s1.e1
DDI-DrugBank.d686.s2|a|Such concomitant use should be administered under careful medical supervision.
DDI-DrugBank.d697.s0|a|Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants
DDI-DrugBank.d697.s0	17	26	Vitamin B1	drug	DDI-DrugBank.d697.s0.e0
DDI-DrugBank.d697.s0	29	36	Thiamine	drug	DDI-DrugBank.d697.s0.e1
DDI-DrugBank.d697.s0	41	54	Loop Diuretics	group	DDI-DrugBank.d697.s0.e2
DDI-DrugBank.d697.s0	62	75	Contraceptives	group	DDI-DrugBank.d697.s0.e3
DDI-DrugBank.d697.s0	78	86	Stavudine	drug	DDI-DrugBank.d697.s0.e4
DDI-DrugBank.d697.s0	89	113	Tricyclic Antidepressants	group	DDI-DrugBank.d697.s0.e5
DDI-DrugBank.d697.s0	false	DDI-DrugBank.d697.s0.e0	DDI-DrugBank.d697.s0.e1
DDI-DrugBank.d697.s0	true	DDI-DrugBank.d697.s0.e0	DDI-DrugBank.d697.s0.e2
DDI-DrugBank.d697.s0	true	DDI-DrugBank.d697.s0.e0	DDI-DrugBank.d697.s0.e3
DDI-DrugBank.d697.s0	true	DDI-DrugBank.d697.s0.e0	DDI-DrugBank.d697.s0.e4
DDI-DrugBank.d697.s0	true	DDI-DrugBank.d697.s0.e0	DDI-DrugBank.d697.s0.e5
DDI-DrugBank.d697.s0	true	DDI-DrugBank.d697.s0.e1	DDI-DrugBank.d697.s0.e2
DDI-DrugBank.d697.s0	true	DDI-DrugBank.d697.s0.e1	DDI-DrugBank.d697.s0.e3
DDI-DrugBank.d697.s0	true	DDI-DrugBank.d697.s0.e1	DDI-DrugBank.d697.s0.e4
DDI-DrugBank.d697.s0	true	DDI-DrugBank.d697.s0.e1	DDI-DrugBank.d697.s0.e5
DDI-DrugBank.d697.s0	false	DDI-DrugBank.d697.s0.e2	DDI-DrugBank.d697.s0.e3
DDI-DrugBank.d677.s0|a|Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) 
DDI-DrugBank.d677.s0	0	13	Phenothiazines	group	DDI-DrugBank.d677.s0.e0
DDI-DrugBank.d677.s0	43	57	CNS depressants	group	DDI-DrugBank.d677.s0.e1
DDI-DrugBank.d677.s0	66	77	barbiturates	group	DDI-DrugBank.d677.s0.e2
DDI-DrugBank.d677.s0	80	90	anesthetics	group	DDI-DrugBank.d677.s0.e3
DDI-DrugBank.d677.s0	93	99	opiates	group	DDI-DrugBank.d677.s0.e4
DDI-DrugBank.d677.s0	102	108	alcohol	drug	DDI-DrugBank.d677.s0.e5
DDI-DrugBank.d677.s0	true	DDI-DrugBank.d677.s0.e0	DDI-DrugBank.d677.s0.e1
DDI-DrugBank.d677.s0	true	DDI-DrugBank.d677.s0.e0	DDI-DrugBank.d677.s0.e2
DDI-DrugBank.d677.s0	true	DDI-DrugBank.d677.s0.e0	DDI-DrugBank.d677.s0.e3
DDI-DrugBank.d677.s0	true	DDI-DrugBank.d677.s0.e0	DDI-DrugBank.d677.s0.e4
DDI-DrugBank.d677.s0	true	DDI-DrugBank.d677.s0.e0	DDI-DrugBank.d677.s0.e5
DDI-DrugBank.d677.s0	false	DDI-DrugBank.d677.s0.e1	DDI-DrugBank.d677.s0.e2
DDI-DrugBank.d677.s0	false	DDI-DrugBank.d677.s0.e1	DDI-DrugBank.d677.s0.e3
DDI-DrugBank.d677.s0	false	DDI-DrugBank.d677.s0.e1	DDI-DrugBank.d677.s0.e4
DDI-DrugBank.d677.s0	false	DDI-DrugBank.d677.s0.e1	DDI-DrugBank.d677.s0.e5
DDI-DrugBank.d677.s0	false	DDI-DrugBank.d677.s0.e2	DDI-DrugBank.d677.s0.e3
DDI-DrugBank.d677.s1|a|as well as atropine and phosphorous insecticides.
DDI-DrugBank.d677.s1	11	18	atropine	drug	DDI-DrugBank.d677.s1.e0
DDI-DrugBank.d677.s1	24	47	phosphorous insecticides	drug_n	DDI-DrugBank.d677.s1.e1
DDI-DrugBank.d677.s1	false	DDI-DrugBank.d677.s1.e0	DDI-DrugBank.d677.s1.e1
DDI-DrugBank.d722.s0|a|There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. 
DDI-DrugBank.d722.s0	51	60	PURINETHOL	brand	DDI-DrugBank.d722.s0.e0
DDI-DrugBank.d722.s0	63	76	mercaptopurine	drug	DDI-DrugBank.d722.s0.e1
DDI-DrugBank.d722.s0	83	89	TABLOID	brand	DDI-DrugBank.d722.s0.e2
DDI-DrugBank.d722.s0	97	107	Thioguanine	drug	DDI-DrugBank.d722.s0.e3
DDI-DrugBank.d722.s0	false	DDI-DrugBank.d722.s0.e0	DDI-DrugBank.d722.s0.e1
DDI-DrugBank.d722.s0	true	DDI-DrugBank.d722.s0.e0	DDI-DrugBank.d722.s0.e2
DDI-DrugBank.d722.s0	true	DDI-DrugBank.d722.s0.e0	DDI-DrugBank.d722.s0.e3
DDI-DrugBank.d722.s0	true	DDI-DrugBank.d722.s0.e1	DDI-DrugBank.d722.s0.e2
DDI-DrugBank.d722.s0	true	DDI-DrugBank.d722.s0.e1	DDI-DrugBank.d722.s0.e3
DDI-DrugBank.d722.s0	false	DDI-DrugBank.d722.s0.e2	DDI-DrugBank.d722.s0.e3
DDI-DrugBank.d722.s1|a|As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    
DDI-DrugBank.d722.s1	35	61	aminosalicylate derivatives	group	DDI-DrugBank.d722.s1.e0
DDI-DrugBank.d722.s1	70	79	olsalazine	drug	DDI-DrugBank.d722.s1.e1
DDI-DrugBank.d722.s1	82	91	mesalazine	drug	DDI-DrugBank.d722.s1.e2
DDI-DrugBank.d722.s1	97	110	sulphasalazine	drug	DDI-DrugBank.d722.s1.e3
DDI-DrugBank.d722.s1	212	222	thioguanine	drug	DDI-DrugBank.d722.s1.e4
DDI-DrugBank.d722.s1	false	DDI-DrugBank.d722.s1.e0	DDI-DrugBank.d722.s1.e1
DDI-DrugBank.d722.s1	false	DDI-DrugBank.d722.s1.e0	DDI-DrugBank.d722.s1.e2
DDI-DrugBank.d722.s1	false	DDI-DrugBank.d722.s1.e0	DDI-DrugBank.d722.s1.e3
DDI-DrugBank.d722.s1	true	DDI-DrugBank.d722.s1.e0	DDI-DrugBank.d722.s1.e4
DDI-DrugBank.d722.s1	false	DDI-DrugBank.d722.s1.e1	DDI-DrugBank.d722.s1.e2
DDI-DrugBank.d722.s1	false	DDI-DrugBank.d722.s1.e1	DDI-DrugBank.d722.s1.e3
DDI-DrugBank.d722.s1	true	DDI-DrugBank.d722.s1.e1	DDI-DrugBank.d722.s1.e4
DDI-DrugBank.d722.s1	false	DDI-DrugBank.d722.s1.e2	DDI-DrugBank.d722.s1.e3
DDI-DrugBank.d722.s1	true	DDI-DrugBank.d722.s1.e2	DDI-DrugBank.d722.s1.e4
DDI-DrugBank.d722.s1	true	DDI-DrugBank.d722.s1.e3	DDI-DrugBank.d722.s1.e4
DDI-DrugBank.d616.s0|a|Interactions between ZADAXIN and other drugs have not been fully evaluated. 
DDI-DrugBank.d616.s0	21	27	ZADAXIN	brand	DDI-DrugBank.d616.s0.e0
DDI-DrugBank.d616.s1|a|Caution should be exercised when administering ZADAXIN therapy in combination with other immunomodulating drugs. 
DDI-DrugBank.d616.s1	47	53	ZADAXIN	brand	DDI-DrugBank.d616.s1.e0
DDI-DrugBank.d616.s1	89	110	immunomodulating drugs	group	DDI-DrugBank.d616.s1.e1
DDI-DrugBank.d616.s1	true	DDI-DrugBank.d616.s1.e0	DDI-DrugBank.d616.s1.e1
DDI-DrugBank.d616.s2|a|ZADAXIN should not be mixed with any other drug.
DDI-DrugBank.d616.s2	0	6	ZADAXIN	brand	DDI-DrugBank.d616.s2.e0
DDI-DrugBank.d642.s0|a|Prothrombin time or other suitable anticoagulation test should be monitored if tigecycline is administered with warfarin.   
DDI-DrugBank.d642.s0	79	89	tigecycline	drug	DDI-DrugBank.d642.s0.e0
DDI-DrugBank.d642.s0	112	119	warfarin	drug	DDI-DrugBank.d642.s0.e1
DDI-DrugBank.d642.s0	true	DDI-DrugBank.d642.s0.e0	DDI-DrugBank.d642.s0.e1
DDI-DrugBank.d642.s1|a|Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective.  
DDI-DrugBank.d642.s1	18	36	antibacterial drugs	group	DDI-DrugBank.d642.s1.e0
DDI-DrugBank.d642.s1	48	61	contraceptives	group	DDI-DrugBank.d642.s1.e1
DDI-DrugBank.d642.s1	79	92	contraceptives	group	DDI-DrugBank.d642.s1.e2
DDI-DrugBank.d642.s1	true	DDI-DrugBank.d642.s1.e0	DDI-DrugBank.d642.s1.e1
DDI-DrugBank.d642.s1	false	DDI-DrugBank.d642.s1.e0	DDI-DrugBank.d642.s1.e2
DDI-DrugBank.d642.s1	false	DDI-DrugBank.d642.s1.e1	DDI-DrugBank.d642.s1.e2
DDI-DrugBank.d642.s2|a|Drug/Laboratory Test Interactions  There are no reported drug-laboratory test interactions.
DDI-DrugBank.d721.s0|a|The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 
DDI-DrugBank.d721.s0	23	28	SKELID	brand	DDI-DrugBank.d721.s0.e0
DDI-DrugBank.d721.s0	50	56	calcium	drug	DDI-DrugBank.d721.s0.e1
DDI-DrugBank.d721.s0	64	70	calcium	drug	DDI-DrugBank.d721.s0.e2
DDI-DrugBank.d721.s0	76	81	SKELID	brand	DDI-DrugBank.d721.s0.e3
DDI-DrugBank.d721.s0	134	141	aluminum	drug	DDI-DrugBank.d721.s0.e4
DDI-DrugBank.d721.s0	147	155	magnesium	drug	DDI-DrugBank.d721.s0.e5
DDI-DrugBank.d721.s0	168	175	antacids	drug	DDI-DrugBank.d721.s0.e6
DDI-DrugBank.d721.s0	210	215	SKELID	brand	DDI-DrugBank.d721.s0.e7
DDI-DrugBank.d721.s0	true	DDI-DrugBank.d721.s0.e0	DDI-DrugBank.d721.s0.e1
DDI-DrugBank.d721.s0	false	DDI-DrugBank.d721.s0.e0	DDI-DrugBank.d721.s0.e2
DDI-DrugBank.d721.s0	false	DDI-DrugBank.d721.s0.e0	DDI-DrugBank.d721.s0.e3
DDI-DrugBank.d721.s0	false	DDI-DrugBank.d721.s0.e0	DDI-DrugBank.d721.s0.e4
DDI-DrugBank.d721.s0	false	DDI-DrugBank.d721.s0.e0	DDI-DrugBank.d721.s0.e5
DDI-DrugBank.d721.s0	false	DDI-DrugBank.d721.s0.e0	DDI-DrugBank.d721.s0.e6
DDI-DrugBank.d721.s0	false	DDI-DrugBank.d721.s0.e0	DDI-DrugBank.d721.s0.e7
DDI-DrugBank.d721.s0	false	DDI-DrugBank.d721.s0.e1	DDI-DrugBank.d721.s0.e2
DDI-DrugBank.d721.s0	false	DDI-DrugBank.d721.s0.e1	DDI-DrugBank.d721.s0.e3
DDI-DrugBank.d721.s0	false	DDI-DrugBank.d721.s0.e1	DDI-DrugBank.d721.s0.e4
DDI-DrugBank.d721.s1|a|Aspirin may decrease bioavailability of SKELID by up to 50% when taken 2 hours after SKELID. 
DDI-DrugBank.d721.s1	0	6	Aspirin	brand	DDI-DrugBank.d721.s1.e0
DDI-DrugBank.d721.s1	40	45	SKELID	brand	DDI-DrugBank.d721.s1.e1
DDI-DrugBank.d721.s1	85	90	SKELID	brand	DDI-DrugBank.d721.s1.e2
DDI-DrugBank.d721.s1	true	DDI-DrugBank.d721.s1.e0	DDI-DrugBank.d721.s1.e1
DDI-DrugBank.d721.s1	false	DDI-DrugBank.d721.s1.e0	DDI-DrugBank.d721.s1.e2
DDI-DrugBank.d721.s1	false	DDI-DrugBank.d721.s1.e1	DDI-DrugBank.d721.s1.e2
DDI-DrugBank.d721.s2|a|The bioavailability of SKELID is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of diclofenac. 
DDI-DrugBank.d721.s2	23	28	SKELID	brand	DDI-DrugBank.d721.s2.e0
DDI-DrugBank.d721.s2	55	66	indomethacin	drug	DDI-DrugBank.d721.s2.e1
DDI-DrugBank.d721.s2	124	133	diclofenac	drug	DDI-DrugBank.d721.s2.e2
DDI-DrugBank.d721.s2	true	DDI-DrugBank.d721.s2.e0	DDI-DrugBank.d721.s2.e1
DDI-DrugBank.d721.s2	false	DDI-DrugBank.d721.s2.e0	DDI-DrugBank.d721.s2.e2
DDI-DrugBank.d721.s2	false	DDI-DrugBank.d721.s2.e1	DDI-DrugBank.d721.s2.e2
DDI-DrugBank.d721.s3|a|The pharmacokinetic parameters of digoxin are not significantly modified by SKELID coadministration. 
DDI-DrugBank.d721.s3	34	40	digoxin	drug	DDI-DrugBank.d721.s3.e0
DDI-DrugBank.d721.s3	76	81	SKELID	brand	DDI-DrugBank.d721.s3.e1
DDI-DrugBank.d721.s3	false	DDI-DrugBank.d721.s3.e0	DDI-DrugBank.d721.s3.e1
DDI-DrugBank.d721.s4|a|In vitro studies show that tiludronate does not displace warfarin from its binding site on protein.
DDI-DrugBank.d721.s4	27	37	tiludronate	drug	DDI-DrugBank.d721.s4.e0
DDI-DrugBank.d721.s4	57	64	warfarin	drug	DDI-DrugBank.d721.s4.e1
DDI-DrugBank.d721.s4	false	DDI-DrugBank.d721.s4.e0	DDI-DrugBank.d721.s4.e1
DDI-DrugBank.d702.s0|a|SPIRIVA has been used concomitantly with other drugs commonly used in COPD without increases in adverse drug reactions. 
DDI-DrugBank.d702.s0	0	6	SPIRIVA	brand	DDI-DrugBank.d702.s0.e0
DDI-DrugBank.d702.s1|a|These include sympathomimetic bronchodilators, methylxanthines, and oral and inhaled steroids. 
DDI-DrugBank.d702.s1	14	44	sympathomimetic bronchodilators	group	DDI-DrugBank.d702.s1.e0
DDI-DrugBank.d702.s1	47	61	methylxanthines	group	DDI-DrugBank.d702.s1.e1
DDI-DrugBank.d702.s1	85	92	steroids	group	DDI-DrugBank.d702.s1.e2
DDI-DrugBank.d702.s1	false	DDI-DrugBank.d702.s1.e0	DDI-DrugBank.d702.s1.e1
DDI-DrugBank.d702.s1	false	DDI-DrugBank.d702.s1.e0	DDI-DrugBank.d702.s1.e2
DDI-DrugBank.d702.s1	false	DDI-DrugBank.d702.s1.e1	DDI-DrugBank.d702.s1.e2
DDI-DrugBank.d702.s2|a|However, the co   administration of SPIRIVA with other anticholinergic   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.
DDI-DrugBank.d702.s2	36	42	SPIRIVA	brand	DDI-DrugBank.d702.s2.e0
DDI-DrugBank.d702.s2	55	69	anticholinergic	group	DDI-DrugBank.d702.s2.e1
DDI-DrugBank.d702.s2	97	107	ipratropium	drug	DDI-DrugBank.d702.s2.e2
DDI-DrugBank.d702.s2	true	DDI-DrugBank.d702.s2.e0	DDI-DrugBank.d702.s2.e1
DDI-DrugBank.d702.s2	true	DDI-DrugBank.d702.s2.e0	DDI-DrugBank.d702.s2.e2
DDI-DrugBank.d702.s2	false	DDI-DrugBank.d702.s2.e1	DDI-DrugBank.d702.s2.e2
DDI-DrugBank.d751.s0|a|AGGRASTAT has been studied on a background of aspirin and heparin. 
DDI-DrugBank.d751.s0	0	8	AGGRASTAT	brand	DDI-DrugBank.d751.s0.e0
DDI-DrugBank.d751.s0	46	52	aspirin	brand	DDI-DrugBank.d751.s0.e1
DDI-DrugBank.d751.s0	58	64	heparin	drug	DDI-DrugBank.d751.s0.e2
DDI-DrugBank.d751.s0	false	DDI-DrugBank.d751.s0.e0	DDI-DrugBank.d751.s0.e1
DDI-DrugBank.d751.s0	false	DDI-DrugBank.d751.s0.e0	DDI-DrugBank.d751.s0.e2
DDI-DrugBank.d751.s0	false	DDI-DrugBank.d751.s0.e1	DDI-DrugBank.d751.s0.e2
DDI-DrugBank.d751.s1|a|The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see
DDI-DrugBank.d751.s1	11	19	AGGRASTAT	brand	DDI-DrugBank.d751.s1.e0
DDI-DrugBank.d751.s1	42	48	heparin	drug	DDI-DrugBank.d751.s1.e1
DDI-DrugBank.d751.s1	54	60	aspirin	brand	DDI-DrugBank.d751.s1.e2
DDI-DrugBank.d751.s1	124	130	heparin	drug	DDI-DrugBank.d751.s1.e3
DDI-DrugBank.d751.s1	136	142	aspirin	drug	DDI-DrugBank.d751.s1.e4
DDI-DrugBank.d751.s1	true	DDI-DrugBank.d751.s1.e0	DDI-DrugBank.d751.s1.e1
DDI-DrugBank.d751.s1	true	DDI-DrugBank.d751.s1.e0	DDI-DrugBank.d751.s1.e2
DDI-DrugBank.d751.s1	false	DDI-DrugBank.d751.s1.e0	DDI-DrugBank.d751.s1.e3
DDI-DrugBank.d751.s1	false	DDI-DrugBank.d751.s1.e0	DDI-DrugBank.d751.s1.e4
DDI-DrugBank.d751.s1	false	DDI-DrugBank.d751.s1.e1	DDI-DrugBank.d751.s1.e2
DDI-DrugBank.d751.s1	false	DDI-DrugBank.d751.s1.e1	DDI-DrugBank.d751.s1.e3
DDI-DrugBank.d751.s1	false	DDI-DrugBank.d751.s1.e1	DDI-DrugBank.d751.s1.e4
DDI-DrugBank.d751.s1	false	DDI-DrugBank.d751.s1.e2	DDI-DrugBank.d751.s1.e3
DDI-DrugBank.d751.s1	false	DDI-DrugBank.d751.s1.e2	DDI-DrugBank.d751.s1.e4
DDI-DrugBank.d751.s1	false	DDI-DrugBank.d751.s1.e3	DDI-DrugBank.d751.s1.e4
DDI-DrugBank.d624.s0|a|In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 
DDI-DrugBank.d624.s0	23	26	TOBI	brand	DDI-DrugBank.d624.s0.e0
DDI-DrugBank.d624.s0	45	48	TOBI	brand	DDI-DrugBank.d624.s0.e1
DDI-DrugBank.d624.s0	69	80	dornase alfa	drug	DDI-DrugBank.d624.s0.e2
DDI-DrugBank.d624.s0	83	91	PULMOZYME	brand	DDI-DrugBank.d624.s0.e3
DDI-DrugBank.d624.s0	109	123	(beta)-agonists	group	DDI-DrugBank.d624.s0.e4
DDI-DrugBank.d624.s0	134	148	corticosteroids	group	DDI-DrugBank.d624.s0.e5
DDI-DrugBank.d624.s0	157	184	anti-pseudomonal antibiotics	group	DDI-DrugBank.d624.s0.e6
DDI-DrugBank.d624.s0	201	215	aminoglycosides	group	DDI-DrugBank.d624.s0.e7
DDI-DrugBank.d624.s0	false	DDI-DrugBank.d624.s0.e0	DDI-DrugBank.d624.s0.e1
DDI-DrugBank.d624.s0	false	DDI-DrugBank.d624.s0.e0	DDI-DrugBank.d624.s0.e2
DDI-DrugBank.d624.s0	false	DDI-DrugBank.d624.s0.e0	DDI-DrugBank.d624.s0.e3
DDI-DrugBank.d624.s0	false	DDI-DrugBank.d624.s0.e0	DDI-DrugBank.d624.s0.e4
DDI-DrugBank.d624.s0	false	DDI-DrugBank.d624.s0.e0	DDI-DrugBank.d624.s0.e5
DDI-DrugBank.d624.s0	false	DDI-DrugBank.d624.s0.e0	DDI-DrugBank.d624.s0.e6
DDI-DrugBank.d624.s0	false	DDI-DrugBank.d624.s0.e0	DDI-DrugBank.d624.s0.e7
DDI-DrugBank.d624.s0	true	DDI-DrugBank.d624.s0.e1	DDI-DrugBank.d624.s0.e2
DDI-DrugBank.d624.s0	true	DDI-DrugBank.d624.s0.e1	DDI-DrugBank.d624.s0.e3
DDI-DrugBank.d624.s0	true	DDI-DrugBank.d624.s0.e1	DDI-DrugBank.d624.s0.e4
DDI-DrugBank.d624.s1|a|Concurrent and/or sequential use of TOBI with other drugs with neurotoxic or ototoxic potential should be avoided. 
DDI-DrugBank.d624.s1	36	39	TOBI	brand	DDI-DrugBank.d624.s1.e0
DDI-DrugBank.d624.s2|a|Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. 
DDI-DrugBank.d624.s2	5	13	diuretics	group	DDI-DrugBank.d624.s2.e0
DDI-DrugBank.d624.s2	27	40	aminoglycoside	group	DDI-DrugBank.d624.s2.e1
DDI-DrugBank.d624.s2	63	72	antibiotic	group	DDI-DrugBank.d624.s2.e2
DDI-DrugBank.d624.s2	true	DDI-DrugBank.d624.s2.e0	DDI-DrugBank.d624.s2.e1
DDI-DrugBank.d624.s2	false	DDI-DrugBank.d624.s2.e0	DDI-DrugBank.d624.s2.e2
DDI-DrugBank.d624.s2	false	DDI-DrugBank.d624.s2.e1	DDI-DrugBank.d624.s2.e2
DDI-DrugBank.d624.s3|a|TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.
DDI-DrugBank.d624.s3	0	3	TOBI	brand	DDI-DrugBank.d624.s3.e0
DDI-DrugBank.d624.s3	51	65	ethacrynic acid	drug	DDI-DrugBank.d624.s3.e1
DDI-DrugBank.d624.s3	68	77	furosemide	drug	DDI-DrugBank.d624.s3.e2
DDI-DrugBank.d624.s3	80	83	urea	drug	DDI-DrugBank.d624.s3.e3
DDI-DrugBank.d624.s3	89	96	mannitol	drug	DDI-DrugBank.d624.s3.e4
DDI-DrugBank.d624.s3	true	DDI-DrugBank.d624.s3.e0	DDI-DrugBank.d624.s3.e1
DDI-DrugBank.d624.s3	true	DDI-DrugBank.d624.s3.e0	DDI-DrugBank.d624.s3.e2
DDI-DrugBank.d624.s3	true	DDI-DrugBank.d624.s3.e0	DDI-DrugBank.d624.s3.e3
DDI-DrugBank.d624.s3	true	DDI-DrugBank.d624.s3.e0	DDI-DrugBank.d624.s3.e4
DDI-DrugBank.d624.s3	false	DDI-DrugBank.d624.s3.e1	DDI-DrugBank.d624.s3.e2
DDI-DrugBank.d624.s3	false	DDI-DrugBank.d624.s3.e1	DDI-DrugBank.d624.s3.e3
DDI-DrugBank.d624.s3	false	DDI-DrugBank.d624.s3.e1	DDI-DrugBank.d624.s3.e4
DDI-DrugBank.d624.s3	false	DDI-DrugBank.d624.s3.e2	DDI-DrugBank.d624.s3.e3
DDI-DrugBank.d624.s3	false	DDI-DrugBank.d624.s3.e2	DDI-DrugBank.d624.s3.e4
DDI-DrugBank.d624.s3	false	DDI-DrugBank.d624.s3.e3	DDI-DrugBank.d624.s3.e4
DDI-DrugBank.d608.s0|a|The in vitro binding of warfarin to human plasma proteins is unaffected by tolmetin, and tolmetin does not alter the prothrombin time of normal volunteers. 
DDI-DrugBank.d608.s0	24	31	warfarin	drug	DDI-DrugBank.d608.s0.e0
DDI-DrugBank.d608.s0	75	82	tolmetin	drug	DDI-DrugBank.d608.s0.e1
DDI-DrugBank.d608.s0	89	96	tolmetin	drug	DDI-DrugBank.d608.s0.e2
DDI-DrugBank.d608.s0	false	DDI-DrugBank.d608.s0.e0	DDI-DrugBank.d608.s0.e1
DDI-DrugBank.d608.s0	false	DDI-DrugBank.d608.s0.e0	DDI-DrugBank.d608.s0.e2
DDI-DrugBank.d608.s0	false	DDI-DrugBank.d608.s0.e1	DDI-DrugBank.d608.s0.e2
DDI-DrugBank.d608.s1|a|However, increased prothrombin time and bleeding have been reported in patients on concomitant TOLECTIN and warfarin therapy. 
DDI-DrugBank.d608.s1	95	102	TOLECTIN	brand	DDI-DrugBank.d608.s1.e0
DDI-DrugBank.d608.s1	108	115	warfarin	drug	DDI-DrugBank.d608.s1.e1
DDI-DrugBank.d608.s1	true	DDI-DrugBank.d608.s1.e0	DDI-DrugBank.d608.s1.e1
DDI-DrugBank.d608.s2|a|Therefore, caution should be exercised when administering TOLECTIN to patients on anticoagulants. 
DDI-DrugBank.d608.s2	58	65	TOLECTIN	brand	DDI-DrugBank.d608.s2.e0
DDI-DrugBank.d608.s2	82	95	anticoagulants	group	DDI-DrugBank.d608.s2.e1
DDI-DrugBank.d608.s2	true	DDI-DrugBank.d608.s2.e0	DDI-DrugBank.d608.s2.e1
DDI-DrugBank.d608.s3|a|In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. 
DDI-DrugBank.d608.s3	55	67	sulfonylureas	group	DDI-DrugBank.d608.s3.e0
DDI-DrugBank.d608.s3	72	78	insulin	drug	DDI-DrugBank.d608.s3.e1
DDI-DrugBank.d608.s3	133	140	TOLECTIN	brand	DDI-DrugBank.d608.s3.e2
DDI-DrugBank.d608.s3	149	167	hypoglycemic agents	group	DDI-DrugBank.d608.s3.e3
DDI-DrugBank.d608.s3	false	DDI-DrugBank.d608.s3.e0	DDI-DrugBank.d608.s3.e1
DDI-DrugBank.d608.s3	false	DDI-DrugBank.d608.s3.e0	DDI-DrugBank.d608.s3.e2
DDI-DrugBank.d608.s3	false	DDI-DrugBank.d608.s3.e0	DDI-DrugBank.d608.s3.e3
DDI-DrugBank.d608.s3	false	DDI-DrugBank.d608.s3.e1	DDI-DrugBank.d608.s3.e2
DDI-DrugBank.d608.s3	false	DDI-DrugBank.d608.s3.e1	DDI-DrugBank.d608.s3.e3
DDI-DrugBank.d608.s3	false	DDI-DrugBank.d608.s3.e2	DDI-DrugBank.d608.s3.e3
DDI-DrugBank.d608.s4|a|Caution should be used if TOLECTIN is administered concomitantly with methotrexate. 
DDI-DrugBank.d608.s4	26	33	TOLECTIN	brand	DDI-DrugBank.d608.s4.e0
DDI-DrugBank.d608.s4	70	81	methotrexate	drug	DDI-DrugBank.d608.s4.e1
DDI-DrugBank.d608.s4	true	DDI-DrugBank.d608.s4.e0	DDI-DrugBank.d608.s4.e1
DDI-DrugBank.d608.s5|a|TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. 
DDI-DrugBank.d608.s5	0	7	TOLECTIN	brand	DDI-DrugBank.d608.s5.e0
DDI-DrugBank.d608.s5	19	54	nonsteroidal anti-inflammatory drugs	group	DDI-DrugBank.d608.s5.e1
DDI-DrugBank.d608.s5	110	121	methotrexate	drug	DDI-DrugBank.d608.s5.e2
DDI-DrugBank.d608.s5	178	189	methotrexate	drug	DDI-DrugBank.d608.s5.e3
DDI-DrugBank.d608.s5	false	DDI-DrugBank.d608.s5.e0	DDI-DrugBank.d608.s5.e1
DDI-DrugBank.d608.s5	true	DDI-DrugBank.d608.s5.e0	DDI-DrugBank.d608.s5.e2
DDI-DrugBank.d608.s5	false	DDI-DrugBank.d608.s5.e0	DDI-DrugBank.d608.s5.e3
DDI-DrugBank.d608.s5	true	DDI-DrugBank.d608.s5.e1	DDI-DrugBank.d608.s5.e2
DDI-DrugBank.d608.s5	false	DDI-DrugBank.d608.s5.e1	DDI-DrugBank.d608.s5.e3
DDI-DrugBank.d608.s5	false	DDI-DrugBank.d608.s5.e2	DDI-DrugBank.d608.s5.e3
DDI-DrugBank.d608.s6|a|Laboratory Tests Because serious GI tract ulceration and bleeding can occur without warning symptoms, physicians should follow chronically treated patients for the signs and symptoms of ulceration and bleeding and should inform them of the importance of this follow-up.
DDI-DrugBank.d765.s0|a|CYP3A4 Inhibitors: Ketoconazole, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of tolterodine when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions). 
DDI-DrugBank.d765.s0	19	30	Ketoconazole	drug	DDI-DrugBank.d765.s0.e0
DDI-DrugBank.d765.s0	135	145	tolterodine	drug	DDI-DrugBank.d765.s0.e1
DDI-DrugBank.d765.s0	true	DDI-DrugBank.d765.s0.e0	DDI-DrugBank.d765.s0.e1
DDI-DrugBank.d765.s1|a|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 
DDI-DrugBank.d765.s1	23	34	ketoconazole	drug	DDI-DrugBank.d765.s1.e0
DDI-DrugBank.d765.s1	84	100	azole antifungals	group	DDI-DrugBank.d765.s1.e1
DDI-DrugBank.d765.s1	107	118	itraconazole	drug	DDI-DrugBank.d765.s1.e2
DDI-DrugBank.d765.s1	121	130	miconazole	drug	DDI-DrugBank.d765.s1.e3
DDI-DrugBank.d765.s1	136	156	macrolide antibiotics	group	DDI-DrugBank.d765.s1.e4
DDI-DrugBank.d765.s1	163	174	erythromycin	drug	DDI-DrugBank.d765.s1.e5
DDI-DrugBank.d765.s1	177	190	clarithromycin	drug	DDI-DrugBank.d765.s1.e6
DDI-DrugBank.d765.s1	196	207	cyclosporine	drug	DDI-DrugBank.d765.s1.e7
DDI-DrugBank.d765.s1	212	222	vinblastine	drug	DDI-DrugBank.d765.s1.e8
DDI-DrugBank.d765.s1	249	257	DETROL LA	brand	DDI-DrugBank.d765.s1.e9
DDI-DrugBank.d765.s1	false	DDI-DrugBank.d765.s1.e0	DDI-DrugBank.d765.s1.e1
DDI-DrugBank.d765.s1	false	DDI-DrugBank.d765.s1.e0	DDI-DrugBank.d765.s1.e2
DDI-DrugBank.d765.s1	false	DDI-DrugBank.d765.s1.e0	DDI-DrugBank.d765.s1.e3
DDI-DrugBank.d765.s1	false	DDI-DrugBank.d765.s1.e0	DDI-DrugBank.d765.s1.e4
DDI-DrugBank.d765.s1	false	DDI-DrugBank.d765.s1.e0	DDI-DrugBank.d765.s1.e5
DDI-DrugBank.d765.s1	false	DDI-DrugBank.d765.s1.e0	DDI-DrugBank.d765.s1.e6
DDI-DrugBank.d765.s1	false	DDI-DrugBank.d765.s1.e0	DDI-DrugBank.d765.s1.e7
DDI-DrugBank.d765.s1	false	DDI-DrugBank.d765.s1.e0	DDI-DrugBank.d765.s1.e8
DDI-DrugBank.d765.s1	true	DDI-DrugBank.d765.s1.e0	DDI-DrugBank.d765.s1.e9
DDI-DrugBank.d765.s1	false	DDI-DrugBank.d765.s1.e1	DDI-DrugBank.d765.s1.e2
DDI-DrugBank.d765.s2|a|Drug-Laboratory-Test Interactions Interactions between tolterodine and laboratory tests have not been studied.
DDI-DrugBank.d765.s2	55	65	tolterodine	drug	DDI-DrugBank.d765.s2.e0
DDI-DrugBank.d712.s0|a|There have been no formal drug interaction studies performed with HERCEPTIN in humans. 
DDI-DrugBank.d712.s0	66	74	HERCEPTIN	brand	DDI-DrugBank.d712.s0.e0
DDI-DrugBank.d712.s1|a|Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.
DDI-DrugBank.d712.s1	18	27	paclitaxel	drug	DDI-DrugBank.d712.s1.e0
DDI-DrugBank.d712.s1	49	57	HERCEPTIN	brand	DDI-DrugBank.d712.s1.e1
DDI-DrugBank.d712.s1	94	102	HERCEPTIN	brand	DDI-DrugBank.d712.s1.e2
DDI-DrugBank.d712.s1	173	181	HERCEPTIN	brand	DDI-DrugBank.d712.s1.e3
DDI-DrugBank.d712.s1	true	DDI-DrugBank.d712.s1.e0	DDI-DrugBank.d712.s1.e1
DDI-DrugBank.d712.s1	false	DDI-DrugBank.d712.s1.e0	DDI-DrugBank.d712.s1.e2
DDI-DrugBank.d712.s1	false	DDI-DrugBank.d712.s1.e0	DDI-DrugBank.d712.s1.e3
DDI-DrugBank.d712.s1	false	DDI-DrugBank.d712.s1.e1	DDI-DrugBank.d712.s1.e2
DDI-DrugBank.d712.s1	false	DDI-DrugBank.d712.s1.e1	DDI-DrugBank.d712.s1.e3
DDI-DrugBank.d712.s1	false	DDI-DrugBank.d712.s1.e2	DDI-DrugBank.d712.s1.e3
DDI-DrugBank.d774.s0|a|Trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).
DDI-DrugBank.d774.s0	0	9	Trilostane	drug	DDI-DrugBank.d774.s0.e0
DDI-DrugBank.d774.s0	29	45	aminoglutethimide	drug	DDI-DrugBank.d774.s0.e1
DDI-DrugBank.d774.s0	50	57	mitotane	drug	DDI-DrugBank.d774.s0.e2
DDI-DrugBank.d774.s0	true	DDI-DrugBank.d774.s0.e0	DDI-DrugBank.d774.s0.e1
DDI-DrugBank.d774.s0	true	DDI-DrugBank.d774.s0.e0	DDI-DrugBank.d774.s0.e2
DDI-DrugBank.d774.s0	false	DDI-DrugBank.d774.s0.e1	DDI-DrugBank.d774.s0.e2
DDI-DrugBank.d598.s0|a|Trimethoprim may inhibit the hepatic metabolism of phenytoin. 
DDI-DrugBank.d598.s0	0	11	Trimethoprim	drug	DDI-DrugBank.d598.s0.e0
DDI-DrugBank.d598.s0	51	59	phenytoin	drug	DDI-DrugBank.d598.s0.e1
DDI-DrugBank.d598.s0	true	DDI-DrugBank.d598.s0.e0	DDI-DrugBank.d598.s0.e1
DDI-DrugBank.d598.s1|a|Trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%. 
DDI-DrugBank.d598.s1	0	11	Trimethoprim	drug	DDI-DrugBank.d598.s1.e0
DDI-DrugBank.d598.s1	63	71	phenytoin	drug	DDI-DrugBank.d598.s1.e1
DDI-DrugBank.d598.s1	108	116	phenytoin	drug	DDI-DrugBank.d598.s1.e2
DDI-DrugBank.d598.s1	true	DDI-DrugBank.d598.s1.e0	DDI-DrugBank.d598.s1.e1
DDI-DrugBank.d598.s1	true	DDI-DrugBank.d598.s1.e0	DDI-DrugBank.d598.s1.e2
DDI-DrugBank.d598.s1	false	DDI-DrugBank.d598.s1.e1	DDI-DrugBank.d598.s1.e2
DDI-DrugBank.d598.s2|a|When administering these drugs concurrently, one should be alert for possible excessive phenytoin effect.
DDI-DrugBank.d598.s2	88	96	phenytoin	drug	DDI-DrugBank.d598.s2.e0
DDI-DrugBank.d766.s0|a|Since trimetrexate is metabolized by a P450 enzyme system, drugs that induce or inhibit this drug metabolizing enzyme system may elicit important drug-drug interactions that may alter trimetrexate plasma concentrations. 
DDI-DrugBank.d766.s0	6	17	trimetrexate	drug	DDI-DrugBank.d766.s0.e0
DDI-DrugBank.d766.s0	184	195	trimetrexate	drug	DDI-DrugBank.d766.s0.e1
DDI-DrugBank.d766.s0	false	DDI-DrugBank.d766.s0.e0	DDI-DrugBank.d766.s0.e1
DDI-DrugBank.d766.s1|a|Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. 
DDI-DrugBank.d766.s1	41	52	trimetrexate	drug	DDI-DrugBank.d766.s1.e0
DDI-DrugBank.d766.s1	133	144	erythromycin	drug	DDI-DrugBank.d766.s1.e1
DDI-DrugBank.d766.s1	147	154	rifampin	drug	DDI-DrugBank.d766.s1.e2
DDI-DrugBank.d766.s1	157	165	rifabutin	drug	DDI-DrugBank.d766.s1.e3
DDI-DrugBank.d766.s1	168	179	ketoconazole	drug	DDI-DrugBank.d766.s1.e4
DDI-DrugBank.d766.s1	186	196	fluconazole	drug	DDI-DrugBank.d766.s1.e5
DDI-DrugBank.d766.s1	true	DDI-DrugBank.d766.s1.e0	DDI-DrugBank.d766.s1.e1
DDI-DrugBank.d766.s1	true	DDI-DrugBank.d766.s1.e0	DDI-DrugBank.d766.s1.e2
DDI-DrugBank.d766.s1	true	DDI-DrugBank.d766.s1.e0	DDI-DrugBank.d766.s1.e3
DDI-DrugBank.d766.s1	true	DDI-DrugBank.d766.s1.e0	DDI-DrugBank.d766.s1.e4
DDI-DrugBank.d766.s1	true	DDI-DrugBank.d766.s1.e0	DDI-DrugBank.d766.s1.e5
DDI-DrugBank.d766.s1	false	DDI-DrugBank.d766.s1.e1	DDI-DrugBank.d766.s1.e2
DDI-DrugBank.d766.s1	false	DDI-DrugBank.d766.s1.e1	DDI-DrugBank.d766.s1.e3
DDI-DrugBank.d766.s1	false	DDI-DrugBank.d766.s1.e1	DDI-DrugBank.d766.s1.e4
DDI-DrugBank.d766.s1	false	DDI-DrugBank.d766.s1.e1	DDI-DrugBank.d766.s1.e5
DDI-DrugBank.d766.s1	false	DDI-DrugBank.d766.s1.e2	DDI-DrugBank.d766.s1.e3
DDI-DrugBank.d766.s2|a|In vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in trimetrexate metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites. 
DDI-DrugBank.d766.s2	56	65	cimetidine	drug	DDI-DrugBank.d766.s2.e0
DDI-DrugBank.d766.s2	101	112	trimetrexate	drug	DDI-DrugBank.d766.s2.e1
DDI-DrugBank.d766.s2	134	146	acetaminophen	drug	DDI-DrugBank.d766.s2.e2
DDI-DrugBank.d766.s2	true	DDI-DrugBank.d766.s2.e0	DDI-DrugBank.d766.s2.e1
DDI-DrugBank.d766.s2	false	DDI-DrugBank.d766.s2.e0	DDI-DrugBank.d766.s2.e2
DDI-DrugBank.d766.s2	false	DDI-DrugBank.d766.s2.e1	DDI-DrugBank.d766.s2.e2
DDI-DrugBank.d766.s3|a|Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. 
DDI-DrugBank.d766.s3	59	73	imidazole drugs	group	DDI-DrugBank.d766.s3.e0
DDI-DrugBank.d766.s3	76	87	clotrimazole	drug	DDI-DrugBank.d766.s3.e1
DDI-DrugBank.d766.s3	90	101	ketoconazole	drug	DDI-DrugBank.d766.s3.e2
DDI-DrugBank.d766.s3	104	113	miconazole	drug	DDI-DrugBank.d766.s3.e3
DDI-DrugBank.d766.s3	159	170	trimetrexate	drug	DDI-DrugBank.d766.s3.e4
DDI-DrugBank.d766.s3	false	DDI-DrugBank.d766.s3.e0	DDI-DrugBank.d766.s3.e1
DDI-DrugBank.d766.s3	false	DDI-DrugBank.d766.s3.e0	DDI-DrugBank.d766.s3.e2
DDI-DrugBank.d766.s3	false	DDI-DrugBank.d766.s3.e0	DDI-DrugBank.d766.s3.e3
DDI-DrugBank.d766.s3	true	DDI-DrugBank.d766.s3.e0	DDI-DrugBank.d766.s3.e4
DDI-DrugBank.d766.s3	false	DDI-DrugBank.d766.s3.e1	DDI-DrugBank.d766.s3.e2
DDI-DrugBank.d766.s3	false	DDI-DrugBank.d766.s3.e1	DDI-DrugBank.d766.s3.e3
DDI-DrugBank.d766.s3	true	DDI-DrugBank.d766.s3.e1	DDI-DrugBank.d766.s3.e4
DDI-DrugBank.d766.s3	false	DDI-DrugBank.d766.s3.e2	DDI-DrugBank.d766.s3.e3
DDI-DrugBank.d766.s3	true	DDI-DrugBank.d766.s3.e2	DDI-DrugBank.d766.s3.e4
DDI-DrugBank.d766.s3	true	DDI-DrugBank.d766.s3.e3	DDI-DrugBank.d766.s3.e4
DDI-DrugBank.d766.s4|a|Patients medicated with these drugs and trimetrexate should be carefully monitored.
DDI-DrugBank.d766.s4	40	51	trimetrexate	drug	DDI-DrugBank.d766.s4.e0
DDI-DrugBank.d615.s0|a|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. 
DDI-DrugBank.d615.s0	0	11	Triprolidine	drug	DDI-DrugBank.d615.s0.e0
DDI-DrugBank.d615.s0	49	82	central nervous system depressants	group	DDI-DrugBank.d615.s0.e1
DDI-DrugBank.d615.s0	94	100	alcohol	drug	DDI-DrugBank.d615.s0.e2
DDI-DrugBank.d615.s0	103	114	barbiturates	group	DDI-DrugBank.d615.s0.e3
DDI-DrugBank.d615.s0	117	125	hypnotics	group	DDI-DrugBank.d615.s0.e4
DDI-DrugBank.d615.s0	128	146	narcotic analgesics	group	DDI-DrugBank.d615.s0.e5
DDI-DrugBank.d615.s0	149	157	sedatives	group	DDI-DrugBank.d615.s0.e6
DDI-DrugBank.d615.s0	164	177	tranquillisers	group	DDI-DrugBank.d615.s0.e7
DDI-DrugBank.d615.s0	true	DDI-DrugBank.d615.s0.e0	DDI-DrugBank.d615.s0.e1
DDI-DrugBank.d615.s0	true	DDI-DrugBank.d615.s0.e0	DDI-DrugBank.d615.s0.e2
DDI-DrugBank.d615.s0	true	DDI-DrugBank.d615.s0.e0	DDI-DrugBank.d615.s0.e3
DDI-DrugBank.d615.s0	true	DDI-DrugBank.d615.s0.e0	DDI-DrugBank.d615.s0.e4
DDI-DrugBank.d615.s0	true	DDI-DrugBank.d615.s0.e0	DDI-DrugBank.d615.s0.e5
DDI-DrugBank.d615.s0	true	DDI-DrugBank.d615.s0.e0	DDI-DrugBank.d615.s0.e6
DDI-DrugBank.d615.s0	true	DDI-DrugBank.d615.s0.e0	DDI-DrugBank.d615.s0.e7
DDI-DrugBank.d615.s0	false	DDI-DrugBank.d615.s0.e1	DDI-DrugBank.d615.s0.e2
DDI-DrugBank.d615.s0	false	DDI-DrugBank.d615.s0.e1	DDI-DrugBank.d615.s0.e3
DDI-DrugBank.d615.s0	false	DDI-DrugBank.d615.s0.e1	DDI-DrugBank.d615.s0.e4
DDI-DrugBank.d615.s1|a|The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. 
DDI-DrugBank.d615.s1	15	35	anticholinergic drugs	group	DDI-DrugBank.d615.s1.e0
DDI-DrugBank.d615.s1	46	53	atropine	drug	DDI-DrugBank.d615.s1.e1
DDI-DrugBank.d615.s1	59	83	tricyclic antidepressants	group	DDI-DrugBank.d615.s1.e2
DDI-DrugBank.d615.s1	138	149	triprolidine	drug	DDI-DrugBank.d615.s1.e3
DDI-DrugBank.d615.s1	false	DDI-DrugBank.d615.s1.e0	DDI-DrugBank.d615.s1.e1
DDI-DrugBank.d615.s1	false	DDI-DrugBank.d615.s1.e0	DDI-DrugBank.d615.s1.e2
DDI-DrugBank.d615.s1	true	DDI-DrugBank.d615.s1.e0	DDI-DrugBank.d615.s1.e3
DDI-DrugBank.d615.s1	false	DDI-DrugBank.d615.s1.e1	DDI-DrugBank.d615.s1.e2
DDI-DrugBank.d615.s1	true	DDI-DrugBank.d615.s1.e1	DDI-DrugBank.d615.s1.e3
DDI-DrugBank.d615.s1	true	DDI-DrugBank.d615.s1.e2	DDI-DrugBank.d615.s1.e3
DDI-DrugBank.d615.s2|a|Triprolidine may effect the metabolism of drugs in the liver.
DDI-DrugBank.d615.s2	0	11	Triprolidine	drug	DDI-DrugBank.d615.s2.e0
DDI-DrugBank.d713.s0|a|The concomitant use of Sanctura with other anticholinergic agents that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects. 
DDI-DrugBank.d713.s0	23	30	Sanctura	brand	DDI-DrugBank.d713.s0.e0
DDI-DrugBank.d713.s0	43	64	anticholinergic agents	group	DDI-DrugBank.d713.s0.e1
DDI-DrugBank.d713.s0	true	DDI-DrugBank.d713.s0.e0	DDI-DrugBank.d713.s0.e1
DDI-DrugBank.d713.s1|a|Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. 
DDI-DrugBank.d713.s1	0	21	Anticholinergic agents	group	DDI-DrugBank.d713.s1.e0
DDI-DrugBank.d713.s2|a|Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 
DDI-DrugBank.d713.s2	101	108	Sanctura	brand	DDI-DrugBank.d713.s2.e0
DDI-DrugBank.d713.s2	135	142	Sanctura	brand	DDI-DrugBank.d713.s2.e1
DDI-DrugBank.d713.s2	266	272	digoxin	drug	DDI-DrugBank.d713.s2.e2
DDI-DrugBank.d713.s2	275	286	procainamide	drug	DDI-DrugBank.d713.s2.e3
DDI-DrugBank.d713.s2	289	299	pancuronium	drug	DDI-DrugBank.d713.s2.e4
DDI-DrugBank.d713.s2	302	309	morphine	drug	DDI-DrugBank.d713.s2.e5
DDI-DrugBank.d713.s2	312	321	vancomycin	drug	DDI-DrugBank.d713.s2.e6
DDI-DrugBank.d713.s2	324	332	metformin	drug	DDI-DrugBank.d713.s2.e7
DDI-DrugBank.d713.s2	338	346	tenofovir	drug	DDI-DrugBank.d713.s2.e8
DDI-DrugBank.d713.s2	false	DDI-DrugBank.d713.s2.e0	DDI-DrugBank.d713.s2.e1
DDI-DrugBank.d713.s2	false	DDI-DrugBank.d713.s2.e0	DDI-DrugBank.d713.s2.e2
DDI-DrugBank.d713.s2	false	DDI-DrugBank.d713.s2.e0	DDI-DrugBank.d713.s2.e3
DDI-DrugBank.d713.s2	false	DDI-DrugBank.d713.s2.e0	DDI-DrugBank.d713.s2.e4
DDI-DrugBank.d713.s2	false	DDI-DrugBank.d713.s2.e0	DDI-DrugBank.d713.s2.e5
DDI-DrugBank.d713.s2	false	DDI-DrugBank.d713.s2.e0	DDI-DrugBank.d713.s2.e6
DDI-DrugBank.d713.s2	false	DDI-DrugBank.d713.s2.e0	DDI-DrugBank.d713.s2.e7
DDI-DrugBank.d713.s2	false	DDI-DrugBank.d713.s2.e0	DDI-DrugBank.d713.s2.e8
DDI-DrugBank.d713.s2	true	DDI-DrugBank.d713.s2.e1	DDI-DrugBank.d713.s2.e2
DDI-DrugBank.d713.s2	true	DDI-DrugBank.d713.s2.e1	DDI-DrugBank.d713.s2.e3
DDI-DrugBank.d713.s3|a|Coadministration of Sanctura with drugs that are eliminated by active renal tubular secretion may increase the serum concentration of Sanctura and/or the coadministered drug due to competition for this elimination pathway. 
DDI-DrugBank.d713.s3	20	27	Sanctura	brand	DDI-DrugBank.d713.s3.e0
DDI-DrugBank.d713.s3	134	141	Sanctura	brand	DDI-DrugBank.d713.s3.e1
DDI-DrugBank.d713.s3	false	DDI-DrugBank.d713.s3.e0	DDI-DrugBank.d713.s3.e1
DDI-DrugBank.d713.s4|a|Careful patient monitoring is recommended in patients receiving such drugs. 
DDI-DrugBank.d713.s5|a|Drug-Laboratory-Test Interactions Interactions between Sanctura and laboratory tests have not been studied.
DDI-DrugBank.d713.s5	55	62	Sanctura	brand	DDI-DrugBank.d713.s5.e0
DDI-DrugBank.d669.s0|a|Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing and anaphylactoid reactions. 
DDI-DrugBank.d669.s0	30	39	vancomycin	drug	DDI-DrugBank.d669.s0.e0
DDI-DrugBank.d669.s0	45	61	anesthetic agents	group	DDI-DrugBank.d669.s0.e1
DDI-DrugBank.d669.s0	true	DDI-DrugBank.d669.s0.e0	DDI-DrugBank.d669.s0.e1
DDI-DrugBank.d669.s1|a|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.
DDI-DrugBank.d669.s1	119	132	amphotericin B	drug	DDI-DrugBank.d669.s1.e0
DDI-DrugBank.d669.s1	135	149	aminoglycosides	group	DDI-DrugBank.d669.s1.e1
DDI-DrugBank.d669.s1	152	161	bacitracin	drug	DDI-DrugBank.d669.s1.e2
DDI-DrugBank.d669.s1	164	174	polymyxin B	drug	DDI-DrugBank.d669.s1.e3
DDI-DrugBank.d669.s1	177	184	colistin	drug	DDI-DrugBank.d669.s1.e4
DDI-DrugBank.d669.s1	187	194	viomycin	drug	DDI-DrugBank.d669.s1.e5
DDI-DrugBank.d669.s1	200	208	cisplatin	drug	DDI-DrugBank.d669.s1.e6
DDI-DrugBank.d669.s1	false	DDI-DrugBank.d669.s1.e0	DDI-DrugBank.d669.s1.e1
DDI-DrugBank.d669.s1	false	DDI-DrugBank.d669.s1.e0	DDI-DrugBank.d669.s1.e2
DDI-DrugBank.d669.s1	false	DDI-DrugBank.d669.s1.e0	DDI-DrugBank.d669.s1.e3
DDI-DrugBank.d669.s1	false	DDI-DrugBank.d669.s1.e0	DDI-DrugBank.d669.s1.e4
DDI-DrugBank.d669.s1	false	DDI-DrugBank.d669.s1.e0	DDI-DrugBank.d669.s1.e5
DDI-DrugBank.d669.s1	false	DDI-DrugBank.d669.s1.e0	DDI-DrugBank.d669.s1.e6
DDI-DrugBank.d669.s1	false	DDI-DrugBank.d669.s1.e1	DDI-DrugBank.d669.s1.e2
DDI-DrugBank.d669.s1	false	DDI-DrugBank.d669.s1.e1	DDI-DrugBank.d669.s1.e3
DDI-DrugBank.d669.s1	false	DDI-DrugBank.d669.s1.e1	DDI-DrugBank.d669.s1.e4
DDI-DrugBank.d669.s1	false	DDI-DrugBank.d669.s1.e1	DDI-DrugBank.d669.s1.e5
DDI-DrugBank.d613.s0|a|A study published in 2002 found that vigabatrin causes a statistically significant increase in plasma clearance of carbamazepine. 
DDI-DrugBank.d613.s0	37	46	vigabatrin	drug	DDI-DrugBank.d613.s0.e0
DDI-DrugBank.d613.s0	115	127	carbamazepine	drug	DDI-DrugBank.d613.s0.e1
DDI-DrugBank.d613.s0	true	DDI-DrugBank.d613.s0.e0	DDI-DrugBank.d613.s0.e1
DDI-DrugBank.d613.s1|a|In 1984, Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy. 
DDI-DrugBank.d613.s1	87	96	vigabatrin	drug	DDI-DrugBank.d613.s1.e0
DDI-DrugBank.d613.s1	103	111	phenytoin	drug	DDI-DrugBank.d613.s1.e1
DDI-DrugBank.d613.s1	131	139	phenytoin	drug	DDI-DrugBank.d613.s1.e2
DDI-DrugBank.d613.s1	true	DDI-DrugBank.d613.s1.e0	DDI-DrugBank.d613.s1.e1
DDI-DrugBank.d613.s1	false	DDI-DrugBank.d613.s1.e0	DDI-DrugBank.d613.s1.e2
DDI-DrugBank.d613.s1	false	DDI-DrugBank.d613.s1.e1	DDI-DrugBank.d613.s1.e2
DDI-DrugBank.d613.s2|a|The concentration of phenytoin falls to 23% within five weeks, according to an experiment published in 1989 by the same two scientists that tried and failed to elucidate the mechanism behind this interaction.
DDI-DrugBank.d613.s2	21	29	phenytoin	drug	DDI-DrugBank.d613.s2.e0
DDI-DrugBank.d782.s0|a|Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine
DDI-DrugBank.d782.s0	0	8	Vindesine	drug	DDI-DrugBank.d782.s0.e0
DDI-DrugBank.d782.s0	310	318	Phenytoin	drug	DDI-DrugBank.d782.s0.e1
DDI-DrugBank.d782.s0	353	371	Live virus vaccines	group	DDI-DrugBank.d782.s0.e2
DDI-DrugBank.d782.s0	412	418	vaccine	drug	DDI-DrugBank.d782.s0.e3
DDI-DrugBank.d782.s0	526	536	Mitomycin-C	drug	DDI-DrugBank.d782.s0.e4
DDI-DrugBank.d782.s0	588	608	Killed virus vaccines	group	DDI-DrugBank.d782.s0.e5
DDI-DrugBank.d782.s0	650	656	vaccine	group	DDI-DrugBank.d782.s0.e6
DDI-DrugBank.d782.s0	true	DDI-DrugBank.d782.s0.e0	DDI-DrugBank.d782.s0.e1
DDI-DrugBank.d782.s0	true	DDI-DrugBank.d782.s0.e0	DDI-DrugBank.d782.s0.e2
DDI-DrugBank.d782.s0	false	DDI-DrugBank.d782.s0.e0	DDI-DrugBank.d782.s0.e3
DDI-DrugBank.d782.s0	true	DDI-DrugBank.d782.s0.e0	DDI-DrugBank.d782.s0.e4
DDI-DrugBank.d782.s0	true	DDI-DrugBank.d782.s0.e0	DDI-DrugBank.d782.s0.e5
DDI-DrugBank.d782.s0	false	DDI-DrugBank.d782.s0.e0	DDI-DrugBank.d782.s0.e6
DDI-DrugBank.d782.s0	false	DDI-DrugBank.d782.s0.e1	DDI-DrugBank.d782.s0.e2
DDI-DrugBank.d782.s0	false	DDI-DrugBank.d782.s0.e1	DDI-DrugBank.d782.s0.e3
DDI-DrugBank.d782.s0	false	DDI-DrugBank.d782.s0.e1	DDI-DrugBank.d782.s0.e4
DDI-DrugBank.d782.s0	false	DDI-DrugBank.d782.s0.e1	DDI-DrugBank.d782.s0.e5
DDI-DrugBank.d651.s0|a|Drug Interactions: Women on oral contraceptives have shown a significant increase in plasma vitamin A levels.
DDI-DrugBank.d651.s0	33	46	contraceptives	group	DDI-DrugBank.d651.s0.e0
DDI-DrugBank.d651.s0	92	100	vitamin A	group	DDI-DrugBank.d651.s0.e1
DDI-DrugBank.d651.s0	true	DDI-DrugBank.d651.s0.e0	DDI-DrugBank.d651.s0.e1
DDI-DrugBank.d759.s0|a|Limited evidence suggests that ascorbic acid may influence the intensity and duration of action of bishydroxycoumarin.
DDI-DrugBank.d759.s0	31	43	ascorbic acid	drug	DDI-DrugBank.d759.s0.e0
DDI-DrugBank.d759.s0	99	116	bishydroxycoumarin	drug	DDI-DrugBank.d759.s0.e1
DDI-DrugBank.d759.s0	true	DDI-DrugBank.d759.s0.e0	DDI-DrugBank.d759.s0.e1
DDI-DrugBank.d769.s0|a|Coumarin-Derivative Anticoagulants: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving ZOLINZA concomitantly with coumarin-derivative anticoagulants. 
DDI-DrugBank.d769.s0	0	33	Coumarin-Derivative Anticoagulants	group	DDI-DrugBank.d769.s0.e0
DDI-DrugBank.d769.s0	151	157	ZOLINZA	brand	DDI-DrugBank.d769.s0.e1
DDI-DrugBank.d769.s0	178	211	coumarin-derivative anticoagulants	group	DDI-DrugBank.d769.s0.e2
DDI-DrugBank.d769.s0	false	DDI-DrugBank.d769.s0.e0	DDI-DrugBank.d769.s0.e1
DDI-DrugBank.d769.s0	false	DDI-DrugBank.d769.s0.e0	DDI-DrugBank.d769.s0.e2
DDI-DrugBank.d769.s0	true	DDI-DrugBank.d769.s0.e1	DDI-DrugBank.d769.s0.e2
DDI-DrugBank.d769.s1|a|Physicians should carefully monitor PT and INR in patients concurrently administered ZOLINZA and coumarin derivatives. 
DDI-DrugBank.d769.s1	85	91	ZOLINZA	brand	DDI-DrugBank.d769.s1.e0
DDI-DrugBank.d769.s1	97	116	coumarin derivatives	group	DDI-DrugBank.d769.s1.e1
DDI-DrugBank.d769.s1	true	DDI-DrugBank.d769.s1.e0	DDI-DrugBank.d769.s1.e1
DDI-DrugBank.d769.s2|a|Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid). 
DDI-DrugBank.d769.s2	6	20	HDAC Inhibitors	group	DDI-DrugBank.d769.s2.e0
DDI-DrugBank.d769.s2	119	125	ZOLINZA	brand	DDI-DrugBank.d769.s2.e1
DDI-DrugBank.d769.s2	137	151	HDAC inhibitors	group	DDI-DrugBank.d769.s2.e2
DDI-DrugBank.d769.s2	160	172	valproic acid	drug	DDI-DrugBank.d769.s2.e3
DDI-DrugBank.d769.s2	false	DDI-DrugBank.d769.s2.e0	DDI-DrugBank.d769.s2.e1
DDI-DrugBank.d769.s2	false	DDI-DrugBank.d769.s2.e0	DDI-DrugBank.d769.s2.e2
DDI-DrugBank.d769.s2	false	DDI-DrugBank.d769.s2.e0	DDI-DrugBank.d769.s2.e3
DDI-DrugBank.d769.s2	true	DDI-DrugBank.d769.s2.e1	DDI-DrugBank.d769.s2.e2
DDI-DrugBank.d769.s2	true	DDI-DrugBank.d769.s2.e1	DDI-DrugBank.d769.s2.e3
DDI-DrugBank.d769.s2	false	DDI-DrugBank.d769.s2.e2	DDI-DrugBank.d769.s2.e3
DDI-DrugBank.d769.s3|a|Monitor platelet count every 2 weeks for the first 2 months.
